Curriculum Vitae

Eleftherios P. Diamandis

Revised April 28, 2017

Department of Pathology
and Laboratory Medicine
Mount Sinai Hospital
Suite L6-201
60 Murray Street
Toronto, Ontario, Canada M5T 3L9

Department of Clinical Biochemistry
University Health Network

200 Elizabeth Street
Toronto, Ontario, Canada M5G 2C4

Department of Laboratory Medicine
and Pathobiology
Faculty of Medicine, University of Toronto
1 King's College Circle, Rm 6231
Toronto, Ontario, Canada M5S 1A8

Contact Information

Mail Address: Box 32
60 Murray Street
Mount Sinai Hospital
Toronto, ON, Canada M5T 3L9

Telephone: 416-586-8443; Fax: 416-619-5521; Mobile: 416-505-2844

E-Mail: eleftherios.diamandis@sinaihealthsystem.ca

Web Site: http:/www.acdcLab.org/

Table of Contents

Date and Place of Birth

October 8, 1952 in Limassol, Cyprus

Elementary Education

Elementary and High School in Limassol, Cyprus. Graduation, June 1970.

Citizenship Status

Citizen of Canada

Citizen of Cyprus

Degrees

1972-76	B.Sc.	Chemistry, University of Athens, Greece
1976-79	Ph.D.	Analytical Chemistry, University of Athens, Greece
1982-84	Clinical Biochemistry Diploma	University of Toronto, Canada
1978-82, 1984-86	M.D.	University of Athens, Greece

Present Positions

Division Head, Clinical Biochemistry, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada [1995 to present]

Professor and Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Ontario, Canada [1997 to present]

Biochemist-in-Chief, Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada [2005 to present]

Hold'em for Life Chair in Prostate Cancer Biomarkers [2010 to present]

Cross-Appointments

Department of Surgery, Faculty of Medicine, University of Toronto [2006 to present]

Previous Positions

Dates	Position Held
1970-1972	Served in the Cyprus Army.
Aug 1976 - Jan 1978	Post-graduate student, Hellenic National Research Foundation.
Jan 1978 - Oct 1979	Research Assistant, Laboratory of Analytical Chemistry, University of Athens.
Nov 1979 - Aug 1982	Instructor, Laboratory of Analytical Chemistry, University of Athens.
Jul - Sep 1981	Post-Doctoral Research Associate, University of Illinois, Urbana-Champaign, USA
Sep 1982 - Aug 1983	Trainee in Clinical Biochemistry, The Hospital for Sick Children, Toronto.
Sep 1983 - Mar 1984	Trainee in Clinical Biochemistry, Mount Sinai Hospital, Toronto.
Apr 1984 - Jul 1984	Trainee in Clinical Biochemistry, Sunnybrook Medical Centre, Toronto.
Aug 1985	Trainee in Pediatrics. Kaplan Hospital, Rehovot, Israel.
1982-1986	Lecturer, University of Athens.
1986-1988	Director of Research and Development, CyberFluor Inc. (Toronto).
1986-1990	Assistant Professor, Department of Clinical Biochemistry, University of Toronto.

Dates	Position Held
1988-1993	Chairman, Scientific Advisory Board, CyberFluor Inc.
1988-1994	Deputy Biochemist-in-Chief, Toronto Western Division, The Toronto Hospital.
Mar - Dec 1994	Director of Laboratories, Doctor's Hospital.
1990-1996	Associate Professor, Department of Clinical Biochemistry, University of Toronto.
1993-1997	Deputy Chair, Department of Clinical Biochemistry, University of Toronto.

Distinctions and Awards

1. Chisholm Memorial Fellowship, Faculty of Medicine, University of Toronto (1983-84).
2. American Association for Clinical Chemistry Award for Outstanding Scientific Achievements by a Young Investigator (1985).
3. The MedChem Laboratories Award for the best poster presentation, at the annual Canadian Society of Clinical Chemists meeting. Co-author of nine winning posters in Vancouver (1985), Winnipeg (1988), Montreal (1991), Toronto (1992), Banff (1993), Quebec City (1994), Chicago (1996), Ottawa (1998), Chicago (2001).
4. Annual Van Slyke Society Research Grant Award of the American Association for Clinical Chemistry (1989).
5. Annual Research Excellence Award of the Canadian Society of Clinical Chemists (1995).
6. Excellence in Teaching Award, Department of Clinical Biochemistry, University of Toronto (1997).
7. Kubasik Lecturer, Upstate New York Section of the American Association for Clinical Chemistry (October 1998).
8. Distinguished Scientist Award, Clinical Ligand Assay Society (CLAS) (1999).
9. American Association for Clinical Chemistry Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research (1999).
10. Van Slyke Award, the New York Metro Section of the American Association for Clinical Chemistry (1999).
11. 1999 Burlina Prize. Co-author of best abstract presented at the International Society for Enzymology meeting in Venice, Italy, June 4-6, 1999.
12. Distinguished Scientist Award, National Academy of Clinical Biochemistry (NACB) (2000).
13. Honorary President, Society of Scientists / Clinical Chemists of Cyprus (April 2000).
14. Recognition of Scientific Contributions by the Municipality of Agios Athanasios, Limassol, Cyprus (2000).
15. Miriam Reiner Award from the Capital Section of the American Association for Clinical Chemistry (2001).
16. Abbott Award from the International Society for Oncodevelopmental Biology and Medicine (ISOBM) (2002).
17. Annual Education Excellence Award of the Canadian Society of Clinical Chemists (2003).
18. Elected "Corresponding Member" of the Academy of Athens (2005).
19. Frey-Werle Commemorative Gold Medal from the Frey-Werle Foundation (2007).
20. The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics from the American Association for Clinical Chemistry (AACC) (2007).
21. Outstanding Contributions to Clinical Biochemistry Award from the Ontario Society of Clinical Chemists (OSCC) (2008).
22. Elected "Member" of the Royal Society of Canada (2008).
23. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)/Abbott Award for Significant Contributions to Molecular Diagnostics (2009).
24. Distinguished Service Award, Department of Laboratory Medicine and Pathobiology, University of Toronto (2010).

25. Dr. Diamandis is highlighted for his citation record in: The Provincial Government of Ontario document entitled "Ontario's Innovation Agenda" (2010) [www.ontario.ca/innovation]; page 11.
26. Excellence in Biomedical Research Nemitsas Prize in Medical Sciences, Takis and Louki Nemitsas Foundation (2010).
27. Named "Hold'em for Life Chair in Prostate Cancer Biomarkers" (2010).
28. Elected Fellow of the American Association for the Advancement of Science (2011).
29. Elected Fellow of the Canadian Academy of Health Sciences (2012).
30. Senior Sustained Excellence in Graduate Teaching Award, Faculty of Medicine, University of Toronto (2013).
31. The Carl R. Joliff Award for Lifetime Achievement in Clinical and Diagnostic Immunology of AACC (2013).
32. Canadian Society of Clinical Chemists Award for Outstanding Contributions to Clinical Chemistry (2014).
33. The JJ Berry Smith Award for Excellence in Doctoral Supervision, University of Toronto, Canada (2014).
34. The Morton K. Schwartz Lectureship Award from the New York Metro Section of the American Association for Clinical Chemistry. (2014)
35. American Association for Clinical Chemistry Award for Outstanding Contributions in Education. (2017)
36. International Federation of Clinical Chemistry and Laboratory Medicine Award for Laboratory Medicine and Patient Care (2017).

Certifications

1985	Certified Clinical Chemist by the Canadian Society of Clinical Chemists
1985	Certified Clinical Chemist by the American Board of Clinical Chemistry
1986-	Fellow, Academy of Clinical Biochemistry of USA
1995	Fellow, Canadian Academy of Clinical Biochemistry
1995	Fellow of the Royal College of Physicians, Canada
2006	Licensed Medical Biochemist, College of Physicians and Surgeons of Ontario, Canada [Registration # 85455]

Society Memberships

1976-	Greek Chemists' Association
1982-	American Association for Clinical Chemistry [AACC]
1982-	Canadian Society of Clinical Chemists [CSCC]
1986-	Founding Member, Canadian Academy of Clinical Biochemistry [CACB]
1989-	Clinical Ligand Assay Society [CLAS]
1989-	International Society of Clinical Enzymology [ISE]
1994-	American Association for Cancer Research [AACR]
1995-	American Association for the Advancement of Science [AAAS]
1995-2002	The Endocrine Society, USA
1995-1998	The Canadian Association of Pathologists [CAP]
1997-	Ontario Medical Association [OMA]
1998-2002	The Society for Biomolecular Screening
2001-2014	Affiliate Member, American Urological Association [AUA]
2005-	American Society for Biochemistry and Molecular Biology [ASBMB]

Experience in Education

University of Athens, Greece

1977-1982	Taught Qualitative and Quantitative Analytical Chemistry, Chemical Instrumentation and Instrumental Analysis to 2nd Year

	Pharmacy Students and 3rd Year Chemistry Students.
1984-1986	Organized and taught a new full course entitled 'Clinical Chemistry' to 4th Year Chemistry Students.

University of Toronto, Canada

1987-1997	Taught in Courses 1509 and 1603 (Graduate Students & Postdoctoral Fellows). Taught Clinicopathological Conferences to 3rd Year Medical Students.
1987-2000	Teacher, Course LMP 1505
1990-1991	Coordinator and Teacher of a Graduate course entitled "Advanced Analytical Biochemistry" (CLB 1506).
1991-2002	Coordinator and Teacher of a Graduate course entitled "Molecular Biology Techniques" (CLB 1510F now LMP 1510F).
1992-1994	Departmental Representative in the "Pathobiology of Disease" course, which started September 1993.
1995-1999	Teacher of course entitled "Cellular and Molecular Mechanisms of Human Disease" (CLB404).
1998-2004	Co-Coordinator and Teacher of University of Toronto Graduate course LMP 1019S entitled "Research Techniques in Molecular Biology and Pathology".
2000-2004	Co-Coordinator and Teacher of University of Toronto Graduate course LMP 1506S entitled "Techniques in Functional Genomics and Proteomics".
2014-	Co-Coordinator and Teacher of University of Toronto Graduate Course LMP 1530H Entitled "Next Generation Genomics in Clinical Medicine".

Other University Activities

1997-	Director of the Royal College Medical Biochemistry Residency Program, University of Toronto
1995-2005	Committee Member, Royal College General Pathology Residency Program, University of Toronto

Organization of Scientific Meetings

Date	Position	Description	Location
June 3 - 6, 1987	Co-organizer	"Update in Analytical Biochemistry" course, Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
May 30 – Jun 1, 1989	Secretary	8th International Congress of Clinical Enzymology	Toronto, Canada
Sept 13 - 15, 1990	Co-organizer	"Advances in Interpretative Biochemistry" course, Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
May 24 - 28, 1992	Co-organizer	Annual Meeting, Canadian Society of Clinical Chemists	Toronto, Canada
May 13- 14, 1994	Organizer	Annual Meeting, Upstate New York Section, American Association for Clinical Chemistry	Corning, NY
Aug 1 - 6, 1994	International Advisory Board	2nd International Conference on f-elements	Helsinki, Finland
Sept 10 - 12, 1994	Scientific Committee	International Symposium: "Enzymology Days"	Athens, Greece
Oct 5 - 6, 1994	Organizer	Annual Meeting, Upstate New York Section, American Association for Clinical Chemistry	Rochester, NY
Nov 17 - 18, 1994	Chairman	First Specialty Conference, Canadian Academy of Clinical Biochemistry: "Molecular Biology in Clinical Medicine - Techniques, Applications and Future Prospects"	Toronto, Canada
Dec 3 - 4, 1994	Scientific Committee	International Symposium on the Health Effects of Moderate Alcohol Consumption	Toronto, Canada
May 24 - 27, 1995	Organizing Committee	Clinical Ligand Assay Society 21st National and 1st International Meeting	Toronto, Canada
Oct 29- Nov 2, 1997	Secretary	Clin Chem '97	Philadelphia
April 23 - 24, 1998	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Raleigh, NC
May 7 - 9, 1998	Treasurer	"Enzymes, Receptors and Drugs in Atherosclerosis and Obesity" (combined meeting of the International Society for Enzymology and the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology)	Toronto, Canada
May 8 - 9, 1998	Organizing Committee	"Standards of Laboratory Practice Guidelines in the Use of Tumour Markers for the Diagnosis and Monitoring of Cancer"	New York, NY

Date	Position	Description	Location
Oct 13, 1998	Organizer	"Prostate Cancer — New Developments" mini-symposium	Toronto, Canada
Oct 23, 1998	Organizer	Kubasik Symposium: "Prostate Specific Antigen — New Developments"	Rochester, NY
April 23 - 24, 1999	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	San Jose, CA
June 4 - 6, 1999	Co-organizer	International Society for Enzymology meeting: "Novel Aspects of Enzymes in Human Disease"	Venice, Italy
June 22, 1999	Organizer	"Recent Advances on Obesity and Atherosclerosis" mini-symposium	Toronto, Canada
Nov 19, 1999	Chair	1-day symposium: "Advanced Biotechnology & Clinical Diagnosis"	Toronto, Canada
May 5 - 6, 2000	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Boston, MA
May 21 - 24, 2000	Organizing Committee	Basic and Clinical Enzymology 2000	Naples, Italy
May 4 - 5, 2001	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Seattle, WA
April 25 - 26, 2002	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	La Jolla, CA
Sept 1 – 3 , 2005	Chair	1st International Symposium on Kallikreins	Lausanne, Switzerland
May 30-Jun 2, 2006	International Advisory Board	Kinin 2006	Berlin, Germany
May 16-19, 2007	Co-Chair Organizing Committee	CLAS Annual Meeting	Puerto Rico
June 9-14, 2007	Member Organizing Committee	CSCC/CAMB/CAP Annual Meeting	Toronto, Canada
Oct 16-18, 2007	International Advisory Board	2nd International Symposium on Kallikreins	Santorini, Greece
Oct 20-24, 2007	Organizing Committee	International Proteolysis Society	Patras, Greece
Aug 30-Sept 2, 2009	Scientific Advisory Board	3rd International Symposium on Kallikreins and Kallikrein-Related Peptidases	Munich, Germany
May 2 - 4, 2010	Organizing Committee	International Society for Enzymology (ISE)	Crete, Greece
Sept 1-4, 2011	Organizing Committee	4th International Symposium on Kallikreins and Kallikrein-Related Peptidases	Rhodes, Greece
Sept 28-Oct 1, 2013	Chair, Program Committee	5th International Syposium on Kallikreins and Kallikrein-Related Peptidases	Toronto, Canada
June 18-20, 2014	Organizing Committee	International Society for Enzymology (ISE)	Kos, Greece
June 29-July 1, 2015	Organizing Committee	International Society for Enzymology (ISE)	Corfu, Greece

Organization of Workshops

Date	Days	Description	Sponsor	Location
May 25, 1992	1	Introduction to Molecular Biology Techniques	Canadian Society of Clinical Chemists	Toronto, Canada
May 29-31, 1992	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
June 25-27, 1993	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
Nov 14-16, 1994	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
April 23, 1995	1	Molecular Biology Workshop	Canadian Society of Clinical Chemists	Whistler, B.C.
Nov 2, 1995		PSA Workshop	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
Aug 2, 1998	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	Chicago, IL

Date	Days	Description	Sponsor	Location
July 25, 1999	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	New Orleans
July 23, 2000	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	San Francisco
July 24, 2000	1/2	Development of New Diagnostics from the Human Genome Project	American Association for Clinical Chemistry	San Francisco
Nov 30, 2000	1/2	Impact of the Human Genome Project on Clinical Diagnostics	AACC Michigan Section	Windsor, ON, Canada
July 29, 2001	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Chicago, IL
Aug 1, 2001	1/2	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Chicago, IL
May 19, 2002	1/2	Genomic and Proteomic Technologies and Their Relevance to Clinical Diagnostics	Canadian Laboratory Medicine Congress	Calgary, ALTA
July 28, 2002	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Orlando, FL
July 31, 2002	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Orlando, FL
July 20, 2003	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Philadelphia, PA
July 23, 2003	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Philadelphia, PA
July 24, 2004	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Los Angeles, CA
July 26, 2004	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Los Angeles, CA
July 24, 2005	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Orlando, FL
July 27, 2005	1	NACB Guidelines for Use of Tumor Markers at the Clinic [EduTrak]	AACC Annual Meeting	Orlando, FL
July 23, 2006	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Chicago, IL
July 25, 2006	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	Chicago, IL
July 17,2007	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	San Diego, CA
July 18, 2007	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	San Diego, CA
July 28, 2008	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Washington, DC
July 29, 2008	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	Washington, DC
July 20, 2009	½	Enzymes as Biomarkers of Human Diseases	AACC Annual Meeting	Chicago, IL
July 25, 2010	½	Tumor Markers: Theory and Clinical Practice	AACC Annual Meeting	Anaheim, CA
July 26, 2011	1	Personalized medicine in cancer management: Old and new roles of tumor markers	AACC Annual Meeting	Atlanta, GA
July 17, 2012	½	The role of proteomics in personalized medicine	AACC Annual Meeting	Los Angeles, CA

Journal Referee

1. Analyst
2. Analytica Chimica Acta
3. Analytical Biochemistry
4. Analytical Chemistry
5. Annals of Clinical Biochemistry
6. Biochimica Biophysica Acta
7. Biochemical and Biophysical Research Communications
8. Biochemistry

9. Biological Chemistry
10. BMC Medicine
11. Brain
12. Breast Cancer Research
13. British Journal of Cancer
14. Cancer Detection and Prevention
15. Cancer Epidemiology Biomarkers and Prevention
16. Cancer Investigation
17. Cancer Research
18. Cell Growth & Differentiation
19. Clinica Chimica Acta
20. Clinical Biochemistry
21. Clinical Cancer Research
22. Clinical Chemistry
23. Clinical Laboratory News
24. DNA and Cell Biology
25. EMBO Journal
26. European Journal of Oral Sciences
27. European Urology
28. Genomics
29. Glia
30. International Journal of Cancer
31. Journal of Biological Chemistry
32. Journal of Cellular Physiology
33. Journal of Clinical Oncology
34. Journal of Immunoassay
35. Journal of Neurochemistry
36. Journal of Pharmaceutical Sciences
37. Journal of Proteomic Research
38. Journal of the National Cancer Institute
39. Journal of Urology
40. Lancet
41. Microchimica Acta
42. Molecular and Cellular Endocrinology
43. Molecular and Cellular Proteomics
44. Nature Biotechnology
45. Nature Medicine
46. Nature Precision Oncology
47. Nature Reviews Cancer
48. Nature Reviews Urology
49. Neurobiology of Aging
50. Neuroscience Letters
51. Oncogene
52. Peritoneal Dialysis International
53. PLoS Medicine
54. Proceedings of the National Academy of Sciences (PNAS)
55. Proteomics
56. Science
57. Science Translational Medicine
58. Sensors and Actuators
59. Talanta
60. Trends in Pharmacological Sciences
61. Tumour Biology
62. Urology
63. Zoological Science

Referee for Granting Agencies

1. National Science Foundation, USA
2. National Sciences and Engineering Research Council (NSERC)
3. Medical Research Council of Canada
4. International Science Foundation
5. Health Services Utilization and Research Commission (HSURC), Province of Saskatchewan
6. Grant Miller Cancer Awards, University of Toronto
7. Dean's Fund Awards, University of Toronto
8. National Medical Research Council of Singapore
9. National Institutes of Health, USA (NIH)

Member of Scientific Advisory / Editorial Boards

1. Member, Board of Editors, Clinical Laboratory News (1992-1996).
2. Member, Scientific Advisory Board, Clinical Biochemistry (1995-).
3. Member, Board of Editors, Clinical Chemistry (1995-2004) and Associate Editor (2008-)
4. Member, Editorial Board, Critical Reviews in Clinical Laboratory Sciences (1998-2002 and 2013) and Associate Editor (2003-2008).
5. Member, Editorial Board, Clinica Chimica Acta (1999-2006).
6. Specialist Advisor, Human Gene Nomenclature Committee, Human Genome Organization (2000-2010).
7. Member, Editorial Advisory Panel, Expert Review of Molecular Diagnostics (2000-).
8. Member, Editorial Advisory Board, Tumour Biology (2001-)
9. Member, Editorial Advisory Board, International Journal of Biological Markers (2002-2012).
10. Special Issue Editor of Clinical Chemistry; Theme: Cancer Diagnostics. Discovery and Clinical Applications (Aug. 2002 issue).
11. Member, Editorial Board, IN VIVO (2003-).
12. Member, Editorial Board, Anticancer Research (2003-).
13. Member, Editorial Board, Clinical Proteomics (2004-) and Associate Editor (2005-).
14. Special Issue Co-Editor, Clinical Biochemistry; Theme: Recent Advances in Cancer Biomarkers (July 2004 issue).
15. Member, Editorial Board, British Journal of Cancer (2005-).
16. Member, Editorial Board, Cancer Letters (2005-2008).
17. Associate Editor, Cancer Research (2005-2008 and 2013-2015).
18. Member, Editorial Advisory Board, Molecular Oncology (2007-).
19. Member, Editorial Board, Expert Opinion on Medical Diagnostics (2007-2009).
20. Member, Editorial Advisory Board, Biomarkers in Medicine (2007-).
21. Member of the Board, Minerva Endocrinologica (2007-).
22. Member, Editorial Advisory Board, International Journal of Cancer (2008-).
23. Section Editor for Medical Biochemistry, Canadian Journal of Pathology (2009-2012).
24. Member, Editorial Board, BMC Medicine (2009-).
25. Member, Editorial Board, Journal of Data Mining in Genomics & Proteomics (2010-).
26. Member, Editorial Board, Clinical Chemistry & Laboratory Medicine (2011-).
27. Member, Editorial Board, Journal of Proteome Research (2011-).
28. Member, Editorial Board, Journal of Clinical Oncology (2012-2014).
29. Member, Editorial Advisory Board, Critical Reviews in Clinical Laboratory Sciences (2013-).
30. Member, Editorial Board, Molecular Cancer Research (2013-2015).
31. Member, Editorial Board, Translational Proteomics (2013-2015).
32. Member, Editorial Board, Journal of Biological Chemistry (2013-2018).
33. Co-Guest Editor, Special Issue of Clinical Chemistry on Cancer (Jan 2013 issue).
34. Co-Guest Editor, Special Issue of Clinical Biochemistry on Clinical Proteomics (April 2013 issue).
35. Co-Guest Editor, Special Issue of eJIFCC on Men's Health (March 2014 issue).

Other Professional Activities

1. Chairman-elect [1994] and Chairman [1995] of the Upstate New York Section of the American Association for Clinical Chemistry.
2. Member, Awards Committee, CLAS Society, [1996 and 1997].
3. Member, Awards Committee, National Academy of Clinical Biochemistry (NACB), USA, [1996].
4. Member, Awards Committee, American Association for Clinical Chemistry (AACC), USA, [2001- 2004].
5. Chair, Laboratory Medicine Practice Guidelines on Tumour Markers. National Academy of Clinical Biochemistry (NACB), USA, [2002-2008].
6. Secretary [Jan. 2000-Dec. 2003], Vice-President [Jan. 2004-Dec. 2007] and President [Jan. 2008-Dec. 2011] of the International Society for Enzymology (ISE).
7. Member of the Board, International Society of Biomarkers in Medicine (ISOBM) [2008-].
8. Member, Clinical Societies Collaboration Committee of the American Association for Clinical Chemistry (AACC) [2011]

Direction of PhD and MSc Theses

	Date	Degree	Name of Student	Title of Thesis	University of
1	June 1980 – June 1986	PhD	A. Mitsana-Papazoglou	Development of new ion-selective electrodes for drug analysis in biological fluids and formulations	Athens
2	Sept 1981 – Nov 1986	PhD	T.K. Christopoulos	Studies on the binding of ligands to macromolecules with ion-selective electrodes	Athens
3	Sept 1991 – Sept 1992	MSc	S. Hassapoglidou	Quantification of the p53 tumour suppressor gene product in cell lines and serum of cancer patients — Development of new methodology and clinical studies	Toronto
4	Sept 1992 -Feb 1996	PhD	H. Yu	Clinical applications of prostatic and non-prostatic prostate specific antigen	Toronto
5	Sept 1993 –Dec 1996	MSc	M. Levesque	Immunoreactive p53 protein as a prognostic indicator in ovarian carcinoma	Toronto
6	Sept 1992 -Jan 1997	PhD	N. Zarghami	Mechanistic and clinical aspects of prostate-specific antigen expression in non-prostatic tissues	Toronto
7	Sept 1992-June 1997	PhD	K. Angelopoulou	Immune response against the p53 tumour suppressor gene product: clinical studies and molecular mechanisms	Toronto
8	Sept 1995 – Sept 1997	MSc	R. Rosenberg (Co-Supervisor)	The effects of plant derived components on sex hormone receptors: Implications for hormone-dependent cancer treatment	Toronto
9	Sept 1996 – May 1998	MSc	M. Black	Molecular forms of prostate specific antigen in female sera	Toronto
10	Dec 1996 –Aug 1999	PhD	M. Levesque	Clinical utility of the p53 tumour suppressor protein in various malignancies	Toronto
11	Sept 1997 – Nov 1999	MSc	C.V. Obiezu	Hormonal regulation of prostate specific antigen and human glandular kallikrein in males and females *in-vivo*: effects of androgens and antiandrogens on plasma and urinary PSA and hK2 levels	Toronto
12	Sept 1999 –Feb 2001	MSc	G. Foussias	Identification, characterization and mapping of novel members of the siglec family.	Toronto
13	Sept 1997 – April 2001	PhD	R. Rosenberg Zand	Flavonoids and hormone-dependent cancers.	Toronto

	Date	Degree	Name of Student	Title of Thesis	University of
14	Sept 1999 – May 2001	MSc	A. Chang	Identification and characterization of a novel kallikrein gene, KLK-L4/KLK13	Toronto
15	Sept 1998 -Feb 2002	PhD	G.J. Soleas	Analytical and biochemical aspects of wine constituents that affect human health	Toronto
16	Sept 1999 –July 2002	PhD	G.M. Yousef	The human kallikrein gene family: New gene discovery, locus characterization and clinical applications	Toronto
17	Sept 1997 –July 2002	PhD	L-Y. Luo	Human kallikrein 10: Genomic and proteomic aspects and its clinical applications	Toronto
18	Sept 2000 – Aug 2002	MSc	M. Zarghooni	The role of human kallikrein 5 in the pathogenesis of Alzheimer's disease	Toronto
19	Sept 2000 – Aug 2002	MSc	N. Memari	Clonig and protein expression of human kallikrein 12	Toronto
20	July 1998 – Nov 2002	PhD	A. Magklara	Co-expression of human kallikreins 2 and 3 in prostate and breast cancer: clinical utility and mechanism of steroid hormonal regulation	Toronto
21	Sept 2000 – May 2003	MSc	C. Borgono	Human kallikrein 14: Proteomic aspects and preliminary applications	Toronto
22	May 2002 – Sept 2003	MSc	M. Sidiropoulos	Tumour-specific loss of humankallikrein 10, KLK10/NES1 by CpG Island hypermethylation in breast	Toronto
23	Sept 2001 – July 2003	MSc	C. Kapadia	Human kallikrein 13:Development of a sensitive and specific immunofluorometric assay and identification of its binding proteins	Toronto
24	Jan 2000 – Sept 2004	PhD	C.V. Obiezu	Human kallikrein 4: Protein expression, enzymatic activity and association to cancer	Toronto
25	Sept 2002 – Sept 2004	MSc	L. Kurlender	Survey of alternative kallikrein transcripts and identification of a human kallikrein 5 splice variant which is differentially expressed in ovarian and prostate cancer	Toronto
26	Sept 2002 – Aug 2004	MSc	K. Oikonomopoulou	A pilot study to evaluate KLK6 as a biomarker for the detection of circularing tumour cells in ovarian cancer patients	Toronto
27	Sept 2002 – July 2005	MSc	I.P. Michael	Human kallikrein 5 (hK5): Biochemical characterization and its role in cancer	Toronto
28	Sept 2003 – Aug 2005	MSc	M. Elliott	Molecular evolution of new and old mammalian kallikrein gene families	Toronto
29	Sept 2004 – May 2006	MSc	S.J.C. Shan	Up-regulation of human tissue kallikrein 6 in ovarian cancer	Toronto
30	May 2003 – Dec 2006	PhD	C.A. Borgono	Functional characterization of human kallikrein 14	Toronto
31	Sept 2004 – Jun 2008	PhD	V. Kulasingam	Identification and validation of candidate breast cancer biomarkers: A mass spetrometric approach	Toronto
32	Sept 2004 – Jul 2008	PhD	J.L.V. Shaw	Distribution of human tissue kallikrein-related peptidases in tissues and biological fluids: Localization, hormonal regulation and physiological functions in the female reproductive system	Toronto
33	Sept 2004 – Aug 2008	PhD	K. Oikonomopoulou	Kallikrein-related peptidases signalling via proteinase-activated receptors	Toronto
34	Sept 2003 – Sept 2008	PhD	G. Sardana	Proteomic analysis of prostate cancer cell line conditioned media for the discovery of candidate biomarkers for prostate cancer	Toronto
35	Sept 2000 – Sept 2008	PhD	N. Memari	Roles of human kallikrein-related peptidases 9 and 12 in cancer	Toronto

	Date	Degree	Name of Student	Title of Thesis	University of
36	Sept 2005 – Dec 2008	PhD	N. Emami	Identification and functional characterization of a novel activation cascade of the KLK family in seminal plasma	Toronto
37	May 2007 - Jun 2009	MSc	C. Kuk	Mining the ovarian cancer ascites proteome for the identification of candidate cancer biomarkers	Toronto
38	Sept 2004 - Dec 2009	PhD	C.G. Gunawardana	Discovery of novel ovarian cancer biomarkers via proteomics and mass spectrometry	Toronto
39	Jan. 2006 – Nov 2010	PhD	J. C-K. Cho	Identification and verification of candidate biomarkers for Down Syndrome and discovery of dysregulated molecular pathways in aminiocytes by proteomics approaches	Toronto
40	Sept. 2008 – Jan. 2011	MSc	S. Makawita	Integrative proteomic analysis of cell line conditioned media and pancreatic juice for the identification of candidate pancreatic cancer biomarkers	Toronto
41	Jan 2005 – May 2012	PhD	I. Prassas	Investigating the anti-cancer properties of cardiac glycosides	Toronto
42	Mar 2007 – Oct 2012	PhD	U. Kuzmanov	Characterization of kallikrein 6 N-glycosylation patterns and identification of sialylated glycoproteins in ovarian cancer	Toronto
43	Jan 2008 – Oct 2012	PhD	J. Bayani	The impact of chromosomal aberrations on the regulation of kallikrein 6 expression in serous ovarian carcinoma	Toronto
44	Sept 2008 – Aug 2013	PhD	A. Eissa	Characterization of kallikrein-related peptidase-8 in normal human epidermis and psoriatic disease	Toronto
45	Sept 2011 – Sept 2013	MSc	A. Chan	Validation of candidate biomarkers for the development of a multi-parametric panel for early detection of pancreatic ductal adenocarcinoma (PDAC)	Toronto
46	Sept 2008 – Nov 2013	PhD	A. Konvalinka	Antiotensin II proteomic signature in human proximal tubular cells as a predictor of renin angiotensin system activity in kidney disease	Toronto
47	Jan 2009 – Jan 2014	PhD	M. Pavlou	Developing a proteomic prognostic signature for breast cancer patients	Toronto
48	Jan 2009 – July 2014	PhD	G. Karagiannis	Proteomic signatures of the Cclorectal cancer desmoplastic invasion front	Toronto
49	Sept 2009 – Aug 2014	PhD	P. Saraon	Identifying mediators of androgen-independent prostate cancer using mass spectrometry-based proteomics.	Toronto
50	Sept 2009 – May 2015	PhD	D. Cretu	Identification and validation of candidate soluble biomarkers for psoriatic arthritis using quantitative proteomics	Toronto
51	Sept 2010 – Aug 2015	PhD	N. Musrap	Proteomic identification of mediators implicated in the metastatic progressiono of ovarian cancer	Toronto
52	Sept 2013 – Sept 2015	MSc	A. DiMeo	Identification of molecular markers for the assessment of aggressive behaviour of small renal masses	Toronto
53	Jan 2014 – Sept 2015	MSc	J. Van	Characterizing the urinary peptidome of adolescents with type 1 diabetes using a discovery-based approach	Toronto
54	Sept 2013 – June 2016	PhD	F. Leung	Intefrating high-throughput technologies for the identification and validation of novel ovarian cancer biomarkers	Toronto
55	Sept 2011 – Jan 2017	PhD	Y. Yu	Investigation of the putative biological substrates for human tissue kallikrein-related peptidase 7	Toronto

The Research Laboratory of Dr. Eleftherios P. Diamandis [April 2013]

Research Coordinator:

1. Antoninus Soosaipillai September 2008 –

Research Technicians

1. Efstrata Panteleli — September 2015–

Research Co-Investigators:

1. Dr. Andrea Bozovic — June 2009 –
2. Dr. Ivan Blasutig — July 2010 –
3. Dr. Vathany Kulasingam — July 2010 –
4. Dr. George Charames — January 2013 –
5. Dr. Ana Konvalinka — November 2013–
6. Dr. Andrei Drabovich — September 2014 –
7. Dr. Davor Brinc — September 2014 –

Mass Spectrometry & Bioinformatics Specialists:

1. Ihor Batruch — March 2007 –
2. Apostolos Dimitromanolakis — September 2010 – March 2016

Post-Doctoral Fellows:

1. Dr. Katerina Oikonomopoulou — January 2012–
2. Dr. Dimitrios Kormpakis — February 2012 – December 2016
3. Dr. Ioannis Prassas — July 2012 –
4. Dr. Panayiota Philippou — February 2014 –
5. Dr. Theano Karakosta — July 2014– April 2017
6. Dr. Ugljesa Djuric — June 2014–
7. Dr. Michaell Papaioannou — January 2016
8. Dr. Mirzo Kanoatov — January 2016

PhD Candidates:

1. Ilijana Begcevic — August 2011 –
2. Sofia Farkona — January 2013 –
3. Christina Schiza — January 2013 –
4. Lampros Dimitrakopoulos — January 2013 –
5. Ashley DiMeo — September 2013–
6. Julie Van — January 2014 –
7. Stella Vasiliou — July 2015 –

MSc Candidates:

1. Malena Mahendran — August 2015 –
2. Caitlin Di Paolo — September 2015 –

Clinical Research Associates:

Special Students:

1. Clare Falia — March 2017 –
2. Michelle Li — March 2015 – September 2016
3. Erandi Munasinghe — April 2015 –April 2016

Research Associates and Post-Doctoral Fellows

Past Post-Doctoral Fellows

1. A. Mitsana-Papazoglou — June 1980-June 1986
2. T.K. Christopoulos — January 1989 to September 1992
3. E.S. Lianidou — June 1989 to February 1990; September 1996; February 1997; June to July 1997
4. S. Kakabakos — September 1990 to July 1991
5. A. Chan — June 1991 to July 1992

6.	R. Evangelista	January to May 1992
7.	D. Tsuyuki	March to July 1996
8.	G. Borchert	March to December 1996
9.	M. Hui	May to October 1997
10.	S. Majumdar	July 1996 to March 1998
11.	K. Angelopoulou	June 1997 to December 1998
12.	B. Bharaj	February 1997 to August 1999; May 2000 to October 2001
13.	C. Shimizu	June 2000
14.	A. Scorilas	October 1998 to August 2000
15.	C. Stephan	April 2001 to September 2001
16.	T. Nakamura	April 2001 to April 2003
17.	A. Mellati	July 2002 to December 2002
18.	A. Magklara	November 2002 to March 2003
19.	X. Duan	November 2002 –September 2003
20.	M. Moridani	September 2003 – December 2003
21.	L-Y. Luo	July 2002 – August 2004
22.	M. Ghosh	December 2002 – December 2004
23.	T. Kishi	April 2001 – December 2005
24.	N. Komatsu	April 2003 – March 2007
25.	M. Paliouras	May 2005 – December 2007
26.	C. Planque	July 2006 – June 2008
27.	Y. Courty	September 2007 – June 2008
28.	N. Memari	September 2008 – December 2008
29.	K. Oikonomopoulou	September 2008 –October 31, 2009
30.	H. Yoon	November 2008 – November 2009
31.	J. Zou	April 2009 – February 2010
32.	J.M. Bauça Rossello	April 2013 – July 2013
33.	H. Kosanam	January 2010 – May 2013
34.	E. Martinez-Morillo	January 2011 – March 2014
35.	A. Drabovich	August 2008 – August 2014
36.	D. Brinc	January 2012 – August 2014
37.	J. Solassol	September 2013 – July 2014
38.	P. Saraon	September 2009 – August 2014
39.	D. Cretu	September 2009 – May 2015
40.	N. Musrap	September 2010 – August 2015

Past Medical Residents

1.	P. Papanastasiou	November 1992 to March 1993
2.	K. Karambolova	May to October 1990
3.	M. Abd Ellatif Said	September 2001 to December 2001
4.	D-E. van der Merwe	October 2004 to October 2005
5.	Dr. Mohammed Mosli	January 2011 – April 2012

Past Research Assistants

1.	R. Kitching	January 1989 to January 1990
2.	H. Edgecomb	June 1994 to March 1995
3.	M. Solomou	November 1994 to June 1995
4.	C. Jia	March to October 1995
5.	D. Melegos	May 1994 to July 1998
6.	M. Black	January 1999 to May 1999
7.	W. Arnett	September 1998 to April 1999
8.	E. Vassilikos	September 1998 to May 1999
9.	G. Wasney	March 2002 to August 2003
10.	C. Linda Grass	September 1988 to August 2006
11.	D. Chin Du	September 2002 to July 2006

12.	I. Karakucuk-Koker	January 2004 to August 2006
13.	R. Thanabalan	May 2007 – June 2008
14.	A. Soosaipillai	September 2005 – August 2008
15.	T. Earle	September 2005 to August 2008
16.	M.Yazdanpanah	January 2006 – December 2008
17.	Valentina Milou	December 2010 – October 2011
18.	Chris Smith	January 2006 – December 2012

Past Undergraduate/Co-Op Students

1.	W. Arnett	September 1996 to September 1997
2.	E. Vassilikos	September 1996 to September 1997
3.	Y. Antebi	September 1994 to May 1995
4.	J. Tsang	September 1998 to June 1999
5.	A. Kwamie	September 2000 to June 2001
6.	G. Sidiropoulos	September 2000 to June 2001
7.	Y. Tomic	September 2001 to June 2002
8.	M. Sidiropoulos	September 2001 to June 2002
9.	M-E. Polymeris	September 2002 to May 2003
10.	C. Davidian	September 2002 to May 2003
11.	J. Cho	September 2004 to May 2005
12.	A. Liu	September 2005 to May 2006
13.	C. Goard	September 2006 to May 2007
14.	A. Li	September 2007 to May 2008
15.	N. Zilbershtein	September 2007 to May 2008
16.	F. Jiang	September 2007 to May 2008
17.	I. Soleas	September to December 2012
18.	Z. Johnston	February to May 2012
19.	K. Adeli	May-August 2013

Past Summer Students & Volunteers

1.	C.C. Bean	June-July 1990 and1991; February-July 1992
2.	G. Oreopoulos	March-July 1992
3.	D. Sahlas	May-July 1993
4.	M. Kalyvas	May-July 1994, 1995 and 1996
5.	J. Karanikolas	May-July 1994
6.	A. Kang	May-September 1994
7.	S. Zammit	May-July 1995 and 1996
8.	A. Karumanchiri	May-July 1996
9.	D. Tambasco	May-July 1996
10.	F. Paiwand	May-August 1996
11.	G. Foussias	May-August 1997; May-July 1998
12.	H. Pappas	May-August 1997; May-July 1998
13.	B. Arnett	May-August 1997; May-July 1998
14.	I. Herrera	May-August in 1998, 1999, 2000, 2001 and 2002
15.	S. Michalitsianos	May-August 1998
16.	N. Matthews	May-August 1998
17.	M. Angelini	May-August 1998
18.	R. Ghatalia	May-August 1999
19.	J. Poulopoulos	May-August 1999 and 2000
20.	S. Croitoru (Taylor)	July-August 1999; May-August 2000
21.	H. Kim	September1999-March 2000
22.	A. Porter	February-September 2000
23.	M. Sidiropoulos	May-August 2000
24.	M. Diamandis	May-August 2000
25.	P. Giannakopoulos	May-August, 2000

26.	L. Rendl	May-August, 2000
27.	A. Kwamie	May-August, 2000
28.	P. Shames	May-August, 2000
29.	G. Sidiropoulos	May-August, 2000 and 2001
30.	P. Diamandis	May-August, 2000; May-June 2003
31.	M. Ordon	September 2000-May 2001
32.	C. Chow	March-July 2001; May-August 2002
33.	M.E. Polymeris	May-August 2001 and 2002
34.	L. Iskander	May-August 2001
35.	K. Lawrie	May-August 2002
36.	C. Popalis	May-August 2002
37.	A. Kopolovic	May-August 2002
38.	K. Kwan	May-August 2002
39.	A. Emadi	May-August 2002 and 2003
40.	M. Elliott	May-August 2002 and 2003
41.	S. Hutchinson	January 2002-August 2002
42.	J. C-K. Cho	May-August 2003 and 2004
43.	S.J. Cui	May-August 2003
44.	C. Kuk	May-August 2004, 2005 and 2006
45.	C. Yeung	May-August 2004 and 2005
46.	N. Fountas	May-August 2004
47.	A. Masotti	May-August 2004 and 2005
48.	S. Khan	May-August 2004 and 2005
49.	B. Bowles	May-August 2004
50.	A. Liu	May-August 2005
51.	J. Fleisher	May-August 2005 and 2006
52.	A. Grass	May-August 2005 and 2006
53.	A. Martin	May-August 2005 and 2006; July-August 2007
54.	Y. Soleas	July-August 2006, 2008, 2009; May-July 2010
55.	A. Campbell	May-August 2005 and 2006
56.	M. Wafer	May-August 2006
57.	R. Thanabalan	May-August 2007
58.	F. Jian	May-August 2007
59.	N. Zilbershtein	May-August 2007
60.	A. Li	May –August 2007
61.	J. Jayakar	May-August 2007
62.	P. Costa	May-August 2007
63.	C. Kuk	May-August 2007
64.	S. Bromberg	July-August 2007
65.	B. Judd	July-August 2007; May-August 2009
66.	B. Knezevic	July-August 2007; May-July 2010
67.	A. Papanastasiou	July-August 2007
68.	S. Dawson	May- August 2008 and 2009
69.	B. Dineley	May- August 2008
70.	S. Makawita	May- August 2008
71.	V. Amodeo	May-August 2009 and 2010
72.	D. Kagedan	May-August 2009
73.	I. Lecker	May-August 2009
74.	I. Soleas	May-August 2009; May-July 2010; May-August 2011; May - August 2011; May – August 2012
75.	K. Moshiri	May-August 2009
76.	J. Presvelos	May-August 2009; May-July 2010
77.	A. Sperou	May-August 2009
78.	T. Parameswaran	April-June 2010; April-June 2011
79.	N. Kumar	May-August 2010

80. M. Carruthers May-August 2010
81. A. Xie May-July 2010; May-August 2011
82. A. Berk May-July 2011
83. P. Ko May-August 2011
84. J. Lai May-August 2011
85. W.A. Fung May-August 2011
86. C. Chrystoja May-August 2011; May-August 2012; May-August 2013
87. S. Petrou June-August 2011; June-August 2012
88. T. Gitter June-August 2011
89. C. Hancock May-August 2012
90. S. Yuan May-July 2012; May-July 2013
91. A. Bery May-July 2012
92. C. Zhao May-August 2012
93. B. Eleftheriades May-August 2013
94. F. Jessa May-July 2013
95. A. Misiak May-August 2013
96. T. Samuel May-July 2013
97. E. Scott May-August 2013
98. N. Sukumar May-July 2013; May-July 2014
99. P. Yousef May-July 2013
100. Y. Nahaei July-August 2013
101. S. Poon May-August 2014
102. A. Tuccitto May-June 2014
103. A. Church May-August 2014
104. Y. E. Kim May-August 2014
105. D. Vasic May-September 2015
106. D. Lin May-July 2015
107. S. Park May-August 2015
108. S. Bala May-July 2015
109. A. Yousef May-August 2015
110. M. Treper June-August 2015
111. R. Gandhi August-October 2015
112. J. Yoganathan June-August 2015
113. G. Soicher May-August 2016
114. C. Samuel May-July 2016
115. J. Lin May-July 2016
116. C. Rampal May-July 2016
117. A. Mastorakos May-July 2016
118. N. Breward May-August 2016
119. M. Cahalan May-July 2016

Committee Member of Graduate Students

1. J. Stone, Ph.D. February 1991 (S. Soldin)
2. J. McLaurin, Ph.D. November 1991 (M. Moscarello)
3. A. Ali, Ph.D. December 1991 (A. Baines)
4. R. Steward, Ph.D. May 1993 (B. Bapat)
5. S. Hahn, Ph.D. September 1994 (D. Goldberg)
6. A. Chatzilias, M.Sc. May 9, 1995 (C. Whiteside)
7. G. Soleas, M.Sc. January 1997 (D. Goldberg)
8. C. Soravia, M.Sc. September 1997 (B. Bapat)
9. P. Ghaunia, PhD. October 1999 (K. Pritzker)
10. J. Lovgren, Ph.D. December 1999, Malmo, Sweden (H. Lilja)
11. J. Choe, Ph.D. September 2000 (T. Cruz)
12. M. Cooper, M.Sc. February 2001 (R. Kandel)
13. P. C. Papageorgiou, M.Sc. April 2001 (D. Osmond)
14. C. Taghibiglou, Ph.D. October 2001 (K. Adeli)

15. G. Charames, M.Sc; Ph.D. September 2002 (B. Bapat)
16. M. Jung, Ph.D. June 2002 (C.C. Liew)
17. L. Pontrelli, M.Sc. July 2002 (K. Adeli)
18. C. Ton, Ph.D. July 2002 (C.C. Liew)
19. V. Vassileva, M.Sc. September 2002 (B. Bapat)
20. A. Liontas, M.Sc. September 2003 (H. Yeger)
21. C. Au, M.Sc. August 2003 (K. Adeli)
22. J-P. Morand, M.Sc. June 2004 (K. Adeli)
23. S. Perera, Ph.D. September 2005 (B. Bapat)
24. E. Christensen, M.Sc. September 2005 (R. Bristow)
25. N. Mousa, Ph.D November 2006 (R. Casper)
26. C. J. Arana M.Sc. July 2008 (R. Kandel)
27. D. Taylor, Ph.D. January 2009 2014(R. Kandel)
28. E. Olkhov, Ph.D. September 2009 – December 2015(B. Bapat)
29. Z. Shoei December 2013 -(L. Hazrati)
30. F. Zhao Januray 2014- (B. Bapat)
31. M. Peters September 2015- (B.Bapat)

Research Grants

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
1	Time-Resolved Fluorometry	CyberFluor Inc.	$250,000	1989-1994	**E.P. Diamandis**	
2	Improved Biotin Streptavidin System	American Association for Clinical Chemistry	$6,000	1989-1990	**E.P. Diamandis**	
3	New Ultrasensitive TR-FIA Methods	MRC -University Industry (with CyberFluor)	$250,000	1989-1992	**E.P. Diamandis**	
4	New Analytical Techniques	Dean's Fund	$10,000	1989-1990	**E.P. Diamandis**	
5	Time-Resolved Fluorescence Techniques	University Research Incentive Fund	$400,000	1992-1995	**E.P. Diamandis**	
6	New Amplification Techniques Based on Molecular Biology	MRC-University Industry (with CyberFluor)	$115,000	1992-1994	**E.P. Diamandis**	
7	Hepatitis C, Detection Techniques	Canadian Red Cross	$146,000	1992-1994	M. Krajden	**E.P. Diamandis**
8	p53 Gene - Clinical Applications	Cancer Research Society	$60,000	1992-1994	**E.P. Diamandis**	
9	Diet and Colon Cancer Risk	Ministry of Health	$250,000	1993-1995	G. McKeown-Eyssen	**E.P. Diamandis**, V. Jazmaji, D. Jenkins, N. Marcon, F. Saibie, H. Stern, D. Baron, L. Cohen, G. Greenberg, G. Kakis, W. Singer, G. Steiner
10	Health Effects of Wine	NRC-IRAP	$250,000	1993-1997	D.M. Goldberg	**E.P. Diamandis**, G. Soleas
11	Sequencing of the p53 Gene	Visible Genetics Inc.	$200,000	1995-1997	**E.P. Diamandis**	
12	Role of PSA in Breast Cancer	Canadian Breast Cancer Foundation	$30,000	1995-1996	**E.P. Diamandis**	
13	Monitoring Prostate Cancer with Ultrasensitive PSA Assays	Pace Corporation	$40,000	1996-1998	**E.P. Diamandis**	
14	Prostate Specific Antigen (PSA) as a Prognostic Indicator in Breast Cancer	National Cancer Institute of Canada (CBCRI)	$97,350	1996-1998	**E.P. Diamandis**	C. Baines, M. Escobar
15	Novel Oncogenes and Tumour Suppressors in Ovarian Cancer	MRC-University Industry (with Nordion International)	$55,000	1996-1998	**E.P. Diamandis**	

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
16	The Role of Growth Factors in Cancer	Diagnostic Systems Laboratories	$140,000	1996-1998	**E.P. Diamandis**	
17	PSA and Prostate Cancer Relapse	MRC-University Industry (with Pace Corp.)	$90,000	1997-1999	**E.P. Diamandis**	
18	Novel PSA Applications	MDS Nordion	$180,000	1996-1999	**E.P. Diamandis**	
19	Prognostic Factors for Metastatic Progression of Localized Prostate Cancer	National Cancer Institute of Canada	$251,000	1998-2000	S. Narod	**E.P. Diamandis**, D. Banerjee, M. Fleshner, L. Kapusta, L. Klotz, M. Jewett, M. Pollak, J. Slingerland, J. Sweet, J. Trachtenberg
20	New Method for Breast Cancer Diagnosis	U.S. Army	$72,000	1998-1999	**E.P. Diamandis**	
21	Serum Insulin-Like Growth Factor-1 and Aggressiveness of Prostate Cancer	Cancer Research Society	$25,000	1998-1999	**E.P. Diamandis**	M. Pollak, J. Trachtenberg, H. Yu
22	Obesity and Related Factors in Breast Cancer - A Prospective Cohort Study	National Cancer Institute of Cancer (CBCRI)	$156,000	1998-2001	P. Goodwin	**E.P. Diamandis**, K. Pritchard, D. McCready, J. Koo, D. Page
23	The Use of Emerging Sequencing Technology to Determine the Clinical Utility of a Mutation in the PSA Gene as a Breast Cancer Risk Factor and Prognostic Marker	Ontario Association of Medical Laboratories	$27,000	1998-1999	B. Hoffman	**E.P. Diamandis**, D. Sutherland, B. Bharaj
24	Cancer Preventive and Anticarcinogenic Properties of Wine and its Components	NSERC-University Industry (with the Canadian Wine Institute)	$180,000	1998 - 2001	**E.P. Diamandis**	D. Goldberg; D. Josephy
25	Development of Functional Foods and Nutraceuticals of Plant Origin	NSERC-University-Industry (with Kellog's Canada Ltd., Loblaw Brands Ltd., Yves Veggie Cuisine, Natural Temptations Bakery, Parrheim Foods, Soy City Foods, Real Roasted Soy and First line Seeds)	$575,435	1998 - 2001	D. Jenkins	P. Connelly, S. Cunnage, **E.P. Diamandis**, R. Josse, L. Leiter, V. Rao, P. Wood, C.J. Jackson, A. Yee
26	The Androgen Receptor Co-Activator ARA$_{70}$. Is it involved in the development of hormone refractory prostate cancer?	MRC-University Industry Program (with DSL Canada)	$315,000	1999 – 2002	**E.P. Diamandis**	
27	A new method for discriminating between prostate cancer and benign prostatic hyperplasia	National Cancer Institute of Canada (Prostate Cancer Research Initiative)	$58,000	2000 -2001	**E.P. Diamandis**	
28	Prognostic factors of metastatic Progression of localized prostate cancer	National Cancer Institute of Canada	$59,365	2000 - 2001	S. Narod	**E.P. Diamandis**, D. Banerjee, M. Fleshner, L. Kapusta, L. Klotz, M. Jewett, M Pollak, J. Slingerland, J. Sweet, J. Trachtenberg
29	Serological diagnosis of breast cancer	Canadian Breast Cancer Research Initiative	$50,000	2000 -2001	**E.P. Diamandis**	
30	A candidate new biomarker for breast cancer diagnosis	National Institutes of Health (NCI, USA)	$200,000	2000 - 2002	**E.P. Diamandis**	

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
31	New Time-Resolved Fluorometric Detection Systems and Selected Applications in Biotechnology	NSERC-University-Industry (with MDS Nordion)	$400,000	2000 – 2003	**E.P. Diamandis**	
32	Polymorphisms in three genes of the androgen pathway: clinical utility as markers of breast and prostate cancer susceptibility and prognosis.	NSERC-University-Industry (with Visible Genetics Inc.)	$335,000	2000 – 2003	**E.P. Diamandis**	B. Hoffman
33	Prostase: a new prostatic cancer biomarker?	NSERC-University Industry (with HDM Diagnostics)	$120,000	Dec 2001 - May 2003	**E.P. Diamandis**	
34	Human kallkrein 6: a serum biomarker for ovarian cancer	EDRN: NIH (USA)	$160,000	Jan 2002 - Jan 2003	**E.P. Diamandis**	
35	Discovery of New Targets for Cancer Vaccines	Aventis-Pasteur	$900,000	Dec 1998 - Dec 2003	**E.P. Diamandis**	
36	Human kallikrein 4 (hK4): A new prostatic biomarker?	NIH (NCI), USA	$300,000	Sept 2002 – Sept 2004	**E.P. Diamandis**	H. Lilja, W. Catalona, H. Yu
37	A new biomarker for ovrian cancer detection	NIH (NCI), USA	$300,000	Sept 2002 – Sept 2004	**E.P. Diamandis**	J. McLaughlin, D. Katsaros, M. Plebani
38	Diagnostic utility of the normal epithelial cell-specific 1 gene (NES1) in ovarian cancer	National Cancer Institute of Canada	$234,000	Jun 2001 - May 2005	**E.P. Diamandis**	
39	Identification and characterization of the Siglec multigene family on chromosome 19q13	NSERC Genomics Project	$360,000	Apr 2002 - Mar 2005	**E.P. Diamandis**	
40	Plant foods including vegetable proteins as part of a functional food cholesterol-lowering dietary portfolio	NSERC/University-Industry	$3.0 M	Jun 2002 – May 2006	D. Jenkins	**E.P. Diamandis**
41	Kallikreins as disease biomarkers	NSERC/University-Industry (with IBEX Technologies)	$1,200,000	Oct 2002 – Sept 2006	**E.P. Diamandis**	
42	Prospective evaluation of prostate biopsies for prostate cancer detection	NCIC	$400,000	Apr 2004 – Mar 2007	R.K. Nam	**E.P. Diamandis**
43	Exploring the potential of tissue kallikreins as novel biomarkers for diagnosis, prognosis and therapy response in ovarian cancer	EORTC – Translational Research	$60,000	May 2004 – Apr 2007	M. Schmitt	N. Reed [UK], G. Daxenbichler [Austria], B. Schmalfeldt, N. Harbeck & F. Jaenicke [Germany], M. Talieri [Greece], M.G. Daidone [Italy], A. Harloszinska [Poland], U. Eppenberger [Switzerland], F.C.G.J. Sweep & E. Berns [The Netherlands], **E.P. Diamandis** [Canada]
44	Biological functions of human kallikrein 14 – A novel serine protease	NSERC/University-Industry (with IBEX Technologies Inc.)	$360,000	Sept 2004 – Aug 2007	**E.P. Diamandis**	
45	Range of action of the kallikrein gene family in MS pathogenesis	National Multiple Sclerosis Society	$567,452	Jan 2005 – Sept 2008	I. Scarisbrick	**E.P. Diamandis**, M. Blaber
46	Ontario Cancer Biomarker Network (OCBN)	Ontario Institute for Cancer Research (OICR)	$6.0 M	Oct 2005 – Dec 2008	**E.P. Diamandis**	50 Co-Investigators

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
47	Identification of Tumor-Associated Antigens As Cancer Vaccine Targets	NSERC/University-Industry (with Aventis Pasteur) Project # CRDPJ 320424 - 04	$400,000	Jan 2006 – Dec 2008	**E.P. Diamandis**	
48	Application of high-throughput screening to identifying small chemical compounds that modulate kallikrein expression in the cancer cell lines	Ontario Institute for Cancer Research (OICR) Project # 06MAY00219	$130,000	Jan 2007 – Dec 2007	**E.P. Diamandis**	
49	Identification of specific small molecular weight inhibitors of human tissue kallikrein enzymes by high-throughput screening	Ontario Institute for Cancer Research (OICR) Project # 07May00326	$130,000	Jan 2008 – Dec 2008	**E.P. Diamandis**	
50	Kallikreins as diagnostic markers of ovarian carcinoma	NIH/NCI	$800,000	Jun 2006 – May 2009	**E.P. Diamandis**	D. Katsaros, H. Kobayashi, J. McLaughlin
51	Human kallikrein 11 (hK11)- Better than PSA as a prostatic biomarker?	Ontario Institute for Cancer Research (OICR) Project # 06NOV00263	$284,000	Apr 2007 – Mar. 2009	**E.P. Diamandis**	W. Catalona, C. Stephan, H. Yu
52	Validation of two novel breast cancer biomarkers	Ontario Institute for Cancer Research (OICR) Project # 07NOV66	$65,000	Jun 2008 – May 2009	**E.P. Diamandis**	
53	Use of seminal fluid protein patters as biomarkers for diseases in the male reproductive tract: Prediction of spermatogenesis in men with azoospermia	The Physicians' Services Incorporated Foundation (PSI)	$158,000	Apr 2007 – Mar 2009	K. Jarvi	L. Kirk, B. Mullen, A. Alotta, L. Spencer, K. Benedict**, E.P. Diamandis**
54	Discovery of a novel candidate biomarker for early ovarian cancer detection	Ovarian Cancer Canada	$30,000	Jul 2008 – Jun 2009	**E.P. Diamandis**	
55	Discovery of cancer biomarkers using proteomics and mass spectrometry	NSERC/University-Industry (YYZ Inc) Project # CRDPJ 320409-04	$900,000	Oct 2007 – Sept 2009	**E.P. Diamandis**	
56	Human kallikrein 8: A novel biomarker for ovarian carcinoma	Ontario Institute for Cancer Research (OICR) Project # 05NOV00193	$468,000	Oct 2007 – Sept 2009	**E.P. Diamandis**	D. Katsaros, J. McLaughlin, M. Plebani
57	ALCAM and BCAM: Two new breast cancer biomarkers	National Institutes of Health (NIH) Project #R21CA137246-02	$297,000	April 2009 – March 2011	**E.P. Diamandis**	G. Soletormos, D. Katsaros, Y. Zheng, M. Gion
58	Novel semen biomarkers to identify sperm production in men with fertility: A non-invasive method to characterize men with azoospermia or no sperm in the semen, into those with and without testicular sperm production	MaRS Innovation [Proof of Principle] Project #: 2010-0103	$50,000	August 2010 – March 2011	K. Jarvi	**E.P. Diamandis**, K. Lo, E. Grober, L. Briollais
59	Kallikrein-related serine proteases as therapeutic targets for cancer	NSERC-University Industry [Proteomic Methods Inc] #CRDPJ 355696-07	$600,000	June 2008 - May 2011	**E.P. Diamandis**	K. Bukhanov, M. Gion, L. Goodglick, S. Keshavjee, M. Moore, A. Pasculescu, M. Plebani, F. Ruckert, E. Sauter, P. Shaw

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
60	Novel semen biomarkers to identify sperm production in men with fertility: A non-invasive method to characterize men with azoospermia or no sperm in the semen, into those with and without testicular sperm production	CIHR [Proof of Principle]	$152,499	April 2011 – March 2012	K. Jarvi and **E.P. Diamandis**	K. Lo, E. Grober, B. Mullen, L. Briollais
61	A proteomic and genetic biomarker panel for improving Prostate Specific Antigen performance and identify individuals at risk of prostate cancer using a unique patient population accrued in the European Randomized Study for Prostate Cancer Screening	Ontario Institute for Cancer Research (OICR) [Cancer Research] Project #08NOV-163	$631,232	July 2009 – June 2012	A. Zlotta	**E.P. Diamandis**, H. Ozcekuj, L. Briollais, N. Fleshner, T. van der Kwast, J. Jarvi, G. Loockwood
62	Genetic, epigenetic and proteomic analysis of the kallikrein family in search for novel diagnostic, prognostic and risk susceptibility algorithms for prostate cancer	CIHR [Operating] Project # 200168	$649,727	July 2009 – June 2012	**E.P. Diamandis**	Z. Zlotta, B. Bapat, L. Broillais, N. Fleshner, H. Ozcelik, T. van der Kwast
63	Identifying biomarkers for psoriatic arthritis: From discovery to prognostication	CIHR [Operating grant] #253085	$100,000	October 1, 2011 – September 30, 2012	V. Chandran	R. Cook, E.P. Diamandis, D. Gladman, B. Rosen
64	Towards non-invasive diagnosis of urogenital diseases by a novel multiparametric biomarker panel in seminal plasma	Merieux Institut [Cancer Research]	$400,000	January 2011 – December 2012	**E.P. Diamandis**	K. Jarvi
65	Defining an angiotensis II signature in the kidney	Kidney Foundation of Canada (KFOC) Project #: KFOC110015	$100,000	October 2011 – March 2013	J. Scholey	**E.P. Diamandis,** A. Konvalinka
66	Semen proteomics to identify novel prostate cancer biomarkers	Canadian Cancer Society Research Institute (CCSRI)	$413,853	July 2010 – June 2013	K. Jarvi	**E.P. Diamandis**, A. Finelli, N. Fleshner, A. Zlotta
67	Discovery of novel biomarkers for Down Syndrome by proteomic analysis of amniotic fluid and amniocyte-conditined media	NSERC-University Industry [Proteomic Methods Inc] Project# CRDPJ380660-09	$740,000	October 2009– September 2013	**E.P. Diamandis**	E. Winsor, K. McEvoy
68	An integrated proteomic approach to novel pancreatic cancer biomarker discovery	Ontario Institute for Cancer Research (OICR) Project # 10NOV-498	$420,296	October 1, 2011 – September 30, 2014	**E.P. Diamandis**	R. Haun, M. Moore, S. Gallinger, F. Ruckert
69	Prediction of successful sperm retrieval in patients with non-obstrusive azoospermia using a panel of protein biomarkers measured in seminal plasma	Canadian Institute of Health Research (CIHR)-PoP Phase I Project #303100	$154,660	October 1, 2013 – September 31, 2014	**K. Jarvi and E.P. Diamandis**	A. Drabovich; K. Lo, E. Grober
70	An integrated systems biology approach for ovarian cancer biomarker discovery	NIH [EDRN-BDL] Project #: 1U01CA152755-01	$1,578,668	September 2010 – Dec 2015	**E.P. Diamandis**	T. Colgan, D. Cramer, J. McLaughlin, B. Rosen, Y. Zheng
71	A new method for detecting androgenic steroid doping by female athletes.	Partnership for clean competition	$150,000	Sept 2015-August 2016	**E.P. Diamandis**	A.Linden-Hirschberg, Yingye Zheng
72	Integrated approach to discover prostate cancer biomarkers in seminal plasma	Canadian Institute for Health Research (CIHR) Project #296571	$417,000	January 1, 2013 – December 31, 2016	**E.P. Diamandis**	A. Drabovich, K. Jarvi

#	Title	Granting Agency	Total Amount	Dates	Principal Investigator	Co-Applicants / Collaborators
73	Non-invasive diagnosis of prostate cancer and stratification of its molecular subtypes using genomic profiling of circulating tumor cells isolated from semen	Astellas Prostate Cancer Innovation Fund	$50,000	February 8, 2016-Feb 2017	A. Drabovich [PI]	**E.P. Diamandis [Co-PI]** K. Jarvi [Co-PI]
	ACTIVE GRANTS					
1	Validation of two novel pancreatic cancer biomarkers: CUZD1 and LAMC2	Canadian Institute of Health Research (CIHR)-Industry-Partnered Collaborative Research Project #299805	$519,632	July 1, 2013 – June 30, 2017	**E.P. Diamandis**	V. Kulasingam, R. Brand, S. Gallinger
2	An integrated systems biology approach for ovarian cancer biomarker discovery (Admin Supplement)	NIH [EDRN-BDL] Project #: 1U01CA152755-01	$100,000	June 2014 – Dec 2015	**E.P. Diamandis**	T. Colgan, D. Cramer, J. McLaughlin, B. Rosen, Y. Zheng
3	Changing the paradigm for male fertility treatment - Standardized automated platform for sperm retrieval	AHSC AFP Innovation Fund	$166,718	April 2015 - March 2017	KC Lo [PI] CL Librach [Co-PI]	SI Moskovtsev, A Gauthier-Fisher, H Balakier, E Shlush, M Felice, M Deault-Bonin, EP Diamandis, A Drabovich
4	Diagnosis of prostate cancer with genomic biomarkers measured in seminal plasma	Canadian Cancer Society Research Institute Project # 703873	$200,000	Sept 2015-August 2017	**E.P. Diamandis**	K.Jarvi, A.Drabovich
5	KLKIN: Netherton Syndrome: From mechanisms to therapeutics	E-Rare Project #:	$403,740	Feb 2016-Jan 2019	A. Hovnanian [PI] **E.P. Diamandis [Co-PI]**	O. Schilling, C Heinis, M. Drag.
6	Prediction of successful sperm retrieval in patients with non-obstructive azoospermia using TEX101 protein measured in seminal plasma by ELISA	CIHR – PoP Program	$160,000	April 1, 2016 – March 31, 2017	K. Jarvi [Nominated PI] A.Drabovich [PI]	**EP. Diamandis [Co-applicant]** K Lo, E Grober, PN Schlegel, J Smith, A Zini
7	Use of semen TEX101 to improve sperm retrieval rates for men with nonobstructive azoospermia	Astellas Prostate Cancer Innovation Fund	$72,000	May 1, 2016 - Apr 30, 2018	A. Drabovich [PI]	**E.P. Diamandis [Co-PI]** K. Jarvi [Co-PI]
8	Validation of subtype-specific ovarian cancer biomarkers for pelvic mass discrimination	CIHR Project #: 383392	$75,000	March 1, 2017 – Feb 28, 2018	V. Kulasingam [PI]	**E.P. Diamandis [Co-PI]** M. Bernardini [Co-PI]

Invited Lectures — National and International Events

1. Fluorescence immunoassay: Current status and future prospects. National Clinical Ligand Assay Meeting, Los Angeles, CA, May 4, 1989.
2. Multiple labelling and time-resolvable fluorophores. Oak Ridge Conference, St. Louis, MO, April 11, 1991.
3. Applications of time-resolved fluorometry. Mitsubishi Research Centre, Yokohama, Japan, August 28, 1991.
4. Time-resolved fluorometry with lanthanide chelates as labels – Principles, applications and new developments. IUPAC International Congress on Analytical Sciences, Chiba, Japan, August 29, 1991.
5. New developments in time-resolved fluorometric immunoassays. Clin Chem 92, Tarrytown, NY, October 16, 1992.
6. Time-resolved fluorometric immunoassay using lanthanide chelates as labels. 20th International Rare Earth Conference, Monterey, CA, September 12, 1993.
7. The p53 tumour suppressor gene product and its application to clinical medicine. International Symposium on Clinical Enzymology. Sidney, Australia, November 10-12, 1993.

8. PSA in the cytosol of breast cancers. 2nd Stanford Conference on International Standardization of PSA Assays. Stanford, MA, September 1, 1994.
9. PSA as a breast cancer marker. Medgenix Diagnostics, Brussells, Belgium, September 2, 1994.
10. PSA as a prognostic indicator in breast cancer. International Symposium on Clinical Enzymology, Athens, Greece, September 11, 1994.
11. Tumour markers in breast cancer. 5th IFCC Bergmeyer Conference, Tutzing, Germany, December 12-14, 1994.
12. Tumour suppressor genes and oncogenes in cancer: Are the present techniques meeting the challenge? Biochemiche Analytic 95. Leipzig, Germany, April 27, 1995.
13. Prostate specific antigen as a prognostic indicator in breast cancer. Cambridge Healthtech Institute "Prognostic Factors in Cancer", Arlington, VA, June 7-8, 1995.
14. PSA: A new growth factor? DSL Third International Scientific Meeting. Feldafing, Germany, September 30 – October 4, 1995.
15. Prostate-specific antigen: New developments and applications in non-prostatic tumours. Clin Chem 95. Teaneck, NJ, October 11-14, 1995.
16. Prostate-specific antigen – a favourable prognostic indicator for women with breast cancer. Second International Congress of the Hellenic Society for Breast Cancer Research, Kos Island, Greece, October 25-28, 1995.
17. Prostaglandin D synthase in amniotic fluid and maternal serum: Possible association with fetal abnormalities. International Colloquium on β-trace. Osaka, Japan, November 17, 1995.
18. Ultrasensitive time-resolved fluorescence immunoassays. 2nd Symposium on Analysis of Peptides. Swedish Academy of Pharmaceutical Sciences. Stockholm, Sweden, January 29-31, 1996.
19. New clinical applications of PSA. Seminar, Department of Pathology and Laboratory Medicine. Hartford Hospital, Hartford, CT, USA, February 13, 1996.
20. New diagnostic applications of PSA. International Conference, PSA/Prostatic Disease. Llanberis, Wales, UK, May 21-22, 1996.
21. Time-resolved fluorometry. Bracco Research. Princeton, NJ, May 30, 1996.
22. Prostaglandin D synthase. Development of analytical methodology and preliminary clinical studies. 10th International Conference on Prostaglandins and the Related Compounds. Vienna, Austria, September 22-27, 1996.
23. Prostate-specific antigen – New Developments. Clinical Ligand Assay Society, Texas Section. Houston, TX, November 2, 1996.
24. Prostate-specific antigen: New Developments. Annual Endocrinological Society of India Conference (ESICON-96), Cochin, India, December 1, 1996. Also gave lectures in New Delhi (Nov. 26, 1996), Lucknow (Nov. 28, 1996), Madras (Dec. 5, 1996) and Mumbai (Dec. 7 & 9, 1996).
25. Prostate-specific antigen, a tumour marker for prostatic and breast carcinoma. Royal Victoria Hospital, Division of Medical Genetics, Department of Medicine, McGill University, Montreal, March 13, 1997.
26. Prostate-specific antigen as a tumour marker for breast and prostatic carcinoma. Visiting Professor, Washington University, School of Medicine, Washington, DC, May 21-22, 1997.
27. PSA as a prognostic and monitoring marker of breast and prostate cancer. 5th Balkan Clinical Laboratory Federation Meeting, Ioannina, Greece, October 10, 1997.
28. Health effects of wine. A myth or a reality? 5th Balkan Clinical Laboratory Federation Meeting, Ioannina, Greece, October 10, 1997.
29. Prostate specific antigen: New knowledge. Fox Chase Cancer Center, Philadelphia, PN, October 31, 1997.
30. Monitoring of prostate cancer with ultrasensitive assays. Conference on new diagnostic tools for prostate cancer. Athens, Greece, December 12, 1997.
31. PSA: Application beyond the prostate. Industry luncheon lecture at the Annual AACC meeting, August, 3, 1998.

32. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and appears to be a new member of the human kallikrein gene family. 4th Annual DSL Scientific Meeting, Gleneden Beach, OR, September 9-12, 1998.
33. Prostate specific antigen: New developments. AACC Upstate New York Section, Rochester, NY, October 23, 1998.
34. Prostate cancer and prostate specific antigen: A review. The Society of Scientific Clinical Laboratory Directors of Cyprus. Limassol, Cyprus, November 1, 1998.
35. Recent developments in tumour markers - clinical applications for disease diagnosis, prognosis and monitoring. 2nd Panhellenic Clinical Chemistry Conference. Glyfada, Athens, November 6, 1998.
36. Ultrasensitive PSA assays – clinical applications. Cross Cancer Centre, Edmonton, Alberta, November 13, 1998.
37. Ultrasensitive PSA and non-prostatic PSA. Commercial presentation at "Tumour Markers at the Millennium", Santa Barbara, CA, February 26 - March 2, 1999.
38. p53 Autoantibodies. Commercial presentation at Tumour Markers at the Millennium. Santa Barbara, CA, February 26-March 2, 1999.
39. The human kallikrein gene family – association with breast and prostate cancer. Annual meeting of the Clinical Ligand Assay Society, Philadelphia, PA, May 7, 1999.
40. Overview of enzymes used in molecular biology. International Society for Enzymology Meeting, Venice, Italy, June 6, 1999.
41. Tumour markers in prostate cancer. IFCC-WorldLab Meeting, Florence, Italy, June 8, 1999.
42. Tumour markers for breast and prostate cancer. Annual meeting of the Society of Clinical Chemists of Quebec, Saint Adele, PQ, Oct. 21, 1999.
43. The new kallikrein gene family – implications in carcinogenesis. Department of Clinical Chemistry, Lund University, Malmo, Sweden, Dec. 15, 1999.
44. The new human kallikrein gene family: Connection to breast and prostate cancer. Feist-Weiller Cancer Centre, Louisiana State University Medical Center, Shreveport, LA, March 18, 2000.
45. Kallikeins and cancer: Visiting Professor, University of Pennsylvania, PA, April 24, 2000.
46. Discovery of new human kallikreins and genomic organization of the human kallikrein gene locus. Enzymology 2000, Naples, Italy, May 21-24, 2000.
47. Birth, growth, death and resurrection of the Clinical Chemist. Athena Society Meeting, Spetses, Greece, Sept. 19-21, 2000.
48. Application of human kallikrein genes in prostate and other cancers. 6th World Hellenic Biomedical Congress, Athens, Greece, Oct. 11-14, 2000.
49. PSA and novel biomarkers in prostate cancer. Prostate Cancer Symposium on "Novel Stragegies in Prostate Cancer Treatment and Diagnosis". Royal Melbourne Hospital, Australia, Nov. 3, 2000.
50. Kallikreins as cancer biomarkers. Plenary lecture at the 38th Annual Scientific Conference of the Australian Association of Clinical Biochemists. Canberra, Australia, Nov. 8-10, 2000.
51. Do I have prostate cancer? A biochemical approach. Industry Workshop, Australian Association of Clinical Biochemists Annual Meeting, Canberra, Australia, Nov. 8-10, 2000.
52. Current trends in biochemical testing for prostate cancer. Pacific Laboratory Medicine Services (PALMS) Pathology Forum. Royal North Shore Hospital, Sydney, Australia, Nov. 8-10, 2000.
53. Time-resolved fluorescence and its applications to immunoassays and molecular diagnostics as well as microarrays. Symposium entitled "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 6, 2001.
54. Prostate cancer biomarkers. Symposium entitled "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 6, 2001.

55. The human kallikrein gene family. Symposium entitled “Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics”. University of Turku, Finland, Feb. 7, 2001.
56. Future of clinical diagnostics and the human genome project. Symposium entitled “Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics”. University of Turku, Finland, Feb. 8, 2001.
57. Sequencing with microarray technology, genomic approaches to developing new diagnostics. 47th Congress of the Egyptian Society of Clinical Chemistry. Cairo, Egypt, Feb. 10, 2001.
58. Development of new tumour markers for prostate and various cancers. 47th Congress of the Egyptian Society of Clinical Chemistry. Cairo, Egypt, Feb. 11, 2001.
59. Time-resolved fluorometry for protein microarrays. Workshop on Protein Microarray Technologies. Boston, MA, Feb. 20, 2001.
60. Two new ovarian cancer biomarkers. Conference entitled: “Tumour Markers: A New Era”. Santa Barbara, CA. March 4, 2001.
61. Towards identification of new prostatic biomarker. Conference entitled “Tumour Markers: A New Era”. Santa Barbara, CA. March 5, 2001.
62. New human kallikrein genes: possible novel disease biomarkers. Department of Pathology, The University of Texas, Southwestern Medical Center, Dallas, TX, March 19, 2001.
63. Clinical application of human kallikrein genes. Eli Lilly, Indianapolis, IN, March 16, 2001.
64. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. University of Montreal, Montreal, PQ, April 6, 2001.
65. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Roswell Park Cancer Institute, Buffalo, NY, April 11, 2001.
66. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. University of Michigan, Ann Arbor, April 13, 2001.
67. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Millennium Pharmaceuticals, Boston, MA, April 20, 2001.
68. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Corixa Corp., Seattle, WA, May 4, 2001.
69. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. 1st Iranian Congress of Cancer Research (Keynote Speaker), Urmia, Iran, May 15, 2001.
70. Three novel ovarian cancer biomarkers. XXIX ISOBM Meeting, Barcelona, Spain, October 1, 2001.
71. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Mauriziano Hospital, Torino, Italy, October 4, 2001.
72. Expression of tissue kallikreins in the pituitary gland. 8th International Pituitary Pathology Meeting, Delphi, Greece, October 6, 2001.
73. Duties and responsibilities of laboratory scientists. International Conference on Laboratory Medicine, Padova, Italy, October 23, 2001.
74. Human kallikreins and cancer: New opportunities for diagnostics and therapeutics. 2nd General Meeting of the International Proteolysis Society, Munich, Germany, November 3, 2001.
75. Human kallikreins: Gene discovery and clinical applications. Capital Section of the American Association for Clinical Chemistry.Washington DC, December 5, 2001.
76. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Pathology Rounds, Department of Pathology, Johns Hopkins University, Baltimore MD, December 6, 2001.
77. Human kallikreins: Gene discovery and clinical applications.CLAS Annual Meeting. Houston TX, May 23, 2002.

78. Evaluation and treatment of PSA recurrence recognizing the hormonal axis in the management of the prostate cancer patient. One day conference organized by Charite Hospital and DPC Academy, Berlin,Germany, June 12, 2002.
79. Human kallikreins and PSA for prostate cancer diagnosis. American Association for Clinical Chemistry Annual Meeting. Orlando, FL, July 31, 2002.
80. Clinical applications of human kallikreins.Molecular Medicine: XXVIII Nordic Congress in Clinical Chemistry. Reykjavik, Iceland, August 11, 2002.
81. The kallikrein family in the testis and testicular neoplasia. 5th Workshop on Carcinoma In-Situ and Testicular Cancer. Copenhagen, Denmark, August 30, 2002.
82. Clinical Applications of human kallikreins. International Society for Fibrinolysis and Proteolysis. Munich, Germany, September 9, 2002.
83. Discovery of the human kallikrein locus. ISOBM Annual Meeting. Boston, MA, September 11, 2002.
84. Human kallikreins: Gene discovery and clinical applications. Hamamatsu University School of Medicine. Hamamatsu, Japan, October 17, 2002.
85. Human kallikreins as cancer biomarkers. International Society for Enzymology Meeting (ISE). Hamamatsu, Japan, October 18, 2002.
86. Tumour markers in ovarian cancer. IX International Symposium on Biology and Clinical Usefulness of Tumour Markers. Barcelona, Spain, February 13, 2003.
87. New tumour markers in ovarian cancer. IX International Symposium on Biology and Clinical Usefulness of Tumour Markers. Barcelona, Spain, February 15, 2003.
88. Kallikreins as tumour markers. Tumour Markers: Discovery to Practice. Santa Barbara, CA, March 3, 2003.
89. Kallikreins: New ovarian cancer biomarkers. 9th Bi-Annual Int'l Forum on Ovarian Cancer, Helene Harris Memorial Trust. Stratford-Upon-Avon, March 27, 2003.
90. Strategies for discoviering new cancer biomarkers. Annual Clinical Ligand Assay Society, Baltimore, MD. May 8, 2003.
91. Kallikreins as cancer biomarkers. IFCC Euromedlab Conference, Barcelona, Spain, June 5, 2003.
92. Kallikreins as diagnostic markers. Early Detection Research Network Meeting, Pittsburg, PA, June 25, 2003.
93. Cancer biomarkers: From discovery to clinical practice – kallikreins as an example. Gordon Conference: New Frontiers in Cancer Detection and Diagnosis, Proctor Academy, Andover, NH, August 17-22, 2003.
94. Practice guidelines for tumour markers. The XXXI Meeting of the International Society for Oncodevelopment Biology and Medicine [ISOBM], Edinburgh, UK, August 30-September 4, 2003.
95. Kallikreins: A new family of serine proteinases [Keynote Lecture]. Proteinase Inhibitors (an IBC Conference), Zurich, Switzerland, September 3-4, 2003.
96. Human kallikreins: Gene locus characterization and clinical applications. 57th Harden Conference, Oxford, UK, September 10-12, 2003.
97. The status of clinical chemistry in Canada. 3rd Athena Society Meeting, Samos, Greece, September 22-26, 2003.
98. Kallikreins as ovarian and prostate cancer biomarkers. The Prostate Cancer Charity Lecture: 5th World Congress on Urological Research, London, UK, September 24-27, 2003.
99. Human kallikreins: A novel family of cancer biomarkers. Lab Rad 2003 International Conference, Cairo, Eqypt, December 12-15, 2003.
100. Human kallikreins: Promising new biomarkers. IBC's 2nd Annual Scientific and Technological Advances in Cancer Research, Reston, VA, February 11-13, 2004.
101. Point/Counterpoint Debate: Serum proteomics pattern diagnostics. Panelists: E. Petricoin III, L. Liotta, S.J. Skates, E.P. Diamandis. IBC's 2nd Annual Scientific and Technological Advances in Cancer Research, Reston, VA, February 11-13, 2004.

102. Limitations of mass spectrometry-derived serum proteomic patterns for cancer diagnostics. Analytica, Munich, Germany, May 11-14, 2004.
103. Human tissue kallikreins: Novel prognostic and diagnostic cancer biomarkers. The XXXII meeting of ISOBM, Helsinki, Finland, June 19-23, 2004.
104. Kallikreins as cancer biomarkers: Recent developments. 5th Central European Conference on Human Tumour Markers. Prague, Czech Republic, October 103, 2004.
105. Mass spectrometry – derived serum proteomic pattern for cancer diagnosis. Novartis Institute for Biomedical Research, Cambridge, MA, USA, March 23, 2005.
106. A 30-year journey in science and medicine. Academy of Athens, Athens, Greece, April 5, 2005.
107. Strategies for discovering new cancer biomarkers: Opportunities and pitfalls. Biomarkers in HIV and Cancer Research, Mathematical Society Institute, Ohio State University, Columbus, OH, April 18-22, 2005
108. Mass spectrometry as a diagnostic tool: Advantages and disadvantages. 22nd International Papillomavirus Conference, Vancouver, BC, April 30 & May 6, 2005.
109. Technology primer for Oncologists: Cancer Proteomics. Meet the Professor Session. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
110. Tumor markers: Present and future. Professional Practice in Clinical Chemistry: A review and update. Alexandria, VA, May 15-19, 2005.
111. Human tissue kallikreins as biomarkers for breast, ovarian and other malignancies, Era of Hope Meeting, Philadelphia, PA, June 8-11, 2005.
112. Human tissue kallikreins: Discovery and clinical applications. Visiting Professor, Medical University of S. Carolina, August 8, 2005.
113. Tumor markers – Present and future. Visiting Professor, Medical University of S. Carolina, August 8, 2005.
114. Kallikrein World. 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3, 2005.
115. Human tissue kallikreins as potential markers of prostate cancer. EDRN Steering Committee Meeting, Seattle, WA, September 20, 2005.
116. Proteomic and genomic technologies for biomarker discovery. Annual ISOBM Meeting, Rhodes Island, Greece, September 25, 2005.
117. Human tissue kallikreins – Update, Annual ISOBM Meeting, Rhodes Island, Greece, September 25, 2005.
118. Mass spectrometry and protein microarrays: Two powerful tools for proteomic research and applications. Proteomics Conference, AACC, Washington, DC, October 24-25, 2005.
119. Proteomic and genomic approaches for discovering cancer biomarkers: Current status and future prospects. National Institutes of Health [NIH], Bethesda, MD, March 3, 2006.
120. Serum kallikreins as biomarkers for cancer. Tumor Markers for Personalized Medicine: The New Frontier. Mauna Lani Resort, Island of Hawaii, March 2-3, 2006.
121. Technology primer for Oncologists: Cancer proteomics. Meet the Professor Session. 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, June 2-6, 2006.
122. Kallikreomics and proteomics. Amgen, Thousand Oaks, CA, USA, August 3, 2006.
123. Junk-Omics®. Athena Society Meeting, Mykonos, Greece, September 5-8, 2006.
124. Quality Assurance in the "Omics Era". Athena Society Meeting, Mykonos, Greece, September 5-8, 2006.
125. Human tissue kallikreins: Physiology, Pathobiology and Clinical Applications. XXV Congress of the Sociedad Española de Bioquímica Clínica y Patología Molecular, Bilbao, Spain, October 9-11, 2006.
126. Kallikrein enzymes as biomarkers for cancer. International Conference on Laboratory Medicine, Padova, Italy, October 24-25, 2006.

127. Human tissue kallikreins: Physiology, Pathobiology and Clinical Applications. Cyprus Neurological Center, Nicosia, Cyprus, March 28, 2007.
128. Is early detection of cancer with serum biomarkers or proteomic profiling feasible? (Invited presentation). Annual American Association for Cancer Research Meeting, Los Angeles, CA, April 14, 2007.
129. Tumor markers: Professional Practice in Clinical Chemistry: A Review and Update.Washington D.C., April 22, 2007.
130. Desquamation: What's new? Barrier Function of Mammalian Skin. Gordon Research Conference, Newport, RI, August 5-10, 2007.
131. Novel biomarkers for prognosis and therapy response in ovarian cancer. EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer". Brussels, Belgium, November 15-17, 2007.
132. An integrated approach for biomarker discovery with tandem mass spectrometry. Thermo Fisher Workshop. Annual AACC Meeting, Washington, DC, July 30, 2008.
133. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Panacea Pharmaceuticals, Gaithersburg, MD, USA, November 5, 2008.
134. 11th European Congress of Endocrinology (ECE), Istanbul, Turkey, April 25-29, 2009
135. An integrated approach for biomarker discovery with tandem mass spectrometry. German Cancer Aid Symposium on "Novel Tools for Risk Assessment and Early Detection of Premalignant Lesions and Cancer". Hotel Bristol, Bonn, Germany, May 6-7, 2009.
136. New biomarker discovery using proteomics and mass spectrometry, Ortho Clinical Diagnostics, Rochester, NY, USA, May 21, 2009.
137. Enzymes as biomarkers of human diseases. Annual AACC/CSCC meeting, Chicago, IL, July 20, 2009.
138. Enzymes and human diseases. Update 2009. International Society for Enzymology, Chicago, IL, July 20, 2009.
139. Personalized medicine-Where are we headed: Whole genome sequencing. 5th Annual Athena Society Meeting, Porto Heli, Greece, September 6-10, 2009.
140. New roles for old molecules: Enzymes in personalized medicine. International Society for Enzymology Meeting (ISE). Island of Crete, Greece, May 2-4, 2010.
141. Role of enzymes in human diseases: new mechanistic aspects. International Society for Enzymology Meeting (ISE), Island of Crete, Greece, May 2-4, 2010.
142. Criteria for candidate prioritization. Early Detection Research Network Conference, Los Angeles, CA, March 8-10, 2011.
143. Integrated proteomic strategies for discovering novel biomarkers: An example with pancreatic cancer. Early Detection Research Network Conference, Los Angeles, CA, March 8-10, 2011.
144. A 30-year journey in Science and Medicine. Nemitsas Lecture, University of Cyprus, Greece, June 15, 2011.
145. Strategies for discovering biomarkers and companion diagnostics with mass-spectrometry-based proteomics. Abbott Lectures, Abbott Park, IL, USA, July 11, 2011.
146. Integrated proteomic strategies for discovering novel biomarkers: An example with pancreatic cancer. Early Detection Research Network Conference (Proteomics Interest Group), Washington, DC, September 13-16, 2011.
147. Towards non-invasive diagnosis of urogenital diseases with a novel multiparametric biomarker panel in seminal plasma. Merieux Conference, Annecy, France, October 25, 2011.
148. Pancreatic cancer and our quest for discovering novel biomarkers for early detection. Upstate New York Section of the AACC Spring Conference, Rochester, N.Y., May 9-11, 2012.
149. Proteomic strategies for discovering novel cancer biomarkers. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Itilo, Mani, May 26-30, 2012.

150. The kallikrein gene family. Physiology, Pathobiology and Clinical Applications. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Itilo, Mani, May 26-30, 2012.

151. Pancreatic cancer and our quest for discovering novel biomarkers for early detection. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Itilo, Mani, May 26-30, 2012.

152. Finding success in a changing world: A roundtable discussion. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Itilo, Mani, May 26-30, 2012.

153. Serum prostate cancer biomarkers. 10th Bi-annual Prostate Cancer Forum, Rotterdam, The Netherlands, June 13-15, 2012.

154. The role of proteomics in personalized medicine. American Association for Clinical Chemistry Annual Meeting, Los Angeles, CA, USA, July 15-19, 2012.

155. Why should I not sequence my genome in 2012? 6th Athena Society Meeting, Costa Navarino, Greece, September 9-13, 2012.

156. Proteomic strategies for discovering novel cancer biomarkers. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Monemvasia, Greece, May 26-June 4, 2013.

157. The kallikrein gene family. Physiology, Pathobiology and Clinical Applications. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Monemvasia, Greece, May 26-June 4, 2013.

158. Pancreatic cancer and our quest for discovering novel biomarkers for early detection. Summer School in Medical and Biosciences Research and Management of the World Hellenic Biomedical Association, Monemvasia, Greece, May 26-June 4, 2013.

159. Diagnosis of Male Reproductive System Disorders with Protein Biomarkers Quantified in Seminal Plasma. Cyprus Institute of Neurology and Genetics, May 15, 2014.

160. The Kallikrein Gene Family Physiology, Pathobiology and Clinical Applications. 3rd Summer School in Medical and Biological Sciences Research and Management. Mani, Laconia, Peloponnese, Greece, May 18, 2014.

161. Proteomic Strategies for Discovering Novel Cancer Biomarkers. 3rd Summer School in Medical and Biological Sciences Research and Management. Mani, Laconia, Peloponnese, Greece, May 18, 2014.

162. Looking for the Sports Gene: Is there one? 3rd Summer School in Medical and Biological Sciences Research and Management. Mani, Laconia, Peloponnese, Greece, May 19, 2014.

163. Should I sequence my genome in 2014? 11th World Hellenic Biomedical Congress, Lakonia, Greece, May 21, 2014.

164. Why some biomarkers do not make it to the clinic. INsPiRE International Conference, Athens, Greece, June 16, 2014.

165. Should I sequence my genome in 2014? International Society for Enzymology Conference, KOS Island, Greece, June 19, 2014.

166. Meet the PSA family members. CSCC Annual Meeting, Charlottetown, PEI, June 21, 2014.

167. The failure of cancer biomarkers to reach the clinic. IFCC Worldlab, Istanbul, June 25, 2014.

168. Should I sequence my genome in 2014? Salon de Actos Hospital Univesitario Central De Asturias. Oviedo Spain October 6-10 2014

169. Cancer biomarker discovery using proteomics. Memorial Sloan-Kettering Cancer Center, New York, October 16, 2014.

170. Research in an era of economic crisis. University of Cyprus, Nicosia, Cyprus, November 24, 2014.

171. Discovery of novel ovarian cancer biomarkers in the Diamandis laboratory 1994-2015 : Early Detection Research Network Workshop, Atlanta, Georgia, March 31, 2015

172. Discovery of prostate cancer biomarkers by using proteomics. Cyprus Institute of Neurology and Genetics, May 14,2015

173. Next generation genomics in clinical medicine. Keynote address. 4th World Hellenic Biomedical Association (WHBA) Summer School, Neo Itilo, Mani, Lakonia, Greece. May 16-23, 2015

174. Moderator of debate entitled "From whole genome sequencing to gene editing: friend or Foe? With panelists Drs Tom Maniatis and Nicholas Katsanis. 4th World Hellenic Biomedical Association (WHBA) Summer School, Neo Itilo, Mani, Lakonia, Greece. May 16-23, 2015

175. Proteomics and Mass Spectrometry. . 4th World Hellenic Biomedical Association (WHBA) Summer School, Neo Itilo, Mani, Lakonia, Greece. May 16-23, 2015

176. The side effects of translational omics. International Society for Enzymology Annual Conference 2015

    Corfu, Greece, June 29- July 1st,2015

177. Newly discovered ovarian cancer biomarkers. International Society for Enzymology Annual Conference 2015, Corfu, Greece, June 29- July 1st,2015

178. Discovery of male infertility biomarkers. International Society for EnzymologyAnnual Conference 2015, Corfu, Greece, June 29- July 1st,2015

179. Next generation genomics and personalized medicine. (Sesion Moderator and speaker) American Assosication for Clinical Chemistry Annual Conference, Atlanta, GA, July 28, 2015

180. The side effects of translational omics: overtesting, overdiagnosis and overtreatment. (Sesion Moderator and speaker) American Assosication for Clinical Chemistry Annual Conference, Atlanta, GA, July 29, 2015

181. Novel male fertility biomarkers. International Society for Enzymology Annual Conference, Syros, Greece, July 1-4, 2016

182. New immunotherapies: The beinging of the end for cancer? American Assosciation for Clinical Chemistry Annual Conference, Philadelphia, PA, July 31-August 4, 2016

Invited Lectures — Local and Commercial Events

1. Ion-selective electrodes in routine clinical chemistry and beyond. Update in Analytical Biochemistry. Toronto, ON, June 3, 1987.

2. Time-resolved fluorescence immunoassay. Update in Analytical Biochemistry, Toronto, ON, June 4, 1987.

3. Fluorescence immunoassay: Current status and future prospects. Ontario Society of Clinical Chemists. Annual Scientific Meeting, Toronto, ON, November 29, 1988.

4. Critical comparison of enzyme immunoassay with other alternative immunoassay techniques. 8th International Congress of Clinical Enzymology, Toronto, June 1, 1989.

5. Time-resolved fluorescence in immunological assays. Department of Chemistry & Biochemistry, University of Windsor, February 16, 1990.

6. New developments in time-resolved fluorescence immunoassay. St. Joseph's Institute of Laboratory Medicine Symposium, London, Ontario, April 26, 1990.

7. Principles and applications of the polymerase chain reaction. Advances in Interpretative Biochemistry. Toronto, ON, September 13, 1990.

8. Principles and recent advances of time-resolved fluorescence immunoassays. 74th Canadian Society of Chemistry Symposium Hamilton, ON, June 5, 1991.

9. Avidin-biotin techniques - Linkages of antibodies to solid phases. Advances in Immunodiagnostic Techniques. Theory and Applications. Toronto, ON, September 12, 1991.

10. Oncogenes and tumour suppressor genes – Biochemical tumour markers of the future. Clinical Research Society of Toronto. Toronto, ON April 11, 1992.
11. Oncogenes and tumour suppressor genes. New biochemical tests and the future of clinical chemistry. Toronto Society of Clinical Chemists, Toronto, ON, April 14, 1992.
12. Nucleic-acid probes. MDS Clinical Biochemistry Symposium, Toronto, ON, June 19, 1992.
13. Serological diagnosis of cancer. Department of Chemistry and Biochemistry, University of Windsor, ON, October 30, 1993.
14. PSA and female breast tissue. Toronto Society for Clinical Chemistry, Toronto, April 5, 1995.
15. PSA, New Insights. Andy Bruce Symposium, Toronto, ON, May 27, 1995.
16. PSA in non-prostatic tissue. Keynote Lecturer, Interuniversity Pathology Research Day, Toronto, ON, June 2, 1995.
17. Prognostic factors in breast cancer. Ontario Society of Medical Technologists' Annual Meeting, Niagara Falls, ON, September 22, 1995.
18. The role of ultrasensitive psa assays in prostate cancer monitoring. The Biology and Treatment of Prostate Cancer, Toronto, ON, November 11, 1996.
19. Clinical applications of the p53 tumour suppressor gene. CSCC Annual Meeting, Ottawa, ON, June 17, 1998.
20. PSA: Free vs total, microassays and other variants. Urology Update 1997, Toronto, ON, Nov. 8, 1997.
21. Clinical applications of ultrasensitive PSA assays. Industry workshop at the Annual CSCC meeting, Ottawa, ON, June 16, 1998.
22. Tumour markers for breast and prostate cancer. MDS Fall Scientific Symposium, Toronto, ON, Oct. 29, 1999.
23. PSA changes in benign prostatic hyperplasia. Urology Update, Toronto, ON, Nov. 6, 1999.
24. The impact of genomics in clinical diagnostics. NRC/IRAP Biotechnology Forum, Toronto, ON, Nov. 29-30, 1999.
25. Human kallikreins: Biotechnology Symposium entitled "Frontiers in Laboratory Medicine", Toronto, ON, Nov 8, 2001.
26. Human kallikreins and clinical applications. Clinical Biochemistry Rounds, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, ON, January 9, 2002.
27. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for ovarian carcinoma. Canadian Conference on Ovarian Cancer Research, Ottawa, ON, May 16-18, 2004.
28. Early diagnosis of ovarian carcinoma by SELDI-TOF mass spectrometry: Opportunities and potential limitations. Canadian Conference on Ovarian Cancer Research, Ottawa, ON, May 16-18, 2004.
29. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for ovarian carcinoma. The Weismann Institute Conference, Toronto, ON, May 31, 2004.
30. Strategies for discovering new cancer biomarkers. Canadian Chinese Association Annual Conference, Toronto, ON, November 26, 2005.
31. Serum kallikreins as biomarkers for cancer plus proteomic approaches biomarkers in prostate cancer workshop. Canadian Prostate Cancer Research Initiative. Niagara-on-the-Lake, ON, May 13, 2006.
32. Strategies for new biomarker identification.Innovation and reform in clinical trials.Toronto, ON, November 1-2, 2006.
33. Human tissue kallikreins: physiology, pathobiology and clinical applications. Samuel Lunenfeld Research Institute Luncheon Presentation. Toronto, ON, April 27, 2007.
34. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Ontario Society of Clinical Chemists (OSCC) Annual Scientific Meeting, Toronto, ON, November 6, 2008.
35. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Convergent Medical Technologies (CMT), Crowne Plaza Hotel, Toronto, ON, November 6, 2008.

36. Ovarian cancer biomarker discovery using proteomics and mass spectrometry, Ovarian Cancer Research Retreat, Princess Margaret Hospital, Toronto, ON, November 21, 2008.
37. Discovery of novel pancreatic cancer biomarkers using proteomics and mass spectrometry. 4th Annual Symposium of the Canadian National Proteomics Network, Toronto, ON, April 23-25, 2012.
38. Seminomics for discovery of male infertility and prostate cancer biomarkers. ThermoFisher Commercial Symposium, American Association for Clinical Chemistry Annual Conference, Atlanta, GA, July 29, 2015

Invited Lectures — Clinical Rounds

1. Renal Rounds, Toronto Western Division, The Toronto Hospital, June 1987.
2. Grand Rounds, Toronto Western Division, The Toronto Hospital, May 1991.
3. Renal Rounds, Toronto General Division, The Toronto Hospital, June 1993.
4. Medical Oncology Rounds, Princess Margaret Hospital, September 20, 1993.
5. Grand Rounds, Toronto Western Division, The Toronto Hospital, February 9, 1994.
6. Immunology Rounds, Toronto Western Division, The Toronto Hospital, February 15, 1994.
7. Renal Rounds, Toronto General Division, The Toronto Hospital, February 18, 1994.
8. Oncology Rounds, The Toronto Hospital Oncology Research Center, November 3, 1994
9. Grand Rounds, Toronto General Division, The Toronto Hospital, February 9, 1995.
10. Endocrine Rounds, Hospital for Sick Children, December 13, 1995.
11. Urology Residents Rounds, Hospital for Sick Children, December 15, 1995.
12. Urology Rounds, Princess Margaret Hospital, July 4, 1997.
13. Measurement of Hormones in Serum with State-of-the-Art Techniques. Advantages and Pitfalls. Postgraduate Endocrine Series, March 27, 1998.
14. The Kallikrein Gene Family. Preventive Oncology Rounds, Ontario Cancer Institute, February 10, 1999.
15. Kallikreins and Breast Cancer. Pathology Rounds, Women's College Hospital, March 30, 1999.
16. Human Kallikreins and Ovarian Cancer. Princess Margaret Hospital, January 21, 2002.
17. Cancer Diagnostics – The Old and the New. Department of Genetics, North York General Hospital, Toronto, December 2, 2002.
18. Kallikreins as Biomarkers for Ovarian Cancer. Ovarian Cancer Clinical Rounds, Princess Margaret Hospital, Toronto, November 22, 2004.
19. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for cancer. Pediatric Clinical Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY, June 23, 2005.

Roundtables

1. Breakfast and Luncheon Roundtable, Annual AACC Meeting, New York, July 1993.
2. Breakfast Roundtable, Annual CSCC Meeting, Quebec City, May 30, 1994.
3. Breakfast and Luncheon Roundtable, Annual AACC Meeting, New Orleans, July 1994.
4. Breakfast Roundtable, Annual CSCC Meeting. Halifax, Nova Scotia, July 7, 1997.
5. Breakfast and Luncheon Roundtable, Annual AACC Meeting. Atlanta, Georgia, July 22, 1997.
6. Breakfast and Luncheon Roundtable, Annual AACC Meeting. Chicago, Illinois, August 4, 1998.
7. Breakfast Roundtable, Annual CLAS Meeting, Houston, Texas, May 25, 2002.

Webinars

1. *Diamandis EP*, Drabovich AP. Biomarker discovery: Translating proteomics into clinical diagnostics**. Nature Publishing Group.** June 4, 2014 (sponsored by Thermo Fisher) http://links.ealert.nature.com/servlet/MailView?ms=NDYwMzY4ODES1&r=MTc3MDc3MzM0MAS2&j=NDQzNzc0NTUyS0&mt=1&rt=0

Interviews: Media Publications & Press Releases

1. Globe and Mail, March 25, 1994.

2. University of Toronto Bulletin, March 28, 1994.
3. The Toronto Star, April 2, 1994.
4. The Toronto Sun, April 3, 1994.
5. The Medical Post, April 5, 1994.
6. AACR Press Release, March 16, 1995.
7. The Toronto Star, March 20, 1995.
8. Clinical Lab Letter, April 15, 1995.
9. Genetic and Engineering News, April 15, 1995.
10. Tomorrow's Medicine Magazine, July 22, 1995.
11. Reader's Digest, December 1995; pg. 101.
12. Physician's Weekly, May 26, 1997.
13. Clinica, October 27, 1997; pg. 18.
14. Globe and Mail, October 30, 1997.
15. Physician's Weekly, July 19, 1999.
16. The Toronto Star, October 6, 1999.
17. The Chronicle of Urology and Sexual Medicine, February 2000.
18. Reuter's Health, June 30, 2003.
19. Analytical Chemistry, November 1, 2003; pgs. 472A-476A.
20. Nature Medicine, 2003;9:980.
21. The New York Times, February 3, 2003.
22. Canadian Living Magazine, September 2004.
23. Nature, January 15, 2004;427:268.
24. National Review of Medicine, February 15, 2004;1:3.
25. Oncology Exchange, February 15, 2004;2: #4.
26. The New York Times, February 3, 2003.
27. The Wall Street Journal, March 12, 2004.
28. National Review of Medicine, March 15, 2004;2: #5.
29. Clinical Laboratory Strategies, March 2004;9:5.
30. The Scientist, April 12, 2004;18:4.
31. Journal of the National Cancer Institute, 2004;96:500-501 [Apr. 7/04 issue].
32. Journal of the National Cancer Institute, 2004;96:816-818 [June 2/04 issue].
33. Technology Review, 2004;66-68 [July/August issue].
34. New York Times, February 3, 2004 [Section F].
35. Sinai Scene, July 15, 2005.
36. Newspaper Apogevmatini (Greece), April 17, 2005.
37. Nature, August 2005,18;436:1060.
38. Ontario Institute of Cancer Research (OICR) Annual Report, 2006; pg 9.
39. Society for Young Clinical Laboratorians (SYCL), March 2006.
40. CAP Today, July 2006;20:7.
41. Homemakers Magazine, October 2006; pgs 58-64.
42. Clinical Chemistry News, February 2007;33:2.
43. JAMA, October 2007; pg 1751.
44. Greek Newspaper "TA NEA", February 17, 2009; http://www.tanea.gr/default.asp?pid=2&ct=1&artid=4502558
45. Science, November 3, 2009.
46. Nature Medicine 2009;15:1339-1343 [Dec. issue 12].
47. Thermo Fisher Scientific 2010;15:22:49 [Mar. 24]: http://www.pr-inside.com/thermo-fisher-scientific-george-mason-r1794708.htm
48. University of Toronto Medical Journal 2010;87:140-143 [No 3]: http://utmj.org/ojs/index.php/UTMJ/
49. MedPage Today, August 12, 2010: http://www.medpagetoday.com/HematologyOncology/OtherCancers/21649
50. Greek News, August 14, 2010 : http://www.kathimerini.gr/4dcgi/_w_articles_kathcolumns_1_14/08/2010_1292727
51. Guardian, British Science, August 17, 2010; http://www. guardian.co.uk
52. Medscape Medical News, August 17, 2010;:http://www.medscape.com/viewarticle/727018
53. Time; August 18, 2010; http://wellness.blogs.time.com/2010/08/18/cancer-biomarkers-dont-live-up-to-their-hyp/
54. TriMed Media Group, Molecular Imaging Magazine, September 2010; http://www.molecularimaging.net/index.php?option=com_articles&division=mii&r=5 :

55. eSinai, Mount Sinai Hospital Foundation, October 4, 2010; www.mshfoundation.ca/Page.aspx?pid=1452
56. SinaiScene, November 8, 2010, pp 4; http://info2/intranet .
57. Live Television Interview, Cyprus Broadcasting Corporation, November 24, 2010.
58. Cyprus Newspaper "Philelefthеros", November 2010; http://www.philenews.com/digital/
59. Cyprus Newspaper "Haravgi", November 2010: http://www.haravgi.com.cy/site-article-50195-gr.php
60. SinaiScene, January 10, 2011, pp3; http://info2/intranet .
61. NCI Bulletin, March 8, 2011, pp2-3; http://www.cancer.gov/ncicancerbulletin/030811/page2.
62. Nature, March 24, 2011;471:428-432; http://www.nature.com/news/2011/110323/full/471428a.html
63. Nature, March 24, 2011;471:S19-S21; http://www.nature.com/nature/outlook/cancerprevention .
64. Cyprus Mail, July 12 2011; http://www.cyprus-mail.com/eleftherios-diamandis/quiet-all-rounder/20110711
65. Science and Technology, July 25, 2011;89:40-43, http://pubs.acs.org/cen/science/89/8930sci1.html
66. University of Toronto "The Bulletin", December 15, 2011;5:1; http://www.news.utoronto.ca/u-t-faculty-honoured-american-association-advancement-science-0
67. Canadian Society of Clinical Chemists News, March 2012, pg 17.
68. Cyprus Television and Radio "RIK" Live Interview in program: "From day-to-day" on Echinococcus and Cancer. May 28, 2012.
69. Pronto, Dispatches-from the Frontiers of Medicine "The Problem with Biomarkers", Fall 12, 2012, pg 19; protomag.com/statics/PROFA12_BIO_F2
70. Cyprus newspaper "Filelefthеros" article: What is the relationship between echinococcus and cancer? (in Greek), March 3, 2013.
71. ScienceDaily, Unreliable commercial lab kits may be hindering the fight against cancer. October 4 & 29, 2013; http://www.sciencedaily.com/releases/2013/10/131004124935.htm ; http://www.reuters.com/article/2013/10/04/aacc-cancer-lab-kits-idUSnPNPH92246+1e0+PRN20131004 http://finance.yahoo.com/news/unreliable-commercial-lab-kits-may-154500477.html http://www.bloomberg.com/article/2013-10-04/aVQaEgqKdQqQ.html
72. MedPage Today, Faulty assays set stage for $500,000 snafu. Oct 9, 2013; http://www.medpagetoday.com/Pathology/GeneralPathology/42183.
73. Greek news: ELLINOKYPRIOS Professor: Discovered new diagnostic tests of male infertility. November 21, 22, 2013; http://www.politis-news.com/cgibin/hweb?-A=250981&-V=articles; http://www.philenews.com/el-gr/koinonia-eidiseis/160/172503/ek-epistimonas-anakalypse-neo-test-diagnosis-tis-andrikis-steirotitas
74. Greek Newspaper: Hopes New diagnostic test for men with azoospermia. November 22, 2013;11:39. http://health.in.gr/news/scienceprogress/article/?aid=1231275189
75. Greek news: New, breakthrough by Greek-Cypriot scientist from: SigmaLive/CNA date: November 21, 2013 11: 59. http://www.sigmalive.com/lifestyle/health/77710
76. Greek news: Biochemical test for spermatozoa of man exempt from painful surgery in the testicles; November 22, 2013. http://www.sigmalive.com/simerini/news/local/583215.
77. Greek news: Breakthrough by Cypriot scientist. November 21, 2013;12:59. http://www.alithia.com.cy/koinonia/item/22459-%CF%83%CE%B7%CE%BC%CE%B1%CE%BD%CF%84%CE%B9%CE%BA%CE%AE-%CE%B1%CE%BD%CE%B1%CE%BA%CE%AC%CE%BB%CF%85%CF%88%CE%B7-%CE%B1%CF%80%CF%8C-%CE%BA%CF%8D%CF%80%CF%81%CE%B9%CE%BF-%CE%B5%CF%80%CE%B9%CF%83%CF%84%CE%AE%CE%BC%CE%BF%CE%BD%CE%B1.html.
78. Greek news: New test for diagnosing male infertility by e/k Prof. breakthrough by Eleftherios Diamanti. November 21, 2013;12:26. http://www.kathimerini.com.cy/index.php?pageaction=kat&modid=1&artid=154774
79. Greek Newspaper "Haniotika Nea". Thursday, November 28, 2013; pgs 30-31.
80. Greek Newspaper "Eleftherotypia". Thursday, November 28, 2013; http://www.enet.gr/?i=news.el.episthmh-texnologia&id=401182.
81. Maclean's "Cures for what ails you: What seems like science fiction is now becoming reality – Ouch, be gone". January 6, 2014, pg 110.
82. Medical Diagnostics: New nanoparticle-based assay provides extremely sensitive test of blood clotting in mice. http://cen.acs.org/articles/92/web/2014/10/Researchers-Use-Synthetic-Biomarkers-Catch.html
83. Research in an era of economic crisis; Cyprus newspaper POLITIS, November 24, 2014 (in Greek language)
84. Research in Cyprus. Cyprus News Agency, November 24, 2014 (in Greek language)
85. Radio interview by Cyprus Broadcasting Corporation, December 1, 2014

86. Can Peter Diamandis solve the Greek economic crisis? Greek Newspaper; I Kathimerini May 17, 2015 (in Greek language)
87. A scientist just raised 4 serious questions about the blood test that made Elizabeth Holmes a billionaire. Business Insider Australia June 27, 2015 Kevin Loria, Lauren F Friedman. http://www.businessinsider.com.au/scientist-skeptical-thranos-blood-test-elizabeth-holmes-2015-6
88. This isn't the first time people have raised major questions about Theranos. Tech Insider October 15, 2015 Kevin Loria. http://www.techinsider.io/science-of-elizabeth-holmes-theranos-update-2015-4
89. The Theranos affair: When silicon valley hype outpaces reality. Los Angeles Times. October 16, 2015 Michael Hiltzik. http://www.latimes.com/business/hiltzik/la-fi-hiltzik-20151017-column.html?ref=yfp
90. The narrative frays for Theranos and Elizabeth Holmes. The New York Times. October 29, 2015 Drew Kelly http://www.nytimes.com/2015/10/30/business/the-narrative-frays-for-theranos-and-elizabeth-holmes.html?_r=0
91. Theranos' 'groundbreaking' approach isn't breaking much new ground. The Washington Post. October 30, 2015 Carolyn Y. Johnson. https://www.washingtonpost.com/news/wonkblog/wp/2015/10/30/theranos-groundbreaking-approach-isnt-breaking-much-new-ground/
92. Semen-based test for diagnosing prostate cancer could reduce unnecessary biopsies; Biopsies are painful and carry some potentially serious risks, including infection, difficulty urinating and erectile dysfunction. Globe and Mail. November 18 2015 Carly Weeks http://www.theglobeandmail.com/life/health-and-fitness/health/semen-based-test-for-diagnosing-prostate-cancer-could-reduce-unnecessary-biopsies/article27315921/
93. Canadian pharmacies testing do-it-yourself blood test kiosks. CTV News. November 27, 2015 Angela Mulholland http://www.ctvnews.ca/health/health-headlines/canadian-pharmacies-testing-do-it-yourself-blood-test-kiosks-1.2678045
94. Oakville biochemist developing new DNA test to detect prostate cancer. Oakville Beaver. December 3, 2015. www.insideHALTON.com
95. A top medical institution ran a secret study on Theranos—here's what they found. TechInsider. Kevin Loria. March 28, 2016. http://www.techinsider.io/s?q=theranos+study+compares+blood+test+to+quest+and+labcorp
96. Theranos and the blood-testing delusion. BloombergView. Faye Flam. April 27, 2016. http://www.bloombergview.com/articles/2016-04-27/theranos-and-the-blood-testing-delusion
97. Something may be working at Theranos, but you don't know what it is. Forbes. Matthew Herper, June 17, 2016 http://www.forbes.com/sites/matthewherper/2016/06/17/something-may-be-working-at-theranos-but-you-dont-know-what-it-is/
98. Theranos' Holmes on the rise, fall and maybe rise again of a medical tech darling. CNN. Jen Christensen, August 1, 2016. http://www.cnn.com/2016/08/01/health/elizabeth-holmes-theranos-rise-fall/index.html
99. Theranos presentation mostly a dud, say scientists. Future of you. Jon Brooks, August 1, 2016. http://ww2.kqed.org/futureofyou/2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/
100. Theranos founder's conference invitation sparks row among scientists: AACC members threaten to resign over high-profile speaking slot allotted to Elizabeth Holmes. Financial Times. David Crow, August 4, 2016. http://www.ft.com/cms/s/0/34b6f16c-59b6-11e6-9f70-badea1b336d4.html#axzz4GOY3YsqC
101. Επιτυχημένοι Μετανάστες, Ύβρις και Ελλάδα. Huffington Post. August 18, 2016 http://www.huffingtonpost.gr/../../eleftherios-diamandis/-_6978_b_11544440.html
102. Trouble Theranos abandons clinical testing. Chemistry World October 14, 2016 https://www.chemistryworld.com/news/troubled-theranos-abandons-clinical-testing-/1017550.article

Podcasts

1. I detected my cancer with my smart phone. Clin Chem 2011;57;1221-1223. **http://media.aacc.org/CCJPodcasts/ClinChem201109_Diamandis-SmartPhones.mp3**
2. Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. Clin Chem 2013;59:1. **http://media.aacc.org/CCJPodcasts/ClinChem_201301_Diamandis.mp3**
3. Tumor Microenvironment–Released Peptides: Could They Form the Basis for an Early-Diagnosis Breast Cancer Test? **Clin Chem** 2014;60:4-6. http://media.aacc.org/CCJPodcasts/ClinChem_201401_Diamandis.mp3

List of Publications: Books

1. *Diamandis EP*, Siskos PA, Papanastasiou-Diamandi A.
   Laboratory Exercises in Clinical Chemistry (~105 pages, in Greek), Athens, 1986.
2. *Diamandis EP*, Siskos PA, Papanastasiou-Diamandi A.
   Lectures in Clinical Chemistry (~ 500 pages, in Greek), Athens 1987.
3. *Diamandis EP*, Christopoulos TK. (Eds.)
   Immunoassay (579 pages). Academic Press, San Diego, CA 1996.
4. *Diamandis EP*, Fritsche HA, Lilja H, Chan DW, Schwartz MK (Eds.)
   Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications (541 pages).
   AACC Press, Washington, DC, 2002.

Book Chapters

1. Hadjiioannou TP, Papastathopoulos DS, *Diamandis EP*. Applications of ion-selective electrodes (ISE) in continuous-flow clinical analysis. In: "Computerization and Automation in Health Facilities". Martin Rubin Editor, pp. 169-196. CRC Press (1984).
2. *Diamandis EP*, Christopoulos TK. Biochemical markers of malignancy. In: "Clinical Chemistry". Wu AHB, Editor, pp 103-111. Health and Education Resources Inc., 1991.
3. *Diamandis EP*, Christopoulos TK. Time-resolved fluorescence immunoassays - Principles and applications In: "Immunochemical Assays and Biosensor Technology for the 1990s". Nakamura R, Kasahara Y, Rechnitz G, Editors, pp 251-271. American Society of Microbiology, 1992.
4. *Diamandis EP*, Christopoulos TK. Time-resolved fluorescence. In: "Non-radioactive labelling and detection of biomolecules" Kessler C, Editor, pp 188-193. Springer-Verlag 1992.
5. *Diamandis EP*, Christopoulos TK. Detection of lanthanide chelates and multiple labelling strategies based on time resolved fluorescence. In: "Nonisotopic DNA Probe Techniques". Kricka LJ, Editor, pp. 263-274. Academic Press, 1992 and pp 377-390, Second Edition, 1995.
6. *Diamandis EP*, Christopoulos TK. Past, present and future of immunoassays. In: "Immunoassay". *Diamandis EP*, Christopoulos TK, Editors, pp. 1-3. Academic Press, Inc. 1996.
7. *Diamandis EP*, Christopoulos TK. Theory of immunoassays. In: "Immunoassay". *Diamandis EP*, Christopoulos TK, Editors, pp. 25-50. Academic Press, Inc. 1996.
8. Christopoulos TK, *Diamandis EP*. Immunoassay configurations. In: "Immunoassay". *E*". *Diamandis EP*, Christopoulos TK, Editors, pp. 227-236. Academic Press, Inc. 1996.
9. Christopoulos TK, *Diamandis EP*. Fluorescence immunoassays. In: "Immunoassay". *Diamandis EP*, Christopoulos TK, Editors, pp. 309-335. Academic Press, Inc. 1996.
10. *Diamandis EP*, Kosravi MJ, Christopoulos TK. Development of in-house immunological assays. In: "Immunoassay". *Diamandis EP*, T.K. Christopoulos TK, Editors, pp. 555-568. Academic Press, Inc. 1996.
11. *Diamandis EP*, Yu H. Non-prostatic sources of prostate-specific antigen. In: "The Urologic Clinics of North America": Prostate-specific antigen: the best prostatic Tumour marker. Oesterling JE, Editor, Vol. 24; pp. 275-282. W.B. Saunders Co., 1997.
12. Goldberg DM, Soleas GJ, Hahn SE, *Diamandis EP*, Karumanchiri A. Identification and assay of trihydroxystilbenes in wine and their biological properties. *In:* Wine: Nutritional and Therapeutic Benefits. Watkins TR, Editor. American Chemical Society, 1997.
13. *Diamandis EP*. Tumour Markers: Past, present and future. In: Tumour Markers: Physiology, Pathobiology, Technology and Clinical Applications. *Diamandis EP*, Fritsche HA, Lilja H, Chan DW, Schwartz MK (Eds.), pp 3-8, AACC Press, 2002.

14. Haese A, Becker C, *Diamandis EP*, Lilja H. Adenocarcinoma of the prostate. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. *Diamandis EP*, Fritsche HA, Lilja H, Chan DW, Schwartz MK (Eds.), pp 193-237, AACC Press, 2002.
15. Yousef GM, *Diamandis EP*. Kallikreins as cancer biomarkers. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. *Diamandis EP*, Fritsche HA, Lilja H, Chan DW, Schwartz MK (Eds.), pp 465-469, AACC Press, 2002.
16. Kishi T, *Diamandis EP*. Neuropsin, human tissue kallikrein 8. In: Handbook of Proteolytic Enzymes 2nd Edn., Barrett AJ, Rawlings ND, Woessner JF (Eds.), Vol. 2, #484, pp 1593, Elsevier 2004.
17. *Diamandis EP*, Luo L-Y. Human tissue kallikrein 10. In: Handbook of Proteolytic Enzymes 2nd Edn., Barrett AJ, Rawlings ND, Woessner JF (Eds.), Vol. 2, #485, pp 1593-1595, Elsevier 2004.
18. Chan DW, Booth RA, *Diamandis EP*. Tumor Markers. In: Tietz Textbook of Clinical Chemistry, 3rd Edition., Burtis CA, Ashwood ER, Bruns D (Eds.), pp 245-295, J. Wiley & Sons, 2004.
19. Harbeck N, Magdolen V, *Diamandis EP*, Ross JS, Ronald MD, Kates E, Schmit M. Tumour-associated proteolytic factors: Markers for tumour invasion and metastasis. In: Molecular Oncology of Breast Cancer. Ross J, Hortobagyi G (Eds.), pp 276-288, Jones and Bartlett 2006.
20. Chan DW, Booth RA, *Diamandis EP*. Tumor Markers. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition. Burtis CA, Ashwood ER, Bruns DE (Eds), pp 745-795, Elsevier 2007.
21. van der Merwe D-E, Oikonomopoulou K, Marshall J, *Diamandis EP*. Mass spectrometry: uncovering the cancer proteome for diagnostics. In: Genomics in Cancer Drug Discovery and Development. Hampton G, Sikora K (Eds.), pp 22-50, Academic Press, 2007.
22. van der Merwe D-E, *Diamandis EP*. To screen or not to screen? In: Tietz Applied Laboratory Medicine, 2nd Edition. Scott MG, Gronowski AM, Eby CS (Eds.), pp 349-354, J. Wiley & Sons, 2007.
23. Yousef GM, *Diamandis EP*. The human kallikrein gene family: New biomarkers for ovarian cancer. In: Ovarian Cancer, 2nd Edition. Stack MS, Fishman DA (Eds.), pp 165-187, Springer, 2009.
24. Eissa A, *Diamandis EP*. Kallikrein-related peptidases: An emerging family of pivotal players in epidermal desquamation and barrier function. In: Skin Moisturization, 2nd Edition. Rawlings AV and Leyden JJ (Eds.): pp 125-145, Informa Healthcare, USA Inc., 2009.
25. Kulasingam V, Smith CR, Batruch I, *Diamandis EP*. Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. In: Serum/Plasma Proteomics, Methods and Protocols, Methods in Mol Biol, Vol 728. Simpson RJ, Greening DW (Eds), pp 207-218, Humana Press 2011.
26. Pavlou MP, *Diamandis EP*. Validation of candidate protein biomarkers. In: Genomic and Personalized Medicine, 2nd Edition, Ginsburg GS, Willard HF (Eds.), Ch 22, Vol. 1, pp 263-271, Elsevier 2012.
27. Bayani J, Petraki CD, Dimitromanolakis A, Milou V, *Diamandis EP*, Schmitt M. Expression of kallikrein-related peptidases under (patho-)physiological conditions. In: Kallikrein-Related Peptidases: Characterization, Regulation and Interactions within the Protease Web. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 1. pp 187-249.
28. Cretu D, Yousef GM, Scorilas A, *Diamandis EP*. Genomic structure of the KLK locus. In: Kallikrein-Related Peptidases: Characterization, Regulation and Interactions within the Protease Web. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 1. pp 4-29.
29. Emami N, *Diamandis EP*. Kallikrein-related peptidases and semen. In: Kallikrein-Related Peptidases: Characterization, Regulation and Interactions within the Protease Web. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 1. pp 311-327.
30. Schmitt M, Dorn J, Kiechle M, *Diamandis EP* and Luo L-Y. Clinical relevance of kallikrein-related peptidases in breast cancer. In: Kallikrein-Related Peptidases: Novel Cancer-Related Biomarkers. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 2. pp. 110-144.

31. Dorn J, Milou V, Kulasingam V, Schmalfeldt B, *Diamandis EP*, Schmitt M. Clinical relevance of kallikrein-related peptidases in ovarian cancer. In: Kallikrein-Related Peptidases: Novel Cancer-Related Biomarkers. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 2. pp. 145-166.
32. Bayani J, *Diamandis EP*. Genomic instability of the KLK-locus in cancer. In: Kallikrein-Related Peptidases: Novel Cancer-Related Biomarkers. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 2. pp 183-199.
33. Milou V, Petraki CD, Dimitromanolakis A, *Diamandis EP*. Expression of KLK proteases under (patho-) physiological conditions. In: Kallikrein-Related Peptidases: Novel Cancer-Related Biomarkers. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds), DeGruyter, Berlin, Germany, 2012, Vol. 2. Pp
34. Milou V, Kulasingam V, Dorn J, *Diamandis EP*. KLK proteases as ovarian cancer biomarkers. DeGruyter, Berlin, Germany. In: KLK Book. MagdolenV, Sommerhoff C, Fritz H, Schmitt M (Eds), 10.2.3. Senior Responsible Author.
35. Luo LY, *Diamandis EP*. Clinical relevance of KLK proteases in breast cancer. DeGruyter, Berlin, Germany. In: KLK Book. Magdolen V, Sommerhoff C, Fritz H, Schmitt M (Eds). In Press. Senior Responsible Author.
36. Eissa A, *Diamandis EP*. Kallikrein-related peptidase 8 (neuropsin). In: Handbook of Proteolytic Enzymes, 3rd Edition. Rawlings ND, Salvesen G (Eds), Oxford: Academic Press 2013, pp 2792-2798.
37. Luo L-Y, *Diamandis EP*. Human tissue kallikrein 10. In: Handbook of Proteolytic Enzymes, 3rd Edition. Rawlings ND, Salvesen G (Eds), Oxford: Academic Press 2013, pp 2798-2801.
38. Cretu D, *Diamandis EP*. Kallikrein-related peptidase 13. In: Handbook of Proteolytic Enzymes, 3rd Edition. Rawlings ND, Salvesen G (Eds), Oxford: Academic Press 2013, pp 2805-2808.
39. Eissa A, *Diamandis EP*. Kallikrein-related peptidase 14. In: Handbook of Proteolytic Enzymes, 3rd Edition. N.D. Rawlings ND, Salvesen G (Eds), Oxford: Academic Press 2013, pp 2809-2813.
40. Drabovich AP, Pavlou MP, Batruch I, *Diamandis EP*. Proteomic and mass spectrometry technologies for biomarker discovery. In Proteomic and Metabolomic Approaches to Biomarker Discovery. Issaq HJ, Veenstra TD (Eds), Elsevier, Academic Press 2013, pp 17-37.
41. Pavlou MP, Blasutig IM, *Diamandis EP*. Bottlenecks in biomarker discovery and validation by using proteomic technologies. In: Comprehensive Biomarker Discovery and Validation for Clinical Applications. Horvatovich P, Bischoff R (Eds), The Royal Society of Chemistry 2013, Chapter 12.
42. Leung F, *Diamandis EP*, Kulasingam V. The current state of ovarian cancer biomarkers and future implications from high-throughput technologies. In Advances in Clinical Chemistry. Gregory S. Makowski. 2014;66:25-77.

Reviews

1980-1989

1. Papastathopoulos DS, *Diamandis EP*, Hadjiioannou TP. Flow-through electrode unit for liquid membrane electrodes. **Anal Chem** 1980;52:2100-2104
2. Siskos PA, *Diamandis EP*. Health and safety in university chemical laboratories. In: "The Sixth Panhellenic Chemistry Conference". **Greek Chemists' Association**, Athens 1981;207-18. [in Greek]
3. *Diamandis EP*, Siskos PA. Standardization in analytical chemistry. **Chimica Chronika**, General Edition, 1983;48:19-48. [in Greek]
4. *Diamandis EP*. Immunoassays with time-resolved fluorescence spectroscopy. Principles and applications. **Clin Biochem** 1988;21:139-150.
5. *Diamandis EP*, Evangelista RA, Pollak A, Templeton E, Lowden JA. Time-resolved fluoroimmunoassays with europium chelates as labels. **Am Clin Prod Rev** 1989;26-22.

1990

6. *Diamandis EP*. Detection techniques for immunoassay and DNA probing applications. **Clin Biochem** 1990;23:437-43.

7. *Diamandis EP*. Analytical methodology for immunoassay and DNA hybridization assays – Current status and selected systems – Critical Review. **Clin Chim Acta** 1990;194;19-50.

8. *Diamandis EP*, Christopoulos TK. Europium chelate labels in time-resolved fluorescence immunoassays and DNA hybridization assays. **Anal Chem** 1990;62;1149A-57A.

1991

9. *Diamandis EP*, Christopoulos TK. The biotin-(strept)avidin system: Principles and applications in biotechnology. **Clin Chem** 1991;37:625-36.

10. *Diamandis EP*. Multiple labelling and time-resolvable fluorophores. **Clin Chem** 1991;37:1486-91.

11. *Diamandis EP*. Time-resolved fluorometry with lanthanide chelates as labels - Principles, applications and new developments. **Anal Sciences** 1991;7:785-787.

1992

12. *Diamandis EP*, Christopoulos TK. Immunological assays based on time-resolved fluorometry and lanthanide chelates as labels. **In-Service Training and Continuing Education**. **AACC** 1992;10:9-26.

13. *Diamandis EP*. Oncogenes and tumour suppressor genes - New biochemical tests. **CRC Crit Rev Clin Lab Sci** 1992;29:269-305.

14. *Diamandis EP*. New tumour markers based on oncogenes and tumour suppressor genes. **Clin Chem News** 1992;18:6-7 (Dec. 1992 issue).

1993-1994

15. Goldberg DM, *Diamandis EP*. Models of neoplasia and their diagnostic implications: A historical perspective. **Clin Chem** 1993;39:2360-74.

16. *Diamandis EP*. Fluorescence spectroscopy. **Anal Chem** 1993;65:454R-9R.

17. *Diamandis EP*. An update on prostate specific antigen. **Clin Chem News** 1993;19:6-8 (Oct. 1993 issue).

18. *Diamandis EP*. Time-resolved fluorometry in nucleic acid hybridization and western blotting techniques. **Electrophoresis** 1993;14:866-75.

19. *Diamandis EP*. The p53 tumour suppressor gene and its clinical applications. **Clin Chem News** 1994;20 (March 1994 issue).

1995

20. *Diamandis EP*. Clinical applications of the p53 tumour suppressor gene. **Clin Chim Acta** 1995;237:79-90.

21. Gudgin Dickson EF, Pollak A, *Diamandis EP*. Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. **J Photochem Photobiol** 1995; 27: 3-19.

22. Gudgin Dickson EF, Pollack A, *Diamandis EP*. Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. **Pharmacol Therapeutics** 1995;66:207-35.

23. *Diamandis EP*. New diagnostic applications and physiological functions of prostate specific antigen. **Scand J Clin Lab Invest** 1995; 55: 105-112.

1996

24. *Diamandis EP*. Prognostic markers in breast cancer. **Clin Lab News** 1996;22:46-51.

25. *Diamandis EP*. Prostate specific antigen – new applications in breast and other cancers. **Anticancer Res** 1996;16:3983-3986.

1997

26. Goldberg DM, Soleas GJ, Hahn SE, *Diamandis EP*, Karumanchiri A. Identification and assay of trihydroxystilbenes and their biological properties **ACS Symposium Series** 1997;661:24-43

27. *Diamandis EP*. Clinical applications of tumour suppressor genes and oncogenes in cancer. **Clin Chim Acta** 1997;257:157-180.

28. *Diamandis EP*. New diagnostic applications of prostate specific antigen. **Br J Urol** 1997; 79(Suppl): 87-91.
29. Soleas GJ, *Diamandis EP*, Goldberg DM. Resveratrol: A molecule whose time has come? And gone? **Clin Biochem** 1997;30:91-113.
30. Soleas GJ, *Diamandis EP*, Goldberg DM. Wine as a biological fluid: History, production and role in disease prevention. **J Clin Lab Anal** 1997;11:287-313.

1998-1999

31. Lopez-Otin C, *Diamandis EP*. Breast and prostate cancer: An analysis of common epidemiological, genetic and biochemical features. **Endocr Rev** 1998;19:365-396.
32. *Diamandis EP*. Prostate specific antigen – its usefulness in clinical medicine. **Trends Endocrinol Metab** 1998;9:310-316.
33. *Diamandis EP*. Prostate Cancer – will we win the battle in the next century? **Clin Lab News** (Oct. issue) 1999;25:14-16.

2000

34. Black MH, *Diamandis EP*. The diagnostic and prognostic utility of prostate specific antigen for diseases of the breast. **Breast Cancer Res Treat** 2000;59:1-14.
35. *Diamandis EP*, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family – implications in carcinogenesis. **Trends Endocrinol Metab** 2000;11:54-60.
36. *Diamandis EP*. Prostate-specific antigen: a cancer fighter and a valuable messenger? **Clin Chem** 2000; 46: 896-900.

2001

37. Yousef GM, *Diamandis EP*. The new human tissue kallikrein gene family: Structure, function and association to disease. **Endocr Rev** 2001; 22:184-204.
38. *Diamandis EP*, Yousef GM. Human tissue kallikrein gene family: A rich source of novel disease biomarkers. **Expert Rev Mol Diagn** 2001;1:182-190.
39. Becker C, Noldus J, *Diamandis E*, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. **Crit Rev Clin Lab Sci** 2001;38:357-399.
40. Scorilas A, Magklara A, Hoffman BR, Bromberg RM, Bjartell A, *Diamandis EP*. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. **Anal Sci** 2001;17:547-550.

2002

41. Stephan C, Jung K, *Diamandis EP*, Rittenhouse HG, Lein M, Leoning SA. Prostate-specific antigen, its molecular forms and other kallikrein markers for detection of prostate cancer. **Urology** 2002;59:2-8.
42. *Diamandis EP*. Duties and responsibilities of laboratory scientists. **Clin Chim Acta** 2002;319:111-115.
43. Yousef GM, *Diamandis EP*. Kallikreins, steroid hormones and ovarian cancer: is there a link? **Minerva Endocrinol** 2002;27:157-166.
44. *Diamandis EP*, Yousef GM. Human tissue kallikreins: A family of new cancer biomarkers. **Clin Chem** 2002;48:1198-1205.
45. Yousef GM, *Diamandis EP*. Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. **Tumour Biol** 2002;23:185-192.
46. Yousef GM, *Diamandis EP*. Human tissue kallikreins: A new enzymatic cascade pathway? **Biol Chem** 2002;383:1045-1057.
47. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Flavonoids and steroid hormone-dependent cancers. **J Chromatogr B Analyt Technol Biomed Life Sci** 2002;777:219-232.

2003

48. Yousef GM, *Diamandis EP*. Human kallikreins: common structural features, sequence analysis and evolution. **Current Genomics** 2003;4:147-165.

49. Yousef GM, Kishi T, *Diamandis EP*. Role of kallikrein enzymes in the central nervous system. **Clin Chim Acta** 2003;329:1-8.

50. Yousef GM, *Diamandis EP*. Tissue kallikreins: New players in normal and abnormal cell growth. **Thromb Haemost** 2003;90:7-16.

51. Yousef GM, *Diamandis* EP. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. **Clin Biochem** 2003;36:443-452.

52. Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafiropoulos N, Simillides G, Yiotakis A, *Diamandis EP*. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. **Oncol Res** 2003;13:381-391.

53. Luo LY, Yousef GM, *Diamandis EP*. Human tissue kallikreins and testicular cancer. **APMIS** 2003;111:225-232.

54. Diamandis EP. Human tissue kallikreins: From genes to clinical applications with emphasis on ovarian cancer. **J Clin Ligand Assay** 2003;26:174-176.

2004

55. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. **Mol Cell Proteomics** 2004;3:367-378.

56. *Diamandis EP*, Yousef GM, Olsson AY. An update on human and mouse glandular kallikreins. **Clin Biochem** 2004;37:258-260.

57. Borgoňo CA, Michael IP, *Diamandis EP*. Human tissue kallikreins: physiologic roles and applications in cancer. **Mol Cancer Res** 2004;2:257-280.

58. Borgoňo CA, *Diamandis EP*. The emerging roles of human tissue kallikreins in cancer. **Nat Rev Cancer** 2004;4:876-890.

2005

59. Kurlender L, Borgoňo C, Michael IP, Obiezu C, Elliott MB, Yousef GM, *Diamandis EP*. A survey of alternative transcripts of human tissue kallikrein genes. **Biochim Biophys Acta** 2005;1755:1-14.

60. Yousef M, Obiezu CV, Luo L-Y, Magklara A, Borgoňo CA, Kishi T, Memari N, Michael P, Sidiropoulos M, Kurlender L, Economopolou K, Kapadia C, Komatsu N, Petraki C, Elliott M, Scorilas A, Katsaros D, Levesque MA, *Diamandis EP*. Human tissue kallikreins: from gene structure to function and clinical applications. **Adv Clin Chem** 2005;39:11-79.

61. Obiezu CV, *Diamandis EP*. Human tissue kallikrein gene family: applications in cancer. **Cancer Lett** 2005;224:1-22.

2006

62. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, *Diamandis EP*, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. **Biol Chem** 2006;387:637-641.

63. Paliouras M, *Diamandis EP*. The kallikrein world: An update on the human tissue kallikreins. **Clin Chem** 2006;387;643-652.

64. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Diamandis EP, Hollenberg MD. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. **Biol Chem** 2006;387:677-85.

65. Petraki CD, Papanastasiou PA, Karavana VN, *Diamandis EP*. Cellular distribution of human tissue kallikreins: immunohistochemical localization. **Biol Chem** 2006;653-663.

2007

66. van der Merwe DE, Oikonomopoulou K, Marshall J, *Diamandis EP*. Mass spectrometry: uncovering the cancer proteome for diagnostics. **Adv Cancer Res** 2007;96:23-50.
67. Paliouras M, Borgono C, *Diamandis EP*. Human tissue kallikreins: The cancer biomarker family. **Cancer Lett** 2007;249;61-79.
68. Gunawardana CG, *Diamandis EP*. High throughput proteomic strategies for identifying tumour-associated antigens. **Cancer Lett** 2007;249:110-119.
69. Emami N, *Diamandis EP*. Human tissue kallikreins: A road under construction. **Clin Chim Acta** 2007;381:78-84.
70. Stephan C, Jung K, Lein M, *Diamandis EP*. PSA and other tissue kallikreins for prostate cancer detection. **Eur J Cancer** 2007;43:1918-1926.
71. Rabien A, Kristiansen G, *Diamandis EP*, Jung K, Stephan C. Aricle in German. **Urologe A** 2007;46:1070-1071.
72. Yousef GM, Denic N, Wadhwa J, Chandracanth, Smith T, Elms F, *Diamandis EP*. Intravagal ectopic parathyroid presenting as a vocal cord paralysis: Case report and review of literature. **J Otolaryngol** 2007;36:E93-95.
73. Emami N, *Diamandis EP*. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. **Mol Oncol** 2007;1:269-287.

2008

74. Kulasingam V, *Diamandis EP*. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. **Nat Clin Pract Oncol** 2008;5:588-599.
75. Prassas I, *Diamandis EP*. Novel therapeutic applications of cardiac glycosides. **Nat Rev Drug Discov** 2008;7:926-935.
76. Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. **Int J Cancer** 2008;123:2007-2012.
77. Emami N, *Diamandis EP*. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. **Clin Chem** 2008;54:1600-1607.
78. *Diamandis EP*, Hoffman B, Sturgeon CM. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. **Clin Chem** 2008;54:1935-1939.
79. Sturgeon CM, Duffy MJ, Stenman U-H, Lilja H, Brŭnner N, Chan DW, Babaian RJ, Bast RC, Dowel B, Esteva F, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee G, Lamerz RN, Looijenga L, Molina R, Nielsen HJ, Rittenhouse HG, Semjonow A, Shih I-M, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman B, *Diamandis EP*. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. **Clin Chem** 2008;54:e11-e79.
80. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Sölétormos G, van der Merwe E, *Diamandis EP*. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in clinical practice: quality requirements. **Clin Chem** 2008;54:e1-e10.
81. Sardana G, Dowell B, *Diamandis EP*. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. **Clin Chem** 2008;54:1951-1960.
82. Eissa A, *Diamandis EP*. Human tissue kallikreins as promiscuous medulators of homeostatic skin barrier functions. **Biol Chem** 2008;389:669-680.
83. Yousef GM, *Diamandis EP*. KLK5 (Kallikrein-related peptidase 5). Atlas Genet Cytogenet Oncol Haematol. June 2008. URL : http://AtlasGeneticsOncology.org/Genes/KLK5ID41085ch19q13.html
84. Hansen KK, Oikonomoupou K, Baruch A, Ramachandran R, BeckP, *Diamandis EP*, Hollenberg MD. Proteinases as hormones: targets and mechanisms for proteolytic signaling. **Biol Chem** 2008;389:971-982.

85. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saiffeddine M, Ramachandran R, *Diamandis EP*. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. **Biol Chem** 2008; 389:643-51.

2009

86. Yousef GM, *Diamandis EP*. The human kallikrein gene family: new biomarkers for ovarian cancer. **Cancer Treat Res** 2009;149:165-187.

87. Gunawardana CG, Memari N, *Diamandis EP*. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. **Clin Biochem** 2009;42:426-429.

88. Sotiropoulou G, Pampalakis G, *Diamandis EP*. Functional roles of human kallikrein-related peptidases. **J Biol Chem** 2009;284:32989-32994.

2010

89. Makawita S, *Diamandis EP*. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. **Clin Chem** 2010;56:212-222.

90. Kulasingam V, Pavlou M, *Diamandis EP*. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. **Nat Rev Cancer** 2010;10:371-378.

91. Oikonomopoulou K, *Diamandis EP*, Hollenberg MD. Kallikrein-related peptidases: Proteolysis and signalling in cancer, the new frontier. **Biol Chem** 2010;391:299-310.

92. Sturgeon CM, Duffy MJ, Hoffman B, Lamerz RM, Fritsche HA, Gaarenstroom K, Bonfrer JMG, Ecke T, Grossman HB, Hayes P, Hoffmann R-T, Lerner S, Lohe F, Louhimo JM, Sawczuk I, Taketa K, *Diamandis EP*. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical and gastric cancers. **Clin Chem** 2010;56:e1-e48.

93. Pavlou MP, *Diamandis EP*. The cancer cell secretome: A good source for discovering biomarkers? **J Proteomics** 2010;73:1896-1906**.**

94. Karagiannis GS, Pavlou MP, *Diamandis EP*. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. **Mol Oncol** 2010;4:496-510.

2011

95. Cho C-KJ, *Diamandis EP*. Application of proteomics to prenatal screening and diagnosis for aneuploidies. **Clin Chem Lab Med** 2011;49:33-41.

96. Saraon P, Jarvi K, *Diamandis EP*. Molecular alterations during progression of prostate cancer to androgen independence. **Clin Chem** 2011;57:1366-1375.

97. Bayani J, *Diamandis EP*. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). **Clin Chem Lab Med** 2011;50:211-233.

2012

98. Konvalinka A, *Diamandis EP*. Searching for new biomarkers of renal diseases through proteomics. **Clin Chem** 2012;58:353-365.

99. Musrap N, *Diamandis EP*. Revisiting the complexity of the ovarian cancer microenvironment - clinical implications for treatment strategies. **Mol Cancer Res** 2012;10:1254-1264.

100. Chung, H, Hamza M, Oikonomopoulou K, Gratio V, Saifeddine M, Virca GD, *Diamandis EP*, Hollenberg MD, Darmoul D. Kallikrein-related peptidase signaling in colon carcinoma cells: Targeting proteinase-activated receptors. **Biol Chem** 2012;393:413-420.

101. Rifai N, *Diamandis EP*, Lo YM, Kricka LJ, Wilding P, Ladenson JH, Wittwer CT. Advancing laboratory medicine through innovation: a tale of six inventors. **Clin Chem** 2012;58:502-510.

102. Leung F, *Diamandis EP*, Kulasingam V. From the bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. **Biomark Med** 2012;6:613-625.

103. Sardana G, *Diamandis EP*. Biomarkers for the diagnosis of new and recurrent prostate cancer. **Biomark Med** 2012;6:587-596.

104. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, *Diamandis EP*. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. **Mol Cancer Res** 2012;10:1403-1418.

2013

105. Pavlou M, *Diamandis EP*, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. **Clin Chem** 2013;59:147-157.

106. Chan A, *Diamandis EP*, Blasutig I. Strategies for discovering novel pancreatic cancer biomarkers. **J Proteomics** 2013;81:126-134.

107. Oikonomopoulou K, Brinc D, Kyriacou K, *Diamandis* EP. Infection and cancer: Revaluation of the hygiene hypothesis. **Clin Cancer Res** 2013;19:2834-2841.

108. Cretu D, *Diamandis EP*, Chandran V. Delineating the synovial fluid proteome: Recent advancements and ongoing challenges in biomarker research. **Crit Rev Clin Lab Sci** 2013;50:51-63.

109. Kuzmanov U, Kosanam H, *Diamandis EP*. The sweet and sour of serological glycoprotein tumor biomarker quantification. **BMC Med** 2013;11:31.

110. Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, Scorilas A, *Diamandis EP*, Dorn J. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (klk) in female and male reproductive organ malignancies. **Radiol Oncol** 2013;47:319-329

111. Dorn J, Bayani J, Yousef G, Yang f, Magdolen V, Kiechle M, *Diamandis EP*, Schmitt M. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. **Thromb Haemost** 2013;110:408-422.

112. Leung F, Musrap N, *Diamandis EP*, Kulasingam V. Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. **Transl Proteomics** 2013;1:74-86.

113. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, **Diamandis EP**, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-.monitoring trials: a proposal by the European Group on Tumor Markers. **Clin Chem** 2013;59:52-9

2014

114. Dorn J, Beaufort N, Schmitt M, *Diamandis EP*, Goettig P, Magdolen V. Function and clinical relevance of kallikrein-related peptidases and other serine proteinases in gynaecological cancers. **Crit Rev Clin Lab Sci** 2014;51:63-84

115. Chrystoja CC, *Diamandis EP*. Whole genome sequencing as a diagnostic test: Challenges and opportunities. **Clin Chem** 2014:60;724-33

116. Drabovich AP, Saraon P, Jarvi K, *Diamandis EP*. Seminal plasma as a diagnostic fluid for disorders of male reproductive system. **Nat Rev Urol** 2014:11;278-88

117. Sokratous K, Hadjisavvas A, *Diamandis EP*, Kyriacou K. The role of ubiquitin-binding domains in human pathophysiology. **Crit Rev Clin Lab Sci** 2014;51:280-90

118. Yu Y, Prassas I, Diamandis EP. Putative kallikrein substrates and their (patho) biological functio. **J Biol Chem**. 2014;395:931-43

119. Oikonomopoulou K, Brinc D, Hadjisavvas A, Christofi G, Kyriacou K, *Diamandis EP*. The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms. **Crit Rev Clin Lab Sci** 2014;51:138-48

120. Bauça JM, Martínez-Morillo E, *Diamandis EP*. Peptidomics of urine and other biofluids for cancer diagnostics. **Clin Chem**. 2014;60:1052-1061

121. Karagiannis GS, Treacy A, Messenger D, Grin A, Kirsch R, Riddell RH, *Diamandis EP*. Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts. **Mol Oncol** 2014;8:1240-1252

122. Leung F, *Diamandis EP*, Kulasingam V. Ovarian cancer biomarkers: Current state and future implications from high-throughput technologies. **Adv Clin Chem.** 2014;66:25-77

2015

123. Prassas I, Eissa A, Poda G,*Diamandis EP*. Unleashing the therapeutic potential of human kallikrein-related serine peptidases. **Nat Rev Drug Discov** 2015;14:183-202

124. Drabovich AP, Martinez-Morillo E, *Diamandis EP*. Toward an integrated pipeline for protein biomarker development. BBA - **Proteins and Proteomics** 2015;1854:677-686

125. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, *Diamandis EP*, Doria-Rose VP, Goddard KAB, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. **J Nat Cancer Inst** 2015;107

126. Cretu D, Liang K, Saraon P, Batruch I, Diamandis EP, Chandran V. Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. **Clin Proteomics**. 2015;12:1

2016

127. Li M, *Diamandis EP*. Technology-driven diagnostics: from smart doctor to smartphone. **Crit Rev Clin Lab Sci**. 2016;53:268-76.
128. Filippou PS, Karagiannis GS, Musrap N, *Diamandis EP*. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. **Crit Rev Clin Lab Sci**. 2016;53:277-91.
129. *Diamandis EP*, Li M. The side effects of translational omics: overtesting, overdiagnosis and overtreatment. **Clin Chem Lab Med** 2016; 54:389-96.
130. Musrap N, *Diamandis EP*. Prostate-specific antigen as a marker of hyperandrogenism in women and its implications for anti-doping. **Clin Chem** 2016;62:1066-74.
131. Farkona S, Diamandis EP, Blasutig I. Cancer immunotherapy: the beginning of the end of cancer? **BMC Med** 2016;14:73
132. Muytjens CM, Vasiliou SK, Oikonomopoulou K, Prassas I, *Diamandis EP*. Putative functions of tissue kallikrein-related peptidases in vaginal fluid. **Nat Rev Urol.** 2016;13:596-607.
133. Musrap N, *Diamandis EP*. Prostate-specific antigen as a marker of hyperandrogenism in women and its implications for antidoping. **Clin Chem.** 2016;62:1066-74

2017

134.

Original Research Papers

1977

1. Hadjiioannou TP, *Diamandis EP*. Analytical study of a new picrate-selective membrane electrode. **Anal Chim Acta** 1977;94:443-447

2. *Diamandis EP*, Hadjiioannou TP. Titrimetric determination of thiourea and silver with a picrate ion-selective electrode. **Mikroch Acta** (Wien) 1977;2:255-260.

3. *Diamandis EP*, Koupparis MA, Hadjiioannou TP. Kinetic potentiometric determination of creatinine in urine with a picrate ion-selective electrode. **Microchem J** 1977;22:498-504.

1980

4. *Diamandis EP*, Hadjiioannou TP. Titrimetric determination of iodide, hexacyanoferrate (II), thiourea, cationic surfactants and of picrate with a picrate ion-selective electrode. **Mikroch Acta** (Wien) 1980;II:27-38.

5. Papastathopoulos DS, *Diamandis EP*, Hadjiioannou TP. Flow-through electrode unit for liquid membrane electrodes. **Anal Chem** 1980;52:2100-104.

6. *Diamandis EP*, Efstathiou CE, Hadjiioannou TP. Automatic determination of ethylene glycol in anti-freeze solutions with a periodate sensitive flow-through electrode. **Analyst** 1980;105:1203-1207.

7. *Diamandis EP*, Hadjiioannou TP. Analytical study of new creatininium and tetramethylammonium cation-selective membrane electrodes. **Anal Lett** 1980;13(B15):1317-1332.

1981

8. *Diamandis EP*, Hadjiioannou TP. Catalytic determination of selenium with a picrate-selective electrode. **Anal Chim Acta** 1981;123:143-150.

9. *Diamandis EP*, Hadjiioannou TP. Potentiometric determination of some common alkaloids with a picrate-selective electrode. **Anal Chim Acta** 1981;123:341-345.

10. Efstathiou CE, *Diamandis EP*, Hadjiioannou TP. Potentiometric determination of nicotine in tobacco products with a nicotine-sensitive liquid membrane electrode. **Anal Chim Acta** 1981;127:173-180.

11. *Diamandis EP*, Athanasiou-Malaki E, Papastathopoulos DS, Hadjiioannou TP. Construction and analytical applications of liquid membrane electrodes for atropine and novatropine. **Anal Chim Acta** 1981;128:239-244.

12. *Diamandis EP*, Papastathopoulos DS, Hadjiioannou TP. Continuous-flow serum albumin determination by reaction with picrate ions, with use of a flow-through picrate ion electrode. **Clin Chem** 1981;27:427-430.

13. *Diamandis EP*, Hadjiioannou TP. Kinetic potentiometric determination of creatinine in serum with a picrate ion-selective membrane electrode. **Clin Chem** 1981;27:455-457.

1982

14. *Diamandis EP*, Hadjiioannou TP. Continuous-flow potentiometric determination of creatinine in urine with a picrate ion-selective electrode. **Microchem J** 1982;27:512-518.

15. Lazarou LA, *Diamandis EP*, Hadjiioannou TP. Spectrophotometric study of the iron(II)-induced perbromate-iodide reaction. Automatic reaction rate method for the ultramicrodetermination of iron. **Chimica Chronica**, New Series, 1982;11:3-10.

16. *Diamandis EP*, Hadjiioannou TP. Continuous-flow determination of reducing sugars and sucrose in natural and industrial products with periodate oxidation and a periodate-sensitive flow-through electrode. **Analyst** 1982;107:1471-1478.

17. Koupparis MA, *Diamandis EP*, Malmstadt HV. Total calcium and magnesium determined in serum with an automated stopped-flow analyzer. **Clin Chem** 1982;28:2149-2152.

18. Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Potentiometric titration of organic cations with sodium tetraphenylborate and a liquid membrane tetraphenylborate ion-selective electrode. **Anal Chim Acta** 1982;143:143-151.

1983

19. *Diamandis EP*, Hadjiioannou TP. Study of the stoichiometry and the kinetics of the Jaffe reaction with a picrate ion-selective electrode. **Microchem J** 1983;28:399-408.

20. *Diamandis EP*, Efstathiou CF, Papastathopoulos DS, Hadjiioannou TP. Continuous-flow determination of reducing sugars in serum by reaction with periodate ions, with use of a flow-through periodate-sensitive electrode. **Microchem J** 1983;28:227-234.

21. *Diamandis EP*, Koupparis MA, Hadjiioannou TP. Kinetic studies with ion-selective electrodes: Determination of creatinine in urine with a picrate ion selective electrode. A laboratory experiment. **J Chem Educ** 1983;60:74-76.

22. Koupparis MA, *Diamandis EP*, Malmstadt HV. Automated determination of crude protein, phosphorus, calcium, iron and magnesium in feeds by using stopped-flow analyzer. **J Assoc Off Anal Chem** 1983;66:188-196.

23. Siskos PA, *Diamandis EP*, Gillieron E, Colbert JC. Potentiometric titration of sulfate, sulphite and dithionate mixtures with use of a lead ion-selective electrode. **Talanta** 1983;30:980-982.

24. Papanastasiou-Diamandi A, Siskos PA, *Diamandis EP*. A direct kinetic fluorometric method for the enzymic determination of lactate in plasma. **Clin Chim Acta** 1983;129:359-364.

25. Papanastasiou-Diamandi A, *Diamandis EP*, Siskos PA. Direct enzymic fluorometric method for the determination of individual bile acids in bile. **Clin Chim Acta** 1983;134:17-23.

26. *Diamandis EP*, Christopoulos TK. Potentiometric titration of pharmaceutical compounds in formulations with sodium tetraphenylborate. **Anal Chim Acta** 1983;152:281-284.

1984

27. Papanastasiou-Diamandi A, *Diamandis EP*, Soldin SK. Enzymic measurement of primary bile acids and the primary bile acid ratio in serum with the IL-Multistat III fluorescence/light scattering centrifugal analyzer. **Clin Biochem** 1984;17:242-248.

28. Ellis G, *Diamandis EP*, Giesbrecht E, Allen L. An automated "high pressure" liquid chromatographic assay for hemoglobin A_{1C}. **Clin Chem** 1984;30:1746-1752.

29. Mitsana-Papazoglou A, *Diamandis EP*, Hadjiioannou TP. Construction and analytical applications of an improved liquid-membrane electrode for salicylate. **Anal Chim Acta** 1984;159:393-396.

1985

30. *Diamandis EP*, Papanastasiou-Diamandi A, Soldin SJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high performance liquid chromatography and inhibition of Na^+-K^+- ATPase. **Clin Biochem** 1985;18:48-55.

31. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Construction of ion-selective electrodes for chlorpromazine, amitriptyline, propantheline and meperidine. Analytical study and application to pharmaceutical analysis. **Analyst** 1985;110:1091-1094.

32. Koupparis MA, *Diamandis EP*, Malmstadt HV. Automated stopped-flow analyzer in clinical chemistry: Determination of albumin with bromcresol green and purple. **Clin Chim Acta** 1985;149:225-235.

33. Christopoulos TK, Mitsana-Papazoglou A, *Diamandis EP*. Ion-selective electrodes for the determination of ionization constants of sparingly soluble organic bases in aqueous solutions. Application to chlorpromazine and amitriptyline. **Analyst** 1985;110:1497-1500.

34. *Diamandis EP*, Papanastasiou-Diamandi A, Christopoulos TK, Hadjiioannou TP. Continuous-flow potentiometric determination of a-amylase activity in serum and urine. **Microchem J** 1985;32:183-190.

1986

35. Gritzapis PC, *Diamandis EP*, Hadjiioannou TP. Determination of the second ionization constant of 3,5-dinitrosalicylic acid (DNSH) and the instability constant of DNS-Fe^+ and titrimetric determination of thiourea with a 3,5-dinitrosalicylate-selective electrode. **Microchem J** 1986;33:62-70.

36. Sarantonis EG, *Diamandis EP*, Karayannis MI. Kinetic study of the reaction between trinitrobenzenesulfonic acid (TNBS) and aminoacids with a trinitrobenzenesulfonate ion-selective electrode. **Anal Biochem** 1986;155:129-134.

37. Christopoulos TK, *Diamandis EP*. A general method for the assay of binders. Application to the potentiometric determination of albumin in human serum, plasma and whole blood. **Clin Biochem** 1986;19:151-160.

1987

38. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Effect of incubation time and temperature on the interference of digoxin-like immunoreactive substances in digoxin immunoassays. **Ther Drug Monitor** 1987;9:461-463.

39. Christopoulos TK, *Diamandis EP*. New flow-through units for solid-state, liquid and PVC-matrix membrane ion-selective electrodes to minimize streaming potentials. **Analyst** 1987;112:1293-1298.

40. Mitsana-Papazoglou A, *Diamandis EP*, Hadjiioannou TP. Ion-selective electrodes for the H-receptor antagonists cimetidine and ranitidine. **J Pharm Sci** 1987;76:485-491.

41. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Koupparis MA. Dissolution studies of drug formulations using ion-selective electrodes as sensors in air-segmented continuous flow analyzer. **J Pharm Sci** 1987;76:724-730.

42. Khosravi MJ, *Diamandis EP*. Immunofluorometry of choriogonadotropin by time-resolved fluorescence spectroscopy, with a new europium chelate as label. **Clin Chem** 1987;33:1994-1999.

43. Chan MA, Bellem AC, *Diamandis EP*. Time-resolved immunofluorometric assay for alpha-fetoprotein in serum and amniotic fluid, with a novel detection system. **Clin Chem** 1987;33:2000-2003.

1988

44. Christopoulos TK, *Diamandis EP*. Use of a sintered glass crucible for easy construction of liquid-membrane ion-selective electrodes. **J Chem Educ** 1988;65:648.

45. Reichstein E, Shami Y, Ramjeesingh M, *Diamandis EP*. Laser-excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4, 7 bis (chlorosulfophenyl)-1, 10 phenanthroline-1,9 dicarboxylic acid as label. **Anal Chem** 1988;60:1069-1074.

46. Evangelista RA, Pollak A, Allore B, Templeton EF, Morton RC, *Diamandis EP*. A new europium chelate for protein labelling and time-resolved fluorometric applications. **Clin Biochem** 1988;21:173-178.

47. *Diamandis EP*, Bhayana V, Conway K, Reichstein E, Papanastasiou-Diamandi A. Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label. **Clin Biochem** 1988;21:291-296.

48. *Diamandis EP*, D'Costa M. Selective determination of urinary free cortisol by liquid chromatography after solid-state extraction. **J Chromatogr Biomed Appl** 1988;426:25-32.

49. Khosravi MJ, Chan MA, Bellem AC, *Diamandis EP*. A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. **Clin Chim Acta** 1988;175:267-276.

50. *Diamandis EP*, Morton RC. Time-resolved fluorescence using a europium chelate of 4, 7-bis (chlorosulfophenyl)-1, 10 phenanthroline-2, 9-dicarboxylic acid (BCPDA). Labelling procedures and applications in immunoassays. **J Immunol Methods** 1988;112:43-52.

51. Khosravi MJ, Morton RC, *Diamandis EP*. Sensitive, rapid procedure for time-resolved immunofluorometry of lutropin. **Clin Chem** 1988;34:1640-1644.

1989

52. Reichstein E, Morton R, *Diamandis EP*. Sensitive time-resolved immunofluorometric assay of thyrotropin in serum. **Clin Biochem** 1989;22:23-29.

53. *Diamandis EP*, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. **Anal Chem** 1989;61:48-53.

54. Papanastasiou-Diamandi A, Bhayana V, *Diamandis EP*. A simple time-resolved fluoroimmunoassay of total thyroxine in serum. **Ann Clin Biochem** 1989;26:238-243.

55. Tan YK, Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometric assay of thyroxine-binding globulin in serum. **J Immunoassay** 1989;10:413-428.

56. Christopoulos TK, *Diamandis EP*. Potentiometric measurements in air-segmented streams without debubbling. **Anal Chem** 1989;61:504-508.

57. Papanastasiou-Diamandi A, Conway K, *Diamandis EP*. Digoxin immunoassay with monoclonal and polyclonal antibodies using time-resolved fluorometry. **J Pharm Sci** 1989;78:617-621.

58. Kahan I, Papanastasiou-Diamandi A, D'Costa M, *Diamandis EP*. Measurement of serum prolactin by a simple and rapid time-resolved immunofluorometric assay. **Clin Chem Enzym Comms** 1989;1:293-303.

59. Bhayana V, *Diamandis EP*. A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. **Clin Biochem** 1989;22:433-438.

60. *Diamandis EP*, Papanastasiou-Diamandi A, Lustig V, Khosravi MJ, Tan A. Time-resolved immunofluorometric assay of human pancreatic isoamylase in serum, with use of two monoclonal antibodies. **Clin Chem** 1989;35:1915-1920.

61. Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometry of follitropin in serum. A new and highly sensitive procedure. **Clin Chem** 1989;35:181.

62. Diamandis EP. A time-resolved fluorescence immunoassay system especially suitable for research applications. **Clin Chem** 1989;35:491.

1990

63. Papanastasiou-Diamandi A, Christopoulos TK, *Diamandis EP*. Effect of solid-phase blocking on the background signal in a time-resolved fluorescence immunoassay system based on labelled streptavidin. **Clin Chem Enzym Comms** 1990;2:177-181.

64. Kahan I, Papanastasiou-Diamandi A, Ellis G, Makela S, McLaurin J, D'Costa M, *Diamandis EP*. Sensitive time-resolved fluorescence immunoassay of somatotropin in serum. **Clin Chem** 1990;36:503-508.

65. Loucari-Yiannakou E, Yiannakou L, Souvatzoglou A, *Diamandis EP*. Radioimmunoassay of digoxin in serum using monoclonal antibodies and assessment of interference by digoxin-like immunoreactive substances (DLIS). **Ther Drug Monitor** 1990;12:195-200.

66. *Diamandis EP*, Ogilvie RR. Ultrasensitive time-resolved immuno- fluorometry of human albumin in urine using monoclonal antibodies - A new assay for microalbuminuria. **Ann Clin Biochem** 1990;27:232-237.

67. Shankaran P, Reichstein E, Khosravi MJ, *Diamandis EP*. Detection of IgG and IgM antibody to rubella virus by time-resolved immunofluorometry. **J Clin Microbiol** 1990;28:573-579.

68. Christopoulos TK, *Diamandis EP*. Binding studies using ion-selective electrodes - Examination of the picrate-albumin interaction as a model system. **Anal Chem** 1990;62:360-367.

69. Morton RC, *Diamandis EP*. Streptavidin-based macromolecular complex labelled with a europium chelator suitable for time-resolved fluorescence immunoassay applications. **Anal Chem** 1990;62:1841-1845.

70. Christopoulos TK, Lianidou ES, *Diamandis EP*. Ultrasensitive time- resolved fluorescence method for α-fetoprotein. **Clin Chem** 1990;36:1497-1502.

71. Lianidou ES, Christopoulos TL, *Diamandis EP*. Assay of creatine kinase isoenzyme MB in serum with time-resolved immunofluorometry. **Clin Chem** 1990;36:1679-1683.

1991

72. Christopoulos TK, *Diamandis EP*. Ultrasensitive determination of europium using microsecond time-resolved fluorometry. **Analyst** 1991;116:627-630.

73. *Diamandis EP*, Christopoulos TK. Time-resolved immunofluorometric detection of antigens separated by high performance liquid chromatography and coated to polystyrene. **Biotechniques** 1991;10:646-648.

74. Christopoulos TK, *Diamandis EP*, Wilson G. Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. **Nucleic Acids Res** 1991;19:6015-6019.

1992

75. Kakabakos SE, Christopoulos TK, *Diamandis EP*. Multianalyte immunoassay based on spatially distinct fluorescent areas quantified by laser-excited solid-phase time-resolved fluorometry. **Clin Chem** 1992;38:338-342.

76. *Diamandis EP*, Christopoulos TK, Bean CC. Quantitative Western blot analysis and spot immunodetection using time-resolved fluorometry. **J Immunol Methods** 1992;147:251-259.

77. Christopoulos TK, *Diamandis EP*. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. **Anal Chem** 1992;64:342-346.

78. Papanastasiou-Diamandi A, Christopoulos TK, *Diamandis EP*. Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluorescence with a terbium chelate. **Clin Chem** 1992;38:545-548.

79. *Diamandis EP*, Grass L, Uldall R, Mendelssohn D, Maini D. An enzymatic method for measuring serum mannitol and its use in hemodialysis patients. **Clin Biochem** 1992;25:457-462.

80. *Diamandis EP*. Europium and terbium chelators as candidate substrates for enzyme-labeled time-resolved fluorometric immunoassays**. Analyst** 1992;117:1879-1884.

81. Hassapoglidou S, *Diamandis EP*. Antibodies to the p53 tumour suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique.
Clin Biochem 1992;25:445-449.

1993

82. Chan AW, *Diamandis EP*, Krajden M. Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. **Anal Chem** 1993;65:158-163.

83. *Diamandis EP*, Hassapoglidou S, Bean CC. Evaluation of non-isotopic labeling and detection techniques for nucleic acid hybridization. **J Clin Lab Analysis** 1993;7:174-179.

84. Hassapoglidou S, *Diamandis EP*, Sutherland DJA. Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. **Oncogene** 1993;8:1501-1509.

85. Yu H, *Diamandis EP*. Ultrasensitive time-resolved immunofluorometric assay of prostate specific antigen in serum and preliminary clinical studies. **Clin Chem** 1993;39:2108-2114.

86. Angelopoulou K, *Diamandis EP*. Autoantibodies against the p53 tumour suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry. **Cancer J** 1993;6:315-321.

1994

87. Levesque MA, *Diamandis EP*, Yu H, Sutherland DJA. Quantitative analysis of mutant p53 protein in breast tumour cytosols and study of its association with other biochemical prognostic indicators in breast cancer. **Breast Cancer Res Treat** 1994;30:179-195.

88. Angelopoulou K, *Diamandis EP*, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumour suppressor gene protein in various cancers. **Int J Cancer** 1994;58:480-487.

89. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, *Diamandis EP*. Immunological quantification of advanced glycosylation end products in the serum of patients on hemodialysis or continuous ambulatory peritoneal dialysis. **Kidney Int** 1994;46:216-222.

90. Wang T, *Diamandis EP*, Lane A, Baines AD. Variable selectivity of the Hitachi chemistry analyzer chloride ion-selective electrode toward interfering ions. **Clin Biochem** 1994;27:37-41.

91. Yu H, *Diamandis EP*, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumours and its association with steroid hormone receptors and patient age. **Clin Biochem** 1994;27:75-79.

92. Yu H, *Diamandis EP*, Levesque MA, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumour metastatic to the ovary. **J Clin Lab Analysis** 1994;8:251-253.

93. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Soleas G, Waterhouse AL. Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. **Anal Chem** 1994;66:3959-3963.

94. Monne M, Croce CM, Yu H, *Diamandis EP*. Molecular characterization of prostate specific antigen mRNA expressed in breast Tumours. **Cancer Res** 1994;54:6344-6347.

95. Yu H, *Diamandis EP*, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. **Breast Cancer Res Treat** 1994;32:291-300.

96. *Diamandis EP*, Yu H, Sutherland DJA. Detection of prostate specific antigen immunoreactivity in breast tumours. **Breast Cancer Res Treat** 1994;32:301-310.

97. Marriott G, Heidecker M, *Diamandis EP*, Marriott YY. Time-resolved delayed luminescence image microscopy using an europium ion chelate complex. **Biophys J** 1994;67:957-965.

1995

98. Yu H, *Diamandis EP*. Prostate specific antigen in milk of lactating women. **Clin Chem** 1995;41:54-58.

99. Levesque M, Yu H, D'Costa M, *Diamandis EP*. Prostate specific antigen expression by various tumours. **J Clin Lab Analysis** 1995;9:123-128.

100. Yu H, *Diamandis EP*. Prostate specific antigen immunoreactivity in amniotic fluid. **Clin Chem** 1995;41:204-210.

101. Yu H, *Diamandis EP*. Measurement of serum prostate specific antigen levels in females and in prostatectomized males with an ultrasensitive immunoassay technique. **J Urol** 1995;153:1004-1008.

102. Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, *Diamandis EP*. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. **Cancer** 1995;75:1327-1338.

103. Yu H, *Diamandis EP*, Monne M, Croce CM. Oral contraceptive-induced expression of prostate specific antigen in the female breast. **J Biol Chem** 1995;270:6615-6618.

104. Soleas GJ, Goldberg DM, *Diamandis EP*, Karumanchiri A, Yan J, Ng E. A derivatized gas chromatographic-mass spectrometric method for the analysis of both isomers of resveratrol in juice and wine. **Am J Enol Vitic** 1995;46:346-352.

105. Yu H, *Diamandis EP*, Prestigiacomo AF. Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumour doubling time after radical prostatectomy. **Clin Chem** 1995;41:430-434.

106. Zarghami N, Yu H, *Diamandis EP*, Sutherland DJA. Quantification of creatine kinase BB isoenzyme in tumour cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. **Clin Biochem** 1995;28:243-253.

107. Yu H, Giai M, *Diamandis EP*, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. **Cancer Res** 1995;55:2104-2110.

108. Pace-Asciak CR, Hahn SE, *Diamandis EP*, Soleas G, Goldberg DM. The red wine phenolics *trans*-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. **Clin Chim Acta** 1995;235:207-219.

109. Yu H, *Diamandis EP*, Levesque M, Asa S, Monne M, Croce CM. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. **Cancer Res** 1995;55:1603-1606.

110. Goldberg DM, Karumanchiri A, Ng E, Yan J, *Diamandis EP*, Soleas GJ. Direct gas chromatographic-mass spectrometric method to assay-cis-resveratrol in wines: Preliminary survey of its concentration in commercial wines. **J Agric Food Chem** 1995;43:1245-1250.

111. Levesque MA, Clark GM, Yu H, *Diamandis EP*. Immunofluorometric analysis of p53 protein and prostate specific antigen in breast tumours and their association with other prognostic indicators. **Br J Cancer** 1995;72:720-727.

112. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, *Diamandis EP*. Prostate specific antigen in serum of women with breast cancer. **Br J Cancer** 1995;72:728-731.

113. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Soleas G, Waterhouse A. A global survey of *trans*-resveratrol concentrations in commercial wines. **Am J Enol Vitic** 1995;46:159-165.

114. Soleas GJ, Goldberg DM, Karumanchiri A, *Diamandis EP*, Ng E. Influences of viticultural and oenological factors on changes in *cis*- and *trans*-resveratrol in commercial wines. **J Wine Res** 1995;6:107-121.

115. Levesque M, Yu H, D'Costa M, Tadross L, *Diamandis EP*. Immunoreactive prostate specific antigen in lung tumours. **J Clin Lab Anal** 1995;9:375-379.

116. Levesque MA, D'Costa M, Tadross L, *Diamandis EP*. Time-resolved immunofluorometric assay of p53 protein. **Clin Chem** 1995;41:1720-1729.

117. Galvan B, Christopoulos TK, *Diamandis EP*. Detection of prostate specific antigen mRNA by reverse-transcription polymerase chain reaction and time-resolved fluorometry. **Clin Chem** 1995;41:1705-1709.

118. Zarghami N, Katsaros D, Yu H, *Diamandis EP*. Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma. **Can J Oncol** 1995;5:401-407.

119. Goldberg DM, Ng E, Karumanchiri A, Yan J, *Diamandis EP*, Soleas GJ. Assay of resveratrol glucosides and isomers in wine by direct-injection high-performance liquid chromatography. **J Chromatography A** 1995;708:89-98.

1996

120. Zarghami N, Giai M, Yu H, Katsaros D, *Diamandis EP*. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. **Br J Cancer** 1996;73:386-390.

121. Zarghami N, *Diamandis EP*. Detection of prostate specific antigen mRNA and protein in breast tumours. **Clin Chem** 1996;42:361-366.

122. Randell E, *Diamandis EP*, Ellis G. Serum prostate specific antigen measured in children from birth to age 18 years. **Clin Chem** 1996;42:420-423.

123. *Diamandis EP*, Yu H, Lopez-Otin C. Prostate specific antigen – a new constituent of breast cyst fluid. **Breast Cancer Res Treat** 1996;38:259-264.

124. Ferguson RA, Yu H, Kalyvas M, Zammit S, *Diamandis EP*. Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. **Clin Chem** 1996;42:675-684.

125. Hoffman BR, Yu H, *Diamandis EP*. Assay of prostate specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. **Clin Chem** 1996;42:536-544.

126. Melegos D, *Diamandis EP*. Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. **Clin Biochem** 1996;29:193-200.

127. Goldberg DM, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR. Wine: does the colour count? **Clin Chim Acta** 1996;246:183-193.

128. Melegos DN, Yu H, *Diamandis EP*. Prostaglandin D_2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. **Clin Chem** 1996;42:1042-1050.

129. Pace-Asciak CR, Rounova O, Hahn SE, *Diamandis EP*, Goldberg DM. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. **Clin Chim Acta** 1996;246:163-182

130. Goldberg DM, Ng E, Yan J, Karumanchiri A, Soleas GJ, *Diamandis EP*. Regional differences in resveratrol isomer concentrations of wines from various cultivars. **J Wine Res** 1996;7:13-24.

131. Goldberg DM, Tsand E, Karumanchiri A, *Diamandis EP*, Soleas G, Ng E. Method to assay the concentrations of phenolic constituents of biological interest in wines**. Anal Chem** 1996;68:1688-1694.

132. James GK, Pudek M, Berean DW, *Diamandis EP*, Archibald BL. Salivary duct carcinoma secreting prostate specific antigen. **Am J Clin Pathol** 1996;106:242-247.

133. Yu H, *Diamandis EP*, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue**. Breast Cancer Res Treat** 1996;40:171-178.

134. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. **Br J Cancer** 1996;74:1242-1247.

135. Levesque MA, D'Costa M, *Diamandis EP*. P53 protein is absent from the serum of patients with lung cancer. **Br J Cancer** 1996;74:1434-1440.

136. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, *Diamandis EP*. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathological features and survival**. Cancer** 1996;78:2146-2152.

137. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. **Clin Biochem** 1996;29:555-562.

138. Melegos DN, *Diamandis EP*, Oda H, Urade Y, Hayaishi O. Immunofluorometric assay of prostaglandin D synthase in human tissue extracts and fluids. **Clin Chem** 1996;42:1984-1991.

139. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein ER, *Diamandis EP*, Yemoto C, Stamey TA. The periurethral glands do not significantly influence the serum prostate specific antigen concentration. **J Urol** 1996;155:1658-1660.

140. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H, *Diamandis EP*. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. **Cancer Epidemiol Biomarkers Prevent** 1996;5:967-970.

141. Goldberg DM, NG E, Karumanchiri A, *Diamandis EP*, Soleas GJ. Resveratrol glucosides are important components of commercial wines. **Am J Enol Vitic** 1996;47:415-520.

1997

142. Angelopoulou K, Stratis M, *Diamandis EP*. Humoral immune response against p53 protein in patients with colorectal carcinoma. **Int J Cancer** 1997;70:46-51.

143. Zarghami N, Grass L, *Diamandis EP*. Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. **Br J Cancer** 1997;75:579-588.

144. Angelopoulou K, *Diamandis EP*. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. **Eur J Cancer** 1997;33:115-121.

145. Yu H, *Diamandis EP*, Wong P-Y, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels between 0.001-01 ug/L. **J Urol** 1997;157:913-918.

146. Melegos D, Yu H, Ashok M, Wang C, Stanczyk F, *Diamandis EP*. Prostate specific antigen in female serum, a potential new marker of androgen excess. **J Clin Endocrinol Metab** 1997;82:777-780.

147. Levesque MA, Tadross L, *Diamandis EP*, D'Costa M. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. **Am J Clin Pathol** 1997;107:308-316.

148. Howarth DJC, Aronson IB, *Diamandis EP*. Immonohistochemical localization of prostate specific antigen in benign and malignant breast tissues. **Br J Cancer** 1997;75:1646-1651.

149. Soleas GJ, Goldberg DM, Ng E, Karumanchiri A, Tsang E, *Diamandis EP*. Comparative evaluation of four methods for assay of cis-and trans-resveratrol. **Am J Enol Vitic** 1997;48:169-176.

150. Zarghami N, Levesque M, D'Costa M, Angelopoulou K, *Diamandis EP*. Frequency of expression of prostate specific antigen mRNA in lung tumours. **Am J Clin Pathol** 1997;108:184-190.

151. Tsuyuki D, Grass L, *Diamandis EP*. Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. **Eur J Cancer** 1997;33:1851-1853.

152. Zarghami N, D'Costa M, Tsuyuki D, Asa SL, *Diamandis EP*. Expression of the prostate specific antigen gene by lung tissue. **Clin Cancer Res** 1997;3:1201-1206.

153. Melegos DN, Freedman MS, *Diamandis EP*. Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. **Prostaglandins** 1997;54:463-474.

154. *Diamandis EP*, Nadkarni S, Bhaumik B, Abdelrahman A. Melegos DN, Borchert G, Black M, Alonso M, Salas A, de los Toyos JR, Sampedro A, Lopez-Otin C. Immunofluorometric assay of pepsinogen C and preliminary clinical applications. **Clin Chem** 1997;43:1365-1371.

155. Zarghami N, Grass L, Sauter ER, *Diamandis EP*. Prostate specific antigen levels in serum during the menstrual cycle. **Clin Chem** 1997;43:1862-1867.

156. Lianidou ES, Melegos DN, *Diamandis EP*. BRCA1 Tumour suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. **Clin Biochem** 1997;30:425-432.

157. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Molecular forms of prostate specific antigen in the serum of women with benign and malignant breast diseases. **Br J Cancer** 1997;76:1087-1094.

158. Soleas GJ, Tomlinson G, *Diamandis EP*, Goldberg DM. Relative contributions of polyphenolic constituents to the antioxidant status of wines: development of a predictive model. **J Agric Food Chem** 1997;45:3995-4003.

159. Degenhardt TP, Grass L, Reddy S, Thorpe SR, *Diamandis EP*, Baynes JW. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia**. Kidney Int** 1997;52:1064-1067.

160. Soleas GJ, *Diamandis EP*, Karumanchiri A, Goldberg DM. A multiresidue derivatization gas chromatographic assay for fifteen phenolic constituents with mass selective detection. **Anal Chem** 1997;69:4405-4409.

1998

161. Angelopoulou K, Levesque MA, Katsaros D, *Diamandis EP*. Exon 5 of the p53 gene is a target for deletions in ovarian cancer. **Clin Chem** 1998;44:72-77.

162. Levesque MA, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, *Diamandis EP*. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. **Int J Cancer** 1998;79:147-152.

163. Griniatsos J, *Diamandis EP*, Gioti J, Karyda I, Vassilopoulos PP, Agnanti N. Correlation of prostate specific antigen immunoreactivity (IR-PSA) to other prognostic factors in female breast cancer. **Anticancer Res** 1998;18:683-688.

164. Lambert-Messerlian GM, Canick JA, Melegos DN, *Diamandis EP*. Increased concentrations of prostate specific antigen in maternal serum from pregnancies affected by fetal Down Syndrome. **Clin Chem** 1998;44:205-208.

165. Randell E, *Diamandis EP*, Goldberg DM. Changes in serum carbohydrate-deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males. **J Clin Lab Anal** 1998;12:92-97.

166. Sauter ER, Babb J, Daly M, Engstrom PF, Ehya H, Malik J, *Diamandis EP*. Prostate-specific antigen production in the female breast: Association with progesterone. **Cancer Epidermiol Biomarkers Prevent** 1998;7:315-320.

167. Kogan I, Ballinger J, Redshaw R, *Diamandis EP*, Melegos DN,Kuba R, Rauth AM. Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice**. Breast Cancer Res Treat** 1998;48:73-80.

168. Luo L, Herbrick J-A, Scherer SW, Beatty B, Squire J, *Diamandis EP*. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. **Biochem Biophys Res Commun** 1998;247:580-586.

169. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Prognostic value of prostate-specific antigen for women with breast cancer: A large U.S. cohort study. **Clin Cancer Res** 1998;4:1489-1497.

170. Katsaros D, Melegos DN, *Diamandis EP*. Prostate specific antigen production by breast tumours after induction with oral contraceptives. **Clin Biochem** 1998;31:285-288.

171. Angelopoulou K, *Diamandis EP*. Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian tumours**. J Clin Lab Anal** 1998;12:250-256.

172. Bharaj BS, Angelopoulou K, *Diamandis EP*. Rapid sequencing of the p53 gene with a new automated DNA sequencer. **Clin Chem** 1998;44:1397-1403.

173. Levesque MA, Yu H, Clark GM, *Diamandis EP*. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. **J Clin Oncol** 1998;16:2641-2650.

174. Levesque MA, D'Costa M, Spratt EH, Yaman MM, *Diamandis EP*. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. **Int J Cancer** 1998;79:494-501.

175. Rosenberg RS, Grass L, Jenkins DJA, Kendall CWC, *Diamandis EP*. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. **Biochem Biophys Res Commun** 1998;248:935-939.

176. Lianidou ES, Angelopoulou A, Katsaros D, Durando A, Massobrio M, *Diamandis EP*. Fragment analysis of the p53 gene in ovarian tumours. **Clin Biochem** 1998;31:551-553.

177. Angelopoulou K, Prody C, *Diamandis EP*. A candidate new gene on human chromosome 5q12 contains a motif that is found in transcriptional co-activators. **Clin Biochem** 1998;31:687-688.

178. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Insulin-like growth factor-binding protein-3 and breast cancer survival. **Int J Cancer** 1998;79:624-628.

179. Rao PN, Wang Z, Cessac JW, Rosenberg RS, Jenkins DJA, *Diamandis EP*. New 11β-aryl substituted steroids exhibit both progestational and antiprogestational activity. **Steroids** 1998;63:523-530.

1999

180. Melegos DN, Grass L, Pierratos A, *Diamandis EP*. Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. **Urology** 1999;53:32-37.

181. Foekens JA, *Diamandis EP*, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. **Br J Cancer** 1999;79:888-894.

182. Borchert GH, Yu H, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. **J Clin Lab Anal** 1999;13:75-81.

183. *Diamandis EP*, Helle SJ, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. **Cancer** 1999;85:891-898.

184. Luo L, *Diamandis EP*. Amplification of human genomic DNA sequences with polymerase chain reaction using a single oligonucleotide primer. **J Clin Lab Anal** 1999;13:69-74.

185. Majumdar S, *Diamandis EP*. The promoter and the enhancer region of the KLK3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. **Br J Cancer** 1999;79:1594-1602.

186. Borchert GH, Melegos DN, Yu H, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. **Clin Biochem** 1999;32:39-44.

187. *Diamandis EP*, Arnett WP, Foussias G, Pappas H, Ghandi S, Melegos DN, Mullen B, Yu H, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. **Urology** 1999;53:596-603.

188. Jenkins DJA, Kendall CWC, Vidgen E, Agarwal S, Rao AV, Rosenberg RS, *Diamandis EP*, Novokmet R, Mehling CC, Perera T, Griffin LC, Thompson LU, Cunnane SC. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures and *ex vivo* androgen and progestin activity: a controlled crossover trial. **Am J Clin Nutr** 1999;69:395-402.

189. Black MH, Grass L, Leinonen J, Stenman U-H, *Diamandis EP*. Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. **Clin Chem** 1999;45:347-354.

190. Lianidou ES, Levesque MA, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, *Diamandis EP*. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. **Anticancer Res** 1999;19:749-756.

191. Scorilas A, *Diamandis EP*, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumour cytosols: an independent favorable prognostic factor in node-positive patients. **Clin Cancer Res** 1999;5:1778-1785.

192. Black MH, Magklara A, Obiezu CV, Melegos DN, *Diamandis EP*. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. **Clin Chem** 1999;45:790-799.

193. Wald NJ, Hackshaw AK, *Diamandis EP*, Melegos DN. Maternal serum prostate-specific antigen and Down Syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Group. **Prenat Diagn** 1999;19:674-676.

194. Yousef GM, Luo L-Y, *Diamandis EP*. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. **Anticancer Res** 1999;19:2843-2852.

195. Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, *Diamandis EP*. Characterization of the BRCA1-like immunoreactivity of human seminal plasma. **Urology** 1999; 54:753-762.

196. Bharaj BS, Vassilikos EJ, *Diamandis EP*. Rapid and accurate determination of $(CAG)_n$ repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. **Clin Biochem** 1999;32:327-332 .

197. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination **Br J Cancer** 1999; 81:490-495.

198. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2**. J Clin Lab Anal** 1999; 13:241-245.

199. Magklara A, Scorilas A, López-Otin C, Vizoso F, Ruibal A, *Diamandis EP*. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. **Clin Chem** 1999; 45:1774-1780.

200. Yousef GM, Obiezu CV, Luo LY, Black MH, *Diamandis EP*. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. **Cancer Res** 1999;59:4252-4256.

201. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. **Clin Chem** 1999;45:1960-1966.

202. Yousef GM, *Diamandis EP*. The new kallikrein-like gene KLK-L2: Molecular characterization, mapping, tissue expression and hormonal regulation. **J Biol Chem** 1999;274:37511-37516.

203. Yousef GM, Luo L-Y, Scherer SW, Sotiropoulou G, *Diamandis EP*. Molecular characterization of zyme/proteaseM/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. **Genomics** 1999;62: 251-259.

204. Sauter ER, Ehya H, Babb J, *Diamandis EP*, Daly M, Klein-Szanto A, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Biologic markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. **Br J Cancer** 1999;81:1222-1227.

2000

205. Black MH, Giai M, Ponzone R, Sismondi P, Yu H, *Diamandis EP*. Serum total and free prostate specific-antigen for breast cancer diagnosis in women. **Clin Cancer Res** 2000;6:467-473.

206. Levesque MA, D'Costa M, *Diamandis EP*. p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness. **J Cancer Res Clin Oncol** 2000;126:48-52.

207. Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, *Diamandis EP*. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. **Br J Cancer** 2000;82:361-367.

208. Angelopoulou K, Yu H, Bharaj B, Giai M, *Diamandis EP*. p53 gene mutation, tumour p53 protein overexpression and serum p53 autoantibody generation in patients with breast cancer. **Clin Biochem** 2000;33:53-62.

209. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, *Diamandis EP*. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. **J Urol** 2000;163:802-805.

210. Scorilas A, Yu H, Soosaipillai AR, Gregorakis AK, *Diamandis EP*. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. **Clin Chim Acta** 2000;292:127-138.

211. Yousef GM, *Diamandis EP*. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). **Genomics** 2000;65:184-194.

212. Jenkins DJA, Kendall CWC, Garsetti M, Rosenberg-Zand RS, Jackson C-J, Agarwal S, Rao AV, *Diamandis EP*, Parker T, Faulkner D, Vuksan V, Vidgen E. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity -- a controlled crossover trial. **Metabolism** 2000;49:537-543.

213. Yu H, Bharaj B, Vassilikos EJK, Giai M, *Diamandis EP*. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. **Breast Cancer Res Treat** 2000;59:153-161.

214. Nam RK, *Diamandis EP*, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papanastasiou P, Jewett MAS, Narod SA. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. **J Clin Oncol** 2000;18:1036-1042.

215. Yousef GM, Scorilas A, *Diamandis EP*. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. **Genomics** 2000;63:88-96.

216. Yousef GM, Chang A, *Diamandis EP*. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. **J Biol Chem** 2000;275:11891-11898.

217. Luo LY, Grass L, *Diamandis EP*. The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. **Anticancer Res** 2000;20:981-986.

218. Bharaj B, Scorilas A, Giai M, *Diamandis EP*. TA repeat polymorphism of the 5alpha-reductase gene in breast cancer. **Cancer Epidemiol Biomarkers Prevent** 2000;9:387-393.

219. Rosenberg Zand RS, Grass L. Magklara A, Jenkins DJA, *Diamandis EP*. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? **Breast Cancer Res Treat** 2000;60:1-8.

220. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJG, Yu H, Howarth DJC, *Diamandis EP*. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. **Clin Chem** 2000;46:859-862.

221. Magklara A, Grass L, *Diamandis EP*. Differential steroid hormone regulation of human glandular kallikerin (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. **Breast Cancer Res Treat** 2000;59:263-270.

222. Obiezu CV, Yousef G, *Diamandis EP*. Identification of exon 1 of prostase/KLK-L1 gene. **Clin Biochem** 2000:33:221-222.

223. Vassilikos EJK, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, *Diamandis EP*. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. **Clin Biochem** 2000;33:115-123.

224. Scorilas A, *Diamandis EP*. Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. **Clin Biochem** 2000; 33:345-350.

225. Bharaj B, Scorilas A, *Diamandis EP*, Giai M, Levesque MA, Sutherland DJ, Hoffman BR. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. **Breast Cancer Res Treat** 2000;61:111-119.

226. Zand RS, Jenkins DJ, *Diamandis EP*. Steroid hormone activity of flavonoids and related compounds. **Breast Cancer Res Treat** 2000;62:35-49.

227. Foussias G, Yousef GM, *Diamandis EP*. Identification and molecular characterization of a novel member of the Siglec family (SIGLEC-9). **Genomics** 2000;67:171-178.

228. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, *Diamandis EP*. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. **Urology** 2000;56:527-532.

229. Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, *Diamandis EP*. Evidence for a dose-response effect between p53 (but not $p21^{WAF1/Cipl}$) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. **Clin Cancer Res** 2000;6:3260-3270.

230. Magklara A, Cheung CC, Asa SL, *Diamandis EP*. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. **Clin Chim Acta** 2000;300:171-180.

231. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, *Diamandis EP*. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family — genomic characterization, mapping, tissue expression and hormonal regulation. **Gene** 2000;254:119-128.

232. *Diamandis EP*, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. **Clin Biochem** 2000;33:369-375.

233. Yousef GM, Chang A, Scorilas A, *Diamandis EP*. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. **Biochem Biophys Res Commun** 2000;276:125-133.

234. Scorilas A, Bjartell A, Lilja H, Moller C, *Diamandis EP*. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry and microarrays. **Clin Chem** 2000;46:1450-1455.

235. Yousef GM, Magklara A, *Diamandis EP*. KLK12 is a novel serine protease and a new member of the human kallikrein gene family — differential expression in breast cancer. **Genomics** 2000;69:331-341.

236. *Diamandis EP*, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H. New nomenclature for the human tissue kallikrein gene family. **Clin Chem** 2000;46:1855-1858.

237. *Diamandis EP*, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. **Clin Biochem** 2000;33:579-583.

238. Luo L-Y, *Diamandis EP*. Preliminary examination of time-resolved fluorometry for protein array applications. **Luminescence** 2000;15:409-413.

239. Foussias G, Yousef GM, *Diamandis EP*. Molecular characterization of SIGLEC8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the SIGLEC8 gene. **Biochem Biophys Res Commun** 2000;278:775-781.

240. Scorilas A, Black MH, Talieri M, *Diamandis EP*. Genomic organization, physical mapping and expression analysis of the human protein arginine methyltransferase 1 gene. **Biochem Biophys Res Commun** 2000;278:349-359.

241. *Diamandis EP*, Yousef GM, Petraki C, Soosaipillai AR. Human kallikrein 6 as a biomarker of Alzheimer's disease. **Clin Biochem** 2000; 33:663-667.

242. Obiezu CV, *Diamandis EP*. An alternatively spliced variant of KLK4 expressed in prostatic tissue. **Clin Biochem** 2000; 33:599-600.

243. Comay D, Cauch-Dudek K, Hemphill D, *Diamandis E*, Wanless I, Heathcote EJ. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? **Digestive Dis Sci** 2000;45:2018-2021.

2001

244. Yousef GM, Scorilas A, Jung K, Ahsworth LK, *Diamandis EP*. Molecular cloning of the human kallikrein 15 gene (KLK15): Up-regulation in prostate cancer. **J Biol Chem** 2001;276:53-61.

245. Luo LY, Soosaipillai A, *Diamandis EP*. Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library. **Biochem Biophys Res Commun** 2001; 280:401-406.

246. Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi MJ, Diamandi A, Gordini G, *Diamandis EP*, Moassobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. **Eur J Cancer** 2001;37:478-485.

247. Scorilas A, Bharaj B, Giai M, *Diamandis EP*. Codon 89 ploymorphism in the human 5 alpha-reductase gene in primary breast cancer. **Br J Cancer** 2001;84:760-767.

248. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, *Diamandis EP*. Levels of insulin-like growth factor-I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. **Urology** 2001;57:471-475.

249. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. **Br J Cancer** 2001;84:643-650.

250. Luo LY, Grass L, Howarth DJC, Thibault P, Ong H, *Diamandis EP*. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. **Clin Chem** 2001; 47:237-246.

251. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, *Diamandis EP*. Molecular cloning, physical mapping and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved bh2 domain of the bcl-2 family. **Genomics** 2001;72:217-222.

252. Luo L-Y, Bunting P, Scorilas A, *Diamandis EP*. Human kallikrein 10: a novel tumour marker for ovarian carcinoma? **Clin Chim Acta** 2001;306:111-118.

253. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, *Diamandis EP*. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. **Clin Cancer Res** 2001;7:806-811.

254. Yousef GM, Magklara A, Chang A, Jung K, *Diamandis EP*. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. **Cancer Res** 2001;61:3425-3431.

255. Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, *Diamandis EP*. Prostate specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. **J Clin Endocrinol Metab** 2001;86:1558-1561.

256. Foussias G, Taylor SM, Yousef GM, Tropak MB, Ordon MH, *Diamandis EP*. Cloning and molecular characterization of two splice variants of a new putative member of the Siglec-3-like subgroup of Siglecs. **Biochem Biophys Res Commun** 2001;284:887-899.

257. Yousef GM, Ordon MG, Foussias G, *Diamandis EP*. Molecular characterization, tissue expression and mapping of a novel Siglec-like gene (SLG2) with three splice variants. **Biochem Biophys Res Comm** 2001;284:900-910.

258. Yousef GM, Diamandis M, Jung K, *Diamandis EP*. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. **Genomics** 2001;74:385-395.

259. Soleas GJ, Angelini M, Grass L, *Diamandis EP*, Goldberg DM. Absorption of *trans*-resveratrol in rats. **Methods Enzymol** 2001;335:145-154.

260. Scorilas A, Kyriakopoulou L, Katsaros D, *Diamandis EP*. Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. **Br J Cancer** 2001;85:190-198.

261. Luo L-Y, Rajpert-De Meyts E, Jung K, *Diamandis EP*. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. **Br J Cancer** 2001;85:220-224.

262. Scorilas A, Yousef GM, Jung K, Rajpert-de Meyts E, Carsten S, *Diamandis EP*. Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumours. **Biochem Biophys Res Comm** 2001;285:400-408.

263. Yousef GM, Bharaj BS, Yu H, Poulopoulos J, *Diamandis EP*. Sequence analysis of the human kallikrein gene locus identifies a unique polymorphic minisatellite element. **Biochem Biophys Res Commun** 2001;285:1321-1329.

264. Soleas GJ, *Diamandis EP*, Goldberg DM. The world of resveratrol. **Adv Exp Med Biol** 2001;492:159-182.

265. Obiezu CV,Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, *Diamandis EP*. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. **Clin Cancer Res** 2001;7:2380-2386.

266. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, *Diamandis EP*. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. **Clin Cancer Res** 2001;7:2372-2379.

267. Sidiropoulos M, Chang A, Jung K, *Diamandis EP*. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. **Br J Cancer** 2001;85:393-397.

268. Soleas GJ, Goldberg DM, Grass L, Levesque M, *Diamandis EP*. Do wine polyphenols modulate p53 gene expression in human cancer cell lines? **Clin Biochem** 2001;34:415-420.

269. Shimizu-Okabe C, Yousef GM, *Diamandis EP*, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. **Neuroreport** 2001;12:2747-2751.

270. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. **Clin Chim Acta** 2001;31:213-219.

271. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, *Diamandis EP*. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. **J Histochem Cytochem** 2001;49:1431-1442.

272. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, *Diamandis EP*, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. **Cancer Res** 2001;61:7811-7818.

273. Chang A, Yousef GM, Jung K, Rajpert-De Meyts E, *Diamandis EP*. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: different expression in the human testis and testicular cancer. **Anticancer Res** 2001;21:147-152.

2002

274. *Diamandis EP*, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human Kallikrein 11: A new biomarker of prostate and ovarian carcinoma. **Cancer Res** 2002;62:295-300.

275. Rosenberg Zand RS, Jenkins DJA, Brown TJ, *Diamandis EP*. Flavonoids can block PSA production by breast and prostate cancer cell lines. **Clin Chim Acta** 2002;317:17-26.

276. Bharaj BB, Luo L-Y, Jung K, Stephan C, *Diamandis EP*. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular and ovarian cancers. **Prostate** 2002;51:35-41.

277. Sauter ER, Tichansky DS, Cervoneva I, *Diamandis EP*. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. **Environ Health Perspect** 2002;110:241-246.

278. Yousef G, Ordon M, Foussias G, *Diamandis EP*. Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new signlec pseudogenes. **Gene** 2002;286:259-270.

279. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, *Diamandis EP*. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favorable prognosis in breast cancer. **Br J Cancer** 2002;86:1457-1464.

280. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, *Diamandis EP*, Hudson TJ, White JH. Expression of profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D(3) analog EB1089 signalling on cell proliferation, differential, and immune system regulation. **Mol Endocrinol** 2002;16:1243-1256.

281. Scorilas A, Levesque MA, Ashworth LK, *Diamandis EP*. Cloning, physical mapping and structural characterization of the human alpha(A)-Adaptin gene. **Gene** 2002;289:191-199.

282. Soleas G, Grass L, Josephy PD, Goldberg DM, *Diamandis EP*. A comparison of the anticarcinogenic properties of four wine polyphenols. **Clin Biochem** 2002;35:119-124.

283. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, *Diamandis EP*. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. **Prostate** 2002;51:126-132.

284. Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, *Diamandis EP*. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. **Clin Biochem** 2002;35:225-231.

285. Sauter ER, Chervoneva I, Diamandis A, Khosravi JM, Litwin S, Diamandis EP. Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. **Cancer Det Prev** 2002;26:149-157.

286. Luo L-Y, *Diamandis EP*, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. **Br J Cancer** 2002;86:1790-1796.

287. Magklara A, Brown TJ, *Diamandis EP*. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. **Int J Cancer** 2002;100:507-514.

288. Mahmoud AAH, Yousef GM, Al-Hifzi I, *Diamandis EP*. Cocayne syndrome in three sisters with varying clinical presentation. **Am J Med Gen** 2002;111:81-85.

289. Stephan C, Cammann H, Semjonow A, *Diamandis EP*, Wymenga LF, Lein M, Sinha P, Leoning SA, Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. **Clin Chem** 2002;48:1279-1287.

290. Yousef GM, Scorilas A, Kyriakopoulou L, Rendel L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. **Clin Chem** 2002;48:1241-1250.

291. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, *Diamandis EP*. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. **Clin Chem** 2002;48:1232-1240.

292. Petraki CD, Karavana VN, Luo L-Y, *Diamandis EP*. Human kallikrein 10 expression in normal tissues by immunohistochemistry. **J Histochem Cytochem** 2002;50:1247-1261.

293. Luo LY, Herrera I, Soosaipillai A, *Diamandis EP*. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. **Br J Cancer** 2002;87:339-343.

294. Sauter ER, Welch T, Magklara A, Klein G, *Diamandis EP*. Ethnic variation in kallikrein expression in nipple aspirate fluid. **Int J Cancer** 2002;100:678-682.

295. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M, *Diamandis EP*. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. **Br J Cancer** 2002;87:1294-1300.

296. Yousef GM, Borgoño CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, *Diamandis EP*. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. **Br J Cancer** 2002;87:1287-1293.

297. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, *Diamandis EP*. Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. **Urology** 2002;60:714-718.

298. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, *Diamandis EP*. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. **Br J Cancer** 2002;87:763-771.

299. Brauer PM, McKeown-Eyssen GE, Jazmaji V, Logan AG, Andrews DF, Jenkins D, Marcon N, Saibil F, Cohen L, Stern H, Baron D, Greenberg G, *Diamandis E*, Kakis G, Singer W, Steiner G. Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. **Am J Epidemiol** 2002;156:702-713.

300. Petraki CD, Karavana VN, Revelos KI, Luo L-Y, *Diamandis EP*. Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. **Histochem J** 2002;34:313-322.

301. Luo LY, Herrera I, Soosaipillai A, **Diamandis EP**. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer 2002; 87: 339-343.

2003

302. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Dristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Leoning SA, *Diamandis EP*. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostatic tissue. **J Urol** 2003;169:361-364.

303. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DH, *Diamandis EP*. Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. **Clin Chem** 2003;49:77-86.

304. Kishi T, Grass L, Soosaipillai A, Scorilas A, Shimizu-Okabe C, *Diamandis EP*. Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids. **Clin Chem** 2003;49:87-96.

305. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, *Diamandis EP*. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. **Clin Biochem** 2003;36:135-143.

306. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman U-H, van der Zee AGJ, Vergote I, *Diamandis EP*. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. **Cancer Res** 2003;63:807-811.

307. *Diamandis EP*, Scorilas A, Fracchioli S, van Gramberen M, de Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman U-H, Massobrio M, van der Zee AGJ, Vergote I, Katsaros D. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. **J Clin Oncol** 2003;21:1035-1043.

308. Yousef GM, Scorilas A, Nakamura T, Ellatif Said M, Ponzone R, Biglia N, Maggiorotto M, Roagna R, Sismondi P, *Diamandis EP*. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. **Breast Cancer Res Treat** 2003;78:149-158.

309. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, *Diamandis EP*. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. **Br J Cancer** 2003;88:1101-1103.

310. Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M,, Massobrio M, *Diamandis EP*, Katsaros D. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. **Am J Clin Pathol** 2003;119:345-355.

311. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, *Diamandis EP*. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. **The Prostate** 2003;54:220-229.

312. Petraki CD, Karavana VN, *Diamandis EP*. Human kallikrein 13 expression in normal tissues: An immunohistochemical study. **J Histochem Cytochem** 2003;51:493-501.

313. Hutchinson S, Luo L-Y, Yousef GM, Soosaipillai A, *Diamandis EP*. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. **Clin Chem** 2003;49:746-751.

314. Yousef GM, Polymeris M-E, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, *Diamandis EP*. Parallel overexpression of seven kallikrein genes in ovarian cancer. **Cancer Res** 2003;63:2223-2227.

315. Nakamura T, Stephan C, Scorilas A, Yousef GM, Jung K, *Diamandis EP*. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. **Urology** 2003;61:1042-1046.

316. Kollara A, *Diamandis EP*, Drown TJ. Secretion of endogenous kallikrein 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. **J Steroid Biochem Mol Biol** 2003;84:493-502.

317. Scorilas A, Chiang PM, Katsaros D, Yousef GM, *Diamandis EP*. Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. **Gene** 2003;310:79-89.

318. Talieri M, *Diamandis EP*, Katsaros N, Gourgiotis D, Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast Tumours. **Thromb Haemost** 2003;89:1081-1088.

319. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, *Diamandis EP*. Human kallikrein 8, a novel biomarker for ovarian carcinoma. **Cancer Res** 2003;63:2771-2774.

320. Yousef GM, Stephan C, Ad Ellatif M, Scorilas A, Jung K, Kristiansen G, Jung M, *Diamandis EP*. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. **The Prostate** 2003;56:287-393.

321. Borgoño CA, Fracchioli S, Yousef GM, Rigault De La Longrais IA, Luo L-Y, Soosaipillai A, Puopolo M, Grass L, Scorilas A, *Diamandis EP*, Katsaros D. Favourable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. **Int J Cancer** 2003.106:605-610.

322. Nam RK, Zhang WW, Trachtenberg J, *Diamandis EP*, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, Narod SA. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. **J Clin Oncol** 2003;21:2312-2319.

323. Yousef GM, Kopolovic AD, Elliott M, *Diamandis EP*. Genomic overview of serine proteases. **Biochem Biophys Res Commun** 2003;305:28-36.

324. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgoño C, Rigault de la Longrais IA, Puopolo M, Massobrio M, *Diamandis EP*. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. **J Clin Oncol** 2003;21:3119-3126.

325. Yousef GM, Kapadia C, Polymeris M-E, Borgono C, Hutchinson S, Wasney GA, Soosaipillai A, *Diamandis EP*. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. **Biochim Biophys Acta** 2003;1628:88-96.

326. Yousef GM, Polymeris M-E, Grass L, Soosaipillai A, Chan P-C, Scorilas A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, *Diamandis EP*. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. **Cancer Res** 2003; 63:3958-3965.

327. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, *Diamandis EP*. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity and regulation by inhibitors. **Biochem Biophys Res Commun** 2003;307:948-955.

328. Luo L-Y, Grass L, *Diamandis EP*. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. **Clin Chim Acta** 2003;337:115-126.

329. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, *Diamandis EP*. The usefulness of serum human kallikrein11 (hK11) for discriminating between prostate cancer and benign prostatic hyperplasia. **Cancer Res** 2003;63:6543-6546.

330. Petraki CD, Gregorakis AD, Papanastasiou PA, Karavana VN, Luo LY, *Diamandis EP*. Immunohistochenmical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. **Prostate Cancer Prostatic Dis** 2003;6:223-227.

331. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth HC, Fracchioli S, Katsaros D, *Diamandis EP*. Human kallikrein 14: A new potential biomarker for ovarian and breast cancer. **Cancer Res** 2003;63:9032-9041.

332. *Diamandis EP*, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. **Tumour Biol** 2003;24:299-309.

2004

333. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Leoning SA, *Diamandis EP*. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. **J Urol** 2004;171:187-191.

334. Talieri M, *Diamandis EP*, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast Tumours: a new potential biomarker for prognosis of breast carcinoma. **Thromb Haemost** 2004;91:180-186.

335. Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, *Diamandis EP*. Complex formation between human kallikrein 13 and serum protease inhibitors. **Clin Chim Acta** 2004;339:157-167.

336. Sauter ER, Lininger J, Magklara A, Hewett JE, *Diamandis EP*. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. **Int J Cancer** 2004;108:588-591.

337. Papageorgiou PC, Pourdjabbar A, Amfilochiadis AA, *Diamandis EP*, Boomsma F, Osmond DH. Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation {beta}-FXIIa? **Am J Physiol Heart Circ Physiol** 2004;286:H837-H846.

338. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, *Diamandis EP*. Kallikrein gene downregulation in breast cancer. **Br J Cancer** 2004;90:167-172.

339. Scorilas A, Borgoňo CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. **J Clin Oncol** 2004;22:678-685.

340. *Diamandis EP*, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjogren M. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. **Clin Biochem** 2004;37:230-237.

341. Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, *Diamandis EP*. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. **Clin Chem** 2004;50:709-716.

342. Yousef GM, Borgoňo CA, Popalis C, Yaboub GM, Polymeris M-E, Soosaipillai A, *Diamandis EP*. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. **Anticancer Res** 2004;24:43-51.

343. Sauter E, Klein G, Wagner-Mann C, *Diamandis EP*. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. **Cancer Det Prev** 2004;28:27-31.

344. Yousef GM, Elliott MB, Kopolovic AD, Serry E, *Diamandis EP*. Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. **Biochim Biophys Acta** 2004;1698:77-86.

345. Antoniou A, Papanastasiou P, Stephanidis A, *Diamandis E*, Androulakakis PA. Assessment of serum prostate specific antigen in childhood. **BJU Int** 2004;93:838-840.

346. Pampalakis G, Kurlender L, *Diamandis EP*, Sotiropoulou G. Cloning and characterization of novel isoforms of the human kallikrein 6 gene. **Biochem Biophys Res Commun** 2004;320:54-61**.**

347. Kurlender L, Yousef GM, Memari N, Robb J-D, Michael IP, Borgoňo C, Katsaros D, Stephen C, Jung K, *Diamandis EP*. Differential expression of a human kallikrein 5 *(KLK5)* splice variant in ovarian and prostate cancer. **Tumour Biol** 2004;25:149-156.

348. Yousef GM, Borgoňo CA, Michael IP, Davidian C, Stephan C, Jung K, *Diamandis EP*. Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers. **Tumour Biol** 2004:25:122-133.

349. Kapadia C, Ghosh CM, Grass L, *Diamandis EP*. Human kallikrein 13 involvement in extracellular matrix degradation. **Biochem Biophys Res Commun** 2004;323:1084-1090.

350. *Diamandis EP*, Borgoňo CA, Scorilas A, Harbeck N, Dorn J, Schmitt M. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. **Clin Biochem** 2004;37:823-829.

351. Yousef GM, Borgoňo CA, Michael IP, *Diamandis EP*. Cloning of a kallikrein pseudogene. **Clin Biochem** 2004;37:961-967**.**

352. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, *Diamandis EP*. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. **Tumour Biol** 2004;25:193-199.

353. Yousef GM, White NMA, Michael I, Memari N, Robb J-D, Katsaros D, Stephan C, Jung K, *Diamandis EP*. The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. **Tumour Biol** 2004;25:221-227.

354. Yousef GM, Borgoňo CA, White NMA, Robb J-D, Michael IP, Oikonomopoulou K, Khan S, *Diamandis EP*. Insilico analysis of the human kallikrein gene 6. **Tumour Biol** 2004;25:282-289.

355. Tran N, Bharaj BS, *Diamandis EP*, Smith M, Li BD, Yu H. Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. **Cancer Epidemiol Biomarkers Prev** 2004;13:2133-2140.

2005

356. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, Stephan C, Jung K, *Diamandis EP*. Intron retention: a common splicing event within the human kallikrein gene family. **Clin Chem** 2005;51:506-515.

357. Felber LM, Borgono CA, Cloutier SM, Kundig CM, Kishi T, Chagas JR, Jichlinski P, Gygi CM, Leisinger H-J, *Diamandis EP*, Deperthes D. Enzymatic profiling of human kallikrein 14 using phage- display substrate technology. **Biol Chem** 2005;386:291-298.

358. Santin AD, *Diamandis EP*, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. **Clin Cancer Res** 2005;11:3320-3325.

359. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, *Diamandis EP*. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. **J Biol Chem** 2005;280:14628-14635.

360. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, Takehara H, *Diamandis EP*. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. **Br J Dermatol** 2005;153:274-281.

361. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, *Diamandis EP*. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. **BJU Int** 2005;96:521-527.

362. Yousef GM, White NMA, Michael IP, Cho JC, Robb JD, Kurlender L, Khan S, *Diamandis EP*. Identification of new splice variants and differential expresson of the human kallikrein 10 gene, a candidate cancer biomarker. **Tumour Biol** 2005;26:227-235.

363. Obiezu CV, Shan SJ, Soosaipilla A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, *Diamandis EP*. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. **Clin Chem** 2005;51:1432-1442.

364. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, *Diamandis EP*, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. **Gynecol Oncol** 2005;99:267-277.

365. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros, D, *Diamandis EP*. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. **Tumour Biol** 2005;26:324-336.

366. Yousef GM, Ejeckam GC, Best LM, *Diamandis EP*. Collecting duct carcinoma associated with oncocytoma: **Int Braz J Urol** 2005;31:465-467.

367. Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, Takehara K, *Diamandis EP*. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. **J Invest Dermatol** 2005;125:1182-1189.

368. Schmitt M, Magdolen V, Mengele K, Reuning U, Foekens J, *Diamandis EP*, Harbeck N. Fibrinolytics, enzyme inhibitors and cancer survival. Haematol Repts 2005;1:28-33.

2006

369. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, *Diamandis EP*. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. **Tumour Biol** 2006;27:1-7.

370. Simon I, Zhou S, Corral L, *Diamandis EP*, Sarno MJ, Wolfert RL, Kim NW. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. **Cancer Res** 2006;66:1570-1575.

371. Fritzsche F, Gansukh T, Borgono C, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, *Diamandis EP*, Dahl E, Kristiansen G. Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. **Br J Cancer** 2006;94:540-547.

372. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 6 expression in salivary gland tumors. **J Histochem Cytochem** 2006;54:337-342.

373. Luo L-Y, Shan SJC, Elliott MB, Soosaipillai A, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. **Clin Cancer Res** 2006;12:742-750.

374. Prezas P, Scorilas A, Yfanti C, Viktorov P, Agnanti N, *Diamandis EP*, Talieri M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. **Biol Chem** 2006;387;1607-1612.

375. Elliott MB, Irwin DM, *Diamandis EP*. In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. **Genomics** 2006;88:591-599.

376. Oikonomopoulou K, Hansen K,K, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, *Diamandis EP*, Hollenberg MD. Proteinase-activated receptors, targets for kallikrein signalling. **J Biol Chem** 2006;281:32095-32112.

377. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, *Diamandis EP*. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. **Clin Chem** 2006;52:1879-1886.

378. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. **Int J Biol Markers** 2006;21:201-205.

379. Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, *Diamandis EP*, Schmitt M. Disease processes may be reflected by correlations among tissue kallikreins proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. **Biol Chem** 2006;387:1121-1128.

380. Slagter MH, Gooren LJG, Scorilas A, Petraki CD, *Diamandis EP*. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. **J Histochem Cytochem** 2006;54:905-910.

381. Slagter MH, Scorilas A, Gooren LJG, de Ronde W, Soosaipillai A, Giltay EJ, Paliouras M, *Diamandis EP*. Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals. **Clin Chem** 2006;52:1546-1551.

382. Slagter MH, Gooren LJG, de Ronde W, Soosaipillai A, Scorilas A, Giltay EJ, Paliouras M, *Diamandis EP*. Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with anti-androgens and estrogens. **Clin Chem** 2006;52:1356-1365.

383. Oikonomopoulou K, Hansen KK, Saiffeddine M, Vergnolle N, Tea I, Blaber M, Blaber SI, Scarisbrick I, *Diamandis EP*, Hollenberg MD. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). **Biol Chem** 2006;387:817-824.

384. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA, Abdel-Malak M, Froberg MK, *Diamandis EP*, Thayer RE. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. **J Mol Diagn** 2006;8:312-319.

385. Prezas P, Arlt MJ, Viktorov P, Soosaipillai A, Holzscheiter L, Schmitt M, Talieri M, *Diamandis EP*, Krűger A, Magdolen V. Overexpression of the human tissue kallikrein genes KLK4, 5, 6 and 7 increases the malignant phenotype of ovarian cancer cells. **Biol Chem** 2006;387:807-811.

386. Stephan C, Meyer HA, Cammann H, Nakamura T, *Diamandis EP*, Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. **Biol Chem** 2006;387:801-805.

387. Pampalakis G, *Diamandis EP*, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers. **Biol Chem** 2006;387:795-799.

388. Obiezu CV, Michael IP, Levesque MA, *Diamandis EP*. Human kallikrein 4: enzymatic activity, inhibition and degradation of extracellular matrix proteins. **Biol Chem** 2006;387:749-759.

389. Memari N, Grass L, Nakamura T, Karakucuk I, *Diamandis EP*. Human tissue kallikrein 9: production of recombinant proteins and specific antibodies. **Biol Chem** 2006;387:833-740.

390. Kishi T, Cloutier SM, Kűndig C, Deperthes D, *Diamandis EP*. Activation and enzymatic characterization of recombinant human kallikrein 8. **Biol Chem** 2006;387:723-731.

391. Felber LM, Kűndig C, Borgoňo CA, Chagas JR, Tasinato A, Jichlinski P, Gygi CM, Leisinger HJ, *Diamandis EP*, Deperthes D, Cloutier SM. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. **FEBS J** 2006;273:2505-2514.

392. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, *Diamandis EP*. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. **J Biol Chem** 2006;281:12743-12750.

393. Santin AD, *Diamandis EP*, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. **Am J Obstet Gynecol** 2006;194:1296-302.

394. Soleas GJ, Grass L, Josephy PD, Goldberg DM, *Diamandis EP*. A comparison of the anticarcinogenic properties of four red wine polyphenols. **Clin Biochem** 2006;39:492-497.

395. Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, *Diamandis EP*, Meyer H, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA-based artifical neural network. **Prostate** 2006;66:651-659.

396. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 13 expression in salivary gland tumors. **Intl J Biol Markers** 2006;21:106-110.

397. Borgoňo CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 8 protein is a favourable prognostic marker in ovarian cancer. **Clin Cancer Res** 2006;12:1487-1493.

398. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, *Diamandis EP*. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. **Int J Urol** 2006;13:238-243.

399. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 6 expression in salivary gland tumors. **J Histochem Cytochem** 2006;54:337-342.

400. Simon I, Zhuo S, Corral L, *Diamandis EP*, Sarno MJ, Wolfert RL, Kim NW. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. **Cancer Res** 2006;66:1570-1575.

401. Luo LY, Shan SJ, Elliott MB, Soosaipillai A, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. **Clin Cancer Res** 2006;12:742-750.

402. Brown DA, Stepham C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, *Diamandis EP*, Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine I combined with prostate-specific antigen improves prostate cancer diagnosis. **Clin Cancer Res** 2006;12:89-96.

403. Luo L-Y, Soosaipillai A, Grass L, *Diamandis EP*. Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. **Tumour Biol** 2006;27:227-234.

404. Oikonomopoulou K, Scorilas A, Michael IP, Grass L, Soosaipillai A, Rosen B, Murphy J, *Diamandis EP*. Kallikreins as markers of disseminated tumour cells in ovarian cancer – a pilot study. **Tumour Biol** 2006;27:104-114.

405. Petraki CD, Gregorakis AK, Vaskamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, *Diamandis EP*. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. **Tumour Biol** 2006;27:1-7.

406. Komatsu N, Tsai B, Sidiropoulos M, Saijoh K, Levesque MA, Takehara K, *Diamandis EP*. Quantification of eight human tissue kallikreins in the stratum corneum and sweat. **J Invest Dermatol** 2006;126:925-929.

407. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Wu HK, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol** 2006;126:2338-2342.

2007

408. Shaw JL, Grass L, Sotiropoulou G, *Diamandis EP*. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identificationof KLK15 in tissues and biological fluids. **Clin Biochem** 2007;40:104-110.

409. Borgoňo CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, *Diamandis EP*. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. **J Biol Chem** 2007;282:2405-2422.

410. Shan SJ, Scorilas A, Katsaros D, *Diamandis EP*. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. **Br J Cancer** 2007;96:362-372.

411. Komatsu N, Saijoh K, Otsuki N, Kishi T, Michael IP, Obiezu CV, Borgono CA, Takehara K, Jayakumar A, Wu HK, Clayman GL, *Diamandis EP*. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. **Clin Chim Acta** 2007;377:228-236.

412. Paliouras M, *Diamandis EP*. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. **Breast Cancer Res Treat** 2007;102:7-18.

413. Borgoňo CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, *Diamandis EP*. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. **J Biol Chem** 2007;282:3640-3652.

414. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, *Diamandis EP*, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman U-H, Jung K, Meyer HA. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. **World J Urol** 2007;25:95-103.

415. Sardana G, Marshall J, *Diamandis EP*. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. **Clin Chem** 2007;53:429-437.

416. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, *Diamandis EP*. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. **Clin Cancer Res** 2007;13:1742-1748.

417. Memari N, Jiang W, *Diamandis EP*, Luo L-Y. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). **Biol Chem** 2007;388:427-435.

418. Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Műller-Holzner E, Gastl G, Zhang Z, *Diamandis EP*. Ovarian cancer specific kallikrein profile in effusions. **Gynecol Oncol** 2007;105:501-507.

419. Komatsu N, Saijoh K, Kuk C, Shirasaki F, Takehara K, *Diamandis EP*. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. **Br J Dermatol** 2007;156:875-883.

420. Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, Takehara K, *Diamandis EP*. Human tissue kallikreins expression in the stratum corneum and serum of atopic dermatitis patients. **Exp Dermatol** 2007;16:513-519.

421. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, *Diamandis EP*. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. **Gynecol Oncol** 2007;106:334-341.

422. Shaw JL, Smith CR, *Diamandis EP*. Proteomic analysis of human cervico-vaginal fluid. **J Proteome Res** 2007;6:2859-2865.

423. Shaw JL, *Diamandis EP*. Distribution of 15 human kallikreins in tissues and biological fluids. **Clin Chem** 2007;53:1423-1432.

424. Memari N, *Diamandis EP*, Earle T, Campbell A, Van Dekken H, Van der Kwast TH. Human kallikrein-related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues. **Prostate** 2007;67:1465-1474.

425. McIntosh MW, Liu Y, Drescher C, Urban N, *Diamandis EP*. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. **Clin Cancer Res** 2007;13:4422-4428.

426. Cho CK, Shan SJ, Winsor EJ, *Diamandis EP*. Proteomic analysis of human amniotic fluid. **Mol Cell Proteomics** 2007;6:1406-1415.

427. Kulasingam V, *Diamandis EP*. Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. **Biol Chem** 2007;388:1113-1119.

428. Yousef GM, Denic N, Wadhwa J, Chandracanth, Smith T, Elms F, *Diamandis EP*. Intravagal ectopic parathyroid presenting as a vocal cord paralysis: Case report and review of literature. **J Otolaryngol** 2007;36:E93-95.

429. Zheng Y, Katsaros D, Shan SJC, Rigault de la Longrais I, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, *Diamandis EP*. A multiparametric panel for ovarian cancer diagnosis, prognosis and response to chemotherapy. **Clin Cancer Res** 2007;13:6984-6992.

430. Borgono CA, Gavigan J-A, Valves J, Bowles B, Harris JL, Sotiropoulou G, *Diamandis EP*. Defining the extended substrate specificity of kallikrein 1-related peptidases. **Biol Chem** 2007;388:1215-1225.

431. Kulasingam V, *Diamandis EP*. Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. **Mol Cell Proteomics** 2007;6:1997-2011.

432. Goard CA, Bromberg IL, Elliott MB, *Diamandis EP*. A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (*KLK*) locus. **Mol Oncol** 2007;1:303-312.

2008

433. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, *Diamandis EP*, Escott N, Skehan A, Prowse O, Thayer RE, Froberg MK, Wilson MJ, Maragh S, Jakupciak JP, Wagner PD, Srivastava S, Dakubo GD, Parr RL. Mitochondrial genome deletion aids in the identification of false- and true- negative prostate needle core biopsy specimens. **Am J Clin Pathol** 2008;129:57-66.

434. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, *Diamandis EP*. "Product Ion Monitoring" assay for for prostate-specific antigen in serum using a linear Ion-trap. **J Proteome Res** 2008;7:640-647.

435. Emami N, *Diamandis EP*. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade: Possible function in seminal plasma and skin. **J Biol Chem** 2008;283:3031-3041.

436. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, *Diamandis EP*, Goodglick L. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. **Clin Cancer Res** 2008;14:1355-1362.

437. Heshmat S, Mullen B, Jarvi K, Soosaipillai A, *Diamandis EP*, Hamilton RJ, Lo KC. Seminal plasma lipocalin-type prostaglandin D synthase: a potential new marker for the diagnosis of obstructive azoospermia. **J Urol** 2008;79:1077-1080.

438. Paliouras M, *Diamandis EP*. Intracellular signaling pathways regulate hormone-dependent human kallikrein gene expression. **Tumour Biol** 2008;29:63-75.

439. Rabien A, Fritzsche F, Jung M, *Diamandis EP*, Leoning SA, Dietel M, Jung K, Stephan C, Kristiansen G. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. **Tumour Biol** 2008;29:1-8.

440. Planque C, Bléchet, Ayadi-Kaddour A, Heuzé-Vourc'h N, Dumont P, Guyétant S, *Diamandis EP*, El Mezni F, Courty Y. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. **Biol Chem** 2008;389:781-786.

441. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, *Diamandis EP*. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. **Biol Chem** 2008;389:739-745.

442. Paliouras M, *Diamandis EP*. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. **Biol Chem** 2008;389:773-780.

443. Emami N, Deperthes D, Malm J, *Diamandis EP*. Major role of the human KLK14 in seminal clot liquefaction. **J Biol Chem** 2008;283:19561-19569.

444. Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, *Diamandis EP*, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. **Ann Oncol** 2008;19:1271-1277.

445. Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, *Diamandis EP*. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. **J Invest Dermatol** 2008;128:1148-1159.

446. Chow T-F C, Crow M, Earle T, El-Said H, *Diamandis EP*, Yousef GM. Kallikreins as microRNA targets: An *in silico* and experimental-based analysis. **Biol Chem** 2008;389:731-738.

447. Sardana G, Jung K, Stepham C, *Diamandis EP*. Proteomic analysis of conditioned media from PC3, LNCaP and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. **J Proteome Res** 2008;7:3329-3338.

448. Oikonomopoulou K, Hansen KK, Baruch A, Hollenberg MD, *Diamandis EP*. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. **Biol Chem** 2008;389:747-756.

449. Sharma N, Oikonomopoulou K, Ito K, Renaux B, *Diamandis EP*, Hollenberg MD, Rancourt DE. Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. **Biol Chem** 2008;389:1097-1105.

450. Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfort RL, Valik D, Nekulov M, Simickova M, Frgala T, *Diamandis EP*. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. **Br J Cancer** 2008;99:1103-1113.

451. Rŭckert F, Henning M, Petraki CD, Wehrum D, Distler M, Denz A, Schröder M, Dawelbait G, Kalthoff H, Saeger H-D, *Diamandis EP*, Pilarsky C, Grűtzmann R. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. **Br J Cancer** 2008:99:1484-1492.

452. Paliouras M, *Diamandis EP*. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10,11 and 14 in breast cancer cells via a membrane bound androgen receptor. **Mol Oncol** 2008;1:413-424.

453. Prassas I, Paliouras M, Datti A, *Diamandis EP*. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: Implications for cancer therapies. **Clin Cancer Res** 2008;14:5778-5784.

454. Bayani J, Paliouras M, Planque C, Shan SJC, Graham C, Squire JA, *Diamandis EP*. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. **Mol Oncol** 2008;2:250-260.

455. Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, *Diamandis EP*, Dimopoulos MA. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). **Cancer Sci** 2008;99:2224-2229.

456. Shaw JLV, Petraki C, Watson C, Bocking A, *Diamandis EP*. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. **Biol Chem** 2008; 389:1513-1522.

457. Shaw LV, *Diamandis EP*. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. **Biol Chem** 2008;389:1409-1419.

458. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 8 expression in salivary gland tumors. **Head & Neck Pathol** 2008;2:169-174.

2009

459. Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, *Diamandis EP*, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. **Thromb Haemost** 2009;101:541-546.

460. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, *Diamandis EP*, Xynopoulos D, Ardavanis A, Arnogiannaki N, Scorilas A. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.**Thromb Haemost** 2009;101:741-747.

461. Chen Y, Yazdanpanah M, Hoffman BR, *Diamandis EP*, Wong P-Y. Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparision with three automated immunoassays. **Clin Biochem** 2009;42:484-490.

462. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, *Diamandis EP*. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. **Mol Cell Proteomics** 2009;8:791-798.

463. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, *Diamandis EP*. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. **Mol Cell Proteomics** 2009;8:661-669.

464. Cherny DZ, Konvalinka A, Zinman B, *Diamandis EP*, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase C beta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: A pilot study. **Diabetes Care** 2009;32:91-93.

465. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, *Diamandis EP*. Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. **Int J Cancer** 2009;125:9-14.

466. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, *Diamandis EP*. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. **Br J Cancer** 2009;100:1659-1665.

467. Christensen E, Pintile M, Evans KR, Lenarduzzi M, Menard C, Catton CN, *Diamandis EP*, Bristow RG. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. **Clin Cancer Res** 2009;15:5576-5583.

468. Sardana G, *Diamandis EP*. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. **Clin Biochem** 2009;42:1483-1486.

469. Emami N, Scorilas A, Soosaipillai A, Earle T, Mullen B, *Diamandis EP*. Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: Their relation to sperm motility. **Biol Chem** 2009;390:921-929.

470. Strojnik T, Kavalar R, Zajc I, *Diamandis EP*, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. **Anticancer Res** 2009;29:3269-3279.

471. Gunawardana G, Kuk C, Smith CR, Batruch I, Soosaipillai A, *Diamandis EP*. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. **J Proteome Res** 2009;8:4705-4713.

472. Oikonomopoulou K, Soosaipillai A, *Diamandis EP*. Evaluation of prostate-specific antigen as a novel biomarker for Hsp90 inhibition. **Clin Biochem** 2009;42:1705-1712.

473. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, *Diamandis EP*. Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. **Mol Cell Proteomics** 2009;8:2746-2758.

2010

474. Pampalakis G, *Diamandis EP*, Katsaros D, Sotiropoulou G. Down-regulation of dicer expression in ovarian cancer tissues. **Clin Biochem** 2010;43:324-327.

475. Emami N, *Diamandis EP*. Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGF beta 1 in semen. **Biol Chem** 2010;391:85-95.

476. Kuk, C, Gunawardana CG, Soosaipillai A, Kobayashi H, Li L, Zheng Y, *Diamandis EP*. Nidogen-2: A new serum biomarker for ovarian cancer. **Clin Biochem** 2010;43:355-361.

477. Chen Y, Yazdanpanah M, Wang Y, Hoffman BR, *Diamandis EP*, Wong P-Y. Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. **Clin Biochem** 2010;43:490-496.

478. Drabovich A, *Diamandis EP*. Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. **J Proteome Res** 2010;9:1236-1245.

479. Ban K, Kim KH, Cho CK, Sauve M, *Diamandis EP*, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1 (9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. **Endocrinology** 2010;151:1520-1531.

480. Hashem NN, Mara TW, Mohamed M, Zhang I, Fung K, Kwan KF, Daley TD, *Diamandis EP*, Darling MR. Human kallikrein 14 (KLK14) expression in salivary gland tumours. **Int J Biol Markers** 2010;25:32-37.

481. Pavlou M, Kulasingam V, Sauter ER, Kliethermes B, *Diamandis EP*. Nipple aspirate fluid proteome of healthy females and patients with breast cancer. **Clin Chem** 2010;56:848-855.

482. Oikonomoupoulou K, Batruch I, Smith CR, Soosaipillai A, *Diamandis EP*, Hollenberg MD. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. **Biol Chem** 2010;391:381-390.

483. White N, Bui A, Mejia-Guerraro S, Chao J, Soosaipillai A, Yousef Y, Mankarous M, Honey RJ, Stewart R, Pace KT, Sugar L, *Diamandis EP*, Dore J, Yousef GM. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. **Biol Chem** 2010;391:411-423.

484. Cho C-K, SmithCR, *Diamandis EP*. Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. **J Proteome Res** 2010;9:3574-3582.

485. Arana CJ, *Diamandis EP*, Kandel RA. Cartilage tissue enhances proteoglycan retention by nucleus pulposus cells in vitro. **Arthritis Rheum** 2010;62;3395-3403.

486. Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Ross MM, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Liotta L, Petricioin E, *Diamandis EP*, Chan DW, Lopez MF. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. **J Proteome Res** 2010;9:6678-6688.

487. Rabien A, Fritzsche F, Jung M, Tolle A, *Diamandis E*, Miller K, Jung K, Kristiansen G, Stephan C. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. **Int J Cancer**. 2010; 127: 2386-2394.

2011

488. Eissa A, Amodeo V, Smith CR, *Diamandis EP*. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. **J Biol Chem** 2011;286:687-706.

489. Bayani J, Marrano P, Graham C, Zheng Y, Li L, Katsaros D, Lassus H, Butzow R, Squire JA, *Diamandis EP*. Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. **Mol Oncol** 2011;5:48-60.

490. Cramer DW, Bast RC Jr, Berg CD, *Diamandis EP*, Goodwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal and ovarian cancer screening trial specimens. **Cancer Prev Res** 2011;4:365-374.

491. Batruch I, Lecker I, Kagedan D, Smith CR, Mullen B, Grober E, Lo K, *Diamandis eP*, Jarvi KA. Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. **J Proteome Res** 2011;10:941-953.

492. Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, Klotz L, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, *Diamandis E*, Yu C, Loblaw DA, Narod SA. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. **J Clin Oncol** 2011;29:2959-2964.

493. Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuze-Vourc'h N, *Diamandis EP*, Courty Y. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. **J Biol Chem** 2011;286:25505-25518.

494. Cho C-K J, Drabovich AP, Batruch I, *Diamandis EP*. Verification of biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay. **J Proteomics** 2011;74:2052-2059.

495. Dorn J, Madgolen V, Gkazepis A, Gerte T, Harlozinska A, Sediaczek P, *Diamandis EP*, Schuster T, Harbeck N, Kiechle M, Schmitt M. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. **Ann Oncol** 2011;22:1783-1790.

496. Dorn J, Harbeck N, Kates R, Ghazapis A, Scorilas A, Soosaipillai A, *Diamandis E*, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. **Ann Oncol** 2011;22:877-883.

497. *Diamandis* EP, Goodglick L, Planque C, Thornquist M. Pentraxin-3 is a novel biomarker of lung carcinoma. **Clin Cancer Res** 2011;17:2395-2399.

498. Makawita S, Smith C, Batruch I, Zheng Y, Ruckert F, Grutzmann R, Pilarsky C, Gallinger S, *Diamandis EP*. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. **Mol Cell Proteomics** 2011;10:M111.008599.

499. Gratio V, Loriot C, Virca GD, Oikonomopoulou K, Walker F, *Diamandis EP*, Hollenberg MD, Darmoul D. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signalling pathway in colon cancer cells. **Am J Pathol** 2011;179:2625-2636.

500. Kosanam H, Makawita S, Judd B, Newman A, *Diamandis EP*. Mining the malignant ascites proteome for pancreatic cancer biomarkers. **Proteomics** 2011;11:4551-4558.

501. Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, *Diamandis EP*. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signalling networks. **Mol Cancer Ther** 2011;10:2083-2093.

502. Drabovich AP, Jarvi K, *Diamandis EP*. Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monitoring assay. **Mol Cell Proteomics** 2011;10:M110-.004127.

503. Kulasingam V, Smith CR, Batruch I, *Diamandis EP*. Immuno-mass spectrometry: Quantification of low-abundance proteins in biological fluids. **Methods Mol Biol** 2011;728:207-218.

2012

504. Kosanam H, Sato M, Batruch I, Smith CR, Keshavjee S, Liu M, *Diamandis EP*. Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. **Clin Biochem** 2012;45:223-230.

505. Florentinus AK, Bowden P, Sardana G, *Diamandis EP*, Marshall JG. Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance. **J Proteomics** 2012;75:1303-1317.

506. Rückert F, Aust D, Böhme I, Werner K, Brnadt A, *Diamandis EP*, Krautz C, Hering S, Saeger H-D, Grützmann R, Pilarsky C. Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method**. J Surg Res** 2012;172:29-39.

507. Batruch I, Smith CR, Mullen BJ, Grober E, Lo KC, *Diamandis EP*, Jarvi KA. Analysis of seminal plasma from patients with non-obstructive azoospermia and identification of candidate biomarkers of male infertility. **J Proteome Res** 2012;11:1503-1511.

508. Petraki C, Dubinski W, Scorilas A, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabril M, Streutker C, *Diamandis EP*, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. **Pathol Res Prac** 2012;208:104-108.

509. Kagedan D, Lecker I, Batruch I, Smith C, Kaploun I, Kirk, L, Groban E, Diamandis EP, Jarvi K. Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry. **Clin Proteomics** 2012;9:2.

510. Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov N, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, *Diamandis EP*, Langer R, Sweep F, Schmitt M, Magdolen V. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. **Biol Chem** 2012;393:391-401.

511. Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, *Diamandis EP*. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. **Oncotarget** 2012;3:267-285.

512. McDermed JE, Sanders R, Fait S, Klem RE, Sarno MJ, Adams TH, *Diamandis EP*. Nucleic acid detection immunoassay for prostate-specific antigen based on immuno-PCR methodology. **Clin Chem** 2012;58:732-740.

513. Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, *Diamandis EP*. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. **Proteomics** 2012;12:799-809.

514. Martinez-Morillo E, Diamandis A, *Diamandis EP*. Reference intervals and biological variation for kallikrein 6: Influence of age and renal failure. **Clin Chem Lab Med** 2012;50:931-934.

515. Martinez-Morillo E, Diamandis A, Romaschin A, *Diamandis EP*. Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage. **PloS One** 2012;7:e45676.

516. Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, *Diamandis EP*. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castrate-resistant prostate cancer. **J Biol Chem** 2012;287:34019-34031.

517. Olkov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Dwiatkowski M, Fleshner NE, *Diamandis EP*, Zlotta AR, Bapat B. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. **Epigenetics** 2012;7:1037-1045.

518. Martinez-Morillo E, Cho C-K, Drabovich A, Shaw J, Soosaipillai A, *Diamandis EP*. Development of a multiplex selected reaction monitoring assay for quantification of biochemical markers of Down syndrome in amniotic fluid samples. **J Proteome Res** 2012;11:3880-3887.

519. Prakash A, Rezai T, Krastins B, Sarracinol D, Athanas M, Russo P, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Oran LP, Fredolini C, Luchini A, Liotta L, Petricoin E, *Diamandis EP*, Chan DW, Nelson RW, Lopez MF. Inter laboratory reproducibility of SRM assays using multiple upfront analyte enrichment strategies. **J Proteome Res** 2012;11:3986-3995.

520. Drabovich AP, Pavlou MP, Dimitromanolakis A, *Diamandis EP*. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. **Mol Cell Proteomics** 2012;11:422-434.

521. Petraki C, Yousef YM, Dubinski W, Lichner Z, Scorilas A, Pasic MD, Komborozos V, Khalil B, Streutker C, *Diamandis EP*, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. **Tumor Biol** 2012;33:1209-1214.

522. Prassas I, Chrystoja CC, Makawita S, *Diamandis EP*. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. **BMC Med** 2012;10:39.

523. Ramachandran R, Eissa A, Mihara K, Oikonomopoulou K, Saifeddine M, Renaux B, *Diamandis EP*, Hollenberg M. Proteinase-activated receptors (PARs): Differential signalling by kallikrien-related peptidases KLK8 and KLK14. **Biol Chem** 2012;393:421-427.

524. Chen Y, Kinney L, Bozovic A, Smith H, Tarr H, *Diamandis EP*, LeBlanc A. Performance evaluation of Siemens ADVIA Centaur and Roche MODULAR analytics E170. Total 25-OH vitamin D assays. **Clin Biochem** 2012;45:1485-1490.

525. Leung F, Soosaipillai A, Kulasingam V, *Diamandis EP*. CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. **Clin Biochem** 2012;45:1543-1546.

526. Darling ME, Hashem NN, Zhang I, Mohamed AB, Fung K, Kwan K, Mara TW, Daley TD, *Diamandis EP*. Kallikrein-related peptidase 10 expression in salivary gland tissues and tumours. **Int J Biol Markers** 2012;27:e381-e388.

2013

527. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon C, Barak V, Bossuyt PM, *Diamandis EP*, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-monitoring trials: a proposal by the European group on tumor markers. **Clin Chem** 2013;59:52-59.

528. Bayani J, Kuzmanov U, Saraon P, Fung WA, Soosaipillai A, Squire JA, *Diamandis EP*. Copy-number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: Impact on kallikrein 6 protein expression. **Clin Chem** 2013;59:296-305.

529. Eissa A, Cretu D, Soosaipillai A, Thavaneswaran A, Pellett F, Diamandis A , Cevikbas F, Steinhoff M, *Diamandis EP*, Gladman D, ChandranV. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. **Clin Chem Lab Med** 2013;51:317-325**.**

530. Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey CM, Jarvi K, *Diamandis EP*. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. **Mol Cell Proteomics** 2013;12:1589-1601.

531. Cho C-KJ, Drabovich AP, Karagiannis GS, Martinez-Morillo E, Dason S, Dimitromanolakis A, *Diamandis EP*. Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in down syndrome. **Clin Proteomics** 2013;12:1589-1601.

532. Begcevic I, Kosanam H, Martinez Morillo E, Dimitromanolakis A, Diamandis P, Kuzmanov U, Hazrati L-N, *Diamandis EP*. Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. **Clin Proteomics** 2013;10:5.

533. Kuzmanov U, Musrap N, Kosanam H, Smith C, Batruch I, Dimitromanolakis A, *Diamandis EP*. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. **Clin Chem Lab Med** 2013;51:1467-1476**.**

534. Karagiannis GS, Berk A, Dimitromanolakis A, *Diamandis EP*. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by bone morphogenetic protein antagonist, gremlin-1. **Mol Oncol** 2013;7:826-839.

535. Konvalinka A, Zhou J, Dimitromanolakis A, Drabovich AP, Fang F, Gurley S, Coffman T, John R, Zhang S-L, *Diamandis EP*, Scholey JW. Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labelling of amino acids in cell culture (SILAC). **J Biol Chem** 2013;288:24834-24847.

536. Oikonomopoulou K, Deangelis RA, Chen H, *Diamandis EP*, Hollenberg MD, Ricklin D, Lambris JD. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. **J Immunol** 2013;191:3858-3866.

537. Childs C, Martinez-Morillo E, Wai AP, Zu MM, Diamandis A, *Diamandis EP*. Exploring the relationship between serum biomarkers, acute intracerebral changes and outcome after severe traumatic brain injury (TBI). **Clin Chem Lab Med** 2013;51:e195-e197.

538. Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, *Diamandis EP*. Laminin, gamma 2 (LAMC2): A promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. **Mol Cell Proteomics** 2013;12:2820-2832.

539. Pavlou MP, Dimitromanolakis A, *Diamandis EP*. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. **Proteomics** 2013;13:1083-1095.

540. Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun R, Blasutig I, *Diamandis EP*. Validation of four candidate pancreatic cancer biomarkers identifies multiple panels to improve the performance of CA19.9. **BMC Cancer** 2013;13:404.

541. Leung F, Dimitromanolakis A, Kobayashi H, *Diamandis EP*, Kulasingam V. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. **Clin Biochem** 2013;46:1462-1468.

542. Radulovic M, Yoon H, Larson N, Wu J, Linbo R, Burda JE, *Diamandis EP*, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA. Kallikrein cascades in traumatic spinal cord injury: In vitro evidence for roles in axonopathy and neuron degeneration. **J Neuropathol Exp Neurol** 2013;72:1072-1089.

543. Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, Scorilas A, *Diamandis EP*, Dorn J. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. **Radiol Oncol** 2013;47:319-329.

544. Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, *Diamandis EP*, Lopez MF, Nedelkov D. Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. **PLOS ONE** 2013;8:e81125

545. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, Jarvi K, *Diamandis EP*. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. **Sci Transl Med** 2013;5:212ra160.

546. Dorn J, Bayani J, Yousef G, Yang f, Magdolen V, Kiechle M, *Diamandis EP*, Schmitt M. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. **Thromb Haemost.** 2013;110:408-422.

547. Kepecs D, Zhang Y, Thai K, Advani S, Yuen D, Connelly K, Kosanam H, *Diamandis EP*, Sefton M, Gilbert R. Application of modular therapy for renoprotection in experimental chronic kidney disease. **Stem Cells** 2013;31:2408-19

2014

548. Saraon P, Trudel D, Kron K, Dimitromanolakis A, Trachtenberg J, Bapat B, van der Kwast T, Jarvi K, *Diamandis EP*. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. **The Prostate** 2014;74: 372-80.

549. Martinez Morillo E, Nielsen H, Batruch I, Drabovich A, Begcevic I, Lopez M, Minthon L, Bu G, Mattsson N, Portelius E, Hansson O, *Diamandis EP*. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for Apolipoprotein E isoforms. **J Proteome Res** 2014;13:1077-87.

550. Karagiannis G, Schaeffer D, Cho C-K, Musrap N, Saraon P, Batruch I, Grin A, Mitrovic B, Kirsch R, Riddell R, *Diamandis EP*. Collective migration of cancer-associated fibroblasts is enhanced by overexpression of tight junction-associated proteins Claudin-11 and Occludin. **Mol Oncol** 2014;8:178-195.

551. Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, *Diamandis EP*, Kiechle M, Magdolen V, Schmitt M. Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. **Biol Chem** 2014;395:95-107.

552. Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja C, Brand R, Kulasingam V, Blasutig I, *Diamandis EP*. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. **Clin Chem** 2014;60:381-8.

553. Karagiannis GS, Saraon, P, Jarvi K, *Diamandis EP*. Proteomic signatures of angiogenesis in androgen-independent prostate cancer. **Prostate** 2014;74:260-72.

554. Karagiannis GS, Pavlou MP, Saraon P, Musrap N, Xie A, Batruch I, Prassas I, Dimitromanolakis A, Petraki C, *Diamandis EP*. In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. **J Proteomics** 2014;103:121-36.

555. Pavlou MP, Dimitromanolakis A, Martinez-Morillo E, Smid M, John A. Foekens JA, Diamandis EP. Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer. **J Proteome Res** 2014;13:2897-909.

556. Martinez-Morillo E, Hernández PG, Begcevic I, Kosanam H, Garcia BP, Alvarez-Menéndez FV, *Diamandis EP*. Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. **J Proteome Res** 2014;13:969-81.

557. Cretu D, Prassas I, Saraon P, Batruch I, Gandhi R, *Diamandis EP*, Chandran V. Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. **Clin Proteomics** 2014;11:27.

558. Smith CR, Batruch I, Bauça JM, Kosanam H, Ridley J, Bernardini MQ, Leung F, *Diamandis EP*, Kulasingam V. Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. **Clin Proteomics** 2014;11:23.

559. Musrap N, Karagiannis GS, Saraon P, Batruch I, Smith C, *Diamandis EP*. Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction. **J Proteomics** 2014;103:204-15.

560. Bery A, Leung F, Smith CR, *Diamandis EP*, Kulasingam V. Deciphering the ovarian cancer ascites fluid peptidome. **Clin Proteomics** 2014;11:13.

561. Kosanam H, Thai K, Zhang Y, Advani A, Connelly KA, *Diamandis EP*, Gilbert RE. Diabetes induces lysine acetylation of intermediary metabolism enzymes in the kidney. **Diabetes** 2014;63:2432-9.

562. Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, *Diamandis EP*, Nielsen HM. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. **Acta Neuropathol** 2014;127:633-43.

563. Walker F, Nicole P, Jallane A, Soosaipillai A, Mosbach V, Oikonomopoulou K, *Diamandis EP*, Magdolen V, Darmoul D. Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. **Biol Chem** 2014;395:1075-86.

564. Sukumar N, Scott E, Dimitromanolakis A, Misiak A, Prassas I, *Diamandis EP*, Konvalinka A. Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences. **Biol Chem.** 2014:395:1037-50

565. Satkunasivam R, Zhang W, Trachtenberg J, Ants T, Stanimirovic A, Yu C, *Diamandis EP*, Sugar L, Kattan MW, Narod SA, Nam RK. Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. **Springerplus** 2014;3:295.

566. Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, *Diamandis EP*, Blasutig IM. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. **Clin Cancer Res** 2014;20:5787-95.

2015

567. Dorn J, Bronger H, Kates R, Slotta-Huspenina J, Schmalfeldt B, Kiechle M, Diamandis EP, Soosaipillai A, Schmitt M, Harbeck N. OVSCORE - A validated score to identify ovarian cancer patients not suitable for primary surgery. **Oncol Letters** 2015; 9:418-424.

568. Korbakis D, Prassas I, Brinc D, Batruch I, Krastins B, Lopez MF, *Diamandis EP*. Delineating monoclonal antibody specificity by mass spectrometry. **J Proteomics** 2015;114:115-24.

569. Karagiannis GS, Musrap N, Saraon P, Treacy A, Schaeffer DF, Kirsch R, Riddell RH, *Diamandis EP*. Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. **Biol Chem** 2015;396:163-83.

570. Florentinus-Mefailoski A, Soosaipillai A, Dufresne J, Diamandis EP, Marshall JG. An enzyme-linked immuno-mass spectrometric assay with the substrate adenosine monophosphate. **Anal Bioanal Chem** 2015;407:1119-30.

571. Taylor DW, Ahmed N, Parreno J, Lunstrum GP, Gross AE, *Diamandis EP*, Kandel RA. Collagen Type XII and Versican are present in the early stages of cartilage tissue formation by both redifferentating passaged and primary chondrocytes. **Tissue Eng Part A** 2015;21:683-93

572. Lennox GK, Eiriksson LR, Reade CJ, Leung F, Mojtahedi G, Ferguson SE, Murphy J, *Diamandis EP*, Kulasingam V, Bernardini MQ. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter? **Int J Gynecol Cancer** 2015; 25:809-14.

573. Korbakis D, Brinc D, Schiza C, Soosaipillai A, Jarvi K, Drabovich AP, *Diamandis EP.* Immunocapture-selected reaction monitoring screening facilitates the development of ELISA for the measurement of native TEX101 in biological fluids. **Mol Cell Proteomics** 2015;14:1517-26

574. Grober E, Garbens A, Božović A, Kulasingam V, Fanipour B, *Diamandis EP*. Accuracy of testosterone concentrations in compounded testosterone products. **J Sex Med** 2015;12:1381-8.

575. Musrap N, Tuccitto A, Karagiannis GA, Saraon P, Batruch I, *Diamandis EP*. Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1). **J Biol Chem** 2015;290:17218-27

576. Yu Y, Prassas I, Dimitromanolakis A, *Diamandis EP*. Novel biological substrates of human kallikrein 7 identified through degradomics. **J Biol Chem** 2015;290:17762-75

577. Rotondo F, Di Ieva A, Kovacs K, Cusimano MD, Syro LV, *Diamandis EP*, Yousef GM. Human kallikrein 10 in surgically removed human pituitary adenomas**. Hormones (Athens)** 2015;14:272-9

578. Di Meo A, Rotondo F, Kovacs K, Cusimano Md, Syro Lv, Di Ieva A, *Diamandis EP*, Yousef GM. Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: An immunohistochemical study. **Appl Immunohistochem Mol Morphol** 2015;23:433-7

579. Korbakis D, Prassas I, Dimitromanolakis A, Davis GJ, Barber E, Reckamp KL, Blasutig I, *Diamandis EP*. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. **Br J Cancer Supp** 2015;113:484-91

580. Drucker KL, Gianinni C, Decker PA, *Diamandis EP*, Scarisbrick IA. Prognostic significance of multiple kallikreins in high-grade astrocytoma. **BMC Cancer** 2015;15:565

581. Martínez-Morillo E, Childs C, Prieto García B, Álvarez Menéndez FV, Romaschin AD, Cervellin G, Lippi G, *Diamandis EP*. Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. **Clin Chem Lab Med** 2015;53:1575-84.

582. Duffy MJ, Sturgeon C, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt P. Validation of new cancer biomarkers: A position statement from the European Group on tumor markers. **Clin Chem** 2015; 61:809-820

2016

583. Dukic L, Simundic AM, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, *Diamandis EP*. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. **Clin Biochem** 2016;49:213-218

584. Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E, Schmalfeldt B, Loessner D, Kotzsch M, Magdolen V. Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. **Am J Cancer Res** 2016;6:61-70

585. Mange A, Dimitrakopoulos L, Soosaipillai A, Coopman P, *Diamandis EP*, Solassol J. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. **J Proteomics**. 2016;142:114-21.

586. Konvalinka A, Batruch I, Tokar T, Dimitromanolakis A, Reid S, Song X, Pei Y, Drabovich AP, *Diamandis EP*, Jurisica I, Scholey JW. Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. **Clin Proteomics** 2016;13:16

587. *Diamandis EP*. Significant increase of serum prostate-specific antigen after exercise. **Clin Chem Lab Med**. 2016;54:e245-6

588. Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC, Serra S, *Diamandis EP*, Kulasingam V. Validation of a novel biomarker panel for the detection of ovarian cancer. **Cancer Epidemiol Biomarkers Prev**. 2016;25:1333-40

589. Karakosta TD, Soosaipillai A, *Diamandis EP*, Batruch I, Drabovich AP. Quantification of human kallikrein-related peptidases in biological fluids by multiplatform targeted mass spectrometry assays. **Mol Cell Proteomics.** 2016;15:2863-76

590. Begcevic I, Brinc D, Drabovich AP, Batruch I, *Diamandis EP*. Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas. **Clin Proteomics**. 2016;13:11

591. Drabovich AP, Pavlou MP, Schiza C, *Diamandis EP*. Dynamics of protein expression reveals primary targets and secondary messengers of estrogen receptor alpha signaling in mcf-7 breast cancer cells. **Mol Cell Proteomics**. 2016;15:2093-107.

592. Di Meo A, Batruch I, Yousef AG, Pasic MD, *Diamandis EP*, Yousef GM. An integrated proteomic and peptidomic assessment of the normal human urinome. **Clin Chem Lab Med.** 2017;55:237-247

593. Oikonomopoulou K, Yu H, Wang Z, Vasiliou SK, Brinc D, Christofi G, Theodorou M, Pavlou P, Hadjisavvas A, Demetriou C, Kyriacou K, *Diamandis EP*. Association between Echinococcus granulosus infection and cancer risk - a pilot study in Cyprus. **Clin Chem Lab Med**. 2016;54:1955-1961

594. Ahmed N, Dorn J, Napieralski R, Drecoll E, Kotzsch M, Goettig P, Farid E, Avril S, Kiechle M, *Diamandis EP*, Schmitt M, Magdolen V. Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. **Biol Chem**. 2016;397:1265-1276

2017

595. Filippou P, Korbakis D, Farkona S, Soosaipillai A, Karakosta T, *Diamandis EP*. A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9. **Clin Proteomics**. 2017;14:4

596. Rajasekeran H, Lytvyn Y, Bozovic A, Lovshin J, *Diamandis EP*, Cattran D, Husain M, Perkins B, Advani A, Reich H, Kulasingam V, Cherney D. Urinary adenosine excretion in type 1 diabetes. **AJP-Renal** 2017

597. Yu Y, Prassas I, Muytjens C, Diamandis EP. Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. **J Proteomics.** 2017;155:40-48.

598. Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek D.H, Fleshner N.E, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T,. Hunter G.A, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg M, Toi A, Shiah Y.J, Fraser M, van der Kwast T, Bristow R.G, Bapat B, *Diamandis E.P*, Boutros P.C,. Zlotta A.R. Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer. **J Natl Cancer Inst**.2017;109;1-11.

599. Clotet S, Soler MJ, Riera M, Pascual J, Fang F, Zhou J, Batruch I, Vasiliou SK, Dimitromanolakis A, Barrios C, *Diamandis EP,* Scholey J, Konvalinka A. Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male SexHormones and Impaired Energy Metabolism in Diabetic Kidney Disease. Mol Cell Proteomics. 2017;16:368-385.

In Press

1. Korbakis D, Schiza C, Brinc D, Soosaipillai A, Karakosta TD, Légaré C, Sullivan R, Mullen B, Jarvi K, Diamandis EP, Drabovich AP. Preclinical evaluation of TEX101 protein ELISA test for the differential diagnosis of male infertility. **BMC Medicine.** 2017 [Epub ahead of print]
2. Darling MR, Woodford R, Cuddy KK, Jackson-Boeters L, Hayter A, Inkaran J, *Diamandis EP*, Khan Z. Kallikrein-related peptidase expression in odontogenic cysts and tumors: An immunohistochemical comparative study. **J Investig Clin Dent.** 2017; [Epub ahead of print]
3. *Diamandis EP,* Stanczyk FZ, Wheeler S, Mathew A, Stengelin M, Glezer E, Nikolenko G, Brown M, Zheng Y, Chen YH, Wu HL, Azziz R. Serum complexed and free prostate specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). **Clin Chem Lab Med.**2017 [Epub ahead of print]
4. Dimitrakopoulos L, Prassas I, Berns EM, Foekens JA, *Diamandis EP,* Charames GS. Variant peptide detection utilizing mass spectrometry: Laying the foundations for proteogenomic identification and validation. **Clin Chem Lab Med.** 2017[Epub ahead of print]

Submitted

1. Ravipaty S, Wu W, Dalvi A, Tanna N, Andreazi J, Friss T, Klotz A, Liao C, Garren J, Schofield S, Diamandis EP, Klein E, Dobi A, Srivastava S, Akmaev V. Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer. **Anal Bioanal Chem**. 2016

Editorials/Commentaries/Perspectives/Reflections/Opinions

1. Goldberg DM, *Diamandis EP*. Clinical chemistry: Death or transfiguration? **Eur J Lab Med** 1994;2:157-159.
2. *Diamandis EP*, Yu H. Prostate cancer, prostate specific antigen and the polymerase chain reaction. **Clin Chem** 1995;41:177-179.
3. *Diamandis EP*, Yu H. New biological functions of prostate specific antigen? **J Clin Endocrinol Meta**b 1995;80:1515-1517.
4. *Diamandis EP*. Automation of molecular diagnostics. **Clin Chem** 1996;42:7-8.
5. *Diamandis EP*, Yu H, Melegos DN. Ultrasensitive prostate specific antigen assays and their clinical application. **Clin Chem** 1996;42:853-857.
6. *Diamandis EP*. Sequencing by microarray technology — a powerful new tool for molecular diagnostics. **Clin. Chem** 2000;46:1523-1525.
7. *Diamandis EP*. Signal amplification in time-resolved fluorometry. **Clin Chem** 2001;47:380-381.
8. *Diamandis EP*. Cancer diagnostics: discovery and clinical applications – Introduction. **Clin Chem** 2002;48:1145-1146.
9. *Diamandis EP*. Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? C**lin Chem** 2003;49:1272-1278.
10. *Diamandis EP*. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. **J Natl Cancer Inst** 2004;96:353-356.
11. *Diamandis EP*. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. **Clin Chem** 2004;50:793-795.

12. *Diamandis EP*. Immunoassay interference: A relatively rare but still important problem. **Clin Biochem** 2004;37:331-332.
13. *Diamandis EP*. Proteomic patterns to identify ovarian cancer: 3 years on. **Expert Rev Mol Diagn** 2004;4:575-577.
14. Hoffman BR, *Diamandis EP*. Recent advances in cancer biomarkers. **Clin Biochem** 2004;37:503-504.
15. *Diamandis EP*, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. **Clin Cancer Res** 2005;11:963-965.
16. Schmitt M, Magdolen V, Mengele K, Reuning U, Foekens J, *Diamandis EP*, Harbeck N. Fibrinolytics, enzyme inhibitors and cancer survival. **Haematologica Reports** 2005;1:28-33.
17. *Diamandis EP*. Lost in (the Business of) Translation: Invest in the Youth. **Clin Cancer Res** 2006;12:669.
18. *Diamandis EP*. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. **Cancer Res** 2006;66:5540-5541.
19. *Diamandis EP*. Validation of breast cancer biomarkers identified by mass spectrometry. **Clin Chem** 2006;52:771-772.
20. *Diamandis EP*, Deperthes D, Lundwall A. The first international symposium on kallikreins. **Biol Chem** 2006;387:635-636.
21. *Diamandis EP*. Peptidomics for cancer diagnosis: Present and future. **J Proteome Res** 2006;5:2079-2082.
22. *Diamandis EP*. Quality of the scientific literature: all that glitters is not gold. **Clin Biochem** 2006;39:1109-1111.
23. *Diamandis EP*. Oncopeptidomics: a useful approach for cancer diagnosis. **Clin Chem** 2007;53:1004-1006.
24. Evans KR, Hoffman BR, *Diamandis EP*. Cancer Biomarkers. **Cancer Lett** 2007;249:1-2.
25. Pavlou M, *Diamandis EP*. The search for new prostate cancer biomarkers continues. **Clin Chem** 2009;55 :1277-1279.
26. *Diamandis EP*. Journal impact factor : it will go away soon. **Clin Chem Lab Med** 2009;47:1317-1318.
27. *Diamandis EP*. Perspective: Audacity is overrated. **Science** 2010;1-3, [http://sciencecareers.sciencemag.org/career_magazine/previous_issues.articles/2009_11_06/caredit.a0900139].
28. *Diamandis EP*. Early prostate cancer antigen-2: A controversial prostate cancer biomarker? **Clin Chem** 2010;56:542-544.
29. *Diamandis EP*. Perspective: Can chemoprevention reduce the risk of prostate cancer? **Clin Chem** 2010;56:1214-1215.
30. *Diamandis EP*. Cancer biomarkers: can we turn recent failures into success? **J Natl Cancer Inst** 2010;102:1462-1467.
31. Pavlou M, *Diamandis EP*. The athletes of science. **Nature** 2011;478:419.
32. Pavlou M, *Diamandis EP*. I detected my cancer with my Smart phone. **Clin Chem** 2011;57:1221-1223.
33. *Diamandis EP*. The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem? **BMC Med** 2012;10:87.
34. Konforte D, *Diamandis EP*. Is early detection of cancer using circulating biomarkers feasible? **Clin Chem** 2013;59:35-37.
35. *Diamandis EP*, Bast RC Jr, Lopez-Otin C. Conquering cancer in our lifetime: new diagnostic and therapeutic trends. **Clin Chem** 2013;59:1-3.
36. *Diamandis EP*, Bast RC Jr, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen and cancer antigens CA125 and CA19-9. **Clin Chem** 2013;59:22-31.
37. Kulasingam V, *Diamandis EP*. Facin-1 is a novel biomarker of aggressiveness in some carcinomas. **BMC Med** 2013;11:53.
38. *Diamandis, EP*. Time to reflect. **Nature** 2013;496:129.

39. Pasic MD, Yousef GM, *Diamandis EP*. The proteomic revolution in laboratory medicine. **Clin Biochem** 2013;46:397-398.
40. *Diamandis EP*. Nobelitis: A common disease among Nobel laureates? **Clin Chem Lab Med** 2013:51:1573-1574.
41. Stephan C, *Diamandis EP*, Kristiansen G. Research forever – Klaus Jung. **Clin Chem Lab Med** 2013; 51:e221.
42. *Diamandis EP*. Point/Counterpoint: Reviewing is a business transaction. **ASBMB Today** 2013;08:16.
43. *Diamandis EP*. Turning a failure into a success down the road. **ASBMB Today** 2013;11:34.
44. *Diamandis EP*. More discussion on Journal Impact Factor. **Clin Chem Lab Med** 2013;51:22271
45. *Diamandis EP*. Learning from Siddhartha. **Clin Chem** 2014;60:429.
46. *Diamandis EP*. Tumor microenvironment-released peptides: Could they form the basis for an early breast cancer diagnostic test? **Clin Chem** 2014;60:4-6.
47. *Diamandis EP*. The Lab's Hall of Fame. **ASBMB Today**; February 2014 (http://www.asbmb.org/asbmbtoday/201402/Mentoring/)
48. *Diamandis EP*. A repository for "rare" tumor markers? **Clin Chem Lab Med** 2014;52:795-7.
49. *Diamandis EP*. Present and future of cancer biomarkers. **Clin Chem Lab Med** 2014;52:791-4.
50. Prassas I, *Diamandis EP*. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. **Clin Chem Lab Med** 2014;52:765-6.
51. Yousef GM, Pasic M, *Diamandis EP*. Highlight: the 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases. **Biol Chem** 2014;395:913-4.
52. *Diamandis EP*. Give credit where it is due. "Thoughts on the 'competition' between senior and young investigators". **ASBMB Today** May 2014
53. *Diamandis EP*. Towards identification of true cancer biomarkers. **BMC Med**. 2014;12:156
54. *Diamandis EP*. The hundred person wellness project and Google's baseline study: Medical revolution or unnecessary and potentially harmful over-testing? **BMC Med** 2015;13:5.
55. *Diamandis EP*. How to meet rock stars and pageant beauties. **ASBMB** 2015;14:58
56. *Diamandis EP*. Support staff: Build reward system for ace technicians. **Nature**. 2015;519:414
57. *Diamandis EP*. The measure of research merit. **Science** 2015 [Article]
58. *Diamandis EP*. Theranos phenomenon: promises and fallacies. **Clin Chem Lab Med** 2015; 53:989-93.
59. *Diamandis EP*. Getting noticed is half the battle. **Science**. 2015;349:206
60. Li M, *Diamandis EP* .Theranos Phenomenon-Part 2. **Clin Chem Lab Med** 2015;53:1911-2
61. Li M, *Diamandis EP*. Theranos promises a new era of preventive health care. **Clin Bio Chem** 2015;48:1027
62. *Diamandis EP*. Who the heck is David Baltimore? **ASBMB Today** 2015 (http://www.asbmb.org/asbmbtoday/201512/Education/Baltimore/)
63. *Diamandis EP*. A replacement for the testosterone "sex gap". **Clin Chem Lab Med**. 2016;54:e61. doi: 10.1515/cclm-2015-0982.
64. *Diamandis EP*, Plebani M. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker. **Clin Chem Lab Med**. 2016;54:e1-2. doi: 10.1515/cclm-2015-0773.
65. *Diamandis EP*. A day in the life of Dr. Bean-and how NIH is wasting $20 Billion per year. **Clin Chem** 2015;61:783-4
66. *Diamandis EP*. Cancer dynamics and the success of cancer screening programs. **Clin Chem Lab Med**. 2016;54:e211-2
67. Li M, *Diamandis EP*. Theranos phenomenon - part 3. **Clin Chem Lab Med**. 2016;54:e145-6

68. The "syndrome of successful immigrant" and Dr. John Ioannidis. Huffington Post, July 12, 2016. http://www.huffingtonpost.gr/../../eleftherios-diamandis/-_6508_b_10939636.html
69. *Diamandis EP*. Theranos phenomenon – part 4: Theranos at an International Conference. **Clin Chem Lab Med.** 2016;54:e243-4
70. *Diamandis EP*. The question I hate the most. **Nature** 2016;350:11
71. Kulasingam V, *Diamandis EP*. Genomic profiling for copy number changes in plasma of ovarian cancer patients – new era for cancer diagnostics? **BMC Med** 2016;14:186
72. *Diamandis EP*, Plebani M. Theranos phenomenon - Part 5: Theranos' presentation at the American Association for Clinical Chemistry Annual Conference 2016. **Clin Chem Lab Med**. 2016;54:e313-4.
73. Dragani TA, Castells A, Kulasingam V, *Diamandis EP*, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology. **BMC Med.** 2016;14:110.
74. *Diamandis EP*. The journal impact factor is under attach – use CAPCI factor instead. **BMC Med.** 2017;15:9
75. Filippou P, *Diamandis EP*. Half-century of cancer biomarkers: lessons from the past and projections for the future. **Jalm.** 2017; [Submitted]
76. *Diamandis EP*. A growing phobia. **Nature.** 2017;544:129.

Questions and Answers

1. *Diamandis EP*, Hanash S, Lopez M, Carr SA, Petricoin EF 3rd. Protein quantificatin by mass spectrometry: Is it ready for prime time? **Clin Chem** 2009;55:1427-1430.
2. *Diamandis EP*, Voelkerding KV, Drmanac R, Angus D, McPherson J. Next-generation sequencing: A new revolution in molecular diagnostics? **Clin Chem** 2009;55:2088-2092.
3. *Diamandis EP*, Walsh PC, Jung K, Catalona WJ, Fleshner N. Prostate cancer screening with prostate-specific antigen testing: More answers or more confusion? **Clin Chem** 2010;56:345-351.
4. *Diamandis EP*, Sidransky D, Laird PW, Cairns P, Bapat B. Epigenomics-based diagnostics. **Clin Chem** 2010;56:1216-1218.
5. *Diamandis EP*, Hudson T, Kallioniemi O, Liu ET, Lopez-Otin C. Cancer genomes. **Clin Chem** 2010;56:1660-1664.
6. Pasic MD, *Diamandis EP*, McLaurin J, Holtzman DM, Schmitt-Ulms G, Quirion R. Alzheimer's disease: Advances in pathogenesis, diagnosis and therapy. **Clin Chem** 2011;57:664-669.
7. *Diamandis EP*, Pantel K, Scher HI, Terstappen L, Lianidou E. Circulating cancer cells and their clinical applications. **Clin Chem** 2011;57:1478-1484.
8. Rifai N, *Diamandis EP*, Lo YM, Kricka LJ, Wilding P, Ladenson JH, Wittwer CT. Advancing laboratory medicine through innovation: a tale of six inventors. **Clin Chem** 2012;58:502-510.
9. Shaw JLV, *Diamandis EP*, Horne A, Barnhart K, Bourne T, Messinis IE. Ectopic pregnancy. **Clin Chem** 2012;58:1278-1285.
10. Shea J, *Diamandis EP*, Sharma AM, Després J-P, Ezzat S, Greenway G. The obesity epidemic. **Clin Chem** 2012;58:968-973.
11. Konforte D, *Diamandis EP*, van Venrooij WJ, Lories R, Ward MM. Autoimmune diseases: Early diagnosis and new treatment strategies. **Clin Chem** 2012;58:1510-1514.
12. Chrystoja C, *Diamandis EP*, Brand R, Ruckert F, Haun R, Molina R. Pancreatic Cancer. **Clin Chem** 2013;59:41-46.
13. Estey M, *Diamandis EP*, Van Der Straeten C, Tower SS, Hart AJ, Moyer TP. Cobalt and chromium measurement in patients with metal hip prostheses. **Clin Chem** 2013;59:880-886.

14. Shea JL, *Diamandis EP*, Hoffman B, Lo YM, Canick J, van den Boom D. A new era in prenatal diagnosis: The use of cell-free fetal DNA in maternal circulation for detection of chromosomal aneuploidies. **Clin Chem** 2013;59:1151-1159.

15. Bailey D, *Diamandis EP*, Greub G, Poutanen SM, Christensen JJ, Kostrzew M. Use of MALDI-TOF for diagnosis of microbial infections. **Clin Chem** 2013;59:1435-1441.

16. Rayner K, Dimmeler S, Calin GA, Thum T, Raizman JE, *Diamandis EP*. Novel biomarkers for acute myocardial infarction: is MicroRNA the new kid on the block? **Clin Chem.** 2014;60:812-7

17. Lin DC, *Diamandis EP*, Januzzi JL Jr, Maisel A, Jaffe AS, Clerico A. Natriuretic peptides in heart failure. **Clin Chem**. 2014;60:1040-6.

18. Teodoro-Morrison T, *Diamandis EP*, Rifai N, Weetjens BJ, Pennazza G, de Boer NK, Bomers MK. Animal olfactory detection of disease: promises and pitfalls. **Clin Chem.** 2014;60:1473-9.

19. Di Meo A, *Diamandis EP*, Rodriguez H, Hoofnagle A, Ioannidis J, Lopez M. What is wrong with clinical proteomics? **Clin Chem** 2014;60:1258-66.

20. Abou El Hassan M, *Diamandis EP*, Karumanchi SA, Shennan AH, Taylor RN. Preeclampsia: An old disease with new tools for better diagnosis and risk management. **Clin Chem** 2015;61:694-8

21. Beriault DR, *Diamandis EP*, Portelius E, Perret-Liaudet A, Salloway S. Biomarkers, assays, and therapies for Alzheimer's Disease. **Clin Chem.** 2015; 61:903-8

22. Raizman JE, *Diamandis EP*, Holmes D, Stowasser M, Auchus R, Cavalier E. A *renin*-ssance in primary aldosteronism testing: Obstacles and opportunities for screening, diagnosis, and management. **Clin Chem.** 2015;61:1022-7

23. Knauer M, *Diamandis EP*, Hulot JS, Kim RB, So DY. Clopidogrel and CYP2C19: Pharmacogenetic testing ready for clinical prime time? **Clin Chem** 2015;61:1235-40

24. Annesley TM, *Diamandis EP*, Bachmann LM, Hanash S, Hart B, Javahery R, Singh RJ, Smith R. A spectrum of views on clinical mass spectrometry. **Clin Chem** 2016;62:30-36

25. Dimitrakopoulos L, Prassas I, *Diamandis EP*, Nesvizhskii A, Kislinger T, Jaffe J, Drabovich A. Proteogenomics: opportunities and caveats. **Clin Chem.** 2016;62:551-7

26. Leung F, Kulasingam V, *Diamandis EP*, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C. Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? **Clin Chem.** 2016;62:1054-60.

27. White-Al Habeeb N, Kulasingam V, *Diamandis EP*, Yousef GM, Tsongalis GJ, Vermeulen L, Zhu Z, Kamel-Reid S. The use of targeted therapies for precision medicine in oncology. **Clin Chem**. 2016;62:1556-1564

28. Vasiliou SK, *Diamandis EP*, Church GM, Greely HT, Baylis F, Thompson C, Schmitt-Ulms G. CRISPR-Cas9 system: Opportunities and concerns. **Clin Chem**. 2016;62:1304-11.

Letters to the Editor

1. *Diamandis EP*, Efstathiou CE, Hadjiioannou TP. Stability of the composite solution Mercury (II)-TPTZ-Iron (II) used for the automated determination of serum chloride. **Clin Chem** 1982;28:254.

2. *Diamandis EP*, Ellis G, Daneman D, Allen LC. Liquid chromatography of glycated hemoglobins with the Daiichi HA-8110 automated analyzer. **Clin Chem** 1984;30:503-504.

3. *Diamandis EP*, Hoffman BR. Total Mg^{2+} measured in serum and urine in the Technicon RA-1000 random access analyzer by use of modified manual calmagite procedure. **Clin Chem** 1984;30:1262.

4. *Diamandis EP*, Levesque M. Assessment of p53 protein overexpression by non-immunohistochemical methods. **J Pathol** 1995;175:93-94.

5. *Diamandis EP*, Yu H. Prostate specific antigen and lack of specificity for prostate cells. **Lancet** 1995;345:1186.

6. *Diamandis EP*, Yu H. Clinical usefulness of prostate specific antigen. **J Urol** 1996;154:294.

7. *Diamandis EP.* BRCA1 protein products: antibody specificity, functional motifs and secreted Tumour suppressors. **Nat Genet** 1996;13:268.

8. *Diamandis EP*, Yu H. Does prostate cancer start at puberty? **J Clin Lab Anal** 1996;10:468-469.

9. Borchert GH, Giai M, *Diamandis EP*. Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. **J Natl Cancer Inst** 1997;89:587-588.

10. Melegos DN, Freedman MS, *Diamandis EP*. Prostate specific antigen in cerebrospinal fluid. **Clin Chem** 1997;43:855.

11. *Diamandis EP*. Clinical application of ultrasensitive prostate specific antigen assays. **J Natl Cancer Inst** 1997;89:1077.

12. *Diamandis EP*. Prostate-specific antigen or human kallikrein 3? Recent developments. **Tumour Biol** 1998;19:65-68.

13. Melegos DN, *Diamandis EP*. Is prostate-specific antigen present in female serum? **Clin Chem** 1998;44:691-692.

14. Zaviacic C, Ablin RJ, • Response, *Diamandis EP*. The Female Prostate. **J Natl Cancer Inst** 1998;90:713-714.

15. *Diamandis EP*. Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer. **Mayo Clin Proc** 1998;73:706-707.

16. Yu H, *Diamandis EP*, Hoffman B. Elevated estradiol and testosterone levels and risk for breast cancer. **Ann Intern Med** 1999;131:715.

17. *Diamandis EP*. β-trace protein as indicator of glomerular filtration rate: • Response: **Urology** 1999;54:941-942.

18. Rosenberg-Zand RS, Jenkins DJA, *Diamandis EP*. Genistein: a potent natural antiandrogen. **Clin Chem** 2000;46:887-888 .

19. *Diamandis EP*. Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. **New Engl J Med** 2000;343:890-891.

20. Bulmer B, Ward G, *Diamandis E*, Nicol D, Clements J. Prostaglandin D synthase does not produce prostate-specific antigen cross-reactivity in renal cell carcinoma. **Clin Chem** 2001 Mar;47(3):607-8.

21. Sauter ER, *Diamandis EP*. Prostate-specific antigen levels in nipple aspirate fluid. **J Clin Oncol** 2001;19:3160.

22. *Diamandis EP*. Proteomic patterns in serum and identification of ovarian cancer. **Lancet** 2002;360:170-171.

23. *Diamandis EP*. Serum proteomic patterns for detection of prostate cancer. **J Natl Cancer Inst** 2003;95:489-490.

24. *Diamandis E.P*. **Re:** Diagnostic potential of serum proteomic patterns in prostate cancer. **J Urol** 2004;171:1244-1245.

25. *Diamandis EP*. Identification of serum amyloid A protein as a potentially useful biomarker for nasopharyngeal cancinoma. **Clin Cancer Res** 2004;10:5293-5294.

26. *Diamandis EP*. OvaCheck: doubts voiced soon after publication. **Nature** 2004;430:611.

27. *Diamandis EP*. Validation of breast cancer biomarkers identified by mass spectrometry. **Clin Chem** 2006;52:771-772.

28. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Wu HK, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, Diamandis EP. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol.** 2006;126:2338-42

29. Komatsu N, Tsai B, Sidiropoulos M, Saijoh K, Levesque MA, Takehara K, *Diamandis EP*. Quantification of eight tissue kallikreins in the stratum corneum and sweat. **J Invest Dermatol** 2006 Apr;126(4):925-9

30. *Diamandis EP*, Kulasingam V, Sardana G. Differential exoprotease activities confer tumor-specific serum peptidome. **J Clin Invest** 2006 [http://www.jci.org/cgi/eletters/116/1/271].

31. Diamandis EP. POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma? **Clin Biochem** 2007;40:1437-1439.

32. *Diamandis EP.* Prostate cancer biomarkers. **CAP Today** 2009;23:14-16.
33. *Diamandis EP*. The time of young scientists. **Science** 2010;329:626.
34. *Diamandis EP.* EPCA-2: A highly specific serum marker for prostate cancer. **Clin Biochem** 2012; 45:600.
35. *Diamandis EP.* Biomarker validation is still the bottleneck in biomarker research. **J Intern Med** 2012;272:620.
36. *Diamandis EP*. Publishing costs: Peer review as a business transaction. **Nature** 2015;517:145.
37. *Diamandis EP*. Support staff: Build reward system for ace technicians. **Nature** 2015;519:414.
38. *Diamandis EP*, Plebani M. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker. **Clin Chem Lab Med.** 2016;54:e1-2
39. *Diamandis EP.* Cancer dynamics and the success of cancer screening programs. **Clin Chem Lab Med**. 2016;54:e211-2
40. *Diamandis EP.* A word of caution on new and revolutionary diagnostic tests (Letter commenting on the paper by Myron G. Best et al in Cancer Cell, 2015;28:666-76). **Cancer Cell** 2016; 29:141-142
41. *Diamandis EP.* Significant increase of serum prostate specific antigen after exercise. **Clin Chem Lab Med.** 2016;54:e245-6
42. *Diamandis EP.* A word of caution on new and revolutionary diagnostic tests. **Cancer Cell**. 2016;29:141-2

Science Fiction

1. *Diamandis EP*. How to win Wimbledon championships: Creating Beklof and Vamos. **Clin Chem** 2009;55:1253-1254.
2. *Diamandis EP*. A conversation with Pheidias and Pericles about the Elgin Marbles and other matters. **Clin Chem** 2010;56:1042-1044.
3. *Diamandis EP*. Playing the trumpet. **Clin Chem** 2011;57:1789.

Patents

PATENTS AWARDED

	Inventor (s)	Country	Title	Patent No.	Date Awarded
1	Diamandis EP, Lowden JA.	USA	Immunoassay methods and reagents and methods for producing the latter.	5,089,423	Feb. 18, 1992
2	Diamandis EP.	USA	Europium and terbium chelators for time-resolved fluorometric assays.	5,312,922 5,854,008	May 17, 1994 Dec. 29, 1998
3	Diamandis EP, Dunn JM, Stevens JK	USA	Method, reagents and kit for diagnosis and targeted screening for p53 mutations.	5,552,283 6,071,726	Sept. 3, 1996 June 6, 2000
4	Diamandis EP.	USA	Detection of prostate-specific antigen in amniotic fluid, maternal serum and breast milk.	5,679,534	Oct. 21, 1997
5	Diamandis EP.	USA	Detection of prostate-specific antigen in breast Tumours.	5,688,658 5,723,302 6,261,766	Nov. 18, 1997 Mar. 3, 1998 July 17, 2001
6	Diamandis EP.	USA	Europium and terbium chelators for time-resolved fluorometric assays.	5,854,008	Dec. 29, 1998
7	Diamandis EP, Redshaw R	USA	Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen.	6,068,830 6,274,118	May 30, 2000 Aug. 14, 2001
8	Yousef GM, Diamandis EP.	USA	Human kallikrein-like genes	7,022,497	Apr. 4, 2006
9	Diamandis EP, Lowden AJ	CAN US	Immunoassay methods and reagents and methods for producing the latter.	1,300,007 5,089,423	May 5, 1992 Feb 18, 1992

	Inventor (s)	Country	Title	Patent No.	Date Awarded
10	Diamandis EP, Morton RC	CAN	Multiple fluorescence labelling with europium chelators.	1,308,022 1,330,061	Sept. 29, 1992 Jun. 7, 1994
11	Diamandis EP	CAN	Detection of prostate-specific antigen in breast tumors	2,161,778	Jun. 7, 2002
12	Diamandis EP	USA	Methods for detecting Alzheimer's disease	6,962,793	Nov 8, 2005
13	Yousef GM, Diamandis EP	USA	Human kallikrein-like genes	7,022,497	Apr 4, 2006
14	Yousef GM, Diamandis EP.	EURO FRAN GR BRIT ITAL SPAIN SWITZ GER USA USA	Novel kallikrein gene (KLK15)	1309703 1309703 1309703 1309703 1309703 1309703 60120712.2.08 7,199,229 7,507,403	Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Apr 3, 2007 Mar 24, 2009
15	Diamandis EP.	JAP EUR FRAN GR BRIT ITAL SPAIN SWITZ GER	Diagnostic methods for ovarian carcinoma (KLK6).	2002-538164 1330652 1330652 1330652 1330652 1330652 1330652 60129151.4-08	Oct 13, 2004 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007
16	Diamandis EP.	USA	Monitoring prostate and ovarian cancer (KLK11)	10/478,333	Oct 14, 2004
17	Kishi T, Diamandis EP.	USA	Methods for detecting ovarian cancer (kallikrein 8).	10/510/321	Dec 29, 2005
18	Diamandis EP.	USA	Detection of nerurodegenerative diseases.	10/868,490	May 19, 2005
19	Yousef GM, Diamandis EP.	USA	Methods for detecting breast and ovarian cancer (hK5).	10/526,029	Apr 6, 2006
20	Yousef GM, Diamandis EP.	USA	Methods for detecting endocrine cancer (hK13), as a biomarker	10/526,111	Jul 20, 2006
21	Diamandis EP.	USA	Methods for detecting prostate cancer (hK11 and PSA).	10/529,088	Aug 4, 2006
22	Diamandis EP.	USA	Methods for detecting endocrine cancer (hK12, hK14 & hK15).	10/529,163	Oct 5, 2006
23	Diamandis EP, Petraki CD.	USA	Assay for detection of renal cell carcinoma (kallikreins 5,6,10 and 11)	10/546,435	Jun 26, 2006
24	Diamandis EP.	EURO	Diagnostic methods for ovarian carcinoma (KLK6).	1,330,652	Jul 6, 2007
25	Luo L-Y, Diamandis EP.	USA	Detection of ovarian cancer (KLK10).	7,741,019	June 22, 2010
26	Yousef GM, Diamandis EP	USA	Novel human kallikrein-like genes	7,022,497	2010
27	Diamandis EP, Cho CKJ, Martinez Morillo E	USA	Biomarkers for the detection and screening of Down Syndrome	8,574,860 B2	November 5, 2013
28	Jarvi K, Diamandis EP and Drabovich A	USA	Markers for the male urogenital tract and methods for detecting conditions of the male urogenital tract	PCT/61/374,030	May 26, 2015

PATENTS PENDING

	Inventor (s)	Country	Title	Application #	Date Filed
1	Yousef GM, Diamandis EP.	CAN	Novel kallikrein gene (KLK15)	2,418,422	Aug 10, 2001
2	Diamandis EP.	USA	Diagnostic methods for ovarian carcinoma (KLK6).	10/399,013	Apr 10, 2003
3	Luo L-Y, Diamandis EP.	JAP EURO	Detection of ovarian cancer (KLK10).	2002-539815 01982020.8 02727132.9	Oct 26, 2001 Nov 1, 2001 May 24, 2002

	Inventor (s)	Country	Title	Application #	Date Filed
4	Diamandis EP.	CAN AUSTR JAP EURO	Method of detecting and monitoring ovarian cancer (1st Prov.) and Method of detecting and monitoring prostate and ovarian cancer (KLK11) (2nd Prov.).	2,448,355 2002-257464 2003-500566	May 24, 2002 May 24, 2002 May 24, 2002
5	Yousef GM, Diamandis EP.	CAN JAP KOREAN	Method for detecting ovarian cancer (KLK9).	2,463,920 2003-536454 10-2004-7005644	Oct 16. 2002 Oct 16, 2002 Oct 16, 2001
6	Diamandis EP.	USA	Localization of disorders associated with kallikreins (hK6).		Oct. 16, 2002
7	Yousef GM, Diamandis EP.	CAN	Methods for detecting endocrine cancer (hK13), as a biomarker	2,497,058 2,497,061	Aug 28, 2003
8	Diamandis EP.	CAN EUR	Methods for detecting prostate cancer (hK11 and PSA).	2.498,147 03753166.2	Sept 26, 2003 Sept 26, 2003
9	Diamandis EP.	CAN	Methods for detecting endocrine cancer (hK12, hK14 & hK15).	2,499,261	Sept 26, 2003
10	Kishi T, Diamandis EP.	EURO CAN	Methods for detecting ovarian cancer (kallikrein 8).	03709529.6 2,481,093	Apr 4, 2003 Apr 4, 2003
11	Diamandis EP.	CAN	Multiple marker assay for detection of ovarian cancer (CA125 & kallikreins 5,6,7,8,10 and 11)	2,516,591	Feb 26, 2004
12	Diamandis EP.	USA	Kallikrein 14 markers for cancer.		Feb. 27, 2003
13	Diamandis EP, Petraki CD.	CAN	Assay for detection of renal cell carcinoma (kallikreins 5,6,10 and 11)	2,516,588	Feb 26, 2004
14	Diamandis EP, Petraki CD.	USA	Assay for detection of prostate cancer.		Feb. 27, 2003
15	Diamandis EP.	USA	Inhibitors of kallikrein 6.		Feb. 27, 2003
16	Diamandis EP.	CAN	Detection of nerurodegenerative diseases.	2,468,651	Jun 14, 2004
17	Yousef GM, Diamandis EP	CAN EUR	Novel human kallikrein-like genes	2,362,885 06076156.6	Mar 9, 2000 Mar 9, 2000
18	Chu C-W, Diamandis EP	USA	Methods and compositions for the identification and diagnosis of diseases and/or conditions of the breast (hK6 & CA15)	60/652,636	Feb 14, 2005
19	Diamandis EP and Kulasingam V	USA INTL	Methods for the detection of breast cancer (ALCAM and BCAM)	60/985,861 PCT/CA2008/001072	Nov 6, 2007 Jun 6, 2008
20	Diamandis EP and Planque CP	USA	Identification of Five Candidate Lung Cancer Biomarkers by Proteomic Analysis of Conditioned Media of Four Lung Cancer Cell Lines	61/245,156 PCT/CA2010/001511	Sept 23, 2009 Sept 23, 2010
21	Diamandis EP and Makawita S	USA	Methods and compositions for the detection of pancreatic cancer	61/436,937	Jan 27, 2011
22	Diamandis EP and Cho C-KJ	USA	Biomarkers for the detection and screening of Down syndrome	61/483,941	May 9, 2011
23	Prassas I, Diamandis EP, Datti A	USA	Pancreatic Cancer Compositions and Methods	61/578,537	Dec 21, 2011
24	Diamandis EP, Makawita S, Prassas I, Chrystoja C, Kosanam HM, Soosaipillai A	USA	Three in one: Bioinformatic identificaton of proteins with tissue-specific expression for biomarker discovery; CUZD1 (CUB and zona pellucida-like domains 1): a new biomarker for pancreatic carcinoma; LAMC2 and DSG2: Two novel pancreatic cancer biomarkers	61/611,955	March 16, 2012
25	Diamandis EP, Cho, CK.J, Martinez-Morillo E	USA	Methods and biomarkers for the detection and screening of Down Syndrome	61/653,847	May 31, 2012
26	Diamandis EP, Kulasingam V, Leung F.	USA	Biomarker for the detection and monitoring of cancer	61/677,870	July 31, 2012

GenBank Submissions

No.	Description	Authors	Accession#	Submitted	Latest Update
1-41	Sequence 1-41 from patent US 5552283	Diamandis,E., Dunn,J.M. and Stevens,J.K.	125682-125722	07-OCT-1996	05-JUL-2002
42	HSU90205 Human lung carcinoma (E.P.Diamandis) Homo sapiens cDNA, MRNA sequence	Diamandis,E.P.	U90205	29-JUL-1997	29-JUL-1997
43	Homo sapiens chromosome 5 external transcribed spacer, complete sequence	Diamandis,E.P. and Prody,C.A.	AF038385	11-DEC-1997	28-SEP-2001
44	Homo sapiens kallikrein 10 (KLK10) gene, complete cds	Luo,L.Y. and Diamandis,E.P.	AF055481	24-MAR-1998	30-AUG-2000
45	Kallikrein 10 [Homo sapiens]	Luo,L.Y. and Diamandis,E.P.	AAC14266	24-MAR-1998	30-AUG-2000
46	Stratum corneum chymotryptic enzyme [Homo sapiens]	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AAD49718	30-DEC-1999	18-SEP-2000
47-48	Kallikrein-like protein 5-related protein 1, 2 [Homo sapiens]	Yousef,G.M., Magklara,A. and Diamandis,E.P.	AAF06065, AAF06066	01-NOV-1999	27-JUN-2000
49	Homo sapiens testis-specific kinase substrate (TSKS) gene, complete cds	Scorilas,A., Yousef,G. and Diamandis,E.P.	AF200923	31-OCT-1999	17-AUG-2001
50	Homo sapiens stratum corneum chymotryptic enzyme	Yousef,G.M., Scorilas,A. and	AF166330	07-JUL-1999	18-SEP-2000

No.	Description	Authors	Accession#	Submitted	Latest Update
	gene, complete cds	Diamandis,E.P.		30-DEC-1999	
51	Homo sapiens trypsin-like serine protease (TLSP) gene, complete cds	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AF164623	01-JUL-1999	26-JUN-2000
52	Trypsin-like serine protease [Homo sapiens]	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AAD47815	01-JUL-1999	26-JUN-2000
53	Homo sapiens kallikrein-like protein 6 (KLKL6) gene, complete cds	Yousef,G.M. and Diamandis,E.P.	AF161221	21-JUN-1999	19-JAN-2000
54	Kallikrein-like protein 6 [Homo sapiens]	Yousef,G.M. and Diamandis,E.P.	AAD50773	21-JUN-1999	19-JAN-2000
55	Kallikrein 14 precursor (Kallikrein-like protein 6) (KLK-L6)	Yousef,G.M. and Diamandis,E.P.	Q9P0G3	~JUN-1999	15-JUN-2002
56	Homo sapiens kallikrein-like serine protease gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF149289	08-MAY-1999	26-JUN-2000
57	Kallikrein-like serine protease; zyme; protease M; neurosin [Homo sapiens]	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AAD51475	08-MAY-1999	26-JUN-2000
58	Homo sapiens kallikrein-like protein 5 gene, alternative splice products, complete cds	Yousef,G.M., Magklara,A. and Diamandis,E.P.	AF135025	13-MAR-1999 01-NOV-1999	27-JUN-2000
59	Homo sapiens sialic acid-binding immunoglobulin-like lectin-9 (SIGLEC9) gene, complete cds	Yousef,G.M., Foussias,G. and Diamandis,E.P.	AF135027	13-MAR-1999 04-NOV-1999	03-AUG-2000
60	Homo sapiens kallikrein-like protein 4 KLK-L4 gene, complete cds	Yousef,G.M. and Diamandis,E.P.	AF135024	13-MAR-1999 19-OCT-1999	26-JUN-2000
61	Homo sapiens kallikrein-like protein 2 KLK-L2 gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF135028	13-MAR-1999	27-JUN-2000
62	Homo sapiens kallikrein-like protein 1 KLK-L1 gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF135023	13-MAR-1999	27-OCT-1999
63	Kallikrein-like protein 3 [Homo sapiens]	Yousef,G.M., Grass,L. and Diamandis,E.P.	AAD26427	13-MAR-1999	24-SEP-2001
64	Kallikrein-like protein 3 splice variant 1 [Homo sapiens]	Yousef,G.M., Grass,L. and Diamandis,E.P.	AAG22845	13-MAR-1999	24-SEP-2001
65	Homo sapiens kallikrein-like protein 3 (KLK9) gene, complete cds, alternatively spliced	Yousef,G.M., Grass,L. and Diamandis,E.P.	AF135026	13-MAR-1999	24-SEP-2001
66	AF098797 Human Homo sapiens genomic clone PAC 42H21, genomic survey sequence	Luo LY	AF098797	20-JAN-1999	01-MAR-2001
67-70	Acid phosphatase variant 1,2,3 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAK09393 - AAK09396	16-NOV-2000	06-JUL-2001
71	Homo sapiens testicular acid phosphatase (ACPT) gene, complete cds, alternatively spliced products	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF321918	16-NOV-2000	06-JUL-2001
72	Homo sapiens alpha-adaptin A related protein (AP2A1) gene, complete cds, alternatively spliced	Scorilas,A. and Diamandis,E.P.	AF289221	25-JUL-2000	10-JUN-2002
73	Homo sapiens Bcl-2 related proline-rich protein (BCL2L12) gene, complete cds, alternatively spliced	Scorilas,A. and Diamandis,E.P.	AF289220	24-JUL-2000	10-APR-2001
74	Bcl-2 related proline-rich protein [Homo sapiens]	Scorilas,A. and Diamandis,E.P.	AAG29496	24-JUL-2000	10-APR-2001
75	Sialic acid binding immunoglobulin-like lectin 8 long splice variant [Homo sapiens]	Foussias,G., Yousef,G.M. and Diamandis,E.P.	AAG00573	14-JUL-2000	08-DEC-2000
76	Homo sapiens sialic acid binding immunoglobulin-like lectin 8 long splice variant (Siglec8) gene, complete cds	Foussias,G., Yousef,G.M.and Diamandis,E.P.	AF287892	14-JUL-2000	08-DEC-2000
77	Testis-specific kinase substrate [Homo sapiens]	Scorilas,A., Yousef,G. and Diamandis,E.P.	AAF12819	19-JUN-2000 10-AUG-2000	17-AUG-2001
78	Sialic acid-binding immunoglobulin-like lectin-like short splice variant [Homo sapiens]	Foussias,G., Taylor,S.M., Yousef,G.M., Tropak,M.B., Ordon,M.H. and Diamandis,E.P.	AAK51233	14-JUN-2000	05-SEP-2001
79	Homo sapiens sialic acid-binding immunoglobulin-like lectin-like splice variants (SLG) gene, complete cds, alternatively spliced	Foussias,G., Taylor,S.M., Yousef,G.M., Tropak,M.B., Ordon,M.H. and Diamandis,E.P.	AF277806	14-JUN-2000	05-SEP-2001
80	Homo sapiens kallikrein serine protease 1 (KLK1) gene, complete cds	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF277050	12-JUN-2000	18-JUL-2000
81	Kallikrein serine protease 1 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAF86333	12-JUN-2000	18-JUL-2000
82	Homo sapiens ser/arg-rich pre-mRNA splicing factor SR-A1 (SR-A1) gene, complete cds	Scorilas,A. and Diamandis,E.P.	AF254411	08-APR-2000	25-JUL-2000
83	HSC 00056 RPCI-11 Human Male BAC Library Homo sapiens genomic clone 3H_NH0288H01, genomic survey sequence	Scherer, S.W. Tsui, L.C., Diamandis, E.	AZ081612	05-APR-2000	07-APR-2000
84	HSC 00055 RPCI-11 Human Male BAC Library Homo sapiens genomic clone H_NH0288H01, genomic survey sequence	Scherer, S.W. Tsui, L.C., Diamandis, E.	AZ081611	05-APR-2000	07-APR-2000
85	Homo sapiens serine protease kallikrein/ovasin/neuropsin type (KLK8) gene, complete cds, alternatively spliced	Magklara,A., Yousef,G.M. and Diamandis,E.P.	AF251125	09-MAR-2000	30-APR-2001
86	Serine protease kallikrein/ovasin/neuropsin type 4	Magklara,A., Yousef,G.M. and	AAF79145	09-MAR-2000	30-APR-2001

No.	Description	Authors	Accession#	Submitted	Latest Update
	[Homo sapiens]	Diamandis,E.P.			
87-90	KLK15 splice variant 1, 2, 3 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAG09469 - AAG09472	06-MAR-2000	03-JAN-2001
91	Homo sapiens KLK15 (KLK15) gene, complete cds, alternatively spliced	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF242195	06-MAR-2000	03-JAN-2001
92	Homo sapiens protein arginine N-methyltransferase 1 (HRMT1L2) gene, complete cds, alternatively spliced	Scorilas,A., Black,M.H. and Diamandis,E.P.	AF222689	07-JAN-2000	10-APR-2001
93	Homo sapiens carcinoembryonic antigen-like proteins (CEAL1) gene, complete dcs, alternatively spliced	Scorilas, A, Chiang PM, Katsaros D, Yousef GM and Diamandis EP.	AF406955	07 AUG 2001	11 JUL 2003
94	Homo sapiens sialic acid binding Ig-like lectin 5 (SIGLEC5) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040820	18-JUN-2001	23-APR-2002
95	Homo sapiens CD33 antigen (CD33) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040541	15-JUN-2001	21-APR-2002
96	Homo sapiens sialic acid binding immunoglobulin-like lectin 6 (SIGLEC6) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040542	15-JUN-2001	21-APR-2002
97	Homo sapiens SIGLECP2 pseudogene, complete sequence	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040545	15-JUN-2001	21-APR-2002
98	Homo sapiens SIGLECP1 pseudogene, complete sequence, alternatively spliced	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040544	15-JUN-2001	21-APR-2002
99	Homo sapiens sialic acid binding immunoglobulin-like lectin 7 (SIGLEC7) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040543	15-JUN-2001	21-APR-2002
100	Homo sapiens siglec-like protein (SLG2) gene and alternatively spliced variants, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY029277	06-APR-2001	06-SEP-2001
101-140	Sequence 1-41 from patent US 6071726	Diamandis,E., Dunn,J.M. and Stevens,J.K.	AR097377 - AR097417	14-FEB-2001	05-JUL-2002
141	Homo sapiens YKLK1 pseudogene, complete sequence	Yousef GM, Borgono CA and Diamandis EP.	AY302756	19 MAY 2003	11 JUL 2003
142	Homo sapiens cancer-associated gene protein gene, complete cds.	Yousef GM, Borgono CA, Davidian CT, Michael I and Diamandis EP.	AY279382	19 APR 2003	11 JUL 2003
143	Homo sapiens kallikrein 15 is oform 5 preproprotein (KLK15) mRNA, complete cds; alternatively spliced	Michael IP, Yousef GM, Du DC and Diamandis EP.	AY373373	24 AUG 2003	22 SPET 2003
144	Homo sapiens kallikrein 15 is oform 6 preproprotein *KLK15) mRNA	Michael IP, Yousef GM, Du DC and Diamandis EP.	AY373374	24 AUG 2003	22 SEPT 2003
145	Homo sapiens kallikrein 14 (KLK14), mRNA	Yousef GM, BorgonoCA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P and Diamandis EP.	NM_022046	05 OCT 2003	
146	Homo sapiens kallikrein 5 isoform e preproprotein (KLK5) mRNA complete cds, alternatively spliced	Michael IP, Kurlender L, Du DC, Diamandis EP.	Bankit 582787	9 NOV-2003	
147	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA, partial sequence.	Michael IP, Elliott MB, Diamandis EP.	AY566267	3 MAR 2003	27 MAR 2004
148	Homo sapiens kallikrein 9 splice variant 2 (KLK9) mRNA, complete cds; alternatively spliced (incomplete 3' UTR)	Kurlender LE, Michael IP, Diamandis EP.	Bankit 602379	16 FEB 2004	
149	Homo sapiens kallikrein 10 splice variant 3 (KLK10) gene, complete cds, alternatively spliced.	Yousef GM, White NMA, Robb J-D, Kurlender L, Diamandis EP.	AY561634	28 FEB 2004	22 MAR 2004
150	Homo sapiens kallikrein 10 (KLK10) Mrna, complete cds.	Yousef GM, White NMA, Robb J-D, Kurlender L, Diamandis EP.	AY561635	28 FEB 2004	22 MAR 2004
151	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA – partial sequence A	Michael IP and Diamandis EP	Bankit 748383	23 OCT 2005	
152	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA – partial sequence B	Michael IP and Diamandis EP	Bankit 761216	23 OCT 2005	
153	KLK11 (Kallikrein-related peptidase 11)	Luo Liu-Ying and Diamandis EP	NM_006853 /144947	MAR 2008	

Abstracts

1978

1. Hadjiioannou TP, Koupparis MA, *Diamandis EP*. New Chloramine-T and picrate ion-selective electrodes. **Proc Analyt Div Chem Soc**, March, 1978, p.78-80.

1980

2. *Diamandis EP*, Papastathopoulos DS. Hadjiioannou TP. Automated serum albumin determination based on the reaction with picrate ions using a flow-through picrate ion-electrode. **Proc of the 1st Balkan Chemistry Days**. Athens, Greece, April 17-19, 1980, p.157.

3. Papastathopoulos DS, *Diamandis EP*, Hadjiioannou TP. A new flow- through electrode unit for liquid membrane electrodes. **Proc of the 1st Balkan Chemistry Days**. Athens, Greece, April 17-19, 1980, p.159.

1982

4. Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Semiautomatic potentiometric titrations of drugs with sodium tetraphenylborate and a tetraphenylborate ion-selective electrode. **Proc of the 1st Panhellenic Pharma Conf**, Athens, Greece, March 14-17, 1982.

1983

5. Sarantonis E, Karayannis MI, *Diamandis EP*. The TNBS-Ion electrode. Some applications in kinetic methods of analysis. Abstracts of the **First Intl Symp of Kinetics in Anal Chem**, Cordoba, Spain, September 27-30, 1983, p.12.

1984

6. Ellis G, *Diamandis EP*, Giesbrecht E, Allen LC. An automated HPLC method for hemoglobin A**. Clin Chem**, 1984;30:978, #198. [AACC- July 29-August 3, 1984]

7. Papanastasiou-Diamandi A, *Diamandis EP*, Soldin SJ. Enzymatic measurement of primary bile acids in serum with the IL-Multistat III fluorescence Light Scattering centrifugal analyzer. **Clin Chem** 1984;30:971, #159. [AACC July 29-August 3, 1984]

8. *Diamandis EP*, D'Costa M. Improved liquid chromatographic determination of urinary free cortisol after solid-state extraction. **Clin Chem** 1984;30:1042, #520. [AACC- July 29-August 3, 1984]

9. *Diamandis EP*, Hoffman B, Pollard A. Hemoglobin measurement in serum and gastric aspirates based on peroxidase activity, automated on the Technicon. RA-1000 Random Access Analyzer. **Revista Brasileira de Analises Clinicas** 1984;16:127. [IFCC-September 3-10, 1984, Columbia].

1985

10. Papanastasiou-Diamandi A, *Diamandis EP*, Souvatzoglou A. Solid-state extraction of digoxin-like substances from human urine. **Clin Biochem** 1985;18:202, #9. [CSCC]

11. Christopoulos TK, *Diamandis EP*. Assay of albumin in serum based on specific ion binding and ion-selective electrode (ISE) potentiometry. **Clin Biochem** 1985;18:202, #009. [CSCC]

12. Christopoulos TK, *Diamandis EP*. Assay of albumin in serum based on specific ion-binding and ion-selective electrode potentiometry. **Clin Chem** 1985;31:904, #8. [AACC]

1986

13. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Assay of catecholamines in urine and serum with high performance liquid chromatography and electrochemical detection. **Proc of the 13th Panhellenic Conf of Greek Endocrinol Soc**, Athens, Greecen April 1986. [in Greek]

14. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Isolation and purification of digoxin like immunoreactive substances from cord blood serum. **Proc of the 13th Panhellenic Conf** of the Greek Endocrinology Society, Athens, Greece, April 1986. [in Greek]

15. Christopoulos TK, *Diamandis EP*. Application of ion-selective electrodes for the study of the binding of ions to albumin. **Proc of the 11th Panhellenic Chemistry Conf**, Athens, Greece, December 1986. [in Greek]

16. Christopoulos TK, *Diamandis EP*. New types of ion-selective electrodes for continuous-flow clinical analysis. **Proc of the 11th Panhellenic Chemistry Conf**, Athens, Greece, December 1986. [in Greek]

17. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Koupparis MA. Ion-selective electrodes for the direct monitoring of the release of the active ingredients in dissolution studies of drugs. Automation with a continuous-flow system. **Proc of the 11th Panhellenic Chemistry Conf**, Athens, Greece, December 1986. [in Greek]

18. *Diamandis EP*, Yiannakou L, Souvatzoglou A. Extraction, purification and characterization of digoxin-like immunoreactive substances (DLIS) from cord blood plasma. **Clin Chem** 1986;32:1080. [AACC & CSCC]

1987

19. Chan MA, *Diamandis EP*. A time-resolved fluoroimmunoassay for the determination of alpha-fetoprotein in serum. **Clin Chem** 1987;33:919, #190. [AACC]

20. Chan MA, Bellem AC, *Diamandis EP*. A time-resolved fluoroimmunoassay for alpha-fetoprotein in serum and amniotic fluid. **Clin Biochem** 1987;20:285, #10. [CSCC]

21. *Diamandis EP*, Reichstein E, Ramjeesingh M. Labelling strategies in time-resolved fluoroimmunoassays and immunofluorometric assays. **Clin Biochem** 1987;20:285, #11. [CSCC]

22. Chan MA, Bellem AC, *Diamandis EP*. A time-resolved fluoroimmunoassay for ferritin in serum. **Clin Biochem** 1987;20:294, #36. [CSCC]

23. *Diamandis EP*, Reichstein E, Conway K. Cortisol assay in serum with competitive immunoassay and time-resolved fluorescence spectroscopy. **Clin Biochem** 1987;20:294, #37. [CSCC]

24. Khosravi MJ, *Diamandis EP*. Determination of human chorionic gonadotropin by a time-resolved immunofluorometric assay. **Clin Biochem** 1987;20:294, #38. [CSCC]

25. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Effect of steroid hormones on the assessment of the level of digoxin like immunoreactive substances. **Proc of the 14th Panhellenic Conf** of the Greek Endocrinology Society. Athens 1987. [in Greek]

1988

26. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Extraction, immunoprecipitation and calculation of the cross-reactivity and concentration of digoxin-like immunoreactive substances (DLIS) in cord blood plasma. **Proc of the 8th Int Congress of Endocrinol**. Tokyo, Japan 1988.

27. *Diamandis EP*, Morton RC. Protein labeling with the fluorescent probe, 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA), procedures and applications in immunoassays. **Clin Chem** 1988;34:1155, #013. [AACC]

28. *Diamandis EP*, Evangelista RA, Pollak A, Templeton EF, Lowden JA. Time-resolved fluoroimmunoassays with europium chelates as labels. A new generation of alternative immunoassays. **Clin Chem** 1988;34:1155, #014. [AACC]

29. *Diamandis EP*, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescent labeling of streptavidin for highly sensitive time resolved immunoassays. **Clin Chem** 1988;34:1157, #021. [AACC]

30. Papanastasiou-Diamandi A, Bhayana V, *Diamandis EP*. A non-isotopic total thyroxine immunoassay with time-resolved fluorescence and a monoclonal antibody. **Clin Chem** 1988;34:1210, #281. [AACC]

31. Reichstein E, Morton RC, *Diamandis EP*. A sensitive assay for TSH with time-resolved fluorescence and monoclonal antibodies. **Clin Chem** 1988;34:1216, #309. [AACC]

32. Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometry of lutropin. A highly sensitive and rapid procedure. **Clin Chem** 1988;34:1221, #336. [AACC]

33. Kahan I, Papanastasiou-Diamandi A, D'Costa M, *Diamandis EP*. A time-resolved immunofluorometric assay for the measurement of prolactin in serum. **Clin Chem** 1988;34:1226, #357. [AACC]

34. Khosravi MJ, Chan MA, Bellem AC, *Diamandis EP*. A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. **Clin Chem** 1988;34:1275, #600. [AACC]

35. *Diamandis EP*, Bhayana V, Conway K, Reichstein E, Papanastasiou-Diamandi A. A time-resolved fluoroimmunoassay of cortisol in serum - a rapid non-isotopic assay. **Clin Chem** 1988;34:1216, #312. [AACC]

36. Khosravi MJ, *Diamandis EP*. A sensitive immunoassay of choriogonadotropin (hCG) by time-resolved fluorescence spectroscopy with a new europium chelate as label. **Clin Chem** 1988;34:1220, #327. [AACC]

37. *Diamandis EP*, Evangelista RA, Pollak A, Templeton EF, Lowden JA. A new generation of time-resolved fluoroimmunoassays with europium chelates as labels. **J Biolumin Chemilumin** 1988;2:200, #55LI.

1989

38. Bhayana V, *Diamandis EP*. A solid-phase time-resolved immuno-fluorometric assay for carcinoembryonic antigen (CEA). **Clin Chem** 1989;35:1077, #059. [AACC]

39. *Diamandis EP*, Papanastasiou-Diamandi A, Lustig V, Khosravi MJ, Tan A. A time-resolved immunofluorometric assay of human pancreatic amylase in serum. **Clin Chem** 1989;35:1117, #241. [AACC]

40. Khosravi M, *Diamandis EP*. Time-resolved immunofluorometry of follitropin in serum. **Clin Chem** 1989;35:1138, #344. [AACC]

41. Reichstein E, *Diamandis EP*. Immunoassay of neonatal hTSH in paper discs using time-resolved fluorescence. **Clin Chem** 1989;35:1139, #345. [AACC].

42. Tan A, Khosravi MJ, *Diamandis EP*, Time-resolved immunofluorometric assay for thyroxine-binding globulin in serum. **Clin Chem** 1989;35:1139, #346. [AACC]

43. Shankaran P, Reichstein E, *Diamandis EP*. Immunoassays for rubella antibodies (IgG and IgM) in serum using time-resolved fluorescence. **Clin Chem** 1989;35:1153, #413. [AACC]

44. McLaurin J, Makela SK, *Diamandis EP*, Ellis G. Evaluation of the CyberFluor time-resolved fluorescence immunoassay for human growth hormone in the diagnosis of growth hormone deficiency. **Clin Biochem** 1989;22:260, #M13. [CSCC]

45. Papanastasiou-Diamandi A, Morton RC, Khosravi MJ, *Diamandis EP*. New assay configurations for competitive-type time-resolved fluoroimmunoassays of haptens. **Clin Biochem** 1989;22:260-261, #M14. [CSCC]

46. Morton RC, *Diamandis EP*. A streptavidin based macromolecular complex labeled with a europium chelator as a universal detection system in time-resolved fluorescence immunoassay. **Clin Biochem** 1989;22:261, #M15. [CSCC]

1990

47. Breborowicz A, Rodela H, Pagiantzis J, *Diamandis EP*, Oreopoulos DG. Glucose toxicity to human mesothelial cells in vitro. **Proc of the 10th Ann Conf on Peritoneal Dialysis**, Dallas, TX, February 1990.

48. Breborowicz A, Rodela H, Pagiantzis J, *Diamandis EP*, Oreopoulos DG. Mesothelial cells produce a growth promoting factor. **Proc of the 10th Ann Conf on Peritoneal Dialysis**, Dallas, TX, February 1990.

49. Christopoulos TL, Lianidou ES, *Diamandis EP*. Ultrasensitive analytical methodologies using time-resolved fluorometry and laser-excited solid-phase measurements. **Clin Chem** 1990;36:1094, #0665. [AACC]

50. Lianidou ES, Christopoulos TK, *Diamandis EP*. Creatine kinase isoenzyme MB quantification in serum with time-resolved immunofluorometry. **Clin Chem** 1990;36:1130, #829. [AACC]

51. Wong T, McLaurin J, Makela SK, *Diamandis EP*, Ellis G. Development of a time-resolved fluorescence immunoassay for 17a- hydroxyprogesterone. **Clin Chem** 1990;36:1150, #0925. [AACC]

1991

52. *Diamandis EP*, Kitching R, Christopoulos TK. Enzyme amplified time-resolved fluoroimmunoassays. **Clin Chem** 1991;37:1038, #0612. [AACC]

53. Christopoulos TK, *Diamandis EP*. Applications of time-resolved fluorometry in molecular biology techniques. **Clin Chem** 1991;37:1060, #0716. [AACC]

1992

54. Hassapoglidou S, *Diamandis EP*. The p53 suppressor gene product quantified in cell lines, Tumour tissue and biological fluids using an ultrasensitive time-resolved fluorescence immunoassay. **Clin Biochem** 1992;25:135, #15. [CSCC]

55. Chan A, Krajden M, *Diamandis EP*. Direct and indirect quantification of polymerase chain reaction products with a time-resolved fluorometric scanner. **Clin Biochem** 1992;25:137, #21. [CSCC]

56. Papanastasiou-Diamandi A, Khosravi MJ, Morton RC, *Diamandis EP*. Total thyroxine immunoassay based enzymatically amplified time-resolved fluorometry. **Clin Biochem** 1992;25:148, #53. [CSCC]

57. *Diamandis EP*, Christopoulos TL. Bean CC. Sensitive and quantitative analysis of Western blots by using time-resolved immunofluorometry. **Clin Chem** 1992;38:987, #0224. [AACC]

58. Hassapoglidou S, *Diamandis EP*. Non-isotopic detection techniques for Southern blot analysis of single-copy genes. **Clin Chem** 1992;38:991, #0240. [AACC]

59. *Diamandis EP*, Grass LC, Uldall R, Mendelsohnn D, Maini D. Mannitol in serum of hemodialysis patients measured by fluorometry and mannitol dehydrogenase from Leuconostoc mesenderoides. **Clin Chem** 1992;38:984, #0213. [AACC]

1993

60. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Waterhouse AL, Soleas GJ. A definitive gas-chromatographic mass-spectrometric assay for resveratrol suitable for industrial and biological samples. **Clin Biochem** 1993;26:126-127, #11. [CSCC]

61. Angelopoulou K, *Diamandis EP*, Kellen J, Bunting P, Sutherland D. Prevalence of antibodies against p53 protein in various cancers. **Clin Biochem** 1993;26:128-129, #16. [CSCC]

62. Angelopoulou K, *Diamandis EP*. New methodology for measuring anti-p53 antibodies in human serum. **Clin Biochem** 1993;26:129, #17. [CSCC]

63. Chan A, Krajden M, *Diamandis EP*. Quantification polymerase chain reaction analysis of pathogenic DNA sequence using an internal DNA sequence standard constructed by recombinant DNA methodology. **Clin Biochem** 1993;26:136-137, #35.[CSCC]

64. Chan A, Jiu Z, Krajden M, *Diamandis EP*. Quantitative analysis of polymerase chain reaction products with high performance liquid chromatography and fluorometric detection. **Clin Biochem** 1993;26:137, #36. [CSCC]

65. Morton RC, Papanastasiou-Diamandi A, *Diamandis EP*, Khosravi MJ. Time-resolved enzyme immunoassay for the determination of thyrotropin in serum. **Clin Biochem** 1993;26:139, #42. [CSCC]

66. Papanastasiou-Diamandi A, Morton RC, *Diamandis EP*, Khosravi MJ. A highly sensitive alpha-fetoprotein (AFP) immunoassay based on enzymatically amplified time-resolved fluorometry. **Clin Biochem** 1993;26:140, #44. [CSCC]

67. Goldberg DM, Karumanchiri A, Eng E, *Diamandis EP*, Yan J, Soleas GJ, Waterhouse AL. Resveratrol content of wines assayed by a direct gas chromatographic-mass spectrometric technique. **Am J En**ol **Vitic** 1993;44:344.

68. Soleas GJ, Goldberg DM, *Diamandis EP*, Karumanchiri A, Ng E, Yan J. A gas chromatographic-mass spectrometric method for the analysis of resveratrol in juice and wine samples. **Am J Enol Vitic** 1993;44:344.

1994

69. Katsaros D, Zola P, Sismondi P, Levesque M, *Diamandis EP*. Prognostic value of p53protein accumulation in ovarian carcinomas. **Cancer Res** 1994;35:234, #1399 [AACC].

70. Angelopoulou K, *Diamandis EP*, Bunting PS. Colorectal carcinoma elicits a humoral immune response against p53 mutant protein. **Clin Biochem** 1994;27:201, #10. [CSCC]

71. Goldberg DM, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR. Is resveratrol the solution to the French paradox? **Clin Biochem**,1994;27:226, #78. [CSCC]

72. Zarghami N , Grass L, Sutherland DJA, *Diamandis EP*. Creatine kinase isoenzyme BB is associated with the estrogen receptor in breast cancer. **Clin Biochem** 1994;27:231, #95. [CSCC]

73. *Diamandis EP*, He Y, Grass L. Androgens, progestins and tamoxifen induce PSA production in the breast cancer cell line T-47D. **Clin Biochem** 1994;27:232, #96. [CSCC]

74. Yu H, *Diamandis EP*, Sutherland DJA. Detection of prostate specific antigen in breast Tumours. **Clin Biochem** 1994;27:232, #97. [CSCC]

75. Levesque M, *Diamandis EP*, He Y, Sutherland DJA. Quantitative analysis of prostate specific antigen and mutant p53 protein in breast Tumour cytosols: Relationships with other prognostic indicators. **Clin Biochem** 1994;27:232, #98. [CSCC]

76. Yu H , *Diamandis EP*, Giai M, Ponzone R, Sismondi P, Katsaros D. Evaluation of prostate specific antigen as a prognostic and predictive indicator for breast cancer patients. **Eur J Cancer** 1994;30:A548, #16.

77. Goldberg D, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR, Roncari DAK. Resveratrol and ethanol are mediators of changes in plasma lipids and lipoproteins. **Atherosclerosis** 1994;109:77, #302.

1995

78. Yu H, *Diamandis EP*, Sutherland DJA. Immunoreactive prostate specific antigen in breast cancer cytosols and its association with steroid hormone receptors. **Cancer Res** 1995;36:245, #1463.

79. Yu H, *Diamandis EP*. Prostate specific antigen (PSA) as a new prognostic marker in female breast cancer: molecular characterization and clinical implication. **Cancer Res** 1995;36:246, #1464.

80. Monne M, Croce CM, Yu H, *Diamandis EP*. Molecular characterization of prostate specific antigen mRNA expressed in breast Tumours. **Cancer Res** 1995;36:249, #1484.

81. *Diamandis EP*. Tumour suppressor genes and oncogenes in cancer: Are the present techniques meeting the challenge? **Eur J Clin Chem Clin Biochem** 1995;33:A121.

82. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid and maternal serum. **J Clin Ligand Assay** 1995;18:66.

83. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid and maternal serum. Possible associations with fetal abnormalities. **Clin Chem** 1995;41:S39, #026 [AACC].

84. Yu H, *Diamandis EP*. Identification of prostate specific antigen in milk of lactating women. **Clin Chem** 1995;41:S39, #027 [AACC].

85. Goldberg DM, Tham L, *Diamandis EP*, Karumanchiri A, Soleas G. The assay of resveratrol and its distribution in human blood. **Clin Chem** 1995;41:S115, #366 [AACC].

86. Angelopoulou K, Stratis M, *Diamandis EP*. Humoral immune response against p53 Tumour suppressor gene product in women with ovarian cancer. **Clin Chem** 1995;41:S218, #811 [AACC].

87. Zarghami N, Giai M, Yu, H, Katsaros D, *Diamandis EP*. Creatine kinase BB isoenzyme levels in Tumour cytosols and survival of breast cancer patients. **Clin Chem** 1995;41:S218, #815 [AACC].

88. Yu H, *Diamandis EP*, Levesque MA, Asa S, Monne M, Croce CM. Expression of the prostate specific antigen gene in a primary ovarian carcinoma. **Clin Chem** 1995;41:S219, #816 [AACC].

89. Levesque MA, *Diamandis EP*, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Immunofluorometrically quantified p53 protein as a prognostic indictor in ovarian carcinoma**. Clin Chem** 1995;41:S224, #839 [AACC].

90. Randell EW, Yu H, *Diamandis EP*, Ellis G. Prostate specific antigen in neonates and infants**. Clin Chem** 1995;41:S230, #866 [AACC].

91. *Diamandis EP*, Levesque MA, Clark GM. Quantitative analysis of mutant p53 proteinin breast carcinoma relationships to other prognostic factors. **Clin Chem** 1995;41:S224, #840 [AACC].

92. Galvan B, Christopoulos TK, *Diamandis EP*. Design of a time-resolved fluorometric hybridization assay for the messenger-RNA of prostate-specific antigen. **Clin Chem**1995;41:1686, #042. [AACC]

93. Tham L, Goldberg DM, *Diamandis EP*, Karumanchiri A, Soleas GJ. Extraction of resveratrol from human blood. **Clin Biochem** 1995;28:339, #58 [CSCC].

94. Angelopoulou KA, Stratis M, *Diamandis EP*. Serum p53 autoantibodies: Incidence in ovarian carcinoma. **Clin Biochem** 1995;28:340, #61 [CSCC]..

95. Levesque MA, Clark GM, *Diamandis EP*. Relationships between mutant p53 protein overexpression and other prognostic indicators in breast cancer. **Clin Biochem** 1995;28:340, #62 [CSCC]..

96. Levesque MA, *Diamandis EP*, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Prognostic value of immunofluorometrically quantified p53 protein in ovarian carcinoma. **Clin Biochem** 1995;28:340, #63 [CSCC]..

97. Zarghami N, Giai M, Yu H, Katsaros D, *Diamandis EP*. Association between breast cancer patient survival and levels of creatine kinase BB in Tumour cytosols. **Clin Biochem** 1995;28:341, #64 [CSCC]..

98. Yu H, *Diamandis EP*, Levesque MA, Asa S, Monne M, Croce CM. Prostate specific antigen gene expression in ovarian cancer post-liver transplantation. **Clin Biochem** 1995;28:341, #65 [CSCC]..

99. Yu H, *Diamandis EP*. The milk of lactating women contains prostate specific antigen. **Clin Biochem** 1995;28:341, #66 [CSCC]..

100. Melegos DN, Yu H, Allen LC, *Diamandis EP*. A possible association between fetal abnormalities and levels of prostate specific antigen in amniotic fluid. **Clin Biochem** 1995;28:341, #67 [CSCC]..

101. Hoffman BR, Yu H, *Diamandis EP*. Prostate cancer screening using prostate specific antigen extracted from dried blood on filter paper. **Clin Biochem** 1995;28:342, #68 [CSCC]..

1996

102. Sauter ER, Daly M, Linahan K, Ehay H, Engstrom PF, Sorling A, Bonney G, Ross E, Yu H, *Diamandis EP*. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. **Cancer Res** 1996;37:213, #1458.

103. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. No associations between IGFBP-3 and p53 or PSA in breast cancer. **Cancer Res** 1996;37:189.

104. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. IGF-1, IGF-11, IGFBP-1 and IGFBP-3 as prognostic markers of breast cancer. **Proc 10th Intl Congress Endocrinol** 1996;2:756, #P3-8.

105. *Diamandis EP*. Prostaglandin D_2 synthase in amniotic fluid and maternal serum: possible association with fetal abnormalities. **Prostaglandins** 1996;51:297.

106. Zarghami N, *Diamandis EP*. Concordance between prostate specific antigen mRNA expression and protein in breast tumours. **Clin Chem** 1996;42:S201, #440 [AACC].

107. D'Costa M, Levesque M, Tadros L, *Diamandis EP*. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer. **Clin Chem** 1996;42:S262, #694 [AACC].

108. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Associations between PSA and IGF-1, IGF-11, IGFBP-3 in breast cancer. **Clin Chem** 1996;42:S264, #703 [AACC].

109. Levesque M, D'Costa M, *Diamandis EP*. p53 protein is absent from the serum of patients with lung cancer. **Clin Chem** 1996;42:S262, #695 [AACC].

110. Melegos DN, Yu H, *Diamandis EP*. Prostaglandin D_2 synthase in amniotic fluid: possible association with fetal abnormalities. **Clin Chem** 1996;42:S238, #593 [AACC].

111. Melegos DN, *Diamandis EP*. Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. **Clin Chem** 1996;42:S238, #594 [AACC].

112. Angelopoulou K, *Diamandis EP*, Dunn JM, Jia Q. Fragment analysis of the p53 gene: Method development and clinical applications. **Clin Chem** 1996;42:S202, #443 [AACC].

113. Zarghami N, Grass L, *Diamandis EP*. Regulation of the prostate specific antigen gene in breast cancer cell lines by steroid hormones. **Clin Chem** 1996;42:S236, #586 [AACC].

114. Yu H, Levesque MA, Khosravi MJ, Papanastasioudiamandis A, Clark GM, *Diamandis EP*. Associations between PSA and IGF-I, IGF-II, IGFBP-1 and IGFBP-3 in breast cancer. **Clin Chem** 1996;42:S264, #703 [AACC].

115. Rozenberg RS, *Diamandis EP*, Kendall CWC, Ransom TPP, Jenkins DJA. The effect of plant derived compounds on sex hormone receptors: Implications for hormone-dependent cancer development and treatment. **FASEB J** 1996;10:A491, #2833.

116. *Diamandis EP*, Melegos DN, Oda H, Urade Y, Hayaishi O. Prostaglandin D Synthase: Development of analytical methodology and preliminary clinical studies. **Prostaglandins Leukotrienes and Essential Fatty Acids** 1996;55:57, #187.

1997

117. Kogan I, Ballinger JR, *Diamandis EP*, Melegos DN, Rauth AM. Prostate specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. **Cancer Res** 1997;38:58, #387.

118. Levesque MA, Yu H, Clark GM, *Diamandis EP*. P53 protein accumulation detected by an ELISA technique is a prognostic factor in a large cohort of breast cancer patients. **Cancer Res** 1997;38:255.

119. Sauter E, Zarghami N, *Diamandis EP*, Engstrom P. PSA levels in nipple aspirate fluid are upregulated by progesterone. **Cancer Res** 1997;38:263, #1767.

120. Angelopoulou K, Katsaros D, *Diamandis EP*. The exon 5 of p53 Tumour suppressor gene is a target for deletions in ovarian cancer. **Cancer Res** 1997;38:270, #1815.

121. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Prognostic value of PSA in breast cancer. A large U.S. cohort study. **Cancer Res** 1997;38:437, #2924.

122. Soleas G. *Diamandis EP*, Tomlinson G, Goldberg DM. Identifying the major phenolic antioxidants of wine. **Atherosclerosis** 1997;134:207.

123. Giai M, Ponzone R, Roagna R, Sgro L, Biglia N, Borchert GH, *Diamandis EP*, Sismondi P. Subfractions of prostate specific antigen differ in serum of normal women and women withmalignant and benign breast diseases. **Breast** 1997;6:335, #P919.

124. *Diamandis EP*, Zarghami N, Grass L, Sauter E. Prostate specific antigen levels in serum during the menstrual cycle. Possible regulation by progesterone. **Proc Endocr Soc 79th Ann Meeting** 1997;385, #P2-402.

125. Majumdar S, *Diamandis EP*. Structural characterization of the prostate specific antigen gene from breast Tumours and cell lines. **Clin Biochem** 1997;30:381, #49 [CSCC].

126. Melegos DN, Freedman MS, *Diamandis EP*. Prostaglandin D Synthase in cerebrospinal fluid and serum from patients with various neuropathologies. **Clin Chem** 1997;43:S185, #360 [AACC].

127. Melegos DN, Freedman MS, *Diamandis EP*. Prostate specific antigen immunoreactivity in cerebrospinal fluid. **Clin Chem**; 1997;43:S185, #361 [AACC].

128. Black MH, *Diamandis EP*, Grass CL. Ultrasensitive immunofluorometric assay for measuring free prostate specific antigen. **Clin Chem** 1997;43:S223, #541 [AACC].

129. Levesque MA, Yu H, Clark GM, *Diamandis EP*. ELISA-detected p53 protein in accumulation is a prognostic factor in a large cohort of breast cancer patients. **Clin Chem** 1997;43: S228, #566 [AACC].

130. Zarghami N, Levesque MA, D'Costa M, Angelopoulou K, *Diamandis EP*. Frequency of prostate specific antigen mRNA expression in lung tumours. **Clin Chem** 1997;43:S231, #582 [AACC].

131. Majumdar S, *Diamandis EP*. The prostate specific antigen (PSA) gene is not mutated in either breast tumours or breast carcinoma cell lines. **Clin Chem** 1997;43:S268, #751 [AACC].

132. Angelopoulou K, Yu H, *Diamandis EP*. P53 autoantibodies in sera of breast cancer patients: Association with p53 gene mutations and p53 protein overexpression**. Clin Chem** 1997;43:S271, #770 [AACC].

133. Lianidou ES, Angelopoulou D, *Diamandis EP*. Identification of deletions and insertions in the p53 gene in ovarian tumours by high resolution fragment analysis and DNA sequencing. **Clin Chem** 1997;43:S272, #771 [AACC].

134. *Diamandis EP*. Prostate specific antigen: A tumour marker for prostatic and breast carcinoma. **Balkan J Clin Lab** 1997;4:25.

135. Goldberg DM, *Diamandis EP*. The beneficial health effects of wine drinking – a myth or a reality? **Balkan J Clin Lab** 1997;4:41.

1998

136. Levesque MA, Lianidou ES, Angelopoulou K, Yu H, Genta F, Durando A, Massobrio M, Bharaj B, *Diamandis EP*. Mutational analysis versus ELISA for the detection of p53 gene abnormalities in ovarian carcinoma. **Proc AACR** 1998;39:230-231.

137. Katsaros D, Levesque M, Genta F, Durando A, Arisio R, Yu H, *Diamandis EP*, Massobrio M. Prognostic and predictive implications of p53 and WAF1 expression in ovarian cancer. **Proc AACR** 1998;39:231.

138. Sauter ER, Ehya H, Babb J, *Diamandis EP*, Daly M, Klein-Szanto AJP, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Nipple aspirate fluid (NAF) cytology predicts residual disease after diagnostic biopsy. **Proc AACR** 1998;39:228.

139. Yu H, Levesque MA, Khosravi MJ, *Diamandis EP*, Clark GM. Insulin-like growth factor binding protein 3 and breast cancer recurrence. **Proc AACR** 1998;39:232.

140. Sauter ER, Daly MB, Engstrom PF, Melegos DN, Diamandis A, Khosravi MJ, *Diamandis EP*. IGFBP-3 expression in nipple aspirate fluid (NAF) correlates with breast cancer risk. **Proc AACR** 1998;39:233.

141. Majumdar S, *Diamandis EP*. Mutations in the regulatory region of the prostate specific antigen gene from breast tumours and cell lines. **Proc AACR** 1998;39:248.

142. Angelopoulou K, Yu H, *Diamandis EP*. Mutational spectrum of the p53 gene, Tumour p53 protein overexpression and serum p53 autoantibody generation in patients with breast cancer. **Proc AACR** 1998;39:547.

143. Bharaj B, Angelopoulou K, *Diamandis EP*. Rapid sequencing of the p53 gene with the MicroGene Blaster automated DNA sequencer. **Proc AACR** 1998;39:547.

144. Klijin JGM, *Diamandis EP*, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Foekens JA. Expression of prostate specific antigen correlates with poor response to tamoxifen therapy in recurrent breast cancer. **Proc AACR** 1998;39:553.

145. Black MH, Giai M, Yu H, *Diamandis EP*. Serum prostate specific antigen levels are elevated in females with breast cancer. **Proc AACR** 1998;39:553.

146. Melegos DN, *Diamandis EP*, Helle SI, Yu H, Lundgren S, Lonning PE. Plasma prostate specific antigen levels and prognostic value in patients with metastatic breast cancer following megestrol acetate treatment. **Proc AACR** 1998;39:553.

147. *Diamandis EP*, Kogan I, Prody C, Angelopoulou K, Zarghami N, Herbrick J, Scherer S. Cloning of a novel nucleotide sequence from human lung tissue. **Proc AACR** 1998;39:133.

148. Luo LY, Herbrick J, Scherer S, *Diamandis EP*. Mapping the normal epithelial cell-specific 1 gene to chromosome 19q13. **Proc AACR** 1998;39:133.

149. Katsaros D, Genta F, Durando A, Danese S, Ricchiardi R, Levesque M, *Diamandis EP*, Massobrio M. Prognostic nd predictive value of p53 and WAF1 expression in epithelial ovarian cancer. **Proc ASCO** 1998;17, #1355.

150. Luo L, *Diamandis EP*. Amplification of human genome DNA sequences with polymerase chain reaction using a single oligonucleotide primer. **Proc Oak Ridge Conf**, April 13-15, 1998.

151. Angelopoulou K, *Diamandis EP*, Zargharmi N, Herbrick J, Scherer S. Cloning of a new gene that is overexpressed in lung cancer cell lines. **Clin Biochem** 1998;31:299. [CSCC]

152. Luo L, Grass, *Diamandis EP*. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and its expression is regulated by steroid hormones. **Clin Biochem** 1998;31:299 [CSCC].

153. Luo L, Grass L, *Diamandis EP*. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and its expression is regulated by steroid hormones. Proc **Endocr Soc** 1998; P3-153.

154. Klijn JGM, *Diamandis EP*, Yu H, Look MP, Gelder MEMV, Van Putten WLJ, Foekens JA. The significance of prostate specific antigen (PSA) in breast cancer. **Eur J Cancer**1998;34:S106.

155. Borcheert GH, Giai M, Ponzone R, Roagna R, Sgro L, *Diamandis EP*, Sismondi P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. **Eur J Cancer**1998;34:S3.

156. Katsaros D, Genta F, Durando A, Danese S, Ricchiardi R, Levesque M, *Diamandis EP*, Massobrio M. p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications. **Eur J Cancer**1998;34:S22.

157. Melegos DN, Grass L, Pierratos A, *Diamandis EP*. Serum prostaglandin D synthase concentration is elevated in humans with renal impairment. **Clin Chem** 1998;44:A20 [AACC].

158. Levesque MA, D'Costa M, Spratt EH, Yaman MM, *Diamandis EP*. Prognostic significance of quantitatively-analyzed p53 protein accumulation in lung carcinoma. **Clin Chem** 1998;44:A42 [AACC].

159. *Diamandis EP*, Angelopoulou K, Zarghami N, Herbrick J, Scherer S. Mapping of a novel 5 Kb sequence on human chromosome 5. **Clin Chem** 1998;44:A43 [AACC].

160. Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, *Diamandis EP*. BRCA1-specific antibodies react strongly with a protein present in seminal plasma. **Clin Chem** 1998;44:A43 [AACC].

161. Reddy PP, Bagli DJ, *Diamandis EP*, Melegos DN, Barrieras D, Merguerian P, McLorie GA, Khoury AE. Prostate specific antigen in the study of dysfunctional voiding. **Pediatrics** 1998;102;839.

1999

162. Yousef GM, Luo LY, *Diamandis EP*, Sotiropoulou G, Herbrick J-A, Scherer SW, Grass L. The zyme/protease M/neurosin gene maps close to the human kallikrein gene family and is hormonally regulated. **Proc AACR** 1999;40:34, #230.

163. Scorilas A, *Diamandis EP*, Levesque MA, Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, Lopez-Otin C. Pepsinogen C, an independent favorable prognostic factor in node-positive breast cancer patients. **Proc AACR** 1999;40:205, #1359.

164. Obiezu CV, Black MH, Magklara A, Levesque MA, Sutherland DJA, Tindall DJ, Young CFY, Sauter ER, *Diamandis EP*. Expression of a prostate-associated protein, human glandular kallikrein (hK2) in breast Tumours and in normal breast secretion. **Proc AACR** 1999;40:378, #2505.

165. Yu H, Bharaj B, Giai M, *Diamandis EP*. CAG repeats of the androgen receptor gene in breast cancer and its association with survival. **Proc AACR** 1999;40:380, #2518.

166. Luo LY, Grass L, *Diamandis EP*. The expression of the normal epithelial cell-specific 1 (NES1) gene is regulated by steroid hormones. **Proc AACR** 1999;40:381, #2521.

167. Vassilikos EJK, Yu H, Trachtenberg J, Nam R, Narod S, *Diamandis EP*. How many prostate cancer patients are considered 'cured' after radical prostatectomy? **Proc AACR** 1999;40:381, #2524.

168. Levesque MA, Yu H, Genta F, Massobrio M, Durando A, Bellino R, *Diamandis EP*, Katsaros D. Expression of p53 but not WAF1 is a predictor of response to platinum-based chemotherapy in patients with epithelial ovarian cancer. **Proc AACR** 1999;40:382, #2531.

169. Bharaj B, Vassilikos E, *Diamandis EP*. Rapid and accurate determination of CAG repeat lengths in androgen receptor gene using PCR and automated fragment analysis. **Proc AACR** 1999;40:468, #3094.

170. Angelopoulou K, Borchert G, Lianidou E, Lilja H, *Diamandis EP*. Characterization of a BRCA1-like compound present in human seminal plasma. **Proc AACR** 1999;40:685, #4519.

171. Magklara A, Black MH, Obiezu CV, Melegos DN, *Diamandis EP*. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity with prostate specific antigen. PSA. **Proc AACR** 1999;40:526, #3467.

172. Arnett WP, Zini A, Jarvi K, *Diamandis EP*. Prostaglandin D synthase in human semen: a marker to differentiate obstructive from non-obstructive. **J Urol** 1999;161:280, #1084.

173. Yousef GM, Luo L-Y, *Diamandis EP*. The human kallikrein gene locus – discovery of six new genes. **IFCC-WorldLab Symp II** – Firenze, Italy, 1999;21, #14.

174. Scorilas A, *Diamandis EP*, Levesque MA, Diamandi A, Koshravi MJ, Giai MJ, Ponzone R, Roagna R, Sismondi P, Lopez-Otin C. Prognostic value of pepsinogen C in breast cancer. **IFCC-WorldLab Symp II**-Firenze, Italy, 1999;25, #18.

175. *Diamandis EP*. Tumour markers in prostate cancer. **Clin Chem Lab Med** 1999;37:S33.

176. Zarghami NZ, *Diamandis EP*, Grass L. PSA mRNA expression during menstrual cycle is upregulated by progesterone. **Clin Chem Lab Med** 1999;37:S159, #M172.

177. Lianidou ES, Politis I, Angelopoulou K, *Diamandis EP*. A simple SSCP protocol for mutational analysis of p53 gene, optimized and evaluated in respect to DNA sequencing. **Clin Chem Lab Med** 1999;37:S229, #T050.

178. Obiezu CV, Giltay EJ, Yu H, Magklara A, Soosaipillai AR, Gooren LJG, *Diamandis EP*. Serum prostate specific antigen is significantly elevated after testosterone administration in female to male transsexuals. **Endo Society** 1999;02, #OR29-4.

179. Obiezu CV, Giltay EJ, Yu H, Magklara A, Gooren LJ, *Diamandis EP*. Dramatic suppression of serum prostate specific antigen and human glandular kallikrein by anti-androgens in male to female transsexuals. **Endo Soc** 1999;521, #P3-382.

180. Goodwin PJ, Ennis M, Madarnas Y, Pritchard KI, Trudeau ME, Hood N, *Diamandis EP*. Fasting insulin as a potential mediator of the adverse prognostic effect of obesity in locoregional breast cancer. **22nd Ann San Antonio Breast Cancer Symp**, San Antonio, TX, USA, December 8-11, 1999.

181. Bharaj B, Scorilas A, Hoffman B, Giai M, *Diamandis* EP. A novel ARE-1 polymorphism in the promoter region of the prostate specific antigen gene in healthy females and women with breast cancer. **Clin Chem** 1999;116, A37.

182. Levesque MA, D'Costa M, *Diamandis EP*. ELISA-determined $p21^{WAF1}$ expression does not correlate with non-small cell lung cancer aggressiveness. **Clin Chem** 1999;45:A111.

183. Scorilas A, Diamandi A, Khosravi MJ, Levesque MA, Lopez-Otin C, De Los Toyos J, Sampedro A, Giai A, Ponzone R, Roagna R, Sismondi P, *Diamandis EP*. Determination of pepsinogen C concentration in breast Tumour cytosols by a highly sensitive immunofluometric assay and its association with other prognostic variables. **Clin Chem** 1999;45:A117.

184. Soleas GJ, Angelini M, *Diamandis EP*, Goldbert DM. The absorption of *trans*-resveratrol in the rat. **Can J Cardiol** 1999;15:210D.

185. Soleas GJ, *Diamandis EP*, Goldberg DM, Grass L. Do alcoholic beverages prevent the development of atherosclerosis in the rabbit? **Can J Cardiol** 1999;15:210D.

186. Scorilas A, Bharaj B, Giai M, *Diamandis EP*. Polymorphisms in the human 5α-reductase gene and breast cancer. **Proc AACR-NCI-EORTC Int Conf,** Washington, DC, USA, November 16-19,1999; p 98, #481.

187. Yousef GM, Luo LY, Black MH, *Diamandis EP*. Molecular characterization, mapping, tissue expression and hormonal regulation of KLK-L2, a new member of the kallikrein gene family. **Proc AACR-NCI-EORTC Int Conf,** Washington, DC, USA, November 16-19, 1999, p 98, #482.

188. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. The ratio of human glandular kallikrein (hK2) to free PSA improve the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. **Proc AACR-NCI-EORTC Int Conf,** Washington, DC, USA, November 16-19, 1999, p 98, #483.

189. Yousef GM, Obiezu CV, Luo LY, Black MH, *Diamandis EP*. The new kallikrein-like gene, Prostase/KLK-L1, is expressed in prostate and breast tissues and is hormonally regulated. **Proc AACR-NCI-EORTC Int Conf,** Washington, DC, USA, November 16-19, 1999, p 99, #484.

190. Diamandis EP. Application of ultrasensitive, third-generation prostate specific antigen assays in breast and prostate cancer. **J Clin Ligand Assay** 1999;22:385.

191. *Diamandis EP*, Angelopoulou K. p53 antibodies. **J Clin Ligand Assay** 1999;22:385.

192. Diamandis EP. Application of ultrasensitive, third-generation prostate specific antigen assays in breast and prostate cancer. **J Clin Ligand Assay** 1999;22:385.

193. Katsaros D, Levesque MA, Genta F, Durando A, Bellino R, Mano MP, Aidals S, *Diamandis EP*, Massobrio M. Dose-receptor effect between p453 concentrations, survival and respnsiveness in patients with epithelial ovarian cancer treaded with platinum-based chemotherapy. **Proc ASCO,** Philadelphia, PA, USA, May 15-18, 1999;18: #1454.

2000

194. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. Human glandular kallikrein (hK2) and prostate specific antigen (PSA) in prostate and breast cancer. **Proc AACR** 2000;41:39, #248.

195. Hoffman BR, Scorilas A, *Diamandis EP*, Giai M, Levesque MA, Bharaj B. A prevalent polymorphism in the proximal androgen response element of the prostate specific antigen gene and its implications in breast cancer prognosis. **Proc AACR** 2000;41:93, #596.

196. Katsaros D, Yu H, Francchioli S, Richiardi G, Danese S, Genta F, Levesque MA, Khosravi JM, Papanastasiou-Diamandi A, Gordini G, *Diamandis EP*, Massobrio M. Insulin-like growth factor binding protein-3 (IGFBP-3) is associated with favorable glinicopathological features and survival in patients with epithelial ovarian cancer. **Proc AACR** 2000;41:501, #3195.

197. Sauter ER, Litwin S, Engstrom F. Diamandis A, Khosravi J, *Diamandis EP*. Fragmented insulin-like growth factor binding protein type-3 is inversely associated with breast cancer risk. **Proc AACR** 2000;41:575, #3661.

198. Obiezu CV, Yousef GM, Katsaros D, *Diamandis EP*. Prostase/KLK-L1 is overexpressed in ovarian Tumours. **Proc AACR** 2000;41:684, #4348.

199. Yousef GM, Foussias G, Magklara A, Grass L, *Diamandis EP*. Cloning of KLK-L5, a new member of the kallikrein gene family and its hormonal regulation in breast cancer cell lines. **Proc AACR** 2000;41:747, #4748.

200. Chang A, Yousef GM, *Diamandis EP*. Discovery of a new human kallikrein-like gene, KLK-L4, and the study of its expression in breast cancer. **Proc AACR** 2000;41:747, #4749.

201. Scorilas A, Bharaj B, Hoffman B, Giai M, *Diamandis EP*. The genotypes of the 5α-reductase gene are related with PSA expression and risk in sporadic breast cancer. **Proc AACR** 2000;41:805, #5116.

202. Rosenberg-Zand R, Jenkins DJ, *Diamandis EP*. Antagonist steroid hormone activity of flavonoids and related compounds in an *in vivo* tissue culture system. **Proc AACR** 2000;41:847, #5377.

203. Kim H, Yousef GM, Katsaros D, *Diamandis EP*. Dramatic overexpression of the kallikrein-like gene 2 (KLK-L2), in ovarian carcinomas. **Clin Biochem** 2000;33:230, #16.

204. Luo LY, *Diamandis EP*. Down-regulation of the normal epithelial cell-specific 1 (NES1) gene is associated with unfavorable outcome of prostate cancer. **Clin Biochem** 2000;33:233, #24.

205. Obiezu CV, Scorilas A, Kim H, *Diamandis EP*. Prostase/KLK-L1 is differentially expressed in normal/benign versus malignant ovarian tissues. **Clin Biochem** 2000;33:234, #27.

206. Rosenberg Zand RS, Jenkins DJA, *Diamandis EP*. Anti-androgen activity of flavonoids. **Clin Biochem** 2000;33:238, #40.

207. Scorilas A, Kyriakopoulou L, *Diamandis EP*. Cloning of a human gene, encoding a member of the SER/ARG-rich family of proteins that interact with RNA POL-II. **Clin Biochem** 2000;33:239, #42.

208. Soleas G, Grass L, Josephy D and *Diamandis EP*. Resveratrol, a red wine constituent, anticarcinogenic properties. **Clin Biochem** 2000;33:240, #44.

209. Yousef GM and *Diamandis EP*. The new human kallikrein gene family on chromosome 19q13.3-q13.4 and associations to various tumours. **Clin Biochem** 2000;33:242, #51.

210. Black MH, *Diamandis EP*. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. **Dept of Defense Breast Cancer Res Prog**, Atlanta, GA, USA, June 8-11, 2000; p 49, #J-5.

211. Scorilas A, Kyriakopoulou LG, Yousef GM, *Diamandis EP*. Molecular characterization of a human homolog of the rat A1 gene. **Proc Endo Society**, Toronto, ON, Canada, June 21-24, 2000; p 112, #437.

212. Chang A, Yousef GM, Magklara A, *Diamandis EP*. Hormonal regulation of a novel kallikrein-like gene, KLK-L4, in breast cancer. **Proc Endo Society,** Toronto, ON, Canada, June 21-24, 2000; p 117, #461.

213. Yousef GM, Magklara A, *Diamandis EP*. KLK-L5 is a new, hormonally regulated member of the kallikrein gene family. **Proc Endo Society,** Toronto, ON, Canada, June 21-24, 2000; p 188, #765.

214. Rosenberg Zand RS, *Diamandis EP*, Stanczyk FZ. Hermaphrodiol may contribute significantly to the estrogenic/androgenic hormonal milieu of breast and prostate cancer cells. **Proc Endo Society,** Toronto, ON, Canada, June 21-24, 2000; p 190, #773.

215. *Diamandis EP*, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Yu H. Changes in serum insulin-like growth factor binging protein-2 (IGFBP-2) and prostate cancer recurrence. **Proc Endo Society,** Toronto, ON, Canada, June 21-24, 2000; p 493, #2036.

216. Magklara A, Cheung CC, Asa SL, *Diamandis EP*. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. **Proc Endo Society,** Toronto, ON, Canada, June 21-24, 2000; p 591, #2442.

217. Yousef GM, *Diamandis EP*. Characterization of the human kallikrein gene locus and discovery of six new genes. **Clin Chem** 2000;46:p A170, #659.

218. *Diamandis EP*, Magklara A, Scorilas A, Catalona WJ. Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2): Two hormonally regulated kallikreins with application in breast and prostate cancer. **Intl Congress of Endocrinol (ICE) Proc**. 2000; # P819.

219. *Diamandis EP*. Kallikreins as cancer biomarkers. **Clin Biochem Revs** 2000;21:107.

220. Jenkins DJ, Kendall CW, Jackson CJ, Garsetti M, Rosenberg-Zand RS, Agarwal S, Rao AV, *Diamandis EP*, Parker R, Faulkner D, Vuksam V, Vidgen E. Effect of soy protein foods on LDL oxidation and ex vivo sex hormone receptor acticvity. **FASEB J** 2000;14:A495.

2001

221. Brauer PM, McKeown-Eyssen G, Jazmaji V, Logan AG, Andrews DF, Jenkins DJ, Marcon N, Sabil F, Cohen I, Stern H, Baron D, Greenberg G, *Diamandis EP*, Kakis G, Singer W, Steiner G. Familial aggregation of diabetes, hypertension and cardiovascular conditions in colorectal hyperplastic polyps. **Amer J Epidemiol** 2001;153:S117.

222. Brauer PM, McKeown-Eyssen G, Jazmaji V, Logan AG, Andrews DF, Jenkins DJ, Marcon N, Sabil F, Cohen I, Stern H, Baron D, Greenberg G, *Diamandis EP*, Kakis G, Singer W, Steiner G. Familial aggregation of prostate cancer in colorectal neoplasia. **Amer J Epidemiol** 2001;153:S117.

223. Yoursef GM, *Diamandis EP*, Cloning of seven novel human kallikrein genes: new poteintial cancer biomarkers. **Clin Chem** 2001;47:A130.

224. Yousef GM, Kyriakopoulou L, Scorilas A, Ponzone R, Giai M, Sismondi P, *Diamandis EP*, Rendel L, Ddiamandis M. A novel potential prognostric marker for breast carcinoma. **Clin Chem** 2001;47:A130.

225. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, *Diamandis EP*. A novel prognostic marker in ovarian cancer. **Clin Chem** 2001;47:A132.

226. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendel L, Diamandis M, Ponzone R, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. **Can Breast Cancer Res Inst (CBCRI),** Quebec, Canada**,** May 3-5, 2001;195.

227. Nam R, Narod SA, Trachtenberg J, Magklara A, *Diamandis EP*. Use of human kallikrein-2 (hK2) levels in patient selection for prostate biopsy. **J Urol** 2001;165:204, #845.

228. Sauter ER, Chervoneva I, Diamandis A, Khosravi J, Litwin S, *Diamandis EP*. NAF biomarkers predict premenopausal and serum biomarkers predict postmenopausal breast cancer risk. **Proc AACR** 2001;42:11, #59.

229. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, *Diamandis EP*. Tumour specific activity of kallikrein 6 protein is a prognostic marker of ovarian carcinoma. **Proc AACR** 2001;42:46-47, #243.

230. Luo L-Y, Bunting P, *Diamandis EP*. The KLK10 gene (also known as the normal epithelial cell-specific 1 gene; NES1): A new serum biomarker for ovarian cancer. **Proc AACR** 2001;42:47, #244.

231. Luo L-Y, Soosaipillai, *Diamandis EP*. Identification of immunoreactive antigens in ovarian and breast carcinoma. **Proc AACR** 2001;42:156-157, #838.

232. Bharaj B, Scorilas A, Giai M, *Diamandis EP*. Dinucleotide repeat length polymorphism on the 3′ untranslated region of the SRD5A2 gene in breast cancer. **Proc AACR** 2001;42:495-496, #2668.

233. Luo L-Y, *Diamandis EP*. Protein array analysis with laser-excited solid-phase time-resolved fluorometry. **Proc AACR** 2001;42:564, #3030.

234. Scorilas A, Katsaros D, Kwamie A, Fracchioli S, *Diamandis EP*. The SR-A1 gene, encoding a new member of the human Ser/Arg-Rich family of pre-mRNA splicing factors, is overexpressed in aggressive ovarian tumours and is an independent unfavourable prognostic indicator in ovarian cancer. **Proc AACR** 2001;42:579, #3106.

235. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Massobrio M, *Diamandis EP*. Human kallikrein 1- (hK10, normal epithelial cell-specific 1, NES1) is a new prognostic biomarker for ovarian carcinoma. **Proc AACR** 2001;42:579, #3107.

236. Luo L-Y, Soosaipillai A, Jung K, *Diamandis EP*. Molecular cloning of a novel gene which appears to be down-regulated in testicular cancer. **Proc AACR** 2001;42:748, #4016.

237. Yousef GM, Scorilas A, Jung K, Ashworth L, *Diamandis EP*. Molecular cloning of a new human kallikrein gene, KLK15, which is up-regulated in prostate cancer. **Proc AACR** 2001;42:748, #4017.

238. Magklara A, Scorilas A, Katsaros D, Fracchioli S, Rigault de la Longrais I, Piccinno R, Yousef GM, *Diamandis EP*. The prognostic value of human KLK8 (neuropsin/ovasin) in ovarian cancer and evidence for alternative splicing. **Proc AACR** 2001;42:781, #4194.

239. Obiezu CV, Jung K, Katsaros D, *Diamandis EP*. Expression of a new splice variant of prostase/KLK4 is associated with tissues regulated by steroids. **Proc AACR** 2001;42:781-782, #4196.

240. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, *Diamandis EP*. Down-regulation of a novel human kallikrein gene, KLK14, in endocrine related cancers. **Proc AACR** 2001;42:782, #4198.

241. *Diamandis EP*, Yousef G, Soosaipillai A, Bunting P. Zyme/protease M/neurosin (KLK5 gene): A new biomarker for ovarian cancer diagnosis and monitoring. **Proc AACR** 2001;42:782, #4200.

242. Rosenberg Zand RS, Jenkins DJA, *Diamandis EP*. Steroid hormone effects of natural products and nutraceuticals. **Proc AACR** 2001;42:870, #4667.

243. Katsaros D, Fracchioli S, Genta F, Yousef GM, *Diamandis EP, Diamandis EP*. Frist evidence of expression of the new human kallikrein gene family members (KLK4, KLK5, KLK6) in epithelial ovarian cancer: Genomic organization, molecular characterization and clinical implications. **Proc ASCO** 2001;20:#839.

244. *Diamandis EP*, Petraki C, Karavana VN, Skoufoggiannis PT, Little S, Howarth DJ, Yousef GM. Immunohistochemical localization of a new serine protease, human kallikrein 6, in the islets of Langerhan's and other endocrine organs. **Proc Endocr Soc Meeting**, London, UK, December 3-4, 2001;206, #P1-266.

245. Magklara A, Brown TJ, *Diamandis EP*. Characterization of androgen receptor and co-factor expression in human breast cancer cell lines. **Proc Endocr Soc Meeting,** London, UK, December 3-4, 2001;570, #P3-573.

246. Kollara A, Rosenberg Zand RS, *Diamandis EP*, Brown TJ. Characterization of androgen-dependent prostate specific antigen (PSA) secretion in androgen receptor-transfected human prostate cancer PC-3 cells. **Proc Endocr Soc Meeting,** London, UK, December 3-4, 2001;592, #P3-676.

2002

247. Chang A, Yousef GM, Kapadia C, Scorilas A, Ponzone R, *Diamandis EP*. Favorable prognostic value of KLK13 gene expression in breast cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43: 45, #230.

248. Yousef GM, Fracchioli S, Kyriakopoulou L, Zarghooni M, Scorilas A, Diamandis M, Puopolo M, Massobrio M, *Diamandis EP*, Katsaros D, Danese S. A new potential independent prognostic marker for ovarian cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43: 47, #236.

249. Borgoño CA, Katsaros D, Luo L-Y, Fracchioli S, Yamaguchi N, Soosaipilla A, Grass L, Rigault de la Longrais IA, Puopolo M, Yousef GM, Scorilas A, *Diamandis EP*. The prognostic value of human kallikrein 11 (hK11, trypsin-like serine protease, TLSP) in ovarian cancer cytosols. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43: 47 #237.

250. *Diamandis EP*, Okui A, Mitsui S, Luo L-Y, Soosaipillai AR, Grass L, Nakamura T, Howarth DJC, Yamaguchi N. Human kallikrein 11: a potential new serum biomarker for prostate and ovarian cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43: 47 #238.

251. Zarghooni M, Bharaj B, Fracchioli S, Katsaros D, Rigault de la Longrais IA, *Diamandis EP*, Puopolo M. Identification of two novel single nucleotide polymorphisms (SNPs) within the human kallikrein 6 gene. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:53-54, #270.

252. Yousef GM, Magklara A, Borgoño C, Memari N, Abd Ellatif M, Grass L, *Diamandis EP*. Regulation of the human kallikrein gene 15 (KLK15) by steroids in breast cancer cell lines. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:117, #587.

253. Luo L-Y, Herrera I, Soosaipillai A, *Diamandis EP*. Identification of heat shock protein 90 as tumour antigen in ovarian cancer by serological screening. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:279, #1384.

254. Stephan C, Yousef G, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Welsh JB, Hampton GM, Leoning SA, Dietel M, *Diamandis EP*. Hepsin, potential new marker for prostate cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:388, #1935.

255. Scorilas A, Kletsas D, Katsaros N, *Diamandis EP*. The new member of apoptosis-related proteins, BCL2L12, is down-regulated in aggressive breast tumours and in arrested human fibroblasts. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:529, #2622.

256. Sotiropoulou G, Tsetsenis T, Rogakos V, Symillides G, Pampalakis G, *Diamandis E*, Yiotakis A. Overexpression of active recombinant human kallikrein 13 and characterization of its proteolytic activity. **Proc AACR** 2002;43:538, #2671.

257. Petraki CD, Karavana VN, Gregorakis A, Papanastasiou P, Luo L-Y, *Diamandis EP*. The immunoexpression of human kallikrein 6 and 10 in benign and malignant prostatic tissues. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:563, #2793.

258. Yousef GM, Diamandis M, Stephan C, Jung K, *Diamandis EP*. Testicular acid phosphatase (ACPT): a new gene which is down-regulated in testicular cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:630, #3127.

259. Scorilas A, Plebani M, Mazza S, Soosaipillai A, Katsaros N, Basso D, Pagano F, *Diamandis EP*. Human glandular kallikrein 2 (hK2) and insulin-like growth factor (IGF-1) as discriminating markers between prostate cancer and benign prostatic hyperplasia. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:730, #3620.

260. *Diamandis EP*, Scorilas A, Yousef GM, Stenman U-H, Henrik A, Soosaipillai A, Grass L, Katsaros D. Human Kallikrein 6: a novel serum biomarker for diagnosis, prognosis and monitoring of ovarian cancer. **Proc AACR** 2002;43:741-742, #3679.

261. Luo L-Y, Fracchioli S, Scorilas A, Grass L, Vergote I, van der Zee A, Stenman U-H, *Diamandis EP*, Katsaros D. Human kallikrein 10 is a new serum marker for ovarian cancer diagnosis and prognosis. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:743, #3686.

262. Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, *Diamandis EP*. Human kallikrein 8 (neuropsin) is a potential tumour biomarker for ovarian cancer. **Proc AACR** 2002;43:743, #3688.

263. Yousef GM, Stephan C, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, *Diamandis EP*. Down-regulation of the human KLK5 gene in prostate cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:763, #3786.

264. Yousef GM, Memari N, Scorilas A, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, *Diamandis EP*. A new favorable prognostic marker for breast cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:916, #4540.

265. Memari N, Nakamura T, Kishi T, Yousef GM, Hoffman BR, *Diamandis EP*. Cloning and protein expression of human kallikrein 12: A new poteintial biomarker for breast cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:917, #4544.

266. Kyriakopoulou LG, Scorilas A, Yousef G, Ponzone R, Biglia N, Roagna R, Cacciari F, Sismondi P, *Diamandis EP*. Prognostic significance of human kallikrein 7 (KLK7) in breast cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:917-918, #4548.

267. Yousef GM, Bharaj B, Hoffman B, Poulopoulos J, *Diamandis EP*. Identification of unique polymorphic minisatellites in the human kallikrein locus and their relation to malignancy. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:930-931, #4609.

268. Bharaj B, Luo L-Y, Jung K, Stephan C, Yu H, *Diamandis EP*. Prostate cancer risk associated with single nucleotide polymorphism (SNP) of the human kallikrein 10 gene. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:931, #4610.

269. Stephan C, Jung K, Soosaipillai A, Cammann H, Leoning SA, *Diamandis EP*. Clinical usefulness of human glandular kallikrein 2 within a neural network to improve prostate cancer detection. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:1067, #5286.

270. Stephan C, Yousef GM, Scorilas A, Nakamura T, Kishi T, Jung M, Jung K, Kristiansen G, Hauptmann S, *Diamandis EP*. Quantitative analysis of kallikrein 15 expression in prostate tissues. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:1067-1068, #5287.

271. Stephan C, Soosaipillai A, Jung K, Kristiansen G, Hauptmann S, *Diamandis EP*. The value of serum hK2 for distinguishing pathological stage and grade of prostate cancer. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:1068, #5288.

272. Obiezu CV, Soosaipillai A, Stephan C, Jung K, Howarth DHC, *Diamandis EP*. Immunofluorometric and immunohistochemical detection of a PSA-related protein, prostase (human kallikrein 4), in normal and cancerous prostatic tissues. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:1069, #5294.

273. Soleas G, Grass L, Josephy PD, *Diamandis EP*, Goldberg DM. The anticarcinogenic effects of red wine polyphenols in a mouse skin model. **Proc AACR**, San Francisco, CA, USA, April 6-10, 2002;43:1145, #5675.

274. Bjartell A, Paju A, Stenman UH, Vaisanen V, Aumuller G, *Diamandis EP*, Becker C, Lilja H. Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues. **Prostate Cancer Prostate Dis**, Cambridge, UK, 2002;3:#S7.

275. Katsaros D, Fracchioli S, Yousef GM, Luo L-Y, Scorilas A, Puopolo M, Stenman U-H, van der Zee AGJ, Vergote I, *Diamandis EP*. Human kallikrein 6 (hK6) and 10 (hK10): New potential biomarkers for diagnosis and prognosis of epithelial ovarian cancer. **Proc ASCO** 2002;21:#817.

276. Luo LY, Katsaros D, Scorilas A, *Diamandis EP*. Serum human kallikrein 10: A novel marker for diagnosis and prognosis of ovarian cancer. **Proc Can Lab Med Congress** 2002;54, P2-05.

277. Yousef GM, Kyriakopoulou LG, Fracchioli S, Zarghooni M, Scorilas A, Diamandis M, Katsaros D, *Diamandis EP*. A new potential independent prognostic marker for ovarian cancer. **Proc Can Lab Med Congress** 2002;54, P2-06.

278. Kyriakopoulou LG, Scorilas A, Yousef GM, Ponzone R, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein 7 (KLK7) as a prognostic marker in breast cancer. **Proc Can Lab Med Congress** 2002;55, P2-07.

279. Diamandis EP. Genomic and proteomic technologies and their relevance to clinical diagnostics. **Proc Can Lab Med Congress** 2002;31, #W204.

280. Kollara A, Casper RF, *Diamandis EP*, Brown TJ. Differential expression of two androgen receptor associated protein 70 (ARA70) isoforms induced by androgen and resveratrol in androgen receptor transfected human prostate cancer PC-3 cells. **The Endocr Soc**, London, UK, November 4-6, 2002;368, P2-200.

281. Nakamura T, Mitsui S, Okui A, Miki T, Yamaguchi N, *Diamandis EP*. Human kallikrien 11: A new biomarker of prostate cancer. **J Urol** 2002;167:286, #1127.

282. Yousef GM, *Diamandis EP*. Prognostic value of kallikreins in endocrine-related malignancies. **Clin Chem** 2002; #A-77.

283. Yousef GM, Scorilas A, Borgono C, Fracchioli S, Richiardi G, Massobrio M, Katsaros D, *Diamandis EP*. Prognostic value of the human kallikrein gene 14 (KLK14) in ovarian cancer. **Clin Chem** 2002; #A-78.

284. Yousef GM, Scorilas A, Fracchioli S, Iskander L, Raouf AA, Massobrio M, Katsaros D, *Diamandis EP*. KLK15 is a new potential independent marker for unfavorable prognosis in ovarian cancer. **Clin Chem** 2002; #D-118.

285. *Diamandis EP*, Luo L-Y, Yousef GM, Bunting P, Soosaipillai A, Grass L. Two new ovarian cancer biomarkers. **J Clin Ligand Assay** 2002;25:118.

286. *Diamandis EP*, Magklara A, Yousef GM, Obiezu CV, Chang A, Sidiropoulos M. Towards identification of new prostatic biomarkers. **J Clin Ligand Assay** 2002;25:118

2003

287. Yousef GM, Borgoño CA, Robb D, Scorilas A, Ponzone R, *Diamandis EP*. Human kallikrein gene 14 (*KLK14*) expression: An indicator of poor prognosis in breast cancer patients. **ACOG, 7th Ann Winter Symp** 2003; #266.

288. Antoniou A, Papanastasiou P, Stefanides A, *Diamandis E*, Androulakakis PA. Assessment of serum PSA in childhood. Proc Eur Soc Pediatric Urology, XIVth Ann Meeting, **Br J Urol Intl** 2003;41-42, #E-60.

289. Nam R, Zhang W, Trachtenberg J, *Diamandis EP*, Jewett MA, Narod SA. A single nucleotide polymorphism of the human kallikrein -2 gene (KLK2) highly correlates with serum hK2 levels and in combination enhances prostate cancer detection. **J Urol** 2003;169:384, #1438.

290. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai A, *Diamandis EP*. Analysis of serum human kallikrein 11 (hK11) for discriminating between prostate cancer and benign prostatic hyperplasia. **J Urol** 2003;169:385, #1439.

291. Barak V, Sherman Y, Doviner V, Edelman D, *Diamandis EP*. Kallikreins 6 and 10 as prognostic markers of ovarian cancer. **J Clin Ligand Assay** 2003;26:215, #16.

292. Yousef GM, Polymeris M, Yacoub GM, Fracchioli S, Scorilas A, Soosaipillai A, Popalis C, Katsaros D, *Diamandis EP*. In silico analysis of kallikrein gene expression in ovarian cancer. **Clin Chem** 2003;49:A96, #D-23.

293. Yousef GM, Borgoňo C, Polymeris A, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Chan P, *Diamandis EP*. Human kallikrein 5 (hK5): A novel serum biomarker for ovarian and breast cancer. **Clin Chem** 2003;49:A96-A97, #D-24.

294. Yousef GM. Borgoňo CA, Scorilas A, Fracchioli S, Iskander L, Rigault de la Longrais IA, Puopolo M, *Diamandis EP*. Prognostic value of human kallikrein gene 14 (KLK14) in ovarian cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:90, #477.

295. *Diamandis EP*, Scorilas A, Yousef G, Kishi T, Luo L-Y, Nakamura T, Rademaker AW, Liu D, Fishman DA. Multiparametric serum analysis of human kallikreins hK5, hK6, hK7, hK8, hK10 and hK11 in combination with CA125 for ovarian cancer diagnosis. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:90, #478.

296. Kapadia C, Chang A, Sotiropoulou G, Yousef G, Grass L, Soosaipillai A, *Diamandis EP*. Development of a sensitive and specific immunofluorometric assay to measure human kallikrein 13 which is overexpressed in ovarian cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:90-91, #479.

297. Kishi T, Grass L, Soosaipillai A, Memari N, Little SP, *Diamandis EP*. Is human kallikrein 7 a new serum biomarker for ovarian cancer? **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:91, #480.

298. Kishi T, Grass L, Soosaipillai A, Scorilas A, Memari N, Shimizu-Okabe C, Schmitt M, Harbeck N, Dorn J, Schmalfeldt B, *Diamandis EP*. Human kallikrein 8 as a serum biomarker for ovarian cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:91, #481.

299. Pampalakis G, *Diamandis EP*, Sotiropoulou G. CpG island methylation as a basis for the aberrant expression of the protease M/human kallikrein 6 gene in breast tumour cells. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:222, #1116.

300. Sidiropoulos M, Pampalakis G, Sotiropoulou G, *Diamandis EP*. CpG island hypermethylation as a basis of differential NES-1/KLK10 gene expression in breast, ovarian and prostate cancers. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:223, #1121.

301. Scorials A, Chang P, Katsaros D, Yousef G, *Diamandis EP*. Cloning of a new gene, CEAL1, which encodes for a carcinoembryonic antigen-like protein: Overexpression in aggressive ovarian cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:244, #1238.

302. Stephan C, Finne P, Stenman U-H, Cammann H, Jung K, *Diamandis EP*. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:489-490, #2489.

303. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaippillai AR, Miki T, *Diamandis EP*. The analysis of serum human kallikrein 11 (hK11) increases discrimination between prostate cancer and benign prostatic hyperplasia. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:490, #2490.

304. Kurlender L L, Yousef G, Chang A, *Diamandis EP*. Differential expression of kallikrein gene splice variants in cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:626, #3156.

305. Magklara A, Mellati AA, Wasney G, Sotiropoulou G, *Diamandis EP*. Characterization of the enzymatic activity of human kallikrein 6 (hK6/zyme) and regulation by inhibitors. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:669-670, #R3365.

306. Kapadia C, Grass L, Wasney G, Obiezu C, Yousef G, *Diamandis EP*. Human kallikrein 13, a potential ovarian cancer marker, binds to alpha 1 antichymotrypsin, alpha 2 macroglobulin and alpha 2 antiplasmin. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:670, #3366.

307. Yousef GM, Borgoňo, Scorilas A, Ponzone R, Biglia N, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein gene 14 (*KLK14*) expression: An indicator of poor prognosis in breast cancer patients. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:670, #3367.

308. Yousef GM, Kurlender LE, Borgoňo CA, Grass L, *Diamandis EP*. Regulation of human kallikrein gene 14 (KLK14) by steroids in breast and ovarian cancer cell lines. **Proc AACR** 2003, Washington, DC, USA, July 11-14,;44:713, #3585.

309. Memari N, Grass L, Michael IP, Obiezu CV, *Diamandis EP*. Hormonal regulation of human tissue kallikrein 12 in prostate, breast and ovarian cancer cell lines. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:713-714, #3586.

310. Luo LY, Grass L, *Diamandis EP*. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:837, #4205.

311. Stephan C,Cammann H, Graefen M, Haese A, Djavan B, Remzi M, Semjonow A, Oberpenning F, Finne P, Stenman U-H, Jung K, *Diamandis EP*. Evaluation of a common program for predicting the outcome of prostate biopsy with 4 different PSA assays at PSA 2-10 ng/ml based on 4366 patients. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:880, #4438.

312. Michael I, *Diamandis E*. Expression profiling of the 15 human kallikrein genes. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:998, #5003.

313. Nakamura T, Stephan C, Scorilas A, Memari N, Yousef GM, Jung K, *Diamandis EP*. Quantitative analysis of KLK11 gene expression in prostatic tissues. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:999, #5006.

314. Nakamura T, Scorials A, Stephan C, Yousef GM, Kristiansen G, Jung K, *Diamandis EP*. Macrophage inhibitory cytokine 1 (MIC-1) gene is up-regulated in human prostatic cancer tissues. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1001-1002, #5019.

315. Obiezu CV, Yousef GM, Jung K, Stephan C, Scorilas A, *Diamandis EP*. Kallikrein gene 5 is differentially expressed in healthy vs cancerous testicular tissues. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1006-1007, #5046.

316. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastassiou PA, Yousef GM, *Diamandis EP*. The immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Correlation with several prognostic factors. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1077, #5412.

317. Petraki CD, Papanastassiou PA, Gregorakis AK, Karavana VN, Luo L, *Diamandis EP*. Down-regulation of human kallikreins 6, 10 and 13 in prostate cancer and correlation with established prognostic parameters. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1077, #5413.

318. Borgoňo CA, Soosaipillai A, Grass L, Fracchioli S, Yousef GM, Katsaros D, *Diamandis EP*. Development of an immunofluorometric assay for human kallikrein 14 (hK14): Preliminary clinical applications. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:11446-1147, #5745.

319. Borgoňo CA, Yousef GM, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*. Human kallikrein 14 (hK14) expression in breast cancer tissues. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1264, #6328.

320. Yousef GM, Grass L, Polymeris M-E, Soosaipillai A, Chan P-C, Scorials A, Borgoňo CA, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, *Diamandis EP*. Human kallikrein 5 (hK5): A novel serum biomarker for breast and ovarian cancer. **Proc AACR**, Washington, DC, USA, July 11-14, 2003;44:1266, #6337.

321. Diamandis EP. Practice guidelines for tumour markers. **Tumour Biol** 2003;24[Suppl]:23, #S-46.

322. Fracchioli S. Borgono CA, Yousef GM, Rigault de la Longrais IA, Puopolo M, Massobrio M, *Diamandis EP*, Katsaros D. Human kallikrein 11 (hK11) and 15 (hK15) expression in ovarian cancer: New independent predictive and prognostic factors. **Proc ASCO** Chicago, IL, USA, May 31-June 3, 2003;22, #3462.

2004

323. Economopoulou K, *Diamandis EP*. Kallikrein 6 as a biomarker for the detection of metastatic cancer cells in blood of ovarian cancer patients. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:241, #1058.

324. Scorilas A, Mathioudaki K, Leoutsakou T, Arnaouti M, *Diamandis EP*. Expression analysis of the SR-A1 gene, encoding for a novel member of the human Ser/Arg-rich family of proteins, in breast cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:397-398, #1728.

325. Borgoňo CA, Ghosh MC, Michael IP, Stoop A, Craik CS, Choe Y, Kapadia C, *Diamandis EP*. Enzymatic action, substrate specificity and regulation of human kallikrein 14 (hK14). **Proc AACR,** Orlando, FL, USA, March 27-31, 2004; 45:415, #1807.

326. Luo L-Y, Grass L, Soosaipillai A, *Diamandis EP*. Trypsin-like enzymatic activity of human kallikrein 10. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:416, #1810.

327. Petraki CD, Gregorakis AK, Papanastassiou A, *Diamandis EP*. The immunohistochemical expressionof human kallikreins 5, 6, 10 and 11 in normal urothelium and urinary bladder cancer. Correlation with histopathological variables. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:417, #1815.

328. Kapadia C, Ghosh MC, Stoop A, Craik CS, Choe Y, Borgoňo C, *Diamandis EP*. Human kallikrein 13: Evaluation of its role in the degradation of extracellular matrix proteins and characterization of its substrate specificity. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:417-418, #1819.

329. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Wasney GA, *Diamandis EP*. Human kallikrein 5 (hK5): Autoactivation, substrate specificity, regulation by inhibitors and cleavage of extracellular matrix and basement membrane components. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:529, #2294.

330. Yousef GM, White N, Kurlender L, Michael I, Desmond-Robb J, Memari N, Grass L, *Diamandis EP*. The KLK5-splice variant 2 is a new biomarker for ovarian cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:764, #3300.

331. Petraki CD, Vaslamatzis MM, Petraki KD, *Diamandis EP*. Correlation between the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 and histopathological variables in colorectal cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:766, #3306.

332. Pampalakis G, *Diamandis EP*. Cloning and characterization of novel isoforms of the human kallikrein 6 gene. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:798, #3454.

333. Kurlender L, Yousef GM, *Diamandis EP*. Differential expression of a novel KLK5 splice variant in ovarian and prostate cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:838, #3632.

334. Michael IP, Kurlender L, Yousef GM, Memari N, Du DC, Katsaros D, *Diamandis EP*. Novel alternative splicing events within the human kallikrein locus. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:979, #4243.

335. Borgoňo CA, Kishi T, Scorilas A, Harbek N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 8 protein (hK8) in ovarian cancer cytosols: A new marker of favorable prognosis. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1025, #4444.

336. Luo L-Y, Soosaipillai A, Grass L, *Diamandis EP*. Human kallikreins 6 and 10 are secreted as zymogen forms in ascites fluid from ovarian cancer patients. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1025-1026, #4447.

337. Memari N, Hussack G, Cui S, Grass L, *Diamandis EP*. Production of polyclonal antibodies against human tissue kallikrein 9. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1027, #4452.

338. Yousef G, Polymeris M-E, Yaboub GM, Fracchioli S, Scorilas A, Soosaipillai A, Popalis C, Desmond-Robb J, Katsaros D, *Diamandis EP*. In silico analysis of kallikrein gene expression in ovarian cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1029, #4461.

339. Obiezu CV, Michael IP, Wasney GA, *Diamandis EP*. Enzymatic activity of prostase/human kallikrein 4 (hK4): Determination of substrate preferences and degradation of extracellular matrix proteins. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1032, #4474.

340. Stephan C, Chianlian X, Kishi T, Nakamura T, Brown DA, Breit SN, Cammann H, Jung K, *Diamandis EP*. Artificial neural network based on PSA, percent free PSA, and three new prostate cancer biomarkers. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1033, #4478.

341. Memari N, Grass L, Hussack G, Soosaipillai A, *Diamandis EP*. Production of polyclonal and monoclonal antibodies against human tissue kallikrein 12. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1212-1213, #5257.

342. Yousef G, Popalis C, Polymeris M-E, White N, Desmond-Robb J, Yacoub GM, Soosaipillai A, *Diamandis EP*. Kallikrein gene down-regulation in breast cancer. **Proc AACR,** Orlando, FL, USA, March 27-31, 2004;45:1213, #5258.

343. Katsaros D, Fracchioli S, Rigault de la Longrais IA, *Diamandis EP*. Human kallikreins (hKs) as novel serum biomarkers for diagnosis, prognosis and monitoring of epithelial ovarian carcinoma. **Int'l J Biol Markers** 2004;19:S29.

344. Yousef GM, Polymeris M, White N, Robb J-D, Yacoub GM, Raouf AA, *Diamandis EP*. Kallikreins are potential new breast cancer biomarkers. **Res & Practice** 2004;200:655, #70.

345. Yousef GM, Polymeris M, Hutchinson S, Robb J-D, Soosaipillai A, Serry E, *Diamandis EP*. The human kallikrein proteins 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors. **Res & Practice** 2004;200:655, #71.

346. Simon I, Kim NW, Sarno M, *Diamandis EP*, Valik D, Nekulova M, Simickova M, Frgala T, Wolfert RL. Characterization of three novel serum biomarkers for the early detection and prognosis of ovarian cancer. **MD Anderson Cancer Ctr 5th Intl Conf,** Houston, TX, USA, December 1-4, 2004.

2005

347. Yousef GM, Katsaros D, *Diamandis EP*. The kallikrein proteins: New potential biomarkers for ovarian cancer. **Mod Pathol** 2005;18, 209A and **Lab Invest** 2005;85, 209A, #972.

348. White NM, Yousef GM, Michael IP, Robb JD, *Diamandis EP*. Differential expression of the human kallikrein 10 gene (*KLK10*), a candidate cancer biomarker. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;83, #36.

349. Yousef GM, White NMA, Borgono CA, Ellatif MA, Soosaipillai A, Robb, JD, *Diamandis EP*. Kallikreins are potential biomarkers for pancreatic and colon cancer. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;83, #37.

350. Elliott MB, Michael IP, Kuk C, Yousef G, *Diamandis EP*. Identification of single nucleotide polymorphisms in the human kallikrein locus: Potential association with cancer susceptibility. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;83, #39.

351. Yousef GM, Elliott MB, White NMA, Borgono CA, Robb JD, Michael IP, Economopoulou K, *Diamandis EP*. Differential expression of the human kallikrein gene 6 (*KLK6*) in various malignancies. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;83, #40.

352. Memari N, Grass L, Bansil A, Cho J-C, Shan SJC, Soosaipillai A, *Diamandis EP*. Production of the extracellular domain of Siglec-9 using an *E-coli* expression system and generation of anti-Siglec-9. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;108, #694.

353. Grutzmann R, *Diamandis EP*, Saeger H-D, Pilarsky C. Human kallikrein 10 mRNA up-regulation but not serum increase of the protein in patients with pancreatic cancer. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;133, #1245.

354. Petraki CD, Veloudis G, Komborozos VA, Scorilas A, Papanastasiou P, *Diamandis EP*. Immunohistochemical evaluation and prognostic significance of human kallikreins 6 and 10 in colorectal cancer. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;133, #1260.

355. Gunawardana G, Luo L-Y, *Diamandis EP*. Retrieval of autoantibodies from ovarian cancer cells present in ascites fluid. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;143, #1534.

356. Borgono CA, Soosaipillai A, GrassL, *Diamandis EP*. Development of a novel immunoassay for human kallikrein 14, a putative ovarian and breast cancer biomarker. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;143, #1547.

357. Michael IP, Yousef GM, Soosaipillai A, Grass L, *Diamandis EP*. A novel ELISA assay for human kallikrein 5, a candidate breast and ovarian cancer biomarker. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;143, #1548.

358. Shaw JL, Obiezu C, Memari N, Karakucuk I, *Diamandis EP*. Production of recombinant human kallikrein 15, a potential prostate and ovarian cancer biomarker. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;143, #1549.

359. Sidiropoulos M, Pampalakis G, Sotiropoulou G, *Diamandis EP*. Expression of human tissue kallikrein 5 in breast and prostate cancer cell lines after treatment with the demethylating agent 5-aza-2′-deoxycytidine. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;175, #1842.

360. Shan SJC, Michael IP, Soosaipillai A, Katsaros D, Rigault de la Longrais IA, Puopolo M, *Diamandis EP*. Over-expression of human kallikren 6 (hK6) protein and mRNA in ovarian carcinoma. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;176, #1860.

361. Leoutsakou T, Talieri M, Mathioudaki K, Stavropoulou P, Arnogianaki N, *Diamandis EP*, Scorilas A. Expression analysis and prognostic significance of SR-A1 gene, encoding for a new member of the human ser/arg-rich family of pre-mRNA splicing factors, in breast and ovarian cancer. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;177, #1899.

362. Memari N, Grass L, Michael IP, Fountas NP, *Diamandis EP*. Hormonal regulation of human tissue kallikrein 9 in human cancer cell lines. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;187, #2141.

363. Michael IP, Harris JL, Li J, Gavigan J-A, Borgono CA, Bowles B, *Diamandis EP*. Characterization of human kallikrein 5 (hK5) substrate specificity using combinatorial peptide libraries. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;229, #2956.

364. Michael IP, Komatsu N, Jayakumar A, Kang Y, Clayman GL, *Diamandis EP*. Regulation of the proteolytic activity of human kallikrein 5 (hK5) by tissue and plasma inhibition. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;229, #2970.

365. Dorn J, Harbeck N, Kates R, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmalfeldt B, Schmitt M. Analysis of the differential expression of proteolytic factors uPA, PAI-I and seven tissue kallikreins (hK5, 6, 7, 8, 10, 11, 13) between primary ovarian carcinoma tissues and corresponding omentum metastases. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;229, #2972.

366. Borgono CA, Felber LM, Cloutier SM, Deperthes D, Li J, Gavigan J-A, Harris JL, Bowles B, *Diamandis EP*. Enzymatic profilinf of human kallikrein 14, a candidate cancer biomarkers, by phage display substrate and positional scanning peptide libraries. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;229, #2975.

367. Sardana G, Marshall J, Grass L, Soosaipillai A, *Diamandis EP*. Proteomic analysis of culture supernatants from prostate cancer cell lines. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;234, #3105.

368. Luo L-Y, Soosaipillai A, Du D, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate cancer biomarker, from seminal plasma. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;236, #3157.

369. van der Merwe D-E, *Diamandis EP*. Mass spectrometry as a cancer diagnostic tool: a meta-analysis of published data. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;307, #4361.

370. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, *Diamandis EP*. Involvement of human kallikreins in a proteolytic cascade pathway in the prostate. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;330, #4835.

371. Oikonomopoulou K, Simon I, Wolfert RL, Valik D, Nekulova M, Simickova M, Frgala T, *Diamandis EP*. Evaluation of human kallikreins 5, 6, 7, 8, 10 and 11 as prognostic markers in serum of ovarian cancer patients. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;332, #4877.

372. Oikonomopoulou K, Scorilas A, Grass L, Soosaipillai A, Rosen B, Murphy J, *Diamandis EP*. Kallikreins as markers of disseminated tumour cells in ovarian cancer. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;332, #4878.

373. Simon I, Kim NW, *Diamandis EP*, Valik D, Mekulova M, Simickova M, Frgala T, Sarno MJ, Wolfert RL. Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue and serum of ovarian cancer patients. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;332, #4882.

374. *Diamandis EP*, van der Merwe D-E, Simon I, Kobayashi H, Terao T. Multiparametric analysis of six tissue kallikreins and CA125 for ovarian cancer diagnosis. **Proc AACR**, Anaheim, CA, USA, April 16-20, 2005;376, #5598.

375. Schmalfeldt B, Kates R, Dorn J, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors on surgical success and survival in ovarian cancer. **Proc ASCO**, Orlando, FL, USA, May 13-17, 2005;471, #5068.

376. Schmalfeldt B, Kates R, Dorn J, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors (uPA, PAI-I, tissue kallikreins) on surgical success and survival in ovarian cancer. **Thromb Haemostasis** 2005;93:A24.

377. Yousef GM, Katsaros D, *Diamandis EP*. The kallikrein proteins: New potential biomarkers for ovarian cancer. **Lab Invest** 2005;85:209A, #972.

378. Diamandis EP. Human tissue kallikreins as biomarkers for breast, ovarian and other malignancies. **Proc Era of Hope,** Philadephia, PA, USA, June 8-11, 2005;100, #P13-9.

379. Komatsu N, Saijoh K, Sidoropoulou G, Tsai B, Levesque MA, Elliott MB, Takehara K, *Diamandis EP*. Quantification of human tissue kallikreins in the stratum corneum: dependence of age and gender. **J Invest Dermatol** 2005;124:A57.

380. Oikonomopoulou K, Hansen K, Saifeddine M, *Diamandis EP*. Cell signaling via proteinase-activated receptors (PARs): A new role for kallikreins. **Intl Proteolysis Soc,** Quebec City, Canada October 15-19,2005;79, #P16.

381. Van Der Merwe D, *Diamandis EP*. Cancer biomarker discovery and validation by mass spectrometry [abstract] American Association for Clinical Chemistry. **Clin Chem** 2005;51:A61.

2006

382. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-Desquamation of Corneocytes. **J Invest Dermatol** 2006;126, #348.

383. Fischer SE, *Diamandis EP*, Ezzat S, Asa SL. SELDI-TOF mass spectrometry analysis of normal, benign and malignant tyroid tissue. **Lab Invest** 2006;86:93A, #420.

384. Fischer SE, *Diamandis EP*, Ezzat S, Asa SL. SELDI-TOF mass spectrometry analysis of normal, benign and malignant tyroid tissue. **Modern Pathol** 2006;19:83A, #420.

385. Oikonomopoulou K, Hanssen K, Saiffedine M, *Diamandis EP*, Hollenberg MD. Kallikrein signaling in cancer via proteinase-activated receptors. **Natl Inst of Health Proteomics Intl Group** 2006; #85.

386. Borgono CA, Michale IP, Komatsu N, Sotiropoulou G, Jayakumar A, Wu H-K, Clayman GL, Blaber M, Mikolajczyk SD, *Diamandis EP*. Multiple human tissue kallikreins are regulated by lympho-eipthelial Kazal-type inhibitor and digest desmoglein 1. **J Inves Dermatol** 2006;126:60, #359.

387. Simon I, *Diamandis EP*, Katsaros D, Kim NW, Wolfert RL. B7-H4 (DD-O110) protein is over-expressed in early-stage ovarian cancer tumor tissue. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #4505.

388. Shan SJC, Scorilas A, Soosaipillai A, Katsaros D, Rigault I, Puopolo M, *Diamandis EP*. Human tissue kallikrein 7 over-expression in ovarian carcinoma: a novel marker of unfavorable prognosis. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #4503.

389. Oikonomopoulou K, Shannon P, Petraki CD, *Diamandis EP*. Immunohisotchemical localization of kallikrein 6 in brain tumors. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #4488.

390. Emami N, Michael IP, *Diamandis EP*. Proteolytic cascades of human tissue kallikreins. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #4368.

391. Petraki C, Papanastasiou PA, Karavana VN, *Diamandis EP*. Immunohistochemical expression of human tissue kallikreins in neoplasms of various organs. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #4358.

392. Kulasingam V, *Diamandis EP*. Comparative qualitative proteomic analysis of conditioned media from breast cancer cell lines. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #3573.

393. Sardana G, Marshall J, *Diamandis EP*. Identification and characterization of novel candidate prostate cancer biomarkers through proteomic analysis of the secretome of three prostate cancer cell lines. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #3572.

394. Memari N, Grass L, Karakucuk EI, Shaw JL, *Diamandis EP*. Protein expression, antibody generation and development of a highly sensitive immunoassay for the detection of human tissue kallikrein 9. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #2889.

395. Shaw JL, Grass L, Soosaipillai A, Sotiropoulou G *Diamandis EP*. Development of an immunoassay for human kallikrein 15, a potential prostate and ovarian cancer biomarker. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #1985.

396. Memari N, *Diamandis EP*, Van Der Kwast T. Immunohistochemical localization and expression profiling of human kallikrein 12 in human prostate cancer tissues. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #1980.

397. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Andrade-Gordon P, Cottrell GS, Bunnett NW, *Diamandis EP*, Hollenberg MD. Kallikrein 14 signaling through proteinase-activated receptors. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #1686.

398. Paliouras M, *Diamandis EP*. Investigating the role of intracellular signaling pathways in regulating kallikrein expression. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #1655.

399. Shan SJC, Katsaros D, Paliouras M, Rigault I, Puopolo M, *Diamandis EP*. Up-regulation of human tissue kallikrein 6 in ovarian carcinoma. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #102.

400. White NMA, Yousef GM, *Diamandis EP*, Dorn J. The human kallikrein gene 6 (KLK6) in combination with CA125 is a more sensitive marker for ovarian cancer than CA125 alone. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #94.

401. Paliouras M, *Diamandis EP*. Coordinated hormone regulation of multiple kallikreins in breast cancer cell lines. **Proc AACR,** Washington, DC, USA, April 1-5, 2006; #91.

402. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol** 2006;126:58, #348.

403. Heshmat SM, Jarvi K, Mullen B, *Diamandis EP*. Seminal plasma lipocalin type PGDS: A potential marker for the diagnosis of obstructive azoospermia. **J Urol** 2006;175:523, #1623.

404. Kundig C, Cloutier SM, Aellen S, Felber LM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ, *Diamandis EP*, Deperthes D. Human kallikrein 2 (hK2) inhibitors suppress tumor growth of prostate cancer xenografts in nude mice. **J Urol** 2006;175:263.

405. Fischer S, Kulasingam V, Paliouras M, *Diamandis EP,* Ezzat S, Asa S. Human thyroid cancer cell lines differentially express PSA, hK6, hK10 and hK11. **Modern Pathol** 2006;19:138, #639.

406. Darling M, Jackson L, Daley T, *Diamandis EP.* Human kallikrein expression in salivary gland tumors. **Modern Pathol** 2006;19:107, #489.

407. Heshmat SM, Jarvi K, *Diamandis EP*, Mullen B, Lo KC. Seminal plasma lipocalin type PGDS: A new marker for obstructive azoospermia. **Fertility & Sterility** 2006;86:S376.

408. Cho CKJ, *Diamandis EP*. Proteomic analysis of normal human amniotic fluid by two-dimensional liquid chromatography and mass spectrometry. **Mol Cell Proteomics** 2006;5:S371.

2007

409. Fischer SE, Kulasingam V, *Diamandis EP,* Ezzat S, Asa SL. Thyroid cancer biomarker discovery using two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS). **Lab Invest** 2007;87:101A.

410. Fischer SE, Kulasingam V, *Diamandis EP,* Ezzat S, Asa SL. Thyroid cancer biomarker discovery using two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS). **Modern Pathol** 2007;20:101A.

411. Rabien A, Fritzsche FR, Jung M, *Diamandis EP,* Loening SA, Jung K, Kristiansen G, Stephan C. High expression levels of the human kallikrein-like peptidases KLK14 and KLK15 in prostatic adenocarcinoma are associated with elevated risk of prostate-specific antigen relapse. **Eur Urol** 2007;6:49.

412. Prassas I, Paliouras M, *Diamandis EP*. High-throughput screening for modulators of tissue-kallikrein expression. **Proc AACR** 2007; #5554.

413. Paliouras M, *Diamandis EP.* Androgens act synergistically to enhance estrogen-induced up-regulation of human tissue kallikreins in breast cancer cells. **Proc AACR** 2007; #4328.

414. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergote N, *Diamandis EP*, Hollenberg MD. Tumour-derived proteinases and signalling: kallikrein-mediated PAR activation and inflammation. **Proc AACR** 2007; #3091.

415. Paliouras M, *Diamandis EP*. Intracellular signaling pathways regulate expression of prostate specific antigen and other kallikreins in human breast cancer cells. **Proc AACR** 2007; #2901.

416. Planque C, Soosaipillai A, Reckamp K, Chia D, Goodglick L, *Diamandis EP*. Human tissue kallikreins as serological biomarkers for lung cancer. **Proc AACR** 2007; #2679.

417. Bayani J, Planque C, Paliouras M, Squire JA, *Diamandis EP*. Chromosomal rearrangements of the kallikrein locus in human cancer cell lines. **Proc AACR** 2007; #1063.

418. Prassas I, Paliouras M, *Diamandis EP*. High-throughput screening for modulators of tissue-kallikrein expression. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

419. Emami N, *Diamandis EP*. Human tissue kallikrein 14 (KLK14): A new member of the seminal proteolytic cascade. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

420. Shaw JLV, Smith CR, *Diamandis EP*. A potential role for human tissue kallikreins in cervico-vaginal physiology. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

421. Oikonomopoulou K, Hansen KK, Chapman K, Vergnolle N, *Diamandis EP*, Hollenberg MD. Kallikreins and carcinogenesis: Put the blame of PARs. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

422. Planque C, Soosaipillai A, Zheng Y, Reckamp K, Chia D, Goodglick L, *Diamandis EP*. A combination of multiparametric members of the tissue kallikrein family improves the diagnosis of non-small cell lung cancer. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

423. Paliouras M, *Diamandis EP*. P13K/AKT activity negatively regulates prostate specific antigen expression in prostate cancer cells – a model for androgen-indepencence. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

424. Kuzmanov U, *Diamandis EP*. Glycosylation pattern of ovarian cancer derived kallikrein 6 and its potential use as a biomarker. **Intl Proteolysis Soc**, October 20-24, 2007, Patras, Greece.

425. Emami N, *Diamandis EP*. Major role of human tissue kallikrein 14 (KLK14) in seminal clot liquefaction. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

426. Shaw JLV, *Diamandis EP*. Hormonal regulation patterns of human tissue kallikreins in cancer cell lines. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

427. Shaw JLV, *Diamandis EP*. A potential role for human tissue kallikreins in cervico-vaginal physiology. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

428. Oikonomopoulou K, Hansen KK, Chapman K, Saifeddine M, Vergnolle N, *Diamandis EP*, Hollenberg MD. Kallikreins as inflammatory modulators in cancer. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 2007.

429. Eissa A, *Diamandis EP*. The role of human tissue kallikreins in skin physiology and pathobiology. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

430. Planque C, Soosaipillai A, Zheng Y, Reckamp K, Chia D, Goodglick L, *Diamandis EP*. A multiparametric diagnostic model in lung cancer using several human tissue kallikrein biomarkers. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

431. Paliouras M, *Diamandis EP*. The influence of intracellular signaling pathways generate regulation of kallikrein gene expression – the development of cancer progression models. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

432. Kuzmanov U, *Diamandis EP*. Glycosylation pattern of ovarian cancer derived kallikrein 6. **2nd Intl Symposium on Kallikreins**, Island of Santorini, Greece**,** October 16-18, 2007.

433. Kulasingam V, Smith CR, Buckler A, Jeffrey DA, *Diamandis EP*. "Product Ion Monitoring" assay for prostate-specific antigen in serum using a linear Ion-Trap. **HUPO- 6th Ann World Congress**, Seoul, S. Korea, October 6-10, 2007.

434. Sardana G, Jung K, Stephan C, *Diamandis EP*. A comparison of the conditioned medium from three prostate cancer cell lines: Validation of candidate biomarkers for prostate cancer. **HUPO- 6th Ann World Congress**, Seoul, S. Korea, October 6-10, 2007.

435. Gunawardana CG, Smith CR, Batruch I, *Diamandis EP*. Analyzing cell-line secretomes using 2D-liquid chromatography and mass spectrometry to reveal novel biomarkers of ovarian carcinoma. **HUPO- 6th Ann World Congress**, Seoul, S. Korea, October 6-10, 2007.

436. Cho C-KJ, Smith CR, Winsor EJ, *Diamandis EP*. Discovery of candidate markers for early detection of Down syndrome through semi-quantitative proteomic analysis of human amniotic fluid. **HUPO- 6th Ann World Congress**, Seoul, S. Korea, October 6-10, 2007.

437. Diamandis EP. Novel biomarkers for prognosis and therapy response in ovarian cancer. **Eur J Cancer** 2007;5:13, #S20.

2008

438. Christensen EJ, Menard C, Evans K, *Diamandis EP*, Chambers AF, Anborgh P, Pintile M, Lenarduzzi M, Bristow RG. Novel biomarkers of radiotherapy response in prostate cancer: A pilot study to determine protein expression patterns in blood and urine during radiotherapy for localized prostate cancer. **Proc AACR** 2008;49:#1003.

439. Alexopoulou DK, Zheng Z, Li L, Soosaipillai A, *Diamandis EP*, Talieri M. Expression analysis of multiple tissue kallikrein-related peptidases in colorectal cancer. **Proc AACR** 2008;49:#1155.

440. Kulasingam V, *Diamandis EP*. Two adhesion molecules: New serological diagnostic breast cancer biomarkers. **Proc AACR** 2008;49:#4437.

441. Klem R, Saunders R, Sanders R, Adams T, McDermed JE, Sarno M, *Diamandis E*. Total PSA (tPSA) level post-prostatectomy (RP) monitored with the NADIA* ultrasensitive PSA assay can predict the risk for biochemical recurrence (BCR). **Clin Chem** 2008;54 (Suppl 6);A136, #C-117.

442. Klem R, Saunders R, Sanders R, Adams T, McDermed JE, Sarno M, *Diamandis E*. Evaluation of post-prostatectory (RP) total PSA (tPSA) levels using the NADIA* (Nucleic Acid Detection ImmunoAssay) untrasenstivie tPSA assay. **Clin Chem** 2008;54 (Suppl 6);A137, #C-119.

443. Cho C-K, Smith C, Winsor E, *Diamandis EP*. Quantitative proteomic analysis of human amniotic fluid. **HUPO-7th Ann World Congress**, Amsterdam, August 16-20, 2008.

444. Kuk C, Soosaipillai A, Kulasingam V, Smith CR, Batruch I, *Diamandis EP*. Ovarian cancer ascites flud subproteome: Home of potential biomarkers for ovarian cancer. **HUPO-7th Ann World Congress**, Amsterdam, August 16-20, 2008.

445. Yazdanpanah M, Chen Y, *Diamandis Ep*m Hoffman B, Wong PY. Determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry. **20th IFCC WorldLab**, Fortaleza, Brazil, September 28-October 2, 2008.

446. Linbo RA, Vandell AGV, Larson NS, Keegan MB, Blaber SI, Blaber M, Sneve DM, Lucchinetti CF, Rodriguez M, *Diamandis EP*, Scarisbrick IA. Association of kallikreins with neuron loss and progressive multiple sclerosis. **Amer Neurol Assoc Ann Meeting**, Chicago, IL, USA, April 12-19. 2008.

447. Courty Y, Oikonomopoulou K, Smith CR, Memari N, Diamandis EP. Identification of CCN proteins as substrates for kallikrein-related peptidases. **Proceedings of the 5th International Workshop on the CCN Family of Genes**, October 2008. Collaborative work with visiting Professor Dr. Yves Courty (INERM U618, Faculté de Médecine, Tours, France).

2009

448. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 in ovarian cancer ascites and cerebrospinal fluids. **Proc AACR**, Denver, CO, USA, April 18-22, 2009; #4738.

449. Bayani J, Katsaros D, Graham C, Rosen B, Murphy J, Bernadini M, Shaw P, Squire J, Diamandis EP. Mechanisms of regulation of the kallikrein (KLK) gene family in ovarian carcinoma. **Proc AACR**, Denver, CO, USA, April 18-22, 2009; #571.

450. Gunawardana G, Kuk C, Smith CR, Batruch I, Diamandis EP. Mining for ovarian cancer biomarkers in conditioned media of ovarian cancer cell lines using 2D-liquid chromatography and mass spectrometry. **Proc AACR**, Denver, CO, USA, April 18-22, 2009; #3555.

451. Kuk C, Gunawardana CG, Soosaipillai A, Kobayashi H, Zheng Y, Lin L, Diamandis EP. Nidogen-2. **Proc AACR**, Denver, CO, USA, April 18-22, 2009; #3554.

452. Prassas I, Diamandis EP. Novel applications of cardiac glycosides in cancer therapies: insights into their molecular mechanism of action. **Proc AACR** April 18-22, 2009; #4621.

453. Makawita S, Smith CR, Batruch I, Diamandis EP. Pancreatic cancer biomarker discovery: Elucidationof candidate biomarkers through mass spectrometry based proteomic analysis of cell line conditioned media. **Proc AACR**, Denver, CO, USA, April 18-22, 2009; #4484.

454. Cramer DW, Bast RC, Clarke C, Coombes K, *Diamandis E*, Fung E, Godwin A, Locksin A, Lu K, McIntosh M, Mor G, Skates S, Sluss P, M thornquist, Zhang Z, Uran N. Phase III validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO screening trial. **Proc AACR**, Denver, CO, USA, April 18-22, 2009;#LB96.

455. Schnabl KL, Yazdanpanah M, Wong P-Y, *Diamandis EP*, Cole D, Vieth R. Isotope-dilution, liquid chromatography-tandem mass spectrometry assay for analysis of 24, 24$(OH)_2$vitamin D_3 and25(OH) metabolites of Vitamins D_2 and D_3 in human serum. **Clin Chem** 2009;55:A232, #E-67.

456. Pavlou M, *Diamandis EP*. Mining the Secretome of 11 Breast cell lines to identify novel breast cancer biomarkers. **HUPO, 8th Ann World Congress**, September 26th - 30th, 2009, Toronto, Canada**.**

457. Makawita S, Smith C, Soosaipillai A, Batruch I, Ruckert F, *Diamandis EP*. Proteomics of Pancreatic Cancer Cell Lines and Pancreatic Juice: A Search for Biomarkers. **HUPO, 8th Ann World Congress**, September 26th - 30th, 2009, Toronto, Canada.

458. Batruch I, Smith CR, *Diamandis EP*, Halbot R, Ho CH, Mullen BJ, Grober E, Lo KC, Jarvi KA. Semen Proteomics: Novel technique to identify biomarkers of reproductive tract disorders**. HUPO, 8th Ann World Congress**, September 26th - 30th, 2009, Toronto, Canada.

459. Rezai T, Krastins B, Sarracino D, Athanas M, Ross M, Zhang H, Kulasingam V, Batruch I, Smith C, Liotta L, Petricoin E, *Diamandis E*, Chan D, Lopez MF. Understanding cross-lab reproducibility for SRM-based mass spectrometry clinical assays. **HUPO, 8th Ann World Congress**, September 26th - 30th, 2009, Toronto, Canada.

460. Drabovich AP, *Diamandis EP*. Development of MRM assays for a large panel of low-abundance proteins in ovarian cancer ascites. **HUPO, 8th Ann World Congress**, September 26th - 30th, 2009, Toronto, Canada; #C258.

461. Oikonomopoulou K, Batruch I, Smith CR, Soosaipillai A, Hollenberg MD, *Diamandis EP*. Functional proteomic analysis of active serine proteinases in ovarian cancer ascites fluid. **HUPO, 8th Ann World Congress**, September 2009, #C202.

462. Drabovich AP, *Diamandis EP*. Targeting low-abundance proteins in ovarian cancer ascites using combinatorial peptide libraries and MRM assays. **EMBO Cancer Proteomics**, Dublin, Ireland, June 8-11, 2009, ID 26.

463. Pavlou M, *Diamandis EP*. Delineating the secretome of eleven breast cancer cell lines in the quest for novel breast cancer biomarkers. **33rd San Antonio Breast Cancer Symp**, San Antonio, TX, USA, December 9-13, 2009.

464. Bayani J, Graham C, Marrano P, Katsaros D, Butzow R, Squire JA, *Diamandis EP*. Genomic Instability of the Kallikrein Locus in Ovarian Carcinoma. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

465. Eissa A, Diamandis EP. Characterization and substrate identification of human kallikrein-8, a keratinocyte-expressed serine protease implicated in skin barrier homeostasis. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

466. Eissa A, Diamandis EP. Biochemical characterization and substrate profiling of human kallikrein-8, a keratinocyte-specific protease implicated in epidermis physiology and pathobiology. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

467. Kündig C, Felber Medlin LM, Emami N, *Diamandis EP*, Deperthes D. Preclinical development of the kallikrein inhibitor MDPK67b. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

468. Courty Y, Guillon-Munoz A, Smith CR, Canepa S, Oikonomopoulou K, *Diamandis EP*. Identification of regulatory CCN proteins as substrates for kallikrein-related peptidase 12: functional implications of proteolysis. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

469. Chow TF, Rofael Y, *Diamandis EP*, White NMA, Faragalla H, Mankaruous M, Girgis A, Yousef GM. MicroRNAs: A new paradigm for kallikrein cancer research. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

470. White NMA, Bui A, Chow TF, Girgis A, Youssef Y, Mankaruous M, *Diamandis E*, Yousef GM. Differential expression of kallikrein related peptidases and microRNAs in renal cell carcinoma (RCC); dissecting the pathogenesis of RCC through in-sillico and experimental techniques. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

471. Oikonomopoulou K, Saifeddine M, Hasen KK, Soosaipillai A, Baruch A, Vergnolle N, Chapman, Batruch I, Smith CR, Ramachandran R, Renaux B, Yu Z, Hollenberg MD, *Diamandis EP*. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

472. Emami N, Kündig C, Felber Medlin LM, Braillard S, *Diamandis EP*, Deperthes D. Animal model selection for preclinical pharmacokinetic assessment of a novel engineered serine protease inhibitor MDPK67b. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

473. Diamandis A, Soosaipillai AR, *Diamandis EP*. Simplified spectrophotometric ELISA assay for KLK6 in serum. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

474. Dorn J, Gerte T, Gkazepis A, Harlozinska A, Sedlaczek S, *Diamandis EP*, Schuster T, Wagner S, Magdolen V, Kremer M, Kiechle M, Schmitt M. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts

ovarian cancer patients' survival. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

475. Gratio V, Loriot C, Oikonomopoulou K, Chung H, *Diamandis EP*, Hollenberg MD, Darmoul D. Ectopic expression of kallikrein-related peptidase 14 induces signaling via proteinase-activated receptor-2 in colon cancer cells. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

476. Yoon H, *Diamandis EP*. Expression and functional characterization of human kallikrein-related peptidases 9 and 12. **3rd Intl Symp on Kallikreins**, Munich, Germany, August 30-September 2, 2009.

477. Gratio V, Loriot C, Oikonomopoulou K, Chung H, *Diamandis EP*, Hollenberg MD, Darmoul D. Aberrant expression of kallikrein-related peptidase 14 induces cell signalling via proteinase-activated receptor-2 in colon cancer. **Proceedings of the 6th General Meeting of International Proteolysis Society**, October 2009.

478. Oikonomopoulou K, Hansen KK, Saifeddine M, Baruch A, Vergnolle N, *Diamandis EP*, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. **Proceedings of the 3rd International Symposium on Kallikreins and Kallikrein-Related Peptidases**, August 2009. Received the E.K. Frey - E. Werle Foundation Young Investigator Award.

479. Gratio V, Loriot C, Oikonomopoulou, Chung H, **Diamandis EP**, Hollenberg MD, Darmoul D. Ectopic expression of Kallikrein-related peptidas 14 induces signalling via proteinase-activated receptor-2 in colon cancer cells. **3rd International Symposium on Kallikrein-related Peptidases (3rd IKS)** August 30-2 September, Munich Germany. **Sixth International Proteolysis Society, surfers' paradise,** October 26-30 Australia.

2010

480. Dorn J, Schuster T, Gkazepis A, Kiechle M, *Diamandis EP*, Harlozinska A, Magdolen V, Schmitt M. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. **Amer Soc Clin Oncol**, Chicago, IL, USA; June 4-8, 2010, #43298.

481. McDermed JE, Klem RE, Adams TH, *Diamandis EP*, Freedland SJ. Postprostatectomy PSA determined with a nucleic acid detection immuno-PCR assay (NADiA) as a prognostic indicator for risk of prostate cancer recurrence. **Amer Soc Clin Oncol**, Chicago, IL, USA; October 18-20, 2010, #60963.

482. Makawita S, Smith C, Batruch I, Ruckert F, *Diamandis EP*. Integrative proteomic profiling of pancreatic cancer cell line supernatants, pancreatic juice and ascites fluid for the indentificatin of novel pancreatic biomarkers. **Proc AACR,** Washington, DC, USA, April 17-21, 2010; #4560.

483. Gratio V, Loriot C, Oikonomopoulou K, Chung H, *Diamandi EP*, Hollenberg MD, Darmoul D. Protease-activated receptor 2, a KLK14 target in colon cancer cells. **Proc AACR,** Washington, DC, USA, April 17-21, 2010; #4104.

484. Eissa A, Cho C-KJ, *Diamandis EP*. Identifying the molecular metastasis via a personalized quantitative proteomics approach. **Proc AACR**, Washington, DC, USA, April 17-21, 2010; #2256.

485. Bayani J, Kuzminov U, Batruch I, Cho C-K, Smith C, Marrano P, Graham C, Butzow R, Katsaros D, Lin L, Zheng Y, Squire JA, *Ciamandis EP*. Integrated genomic, microRNA (mRNA) and proteomic profiling of ovarian carcinoma for biomarker discovery. **Proc AACR**, Washington, DC, USA, April 17-21, 2010; #3037.

486. Karagiannis GS, *Diamandis EP*. Discovery of candidate biomarkers for colorectal cancer using mass spectrometry-based proteomic analysis of cell line conditioned media. **Proc AACR**, Washington, DC, USA, April 17-21, 2010; #4573.

487. Pavlou M, Sauter ER, Kliethermes B, *Diamandis EP*. Mining the proteome of breast cancer cell lines and nipple aspirate fluid in the quest for novel breast cancer biomarkers. **Proc AACR**, Washington, DC, USA, April 17-21, 2010; #4574.

488. Pavlou MP, Drabovich AP, *Diamandis EP*. Combining quantitative proteomics to identify and validate estrogen-regulated proteins in breast cancer cells. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

489. Drabovich A, Batruch I, Jarvi K, *Diamandis EP*. Multiplex SRM assay to verify biomarkers for differential diagnosis of azoospermia. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

490. Batruch I, Smith CR, Mullen BJ, Grober E, Lo KC, *Diamandis EP*, Jarvi KA. Seminal plasma proteomics: identification of candidate biomarkers for non-obstructive azoospermia. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

491. Karagiannis GS, *Diamandis EP*. A comprehensive platform for the identification of secreted markers of epithelial-to-mesenchymal transition in colorectal cancer, using secretome analysis. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

492. Karagiannis GS, *Diamandis EP*. Quantitative Proteomic approaches for the identification of key regulators of the metastatic cascade in colorectal cancer desmoplastic microenvironment. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

493. Karagiannis GS, Cho CK, Makawita S, Cretu D, *Diamandis E*. A quantitative proteomic approach to identify key mediators of cancer progression in "tumor-host cell interaction" model systems. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

494. Karagiannis GS, *Diamandis EP*. Discovery of candidate biomarkers for colorectal cancer using mass spectrometry-based proteomic analysis of cell line conditioned media. **HUPO- Human Proteome World Congress**, Sydney, Australia, September 19-23, 2010.

495. Drabovich AP, Batruch I, *Diamandis EP*, Jarvi K. Developing mass spectrometry-based assays to verify protein biomarkers of obstructive azoospermia. **Ann C.J. Robson Res Day** 2010.

496. Bayani J, Kuzmanov U, Batruch I, Cho J, Smith C, Marrano P, Graham C, Butzow R, Katsaros D, Li L, Zheng Y, Squire JA, *Diamandis EP*. Integrated genomic, microRNA (miRNA) and proteomic profiling of ovarian carcinoma. **5th Canadian Conf**, Toronto, ON, Canada, May 2010.

497. Konvalinka A, *Diamandis EP*, Scholey JW. Defining an angiotensin II-stimulated proteome in human kidney cells. **Amer Soc Nephrol 43rd Ann Meeting**, Denver, CO, USA, November 19, 2010, #1777.

498. Gratio V, Beaufort N, Magdolen V, Walker F, *Diamandis EP*, Hollenberg MD, Darmoul D. Proteinase-activated receptors signaling by Kallikrein 4 and 14 in colonic cancer cells. **The 12th International Symposium on Proteases, Inhibitors and Biological Control.** Portoroz, September 25-29. Slovenia

2011

499. Karagiannis GS, Musrap N, *Diamandis EP*. Disruption of BMP-7 from oncogenic signals of cancer-associated stroma, generates specific mesenchymal signatures in colorectal cancer cells. **Keystone Symposia on Molecular and Cellular Biology: Epithelial Plasticity and Epithelial-to-Mesenchymal Transition**, Vancouver, BC, Canada, January 21-26, 2011.

500. Karagiannis GS, Musrap N, *Diamandis EP*. Disruption of BMP-7 from oncogenic signals of cancer-associated stroma, generates specific mesenchymal signatures in colorectal cancer cells. **Keystone Symposia on Molecular and Cellular Biology: Epithelial Plasticity and Epithelial-to-Mesenchymal Transition**, Vancouver, BC, Canada, January 21-26, 2011.

501. Karagiannis GS, *Diamandis EP*. Cancer-specific motogenic signals induce collective migratory pattern in myofibroblasts via increased tight junction formation. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, # LB-282.

502. Karagiannis GS, Musrap N, *Diamandis EP*. Myofibroblasts induce specific epithelial-to-mesenchymal transition (EMT) patterns in colorectal cancer cells by enhanced secretion of bone morphogenic protein (BMP) inhibitors. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #4923.

503. Bayani J, Kuzmanov U, Smith C, Batruch I, Presvelos J, Graham C, Squire JA, *Diamandis EP*. Integrated genomic, microRNA (miRNA) and proteomic profiling by stable isotope labeling with amino acids in cell culture (SILAC) of ovarian carcinoma for biomarker discovery. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #1168.

504. Saraon P, Jarvi K, *Diamandis EP*. High-Throughput Proteomic Analysis identifies protein S as a potential modulator of androgen-independent prostate cancer. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #LB-332.

505. Saraon P, Cretu D, Smith C, Batruch I, Mizokami A, Jarvi K, Diamandis EP. High-throughput proteomics using stable isotope labelling with amino acids in cell culture (SILAC) reveals potential modulators of androgen-independent prostate cancers. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #4870.

506. Prassas, I, Makawita S, *Diamandis EP*. An integrated *in silico* and proteomic approach towards the identification of novel cancer biomarkers based on tissue specificity. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #5075.

507. Kuzmanov U, Smith CR, Soosaipillai AR, *Diamandis EP*. ELISA coupled anion exchange methodology for separation of KLK6 glycoprotein subpopulations in biologival fluids. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #2223.

508. Makawita S, Kosanam H, *Diamandis EP*. Mining the pancreatic cancer ascites fluid proteome with mass spectrometry. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #5103.

509. Makawita S. Smith C, Batruch I, Ruckert F, *Diamandis EP*. Towards a multiparametric biomarker panel for pancreatic cancer detection. **Proc AACR**, Orlando, FL, USA, April 2-6, 2011, #5105.

510. McDermed JE, Sanders R, Soosaipillai AR, Klem RE, Sarno MJ, *Diamandis* EP. Development and analytical validation of a new prostate-specific antigen (PSA) assay (NADiA® ProsVue™), based on immuno-PCR technology. **AACC** 2011, #A-18.

511. Gratio V, Magdolen V, *Diamandis EP*, Hollenberg MD, Darmoul D. Role of kallikrein-related peptidases 4 and 14 signalling through proteinase-activated receptors in colonic cancer cells. **4th International Symposium on Kallikrein-Related Peptidase (ISK2011),** Rhodes Is., Greece, September 1-4, 2011.

512. Cretu D, *Diamandis EP*. Altered expression of kallikrein-related peptidases (KLKs) in cytokine-induced synovial fibroblasts. **4th Intl Symposium on Kallikreins:** Rhodes Is., Greece, September 2-4, 2011.

513. Dimitromanolakis A., Milou V., *Diamandis E.P*. Differential expression of kallikrein genes in normal and cancerous tissues. **4th Intl Symposium on Kallikreins:** Rhodes Is., Greece, September 2-4, 2011.

514. Milou V, Dimitromanolakis A, *Diamandis EP*.Gene expression profiling of ovarian cancer biomarkers with emphasis on the KLK family. **4th Intl Symposium on Kallikreins:** Rhodes Is., Greece, September 2-4, 2011.

515. Drabovich AP, Jarvi K, *Diamandis EP*. Differential diagnosis of azoospermia with proteomic biomarkers quantified in seminal plasma by multiplex selected reaction monitoring assay. **HUPO-Human Proteome Organisation Congress**, September 6, 2011, Geneva, Switzerland, #2699.

516. Drabovich AP, Pabvlou M, *Diamandis* EP.Quantitative analysis of energy metabolic pathways in breast cancer cells under different growth conditions by Selected Reaction Monitoring. **HUPO-Human Proteome Organisation Congress**, September 5, 2011, Geneva, Switzerland.

517. Drabovich AP, Pabvlou M, *Diamandis* EP.Targeted mass spectrometry for quantitative proteomic analysis of energy metabolic pathways in breast cancer cells. **36th Fed of Eur Biochemical Societies Congress**, June 26, 2011, Torino, Italy.

518. Drabovich AP, *Diamandis* EP.Verification of protein biomarkers with mass spectrometry-based selected reaction monitoring". **26th Intl Symposium on MicroScale Bioseparations**, May 5, 2011, San Diego, CA, USA, #72.

519. Kulasingam V, *Diamandis EP*. Proteomic approaches for novel biomarker discovery. **21st IFCC World Lab** Berlin, Germany, May 15-19, 2011.

520. Oikonomopoulou K, DeAngelis RA, Chen H, Ricklin D, Hollenberg MD, *Diamandis EP*, Lambris JD. Kallikrein-related peptidases as modulators of the innate immune response. **Proceedings of the 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases,** September 2011, #OP07.

521. Musrap N, Karagiannis GS, Smith C, Batruch I, *Diamandis EP*. High-throughput proteomics reveals novel mediators of ovarian cancer and peritoneal mesothelial cell interac tion during metastasis in an in-vitro co-culture model. **Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy Conf,** Orlando, FL, USA, November 3-6, 2011, #260239-1.

522. Karagiannis GS, Musrapy N, Petraki C, *Diamandis EP*. Proteomic analysis of desmoplastic cocultures reveals collagen XII, as a putative marker of myofibroblastic induction during colorectal cancer metastasis. **Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy Conf,** Orlando, FL, USA, November 3-6, 2011, #260639-2.

523. Musrap N, Karagiannis **GS,** *Diamandis EP*. Induction of mesenchymal-epithelial transition (MET) in ovarian cancer cells through mesothelial-ovarian cancer mediated crosstalk. **CCRC-The Canadian Cancer Res Conf**, Toronto, ON, Canada, November 27-30, 2011, #B16.

524. Saraon P, Cretu D, Smith C, Batruch I, Morrissey C, Mizokami A, Jarvi K, *Diamandis EP*. High-throughput proteomics reveals an up-regulation of ketogenic pathway enzymes during the progression of prostate cancer to androgen-independence. **CCRC-The Canadian Cancer Res Conf**, Toronto, ON, Canada, November 27-30, 2011, #G28.

2012

525. Bozovic A, *Diamandis EP*. High Throughput Liquid Chromatography-Tandem Mass Spectrometry Method for Serum 25-hydroxyvitamin D using a TurboFlow Online Extraction Technology. **MSACL- The Association for Mass Spectrometry Applications to the Clinical Lab**. January 14-18, 2012, San Diego, CA, USA, #59.

526. Konvalinka A. Diamandis EP. Scholey JW. Defining an Angiotensin II-stimulated proteome in human kidney cells. **6th Annual Young Investigators' Forum**, February 10, 2012, Montreal, Que, Canada.

527. Sotiropoulou G, Pampalakis G, Smith C, Zoumpourlis V, *Diamandis EP*. Molecular basis for the concentration-dependent tumor suppressing effects of KLK6 in breast cancer. **AACR Annual Meeting,** March 31-April 4, 2012, Chicago, IL, USA, #4916.

528. Saraon P, Cretu D, Morrissey C, Jarvi K, *Diamandis EP*. High-throughput proteomic analysis identifies protein s as a modulator of high grade and castrateresistant prostate cancer. High-throughput proteomic analysis identifies protein s as a modulator of high grade and castrateresistant prostate cancer. **AACR Annual Meeting**, March 31-April 4, 2012. Chicago, IL, USA, #LB-293.

529. Saraon P, Cretu D, Jarvi K, *Diamandis EP*. High-throughput proteomics reveals that enzymes of the ketogenic pathway are upregulated during prostate cancer progression. **AACR Annual Meeting**, March 31-April 4, 2012. Chicago, IL, USA, #4119.

530. Drabovich A, Batruch I, Jarvi K, *Diamandis EP*. Verification of Male Infertility Biomarkers in Seminal Plasma by Multiplex SRM Assay. **CNPN - Canadian National Proteomics Network Symposium**, April 23-25, 2012, Toronto, ON, Canada, #3217.

531. Konvalinka A. Diamandis EP. Scholey JW. Nrf2 Target proteins are regulated by angiotensin ii in kidney cells. **CNPN - Canadian National Proteomics Network Symposium**, April 23-25, 2012, Toronto, ON, Canada.

532. Martinez Morillo E, Shaw JL, Soosaipillai A, *Diamandis EP*. Development of selected reaction monitoring assays for quantification of biochemical markers of Down syndrome in amniotic fluid samples. **CNPN - Canadian National Proteomics Network Symposium**, April 23-25, 2012, Toronto, ON, Canada.

533. Bayani J, Kuzmanov U, Saraon P, Batruch I, Smith C, Fung W, Squire JA, *Diamandis EP*. Mechanisms of kallikrein 6 expression and biomarker discovery in ovarian carcinomas: an integrated, mirna and proteomic profiling approach. **6th Canadian Conference on Ovarian Cancer**, May 27-29, 2012, Quebec City, Que., Canada, #46.

534. Leung F, Dimitromanolakis A, *Diamandis EP*. Integrating high throughput technologies for the identification and validation of ovarian cancer biomarkers. **6th Canadian Conference on Ovarian Cancer**, May 27-29, 2012, Quebec City, Que., Canada, #43.

535. Musrap, N., Karagiannis, G.S., Smith, C., Batruch, I., and Diamandis, E.P. Identification of mediators implicated in the metastatic progression of ovarian cancer to peritoneal mesothelium using high-throughput proteomics. **6th Canadian Conference on Ovarian Cancer**, May 27-29, 2012, Quebec City, Que., Canada.

536. Konvalinka A. Diamandis EP. Scholey JW. Bioinformatic Toolkit Uncovers Nrf2 Protein Network in Angiotensin II Treated Proximal Tubular Cells. **ISN Forefronts Symposium,** June 7-10, 2012, Ann Arbor, MI, USA, #550017.

537. Fu L, Kulasingam V, Soosaipillai A, Catomeris P, *Diamandis EP*, Cole DEC. Identification and characterization of an antibody-bound thyroid-stimulating hormone (YSH) with differential effects on various clinically available serum TSH assays. **56th Annual CSCC Conference/33rd Annual SQBC Conference**, June 17-20, 2012, Quebec, QC, Canada, #P529.

538. Martinez Morillo E, Diamandis A, Romaschin AD, *Diamandis EP*. Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage. **AACC Annual Meeting**, July 15-19, 2012, Los Angeles, Ca, USA, #D-79.

539. Martinez Morillo E, Shaw JL, Soosaipillai A, *Diamandis EP*. Development of selected reaction monitoring assays for quantification of biochemical markers of Down syndrome in amniotic fluid samples. **AACC Annual Meeting**, July 15-19, 2012, Los Angeles, Ca, USA.

540. Begcevic I, Kosanam H, Martinez-Morillo E, Batruch I, Diamandis P, Hazrati L-N, Diamandis EP. Shotgun proteomics of hippocampus region in Alzheimer's disease patients - seeking new biomarkers. **HUPO- Human Proteome Organisation Congress 11th Annual World Congress,** September 9-13, 2012, Boston, MA, USA, #568.

541. Saraon P, Cretu D, Jarvi K, *Diamandis EP*. Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway are Associated with High Grade Prostate Cancer. **HUPO- Human Proteome Organisation Congress 11th Annual World Congress,** September 9-13, 2012, Boston, MA, USA, #171.

542. Cretu D, Batruch I, Gladman DD, Pellet F, Saraon P, *Diamandis EP*, Chandran V. Quantitative Proteomic Profiling of Synovial Fluid for the Identification of Psoriatic Arthritis Soluble Biomarkers. **HUPO-Human Proteome Organisation Congress 11th Annual World Congress,** September 9-13, 2012, Boston, MA, USA, #260.

543. Drabovich A, Jarvi K, *Diamandis EP*. Differential diagnosis of male infertility with proteomic biomarkers quantified in seminal plasma by SRM assay. **HUPO- Human Proteome Organisation Congress 11th Annual World Congress,** September 9 - 13, 2012, Boston, MA, USA, #423.

544. Drabovich A, Pavlou M, Dimitromanolakis A, *Diamandis EP*. Quantitative analysis of metabolic and estradiol signaling pathways in breast cancer cells by selected reaction monitoring. **HUPO- Human Proteome Organisation Congress 11th Annual World Congress,** September 9-13, 2012, Boston, MA, USA, #421.

545. Konvalinka A. *Diamandis EP*. Scholey JW. Proteomic and Bioinformatic Analyses Identify Angiotensin II Regulated Proteins in Kidney Cells. **HUPO- Human Proteome Organisation Congress 11th Annual World Congress,** September 9-13, 2012, Boston, MA, USA, #259.

546. Chrystoja C, Kosanam H, Prassas I, Chan A, Dimitromanolakis A, Makawita s, Soosaipillai A, Blasutig I, *Diamandis EP*. Validation of candidate serum biomarkers demonstrates the potential of CUZD1 and LAMC2 to complement CA19.9 for pancreatic cancer diagnosis. **AACR Conference**, June 18-21, 2012, Lake Tahoe, NV, USA, Poster Session A.

547. Darmoul D, *Diamandis EP*, Hollenberg MD. Kallikerin 14 induces epithelial-mesenchymal transition-like changes in colon cancer cells. A**nnual Meeting of the American Association for Cancer Research**, Chicago, IL, USA, March 31-4th April, 2012.

548. Cretu D, Batruch I, Gladman DD, Pellet F, Saraon P, *Diamandis EP*, Chandran V. Proteomic profiling of synovial fluid reveals candidate psoriatic arthritis biomarkers. **American College of Rheumatology (ACR) Annual Meeting**, November 9-14, 2012, Washington, DC, USA, 64 Suppl 10:560.

2013

549. Dukic L, Simundic A, Martinic-Popovic, *Diamandis EP*. Role of kallikrein 6 (KLK6) in the differential diagnosis of dementia. **IFCC-EFLM - EUROLabMed**, May 19-23, 2013, Milan, Italy. Biochimica Clinica, 37:S362, #T142.

550. Musrap N, Karagiannis GS, Smith C, Batruc I, *Diamandis EP*. Proteomic profiling of ovarian cancer and mesothelial cells reveals novel mediators implicated in the metastatic progression of ovarian cancer to the peritoneum. **AACR: Advances in Ovarian Cancer Research: From Concept to Clinic**, September 18-21, 2013, Miami, FL, USA, #B61.

551. Musrap N, Batruch I, *Diamandis EP*. Delineating differential protein expression during the formation of ovarian cancer spheroids using high-throughput proteomics. **CCRC- The Canadian Cancer Research Conference**, November 3-6, 2013, Toronto, ON, Canada, #P-08.

552. Leung F. Dimitromanolakis A, *Diamandis EP*, and Kulasingam V. Integrating high-throughput technologies for identification and validation of ovarian cancer biomarkers. **The 2nd Canadian Cancer Research Conference Abstract Book,** November 3-6, 2013, Toronto, ON, Canada, 311

2014

553. Karagiannis GS, Kirsch R, Riddell RH, *Diamandis EP*. Bone Morphogenetic Protein Antagonist Signatures in the Colorectal Cancer Desmoplastic Invasion Front. **4th International Conference on Tumor Progression and Therapeutic Resistance**, Boston, Massachusetts, US, March 9th-11th, 2014.

554. Di Meo A, White NMA, Masui O, DeSouza LV, Metias S, Romaschin AD, Honey J, Stewart R, Pace K, Lee J, Jewett MA, Bjarnason GA, Sui M, *Diamandis EP*, Yousef GM. Tissue-based identification of clear cell renal cell carcinoma markers using iTRAQ LC-MS analysis. **United States and Canadian Academy of Pathology Conference**, United States, California, San Diego. 2014 March.

555. Di Meo A, White NMA, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Sui M, *Diamandis EP*, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma. **United States and Canadian Academy of Pathology Conference**, United States, California, San Diego. 2014 March

556. Di Meo A, White-Al Habeeb NMA, Scorilas A, Rotondo F, Masui O, Seivwright A, Gabril M, Girgis AH, Jewett M, Diamandis EP, Yousef GM. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.**Roderick Ross Research**, Canada 2014

557. Di Meo A, Batruch I, Dimitromanolakis A, Jewett M, Diamandis EP, and Yousef GM. Analysis of the urinary proteome and peptidome to identify prognostic biomarkers for small renal masses.**Roderick Ross Research**, Canada. 2014

558. Korbakis D, Prassas I, Brinc D, Batruch I, Krastins B, Lopez, MF, *Diamandis EP*. Delineating monoclonal antibody specificity by Mass Spectrometry. **Proc 8th LMP Postgraduate Research Day:** P16, March 11, 2014

559. Korbakis D, Brinc D, Prassas I, Batruch I, Krastins B, Lopez MF, *Diamandis EP*. Identification of antibody specificity using complex biological fluids. **Proc 62nd ASMS Conference:** P99, Baltimore, Maryland June 15, 2014

560. Konvalinka A, Drabovich A, Diamandis EP, Scholey JW. Development of Assays for Quantification of Angiotensin II Signature Proteins in Human Urine. Poster presentation, **HUPO 13th Annual Congress**, Madrid, Spain, Oct. 6 2014

561. Briollais L, Xu J, Kwiatkowski M, Friedlander M, Recker F, Kuk C, Hanna S, Fleshner NE, Bapat B, Juvet T, Li H, Chadwick K, Trachtenberg J, Nesbitt ME, Van Der Kwast TH, *Diamandis E*, Zlotta AR, Ozcelik H. Fine-mapping of the Kallikrein region and its role in prostate cancer aggressiveness: Results from a Canadian cohort and the European Randomized Study for Prostate Cancer Screening. **Eur Urol Suppl**. October 24, 2014:13; e206.

562. Cretu D, Liang K, Gladman DD, *Diamandis EP*, Chandran V. Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers. **ACR [American College of Rheumatology].** Boston, Massachusetts, US, November 14-19, 2014,

563. Konvalinka A, Drabovich A, Diamandis EP, Scholey JW. Development of Assays for Quantification of Angiotensin II Signature Proteins in Human Urine. Poster presentation, **American Society of Nephrology Annual Meeting**, SA-PO486, Philadelphia, US, Nov. 15 2014

2015

564. Konvalinka A, Drabovich A, Batruch I, *Diamandis EP*, Scholey JW. Quantification of angiotensin II signature proteins in human urine. **Advances in Organ Transplantation Conference**, Cambridge, Boston, April 17, 2015

565. Bozovic A, Batruch I, John R, *Diamandis EP*, Kulasingam V. Amyloidosis subtyping in formalin-fixed paraffin embedded tissue by mass spectrometry. **Canadian Society of Clinical Chemists (CLMC CAP. CSCC).** Montreal, Quebec June 20-24, 2015

566. Di Meo A, Batruch I, Dimitromanolakis A, Jewett M, *Diamandis EP*, Yousef GM. Analysis of the urinary proteome and peptidome to identify prognostic biomarkers for small renal masses.**United States and Canadian Academy of Pathology Conference,** Toronto, Ontario. 2015 March

567. Schiza C, Korbakis D, Brinc D, Drabovich AP, Soosaipillai A, Jarvi K, *Diamandis EP*. Identification of TEX101 protein interactome in testicular germ cells by immunoprecipitation-MS. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

568. Begcevic I, Brinc D, Drabovich A, Batruch I, *Diamandis, EP*. Identification of brain-related cerebrospinal fluid proteins in neurodegenerative diseases. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

569. Korbakis D, Brinc D, Schiza C, Prassas I, Batruch I, Drabovich AP, DiamandiS EP. Immunoaffinity-MS platform for antibody screening and native protein analysis in biological fluids. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

570. Leung F, Bernardini MQ, Clarke B, Rouzbahman M, Diamandis EP, Kulasingam V. Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

571. Dimitrakopoulos L, Prassas I, Charames GS, Diamandis EP. A proteogenomic study on p53 mutant peptide detection reveals biological and technical limitations. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

572. Van JA, DiMeo A, Batruch I, Diamandis EP, Scholey JW, Konvalinka A. Characterizing the urinary peptidome to infer protease activity in the diabetic kidney. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

573. Drabovich AP, Korbakis D, *Diamandis EP*, Jarvi K**.** Diagnosis of urological disorders with protein biomarkers quantified in seminal plasma. **HUPO 14th Annual World Congress,** Vancouver, BC. September 27 - 30, 2015

574. Leung F, Bernardini MQ, Clarke B, Rouzbahman M, *Diamandis EP*, Kulasingam V. Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. **AACR Advances in Ovarian Cancer Research conference,** Orlando, FL. October 17-20, 2015

2016

575. Van JAD, Di Meo A, Batruch I, *Diamandis EP*, Scholey JW, Konvalinka A. Characterizing the urinary peptidome to infer protease activity in the diabetic kidney. **American Society of Nephrology Kidney Week**, Chicago, IL. November 15-20, 2016.

576. Konvalinka A, Batruch I, Tokar T, Reid S, Dimitromanolakis A, Song X, Pei Y, *Diamandis EP*, Jurisica I, Scholey J. Presenter. Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and chronic kidney diseases by selected reaction monitoring. ***American Society of Nephrology Annual Meeting***. November 2016 Chicago, Illinois, United States

577. Reid S, Batruch I, Tokar T, Dimitromanolakis A, Song X, Pei Y, *Diamandis EP*, Jurisica I, Scholey J, Konvalinka A. Presenter. Quantification of angiotensin II signature proteins in urine of patients with kidney transplant and chronic kidney disease. ***Canadian Society of Transplantation Annual Meeting***. October 2016 Quebec City, Quebec, Canada. Presenter(s): Reid, Shelby. (Trainee Presentation).

578. Konvalinka A, Batruch I, Tokar T, Reid S, Dimitromanolakis A, Song X, Pei Y, *Diamandis EP*, Jurisica I, Scholey J. Invited Speaker. Quantification of Angiotensin II-Regulated Proteins in Urine of Patients with Polycystic and Chronic Kidney Diseases by Selected Reaction Monitoring. ***Human Proteome Organization (HUPO)***. Sept. 20, 2016 Taipei, Taipei, Taiwan, Province Of China

2017

579. Ravipaty S, Wu W, Dalvi A, Tnna N, Andreazi J, Friss T, Kotz A, Liao C, Garren J, Schofield S, *Diamandis EP*, Klein EA, Dobi A, Srivastava S, Tekumalla P, Kiebish MA, Vishnudas VK, Sarangarajan R, Narain NR, Akmaev V. Clinical validation of a serum protein panel (FLNA, FLNB and KRT19) for diagnosis and prognosis of prostate cancer. ***American Association for Cancer Research (AACR).*** April 1-5, 2017, Washington DC